46. 悪性関節リウマチ Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
(+) erythromefloquine
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+) isomer of racemic mefloquine
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+) isomer or racemic mefloquine
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+)erythromefloquine
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1-
Pfizer S.A.
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1-
Pfizer S.A.
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(CDP6038
R-Pharm
2017 Phase 3 EUCTR2015-005309-35-LV Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-HU Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-GB Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005307-83-LV Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005308-27-HU Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
2016 Phase 3 EUCTR2015-005308-27-DE Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-LT Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-HU Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-DE Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International LLC
2017 Phase 3 EUCTR2015-005309-35-PL Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-LT Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-DE Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-CZ Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005308-27-CZ Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
2016 Phase 3 EUCTR2015-005307-83-CZ Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-BG Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International, LLC.
2017 Phase 3 EUCTR2015-005309-35-BG Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
0109-0012A 100 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2014 Phase 2 EUCTR2013-001492-20-PT Ireland;Portugal;Spain;United Kingdom;
2014 Phase 2 EUCTR2013-001492-20-ES Ireland;Portugal;Spain;United Kingdom;
2013 Phase 2 EUCTR2013-001492-20-GB Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 25 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 50 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0114-0006B
Novo Nordisk A/S
2012 Phase 2 EUCTR2011-005376-42-ES Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-LV Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-HU Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-BG Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
0881
Wyeth Pharmaceuticals
2005 - EUCTR2004-000563-96-FI Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2005 - EUCTR2004-000563-96-AT Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-SE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-IE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-HU Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-ES Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-DK Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
- Phase 4 EUCTR2004-000563-96-NO Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth Pharmaceuticals France
2008 Phase 4 EUCTR2007-000896-41-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-001625-10-PL Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-DE Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-AT Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000896-41-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2010 Phase 4 EUCTR2008-002623-85-SE France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2010 - EUCTR2007-000896-41-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2007-000896-41-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 Phase 4 EUCTR2008-002623-85-FR France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2008-002623-85-ES France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
2008 - EUCTR2007-000896-41-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
1 ml NaCl
Vrije Universiteit Brussel
2010 - NCT01154647 Belgium;
1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c
Merck Sharp & Dohme (Sweden) AB
2004 - EUCTR2004-000074-31-SE Sweden;
Merck Sharp & Dohme BV
2005 Phase 2 EUCTR2004-000074-31-BE Belgium;Sweden;
118-42-3
Karolinska Institutet
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
13-valent pneumococcal conjugate vaccine
Region Skane
2016 Phase 4 NCT03762824 -
15-O labeled water
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2001 Phase 1 NCT00014794 United States;
18F-FDG
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
18F-GE-180
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
18F]PEG-Folate
VU Medical Center, department of Rheumatology
2020 Phase 4 EUCTR2018-004429-94-NL Netherlands;
2018 Phase 4 EUCTR2018-001114-15-NL Netherlands;
2 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
2-HOBA
Vanderbilt University Medical Center
2022 Phase 2 NCT05274243 United States;
2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt
Knowledge Centre for Rheumatology and Back Diseases
2013 Phase 4 EUCTR2013-004006-26-DK Denmark;
23-Valent Pneumococcal Polysaccharide Vaccine
Genentech, Inc.
2010 Phase 4 NCT01163747 United States;
23-valent pneumococcal polysaccharide vaccine
Genentech, Inc.
2006 Phase 2 NCT00282308 United States;
Region Skane
2016 Phase 4 NCT03762824 -
2593
Aarhus University Hospital, Denmark
2007 Phase 4 EUCTR2007-000082-38-DK Denmark;
331731-18-1
AbbVie Deutschland GmbH & Co. KG
2015 Phase 4 EUCTR2014-001114-26-SE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 4 EUCTR2014-001114-26-NL Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 4 EUCTR2014-001114-26-IT Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-IE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-HU Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-GR Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-GB Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-FR Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-ES Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-DE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-AT Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Abbott Japan Co., Ltd.
- - EUCTR2014-004558-33-Outside-EU/EEA Japan;
35565011
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
2016 Phase 3 EUCTR2015-000570-35-IT Italy;
4 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide
Astellas Pharma Global Development
2013 Phase 2 EUCTR2011-006021-23-CZ Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 Phase 2 EUCTR2011-006021-23-BG Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 - EUCTR2011-006021-23-HU Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2012 - EUCTR2011-006021-23-BE Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
Astellas Pharma Global Development Inc. (APGD)
2013 Phase 2 EUCTR2011-006021-23-PL Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019871-31-GB Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2010-019871-31-SK Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019871-31-BE Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
2011 - EUCTR2010-019871-31-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
6 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
68Ga-BNOTA-PRGD2
Peking Union Medical College Hospital
2012 Early Phase 1 NCT01940926 China;
68Ga-FAPI
Peking Union Medical College Hospital
2020 Early Phase 1 NCT04514614 China;
68Ga-NEB
Peking Union Medical College Hospital
2019 Phase 1 NCT04273334 China;
7-valent Pneumococcal Conjugate vaccine
Dept of Rheumatology, Lund University Hospital, Lund, Sweden
2008 - EUCTR2007-006539-29-SE Sweden;
70930.00.00
medac Gesellschaft für klinische Spezialpräparate mbH
2012 - EUCTR2012-000222-21-DE Germany;
8594739041288
Merck & Co., Inc.
2005 Phase 2 EUCTR2004-004302-24-CZ Czech Republic;Finland;Germany;Italy;Spain;
89Zr-DFO-CZP
Robert Flavell, MD, PhD
2018 Phase 1 NCT03546335 United States;
9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline
OxyPharma AB
2008 - EUCTR2006-004834-33-PL Bulgaria;Latvia;Poland;United Kingdom;
2007 Phase 2 EUCTR2006-004834-33-GB Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
2007 - EUCTR2006-004834-33-BE Belgium;Bulgaria;Latvia;Poland;United Kingdom;
9512
Center for Research and Development Uppsala University/County Council of Gävleborg
2014 Phase 4 EUCTR2014-000993-20-SE Sweden;
99mTc-3PRGD2
First Affiliated Hospital of Fujian Medical University
2015 Phase 0 NCT02723760 China;
99mTc-S-HYNIC Certolizumab pegol
Ghent University Hospital
2017 Phase 4 EUCTR2016-004300-65-BE Belgium;
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
99mTc-rhAnnexin V-128
Advanced Accelerator Applications
2014 Phase 1/Phase 2 NCT02328027 Switzerland;
A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
University of Minnesota - Clinical and Translational Science Institute
2004 - NCT01600521 China;
AB1010
AB Science
2014 - EUCTR2010-020992-21-DE Argentina;Bosnia and Herzegovina;Czech Republic;Germany;Greece;India;Mexico;Monaco;Morocco;Philippines;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Tunisia;Ukraine;United States;
2012 Phase 3 EUCTR2010-020992-21-GR Czech Republic;Germany;Greece;India;Monaco;Poland;Romania;Slovakia;Spain;Thailand;Turkey;United States;
2011 Phase 3 EUCTR2010-020992-21-SK Czech Republic;France;Germany;Greece;India;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;United States;
2011 - EUCTR2010-020992-21-ES Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
2011 - EUCTR2010-020992-21-CZ Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
ABA, open-label (OL)
Bristol-Myers Squibb
2005 Phase 3 NCT00095147 Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
ABBV-105
AbbVie
2019 Phase 2 NCT03823378 Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom;
2018 Phase 2 NCT03682705 Belgium;Canada;Czechia;Germany;Hungary;Ireland;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-002306-31-HU Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-BE Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-BE Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
ABBV-105, A-1519938.0
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-000666-10-HU Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-000666-10-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2018 Phase 2 EUCTR2018-000666-10-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABBV-154
ABBVIE DEUTSCHLAND GMBH & CO. KG
2021 Phase 2 EUCTR2020-005303-39-IT Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2021 Phase 2 NCT04888585 Australia;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005303-39-PL Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-NL Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-GR Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-ES Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-DE Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ABBV-257
AbbVie
2015 Phase 1 NCT02531178 Germany;
ABBV-3373
AbbVie
2019 Phase 2 NCT03823391 Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-003053-21-PL Israel;Poland;Puerto Rico;United States;
ABP 501
Amgen
2014 Phase 3 NCT02114931 Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 3 NCT01970475 Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Amgen Inc
2014 Phase 3 EUCTR2013-000525-31-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-000525-31-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Amgen Inc.
2014 Phase 3 EUCTR2013-004654-13-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-004654-13-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
ABP 710
Amgen
2016 Phase 3 NCT02937701 Australia;Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Spain;United States;
ABP 710 - Biosimilar to infliximab
Amgen Inc.
2016 Phase 3 EUCTR2014-004704-29-PL Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-HU Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-ES Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-DE Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-CZ Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-BG Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
ABP 798
Amgen
2016 Phase 3 NCT02792699 Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 - Biosimilar to rituximab
Amgen Inc
2015 Phase 1;Phase 3 EUCTR2013-005543-90-BG Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-PL Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-HU Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-DE Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 Biosimilar to Rituximab
Amgen Inc
2017 Phase 1;Phase 3 EUCTR2013-005543-90-EE Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABT 494
AbbVie Deutschland GmbH & Co. KG
2014 Phase 2 EUCTR2013-003984-72-LV Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 Phase 2 EUCTR2013-003984-72-CZ Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 Phase 2 EUCTR2013-003530-33-NL Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-LV Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-ES Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-NL Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-CZ Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-BE Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 - EUCTR2013-003984-72-SK Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 - EUCTR2013-002358-57-HU Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co.KG
2014 - EUCTR2013-003984-72-HU Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
AbbVie Inc.
2014 - EUCTR2013-003984-72-ES Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 - EUCTR2013-002358-57-ES Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABT-122
AbbVie
2015 Phase 2 NCT02433340 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 NCT02141997 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
2013 Phase 1 NCT01853033 United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-001471-31-RO Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2014-001471-31-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2017 Phase 3 EUCTR2016-000933-37-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;European Union;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-IT Argentina;Australia;Austria;Barbados;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2014 Phase 2 NCT02049138 Australia;Belgium;Bulgaria;Chile;Czech Republic;Czechia;Hungary;Israel;Latvia;Mexico;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 Phase 2 NCT01960855 Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2012 Phase 1 NCT01741493 United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-002306-31-HU Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-BE Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-HU Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-000666-10-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-BE Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000933-37-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2018-000666-10-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-SE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-DE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-BE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-LV Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-ES Argentina;Australia;Belarus;Brazil;Canada;Chile;Colombia;European Union;Hungary;Israel;Korea, Democratic People's Republic of;Latvia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;United States;
2016 Phase 3 EUCTR2015-003376-75-PT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-PL Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-GR Argentina;Australia;Austria;Belgium;Chile;Colombia;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-ES Argentina;Australia;Austria;Chile;Colombia;European Union;Israel;Japan;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-BE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003335-35-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-SI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-NO Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-LV Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-FR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-SI Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-RO Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-PT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-PL Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-LV Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-LT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-IE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-HU Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003334-27-HR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-GR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003334-27-GB Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-FI Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-ES Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-CZ Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-BG Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-BE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003333-95-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-ES Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003333-95-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Norway;Poland;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003332-13-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 - EUCTR2015-003332-13-NO Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Hong Kong;Israel;Kazakhstan;Korea, Republic of;Malaysia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Switzerland;Taiwan;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2015-003334-27-SK Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-003333-95-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-LV Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ABT-Humira
Abbott GmbH & Co. KG
2008 - EUCTR2007-005905-23-GB Germany;United Kingdom;
2008 - EUCTR2007-005905-23-DE Germany;United Kingdom;
ABX464
Abivax
2019 Phase 2 EUCTR2019-001578-27-HU Hungary;
2019 Phase 2 EUCTR2018-004677-27-HU Belgium;Hungary;
2019 Phase 2 EUCTR2018-004677-27-BE Belgium;Hungary;
Abivax S.A.
2019 Phase 2 NCT04049448 Belgium;Czechia;France;Hungary;Poland;
2019 Phase 2 NCT03813199 Belgium;Czechia;France;Hungary;Poland;
AC430
Daiichi Sankyo Inc.
2010 Phase 1 NCT01287858 United States;
ACZ885
NOVARTIS FARMA
2007 - EUCTR2007-001665-15-IT Germany;Italy;Netherlands;Spain;
2007 - EUCTR2006-001553-10-IT Germany;Italy;Netherlands;
Novartis
2007 Phase 2 NCT00554606 Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United States;
2007 Phase 1/Phase 2 NCT00505089 Belgium;Germany;Netherlands;Poland;
2003 Phase 1/Phase 2 NCT00619905 Germany;Netherlands;Switzerland;
Novartis Farmacéutica S.A.
2009 Phase 2 EUCTR2008-005320-81-ES Austria;Belgium;Germany;Spain;
Novartis Pharma AG
2007 - EUCTR2006-001550-27-FI Austria;Finland;Germany;Spain;
2007 - EUCTR2006-001550-27-DE Austria;Finland;Germany;Spain;
2006 - EUCTR2006-001550-27-BE Austria;Belgium;Finland;Germany;Spain;
2006 - EUCTR2006-001550-27-AT Austria;Finland;Germany;Spain;
Novartis Pharma Services AG
2009 - EUCTR2008-005320-81-DE Austria;Germany;Spain;
2009 - EUCTR2008-005320-81-BE Austria;Belgium;Germany;Spain;
2008 - EUCTR2008-005320-81-AT Austria;Germany;Spain;
2007 - EUCTR2007-001665-15-DE Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-DE Austria;Germany;Spain;
2007 - EUCTR2006-001553-10-DE Germany;Italy;Netherlands;
ACZ885 (investigational)
Novartis
2007 Phase 2 NCT00504595 Russian Federation;Spain;Switzerland;Turkey;
ACZ885 Drug Substance
Novartis Farmaceutica S.A.
2007 - EUCTR2007-001665-15-ES Belgium;Germany;Italy;Netherlands;Spain;
Novartis Farmacéutica S.A
2007 - EUCTR2006-004669-32-ES Spain;
Novartis Farmacéutica, S.A.
2007 - EUCTR2007-000491-16-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2007 Phase 2 EUCTR2006-001553-10-BE Belgium;Germany;Italy;Netherlands;
2007 - EUCTR2007-001665-15-NL Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-BE Belgium;Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-BE Austria;Belgium;Germany;Spain;
2007 - EUCTR2007-000491-16-AT Austria;Germany;Spain;
2007 - EUCTR2006-004666-14-DE Germany;
2007 - EUCTR2006-004666-14-BE Belgium;Germany;
2007 - EUCTR2006-001553-10-NL Germany;Italy;Netherlands;
AD 452
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
Sosei
2005 Phase 2 NCT00141934 United States;
AD 452 18 mg tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
AD 452 4.5 mg Tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
AD 452 9 mg tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
ADALIMUMAB HUMIRA
Pfizer Inc
2020 Phase 4 EUCTR2019-000284-24-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2019 Phase 3 EUCTR2019-000284-24-LT Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
ADALIMUMAB-EU
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
ADL5859
Cubist Pharmaceuticals LLC
2007 Phase 2 NCT00626275 United States;
AGM 719
Amgen
2002 Phase 2 NCT00038298 United States;
AI-1000 G2
Hoffmann-La Roche
2016 Phase 4 NCT02682823 United States;
AIN457
NOVARTIS FARMA
2012 - EUCTR2012-002760-27-IT Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000275-13-IT Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
Novartis Farma S.p.A.
2013 - EUCTR2013-000944-25-IT Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
Novartis Farmaceutica, S.A.
2012 - EUCTR2012-002760-27-ES Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Novartis Farmacéutica S.A.
2011 - EUCTR2011-000102-21-ES Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
Novartis Pharma AG
2012 - EUCTR2012-002760-27-SK Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2012-002760-27-HU Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2012-002760-27-CZ Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2011-006058-94-PT Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2012 - EUCTR2011-006058-94-GR Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 - EUCTR2011-000275-13-HU Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000275-13-GB Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000275-13-BE Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000102-21-SK Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2010-024516-34-SK Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
2011 - EUCTR2010-024516-34-HU Bulgaria;Canada;Hungary;Italy;United States;
2011 - EUCTR2010-024516-34-BG Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132209 -
2012 Phase 3 JPRN-JapicCTI-132091 -
Novartis Pharma Services AG
2013 - EUCTR2012-002760-27-BG Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Novartis Pharma Services AG
2013 - EUCTR2013-000944-25-HU Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
2013 - EUCTR2011-006058-94-DE Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2012 - EUCTR2012-002760-27-DE Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2011-006058-94-CZ Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 Phase 2 EUCTR2011-001220-38-GB Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 Phase 2 EUCTR2011-001220-38-BE Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 - EUCTR2011-001220-38-DE Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 - EUCTR2011-000102-21-HU Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-DE Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-CZ Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-BG Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2009 - EUCTR2009-011000-34-SK Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-HU Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-DE Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-CZ Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-BE Belgium;Czech Republic;Germany;Hungary;Slovakia;
Novartis Pharmaceuticals
2011 Phase 3 NCT01350804 Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2005 Phase 1/Phase 2 NCT00669942 Belgium;Germany;Netherlands;Singapore;Spain;United States;
AIN457F
NOVARTIS FARMA
2012 - EUCTR2011-006058-94-IT Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 - EUCTR2011-000102-21-IT Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2010-024516-34-IT Bulgaria;Canada;Hungary;Italy;United States;
AK106-001616
Asahi Kasei Pharma Corporation
2011 Phase 2 NCT01285752 Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-SK Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-HU Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
2011 - EUCTR2010-021558-21-GB Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-DE Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
2010 - EUCTR2010-021558-21-CZ Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2009 Phase 2 NCT00902369 Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
2009 - EUCTR2008-006075-75-HU Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-GB Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-DE Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-CZ Czech Republic;Germany;Hungary;United Kingdom;
ALD518 monoclonal antibody (anti IL-6 mAb)
Alder Biopharmaceuticals, Inc
2008 - EUCTR2008-004931-39-PL Poland;
ALX-0061
Ablynx
2015 Phase 2 NCT02518620 Belgium;Bulgaria;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;
2015 Phase 2 NCT02309359 Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 NCT02287922 Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
2014 Phase 1 NCT02101073 Netherlands;
2011 Phase 1/Phase 2 NCT01284569 Czech Republic;Czechia;Hungary;Netherlands;Poland;
Ablynx NV
2015 Phase 2 EUCTR2014-003034-42-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003033-26-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-CZ Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-CZ Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
ALX-0061 Nanobody
Ablynx NV
2011 - EUCTR2010-022865-81-HU Czech Republic;Hungary;
2011 - EUCTR2010-022865-81-CZ Czech Republic;Hungary;
AMG 108
AMGEN S.P.A.
2007 - EUCTR2006-003698-29-IT Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-IT Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
Amgen
2006 Phase 2 NCT00369473 Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2006 Phase 2 NCT00293826 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;Sweden;United Kingdom;United States;
Amgen Inc.
2007 - EUCTR2006-003698-29-LV Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-IE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-HU Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-EE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-AT Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-LV Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-IE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-EE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2006-003698-29-SK Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
2006 Phase 2 EUCTR2006-003698-29-FR Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-SK Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-GB Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-ES Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-SE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-NL Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-GB Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-CZ Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-BE Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-SE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-NL Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-CZ Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-BE Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-AT Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
AMG 162
DAIICHISANKYO Co.,Ltd.
2013 Phase 3 JPRN-JapicCTI-132277 -
2010 Phase 2 JPRN-JapicCTI-101263 -
AMG 357
Amgen
2015 Phase 1 NCT02499315 United States;
AMG 570
Amgen
2017 Phase 1 NCT03156023 Germany;United States;
AMG 592
Amgen
2018 Phase 1/Phase 2 NCT03410056 Bulgaria;Germany;Poland;Spain;United States;
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-001944-36-ES Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2017-001944-36-PL Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMG 714
Amgen
2002 Phase 2 NCT00433875 -
AMG 719
Amgen
2002 Phase 2 NCT00038298 United States;
AMG 827
Amgen
2010 Phase 2 NCT01059448 Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom;United States;
2009 Phase 2 NCT00950989 Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States;
2008 Phase 1/Phase 2 NCT00771030 Canada;Mexico;United States;
Amgen Inc
2010 Phase 2 EUCTR2009-012566-32-HU Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-PL Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-LV Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-GB Australia;Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-CZ Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-BG Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-012566-32-CZ Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-012566-32-BG Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-PL Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-LV Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-GB Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
AMG592
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-001944-36-ES Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-001944-36-BG Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2017-001944-36-PL Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMP-110
MedImmune LLC
2014 Phase 1 NCT02277574 United States;
2013 Phase 1 NCT01878123 United States;
AMT-101
Applied Molecular Transport Inc.
2020 Phase 2 EUCTR2020-003955-14-DE Germany;
AP1189
SynAct Pharma ApS
2020 Phase 2 EUCTR2019-001185-15-NO Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2020 Phase 2 EUCTR2019-001185-15-BG Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2019 Phase 2 EUCTR2019-001185-15-SE Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2019 Phase 2 EUCTR2019-001185-15-DK Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
SynAct Pharma Aps
2019 Phase 2 NCT04004429 Denmark;Norway;
APLA12
VA Office of Research and Development
2009 Phase 1 NCT01123655 United States;
ARA290
LUMC
2011 - EUCTR2010-023469-22-NL Netherlands;
ARAVA
sanofi-aventis Groupe
2008 - EUCTR2007-000886-40-IT Italy;Portugal;
ARAVA®
sanofi-aventis groupe
2007 Phase 3 EUCTR2007-000886-40-CZ Czech Republic;Italy;Portugal;
2007 - EUCTR2007-000886-40-PT Italy;Portugal;
ARRY-371797, p38 inhibitor
Array Biopharma, now a wholly owned subsidiary of Pfizer
2008 Phase 1 NCT00729209 United States;
ARRY-438162
Array BioPharma Inc.
2008 - EUCTR2007-007859-14-PL Hungary;Poland;
2008 - EUCTR2007-007859-14-HU Hungary;Poland;
ARRY-438162, MEK inhibitor
Array Biopharma, now a wholly owned subsidiary of Pfizer
2008 Phase 2 NCT00650767 Argentina;Brazil;Hungary;Peru;Poland;Romania;United States;
ART621
Arana Therapeutics Ltd
2009 Phase 2 NCT00928317 Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland;United States;
2009 Phase 2 NCT00854685 Sri Lanka;
2009 - EUCTR2009-014824-40-CZ Czech Republic;
2009 - EUCTR2008-006930-92-CZ Czech Republic;
AS Domelock System
Zimmer Biomet
2017 - NCT03312465 Belgium;Germany;Switzerland;United Kingdom;
ASK8007
Astellas Pharma Inc
2007 Phase 1/Phase 2 NCT00411424 Belgium;France;Hungary;Ireland;Netherlands;Spain;United Kingdom;
ASP015K
Astellas Pharma Global Development
2013 Phase 2 EUCTR2011-006021-23-CZ Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 Phase 2 EUCTR2011-006021-23-BG Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 - EUCTR2011-006021-23-HU Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2012 - EUCTR2011-006021-23-BE Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
Astellas Pharma Global Development Inc. (APGD)
2013 Phase 2 EUCTR2011-006021-23-PL Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide
Astellas Pharma Global Development, Inc. (APGD)
2013 - EUCTR2011-006020-20-PL Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006020-20-BG Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-PL Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-HU Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-BG Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 Phase 2 EUCTR2011-006018-15-BE Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006020-20-HU Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006020-20-CZ Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006018-15-CZ Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
ASP1707
Astellas Pharma Global Development, Inc.
2016 Phase 1 NCT02867306 Moldova, Republic of;
Astellas Pharma Inc
2016 Phase 2 NCT02884635 Japan;
ASP2408
Astellas Pharma Global Development, Inc.
2012 Phase 1 NCT02052375 United States;
ASP2409
Astellas Pharma Global Development, Inc.
2012 Phase 1 NCT02171143 United States;
ASP5094
Astellas Pharma Global Development, Inc.
2016 Phase 1 NCT02698657 Poland;United States;
Astellas Pharma Inc
2017 Phase 2 NCT03257852 Japan;
ATI-450
Aclaris Therapeutics, Inc.
2020 Phase 2 NCT04247815 United States;
ATN-103
Ablynx
2010 Phase 2 NCT01063803 Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland;United States;
2009 Phase 1/Phase 2 NCT00959036 Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland;United States;
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
2010 - EUCTR2009-015636-15-HU Belgium;Canada;Germany;Hungary;Japan;Russian Federation;South Africa;Switzerland;United States;
2010 - EUCTR2008-007185-33-DE Belgium;Germany;Hungary;Netherlands;United Kingdom;
2010 - EUCTR2008-007185-33-BE Belgium;Germany;Hungary;Netherlands;United Kingdom;
Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company
2009 - EUCTR2008-007185-33-GB Belgium;Germany;Hungary;Netherlands;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2010 - EUCTR2008-007185-33-NL Belgium;Germany;Hungary;Netherlands;United Kingdom;
2009 - EUCTR2008-007185-33-HU Belgium;Germany;Hungary;Netherlands;United Kingdom;
ATN-103 10 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 10 mg q8wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 30 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 80 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 80 mg q8wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
AVE9897
Millennium Pharmaceuticals Inc
2006 Phase 2 EUCTR2005-006165-14-GB Czech Republic;Netherlands;United Kingdom;
2006 - EUCTR2005-006165-14-NL Czech Republic;Netherlands;United Kingdom;
2006 - EUCTR2005-006165-14-CZ Czech Republic;Netherlands;United Kingdom;
AZD5672
ASTRAZENECA
2008 - EUCTR2007-007539-14-IT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AstraZeneca
2009 Phase 1 NCT00887770 United Kingdom;
2009 Phase 1 NCT00871767 United Kingdom;
2008 Phase 2 NCT00713544 Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
2008 Phase 1 NCT00711074 United Kingdom;
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AZD9056
AstraZeneca
2009 Phase 1 NCT00920608 -
2008 Phase 1 NCT00700986 United Kingdom;
2007 Phase 2 NCT00520572 Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AZD9056 hydrochloride
AstraZeneca AB
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
AZD9567
AstraZeneca
2018 Phase 2 NCT03368235 Denmark;Netherlands;Sweden;
2016 Phase 1 NCT02760316 Germany;United Kingdom;
AZD9567 Monohydrat
AstraZeneca
2015 Phase 1 NCT02512575 Germany;
AZD9567 monohydrate
AstraZeneca AB
2017 Phase 2 EUCTR2017-000838-64-SE Denmark;Netherlands;Sweden;
2017 Phase 2 EUCTR2017-000838-64-NL Denmark;Netherlands;Sweden;
2017 Phase 2 EUCTR2017-000838-64-DK Denmark;Netherlands;Sweden;
Abatacept
AbbVie
2017 Phase 3 NCT03086343 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Academisch Medisch Centrum Amsterdam
2010 - EUCTR2010-021435-14-NL Netherlands;
Arthritis & Rheumatic Disease Specialties Research
2011 Phase 3 NCT01351480 United States;
Astellas Pharma Inc
2011 - NCT01339481 United States;
Astellas Pharma Korea, Inc.
2019 Phase 4 NCT03737708 Korea, Republic of;
BRISTOL-M.SQUIBB
2005 - EUCTR2004-005102-68-IT Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 3 EUCTR2020-000350-96-IT Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Brigham and Women's Hospital
2020 - NCT04529902 United States;
2020 - NCT04529876 United States;
2020 - NCT04529863 United States;
Bristol Myers Squibb International Corporation
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-IT Denmark;Finland;France;Germany;Italy;Sweden;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2006 - EUCTR2005-000784-26-IT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
- - EUCTR2005-000443-28-Outside-EU/EEA Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
Bristol-Myers Squibb
2021 Phase 3 NCT04909801 Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2018 Phase 1 NCT03714022 United States;
2017 - NCT03457792 Germany;
2017 - NCT03188081 Italy;
2016 - NCT02037737 -
2015 Phase 4 NCT02557100 Algeria;Canada;Mexico;United States;
2015 Phase 3 NCT02504268 Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;United States;
2015 - NCT02598466 -
2014 - NCT02169544 -
2013 Phase 4 NCT01758198 Japan;
2013 Phase 3 NCT01844895 -
2013 Phase 1 NCT01890473 Argentina;Mexico;Peru;South Africa;United States;
2012 - NCT02090556 Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom;
2010 Phase 3 NCT01142726 Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Norway;Poland;Russian Federation;South Africa;Sweden;United States;
2010 Phase 1 NCT01221636 United States;
2009 Phase 3 NCT00929864 Argentina;Canada;Chile;Peru;United States;
2008 Phase 3 NCT00767325 Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 - NCT02109666 Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland;
2007 Phase 3 NCT00989235 -
2007 Phase 3 NCT00547521 Australia;Brazil;Canada;Mexico;Peru;South Africa;United States;
2007 Phase 3 NCT00533897 Argentina;Brazil;Canada;Mexico;South Africa;United States;
2007 Phase 3 NCT00420199 Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 NCT00409838 Korea, Republic of;
2006 Phase 3 NCT00484289 Japan;
2006 Phase 2 NCT00345748 Japan;
2006 Phase 1/Phase 2 NCT00254293 United States;
2005 Phase 3 NCT00124982 Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
2005 Phase 3 NCT00122382 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;United States;
2005 Phase 2 NCT00124449 Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom;United States;
2003 Phase 3 NCT00095173 Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
2003 Phase 1 NCT00162201 United Kingdom;
2002 Phase 3 NCT00048581 United States;
2002 Phase 3 NCT00048568 United States;
2000 Phase 2 NCT00162279 United States;
2000 Phase 1/Phase 2 NCT00279760 Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 - EUCTR2007-004241-15-IT Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-AT Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
Bristol-Myers Squibb K.K.
2013 Phase 4 JPRN-JapicCTI-132121 -
Cambridge University Hospitals NHS Foundation Trust
2018 Phase 2 NCT03084419 United Kingdom;
Columbia University
2019 Phase 4 NCT03619876 United States;
Dr. Larry W. Moreland
2015 Phase 4 NCT02353780 United States;
Hokkaido University Hospital
2013 - JPRN-UMIN000010286 Japan;
Jeffrey Curtis
2021 Phase 4 NCT05080218 United States;
Jiangsu Simcere Pharmaceutical Co., Ltd.
2016 Phase 1 NCT02805010 -
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Leiden University Medical Center
2018 Phase 4 NCT03492658 Netherlands;
Maldonado A Michael
2021 Phase 3 JPRN-jRCT2071210068 Australia;France;Germany;Japan;Taiwan;USA;
NHS Greater Glasgow and Clyde
2016 Phase 4 NCT02652273 United Kingdom;
2015 Phase 4 EUCTR2014-004419-35-GB United Kingdom;
NYU Langone Health
2019 Phase 4 NCT03652961 United States;
National Health Organization Nagoya Medical Center
2010 - JPRN-UMIN000011789 Japan;
Novartis Pharmaceuticals
2011 Phase 3 NCT01350804 Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Osaka Medical College
2014 - JPRN-UMIN000013440 Japan;
Shinshu University
2018 Phase 2 NCT03784261 Japan;
St George's, University of London
2020 Phase 4 EUCTR2019-004468-23-GB United Kingdom;
St.Marianna University School of Medicine
2014 - JPRN-UMIN000015175 Japan;
The Cleveland Clinic
2013 Phase 2 NCT02027298 United States;
The First Hospital, Jilin University
2016 Phase 1 study ChiCTR-IIR-16008693 China;
University Hospital, Montpellier
2016 - NCT02547493 France;Monaco;
University of California, Los Angeles
2014 - NCT02053727 United States;
2011 Phase 3 NCT01299961 United States;
University of Leeds
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Occupational and Environmental Health, Japan
2010 - JPRN-UMIN000008756 Japan;
University of Washington
2019 Phase 4 NCT03882008 United States;
Vastra Gotaland Region
2017 - NCT03440892 Sweden;
Yokohama City University Graduate School of Medicine
2014 - JPRN-UMIN000015217 Japan;
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Bristol-Myers Squibb
2005 Phase 3 NCT00095147 Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
Abatacept (BMS-188667)
Bristol-Myers Squibb
2011 Phase 1 NCT01439204 United States;
2000 Phase 2 NCT00162266 Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom;United States;
Abatacept (IV)
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept (SC)
Bristol Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept + Methotrexate
Bristol-Myers Squibb K.K.
2015 Phase 3 JPRN-JapicCTI-153081 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept + csDMARD
New York University School of Medicine
2019 Phase 4 NCT03700021 United States;
Abatacept Injection
Fundacion Clinic per a la Recerca Biomédica
2019 Phase 4 NCT03669367 -
St George's, University of London
2020 Phase 4 NCT04255134 United Kingdom;
University of Erlangen-Nürnberg Medical School
2019 Phase 2 NCT04120831 Germany;
Abatacept Placebo
Bristol-Myers Squibb K.K.
2015 Phase 3 JPRN-JapicCTI-153081 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept Prefilled Syringe
Lille Catholic University
2018 Phase 4 NCT03227419 France;
Abatacept combination product (ACP)
Bristol-Myers Squibb
2009 Phase 3 NCT01173120 -
Abatacept, rituximab or tocilizumab
University Hospital, Strasbourg, France
2009 Phase 4 NCT01000441 France;Monaco;
Acalabrutinib
Acerta Pharma BV
2015 Phase 2 NCT02387762 United States;
Aceclofenac
Chung Shan Medical University
2007 Phase 4 NCT04144101 -
Acellbia
Biocad
2015 Phase 3 NCT02744196 -
Acetaminophen
Hoffmann-La Roche
2011 Phase 4 NCT01382940 United States;
Kojima Toshihisa
2016 - JPRN-jRCTs041180071 Japan;
Merck Sharp & Dohme Corp.
2011 Phase 1 NCT01390441 Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
Nekoyama Miyao Hospital
2016 - JPRN-UMIN000018931 Japan;
Osaka City University Medical School, Department of Orthopedic Surgery
2014 - JPRN-UMIN000012364 Japan;
Yamaguchi University
2018 - JPRN-UMIN000031692 Japan;
Acetaminophen tablets
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
2014 Phase 2 NCT02029599 China;
Acide folique
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
Actemra
F. Hoffmann- La Roche Ltd
2009 - EUCTR2008-000587-17-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Limited
2007 - EUCTR2007-001114-17-GB United Kingdom;
F. Hoffmann-La Roche Ltd
2010 Phase 3 EUCTR2008-006924-68-AT Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-000587-17-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-000587-17-DE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-SE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-PT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-GB Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-FI Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-DK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-CZ Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-AT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
ROCHE
2009 - EUCTR2008-000587-17-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Actemra(EU-licensed)
Bio-Thera Solutions
2018 Phase 3 NCT03830203 China;
Acthar
Veena Ranganath, MD, MS
2017 Phase 4 NCT02541955 United States;
Acthar Gel
Mallinckrodt
2016 Phase 4 NCT02919761 Argentina;Colombia;Mexico;Peru;Puerto Rico;United States;
Acthar Injectable Product
Attune Health Research, Inc.
2018 Phase 3 NCT03511625 United States;
Active Stimulation
Galvani Bioelectronics
2021 - NCT05003310 United States;
Active comparator
Asahi Kasei Pharma Corporation
2011 Phase 2 NCT01285752 Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
2009 Phase 2 NCT00902369 Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
Acupuncture
Chinese Academy of Sciences
2012 - NCT01619176 China;
Acycloguanosine
Università Popolare Homo & Natura
2015 Phase 1 NCT02633332 Italy;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Adalimuab, Etanercept, Tocilizumab, or Abatacept
Hanyang University
2020 - NCT04449224 Korea, Republic of;
Adalimumab
Department of Rheumatology and Clinical Immunology
AbbVie
2019 Phase 2 NCT03823391 Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
2016 - NCT02750800 Hungary;
2016 - NCT02668640 China;
2015 Phase 4 NCT02198651 Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 NCT02629159 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02141997 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
2013 - NCT01768858 Austria;
2007 Phase 1 NCT00650156 China;
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01561313 Belgium;Czech Republic;
2012 Phase 2 NCT01502423 Australia;Canada;Germany;
2012 - NCT01736189 Japan;
2010 Phase 4 NCT01185288 Puerto Rico;United States;
2010 Phase 4 NCT01162421 Canada;
2010 Phase 3 NCT01185301 Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain;United States;
2009 Phase 4 NCT00808509 Sweden;
2000 Phase 3 NCT00195663 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
Abbott
2008 Phase 3 NCT00690573 Japan;
2007 Phase 3 NCT01231321 Russian Federation;
2007 Phase 3 NCT00647270 Australia;Canada;Germany;Puerto Rico;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00538902 China;
2006 Phase 4 NCT00420927 Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2006 Phase 3 NCT00603993 Japan;
2004 Phase 4 NCT00234897 United States;
2004 Phase 3 NCT00235872 Japan;
2004 Phase 2/Phase 3 NCT00647491 Japan;
2004 - NCT00650390 -
2003 Phase 4 NCT00649922 -
2003 Phase 3 NCT00647920 Taiwan;
2003 Phase 3 NCT00235859 -
2003 Phase 3 NCT00234936 -
2003 Phase 3 NCT00234845 United States;
2003 Phase 2 NCT00235833 Japan;
2003 - NCT00649545 -
2003 - NCT00234884 Australia;Austria;Belgium;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;United Kingdom;
2002 Phase 3 NCT00448383 -
2002 Phase 3 NCT00049751 United States;
2002 - NCT00650026 -
2000 Phase 3 NCT00195702 Canada;United States;
2000 Phase 3 NCT00195650 Canada;United States;
Abbott GmbH & Co. KG
2008 - EUCTR2007-005905-23-GB Germany;United Kingdom;
2008 - EUCTR2007-005905-23-DE Germany;United Kingdom;
2008 - EUCTR2006-004139-31-NO Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-004139-31-GR Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-SK Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-HU Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-FR Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-SE Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-NL Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-GB Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-ES Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-DE Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-CZ Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-BE Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-AT Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2009 Phase 3 JPRN-JapicCTI-090751 -
2008 Phase 3 JPRN-JapicCTI-080587 -
Abbott Scandinavia AB
2008 - EUCTR2008-004398-16-SE Sweden;
Amgen
2013 Phase 3 NCT01970475 Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Astellas Pharma Korea, Inc.
2019 Phase 4 NCT03737708 Korea, Republic of;
AstraZeneca
2011 Phase 2 NCT02092961 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
2011 Phase 2 NCT01264770 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Biogen
2006 Phase 2 NCT00298272 United States;
Biologic Mate Study Group
2014 - JPRN-UMIN000015616 Japan;
Bristol-Myers Squibb
2021 Phase 3 NCT04909801 Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
2015 Phase 4 NCT02557100 Algeria;Canada;Mexico;United States;
2009 Phase 3 NCT00929864 Argentina;Canada;Chile;Peru;United States;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
CSL Behring
2011 Phase 2 NCT01373151 Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
Charité-Universitätsmedizin Berlin
Cinnagen
2015 Phase 3 NCT03172325 Iran, Islamic Republic of;
Columbia University
2019 Phase 4 NCT03619876 United States;
Department of Rheumatosurgery, Osaka City University Medical School
2009 Phase 4 JPRN-UMIN000002340 Japan;
Dept. of Rhematology UMAS
2005 - EUCTR2005-000129-47-SE Sweden;
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
2011 - JPRN-UMIN000013750 Japan;
EMD Serono
2007 Phase 2 NCT00595413 Germany;United States;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-132125 -
Eli Lilly and Company
2012 Phase 3 NCT01710358 Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2011 - EUCTR2010-023587-40-IT Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Fen Li
2016 Phase 4 NCT02878161 -
Genentech, Inc.
2016 Phase 2 NCT02833350 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2010 Phase 2 NCT01225393 Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
Georgetown University
2013 Phase 4 NCT01793519 United States;
Gilead Sciences
2016 Phase 3 NCT02889796 Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Glostrup University Hospital, Copenhagen
2009 - NCT01029613 Denmark;
Goupe d'Etudes et de Recherche Clinique En Rhumatologie
2004 Phase 4 NCT00291915 France;
Hamed Rezaei
2012 Phase 4 NCT01609205 Sweden;
Heinrich-Heine University, Duesseldorf
2014 Phase 3 NCT02150473 Germany;
Hoffmann-La Roche
2011 Phase 4 NCT01283971 Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
2011 - NCT01592292 Korea, Republic of;
2010 Phase 4 NCT01119859 Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Norway;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Hvidovre University Hospital
2005 Phase 4 NCT00216177 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Janssen Research & Development, LLC
2014 Phase 3 NCT02019472 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
Jonathan Graf
2013 Phase 4 NCT01893996 United States;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Karolinska Institutet
2010 - NCT01197144 Sweden;
Keio University
2018 Phase 4 NCT03505008 Japan;Korea, Republic of;Taiwan;
2011 Phase 4 NCT01270035 Japan;
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Leeds University
2014 - JPRN-UMIN000016928 Japan,Europe;
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Maldonado A Michael
2021 Phase 3 JPRN-jRCT2071210068 Australia;France;Germany;Japan;Taiwan;USA;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
Merck Serono International
2008 Phase 2 EUCTR2007-002536-29-FR Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 Phase 2 EUCTR2007-002536-29-ES Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-PT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-GR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-DE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-CZ Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BG Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BE Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 Phase 2 EUCTR2007-002536-29-FI Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-SE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-AT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
- - EUCTR2007-002536-29-PL Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck Sharp & Dohme Corp.
2008 - NCT00724672 -
Mianyang Hospital of Traditional Chinese Medicine
2021 Phase 4 ChiCTR2100044045 China;
NHS Greater Glasgow and Clyde
2022 - NCT05090124 -
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2009 Phase 4 NCT00837434 United States;
2008 Phase 4 NCT00796705 United States;
Novo Nordisk A/S
2014 Phase 2 NCT02097264 Ireland;Portugal;Spain;United Kingdom;
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
Osaka City University Medical School
2012 - JPRN-UMIN000010315 Japan;
2010 - JPRN-UMIN000003880 Japan;
Osaka Medical College
2015 - JPRN-UMIN000016950 Japan;
Ottawa Hospital Research Institute
2022 Phase 4 NCT05153200 -
PFIZER
2008 - EUCTR2007-002066-35-IT Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Pfizer
2020 Phase 3 NCT04230213 Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2015 Phase 3 NCT02480153 Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 4 NCT02092467 Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2007-002066-35-SK Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-GR Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-BG Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-HU Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-DE Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-CZ Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2009 - EUCTR2008-008338-35-DE Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Reade Rheumatology Research Institute
2020 Phase 4 NCT04251741 Netherlands;
2020 Phase 4 NCT04222920 Netherlands;
2020 Phase 4 NCT04194827 Netherlands;
Rennes University Hospital
2017 - NCT03110094 France;
Sanofi
2015 Phase 3 NCT02332590 Chile;Czech Republic;Czechia;France;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 Phase 3 NCT01764997 Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Skåne University Hospital
2005 Phase 4 NCT01270087 Sweden;
Takeda
2015 Phase 2 NCT02393378 Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
The Rheumatological Center of Helsinki
2011 Phase 4 NCT01405326 Finland;
University Hospital, Bordeaux
2021 Phase 3 NCT04870203 France;Monaco;
University Hospital, Rouen
2006 Phase 4 NCT00234234 France;
University Hospital, Tours
2011 Phase 4 NCT01382160 France;
2006 - NCT00497614 France;
University of Aarhus
2007 Phase 3 NCT00660647 Denmark;
University of Leeds
2013 Phase 4 NCT02056184 United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Université de Sherbrooke
2013 Phase 4 NCT02035800 Canada;
2008 - NCT00814866 Canada;
Yazawa Rie
2017 Phase 1 JPRN-jRCT2071200057 Japan;
Yonemura Takuma
2015 Phase 1 JPRN-jRCT2071200058 Japan;
Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042440 China;
Adalimumab (ADA)
UCB Pharma SA
2011 Phase 4 NCT01500278 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Adalimumab (HUMIRA®)
Abbott
2006 - NCT01078571 Spain;
Adalimumab (Humira)
Hvidovre University Hospital
2004 Phase 4 NCT00696059 Denmark;
R-Pharm
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (Humira®)
R-Pharm
2017 Phase 3 EUCTR2015-005307-83-LV Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-LT Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-HU Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-DE Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International LLC
2016 Phase 3 EUCTR2015-005307-83-CZ Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-BG Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (up to 9 months exposure)
Abbott
2005 Phase 4 NCT00233558 United States;
Adalimumab - GP2017
Sandoz
2016 Phase 3 NCT02744755 Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab - US licensed Humira
Sandoz
2016 Phase 3 NCT02744755 Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab 40 mg subcutaneous (SC) every other week (EOW)
Abbott
2000 Phase 3 NCT00233571 -
Adalimumab 40mg q2w
R-Pharm
2016 Phase 3 NCT02760407 Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab Injection
St George's, University of London
2020 Phase 4 NCT04255134 United Kingdom;
Adalimumab PFS and Pen
Samsung Bioepis Co., Ltd.
2015 Phase 2 NCT02565810 Poland;
Adalimumab delivered in Physiolis autoinjector
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in Physiolis syringe
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in current autoinjector
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in current syringe
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab with methotrexate
Pfizer
2014 Phase 4 NCT02187055 Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Adalimumab, current formulation
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01712178 Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, new formulation
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01712178 Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, plus prednisone
IRCCS Policlinico S. Matteo
2007 Phase 4 NCT00480272 Italy;
Adalimumab-Pfizer
Pfizer Inc
2020 Phase 4 EUCTR2019-000284-24-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2019 Phase 3 EUCTR2019-000284-24-LT Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Adalimummab
Hvidovre Hospital
2009 Phase 4 EUCTR2009-014394-41-DK Denmark;
Adefovir
Department of general internal medicine, Kyushu-University hospital
2012 - JPRN-UMIN000018017 Japan;
Administration of Cimzia®
University Hospital, Ghent
2012 Phase 3 NCT01590966 Belgium;
Agrippal S1 (Influenza vaccination)
Tel-Aviv Sourasky Medical Center
2009 Phase 4 NCT01002716 Israel;
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)
The Newcastle upon Tyne Hospitals NHS Foundation Trust
2012 Phase 4 EUCTR2010-021146-22-GB United Kingdom;
Alendronat Teva
Aarhus University Hospital
2015 Phase 2 EUCTR2015-003638-28-DK Denmark;
Alendronate
Chinese University of Hong Kong
2012 Phase 4 NCT01770106 Hong Kong;
People's Hospital, Peking University
2009 - ChiCTR-TRC-09000473 China;
University of Aarhus
2015 Phase 2 NCT02944799 Denmark;
Alendronate versus alfacalcidol (1-alpha OH vitamin D)
UMC Utrecht
2000 Phase 3 NCT00138983 Netherlands;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05003934 Antigua and Barbuda;
Allogeneic Mesenchymal Precursor Cells
Mesoblast, Ltd.
2013 Phase 2 NCT01851070 Australia;United States;
Allopurinol
University of Dundee
2005 Phase 4 EUCTR2005-000551-15-GB United Kingdom;
Amoxapine & dipyridamole
CombinatoRx, Inc
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
Amoxicilina
Dra Beatriz Lozano-Hospital Universitario de Canarias
2018 Phase 4 EUCTR2017-003259-40-ES Spain;
Anakinra
Amgen
2001 Phase 2 NCT00037700 United States;
2000 Phase 2 NCT00037648 United States;
Prof. Roberto Giacomelli
2013 Phase 4 NCT02236481 Italy;
Swedish Orphan Biovitrum
2012 - NCT02915094 Germany;
University of Athens
2011 - NCT01566201 Greece;
Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital
2008 Phase 3 study ChiCTR-TRC-09000383 China;
Anakinra (Kineret®)
Amgen
2004 Phase 3 NCT00117091 -
Anakinra (r-metHuIL-1ra)
Amgen
2005 Phase 4 NCT00111410 -
Anakinra and PEG sTNF-R1
Amgen
2001 Phase 2 NCT00537667 -
Andecaliximab
Gilead Sciences
2016 Phase 2 NCT02862574 Australia;Hungary;Taiwan;United States;
Angiotensin receptor blockers
Sherief Abd-Elsalam
2018 Phase 3 NCT03770702 Egypt;
Anifrolumab
Josef Smolen, Univ. Prof. Dr.
2018 Phase 2 NCT03435601 Austria;
Anifrolumab (MEDI-546)
Medical University of Vienna
2017 Phase 2 EUCTR2017-001717-92-AT Austria;Italy;Switzerland;
Anit human granulocyt-macrophage colony-stimulating factor (GM-CSF)monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti IL 6 mAb
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti IL-1beta antibody, subclass IgG4
Eli Lilly and Company Limited
2007 - EUCTR2005-002660-29-HU Hungary;Spain;
Anti IL-1ß antibody, subclass IgG4
Eli Lilly and Company Limited
2007 - EUCTR2005-002660-29-HU Hungary;Spain;
Anti LP40 antibody, subclass IgG4 LA294
Eli Lilly and Company
2009 Phase 2 EUCTR2008-004875-23-FR Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-PL Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-HU Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-DE Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-BE Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-AT Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-001105-42-PL Austria;Belgium;France;Germany;Poland;
2008 Phase 2 EUCTR2008-001105-42-FR Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-DE Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-BE Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-AT Austria;Belgium;France;Germany;Poland;
Eli Lilly and Company limited
2009 Phase 2 EUCTR2008-004894-16-HU Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-PL Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-DE Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-CZ Czech Republic;Germany;Hungary;Poland;
Anti TNF + Meth
Hamad Medical Corporation
2012 Phase 3 NCT01724268 Qatar;
Anti human granulocyte-macrophage colo
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2019 Phase 3 EUCTR2019-000868-18-IT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2021 Phase 3 EUCTR2019-000878-30-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000868-18-DE Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000867-26-DE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-LT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-HU Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-ES Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-CZ Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-PL Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-HU Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-GB Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-ES Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-EE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-BG Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LV Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-HU Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-GB Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-ES Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-CZ Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-000878-30-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody
GlaxoSmithKline Research & Development Limited
2018 Phase 2 EUCTR2015-004386-91-PL Germany;Poland;United States;
2016 Phase 2 EUCTR2015-004386-91-DE Germany;Poland;United States;
2015 Phase 2 EUCTR2014-003453-34-PL Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-HU Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-GB Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-ES Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-EE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-DE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-CZ Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-C5aR
Novo Nordisk A/S
2012 - EUCTR2009-011791-30-HU Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 Phase 2 EUCTR2009-011791-30-GB Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 - EUCTR2009-011791-30-DK Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 - EUCTR2009-011791-30-CZ Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
Anti-CD20 small modular immunopharmaceutical, WYE-400087
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
2010 - EUCTR2009-010516-15-PL Greece;Hungary;Poland;Spain;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2010 Phase 2 EUCTR2009-010516-15-GR Greece;Hungary;Poland;Spain;
2010 Phase 2 EUCTR2009-010516-15-ES Greece;Hungary;Poland;Spain;
2009 - EUCTR2009-010516-15-HU Greece;Hungary;Poland;Spain;
Anti-GM-CSF receptor alpha
MedImmune Ltd
2010 - EUCTR2009-014735-20-PL Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-LT Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-HU Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
2010 - EUCTR2009-014735-20-CZ Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-BG Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
2009 - EUCTR2009-014735-20-LV Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2009 - EUCTR2009-014735-20-EE Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
Anti-IL-20
Novo Nordisk A/S
2010 Phase 1 NCT01038674 Belgium;Poland;
2008 Phase 1 NCT00818064 Netherlands;
Anti-IL-20 (109-0012)
NOVO NORDISK
2011 - EUCTR2010-021283-14-IT Hungary;Italy;Portugal;Spain;United Kingdom;
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-021283-14-PT Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-HU Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-GB Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-ES Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-021283-14-CZ Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
Anti-IL-6 mAb
Bristol-Myers Squibb International Corporation
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-HU Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-DE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-BE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal Antibody
Bristol-Myers Squibb International Corporation
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-TNF
Hospital Universitari Vall d'Hebron Research Institute
2016 - NCT02804204 Spain;
Anti-TNF Biologics Therapy
Queen Mary University of London
2015 - NCT02620189 United Kingdom;
Anti-TNF humanized antibody Fab fragment - PEG conjugate
UCB Pharma S.A.
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
Anti-TNF humanized antibody Fab' fragment - PEG conjugate
UCB Pharma S.A.
2009 - EUCTR2007-005288-86-FR France;
Anti-TNF suspended perioperatively
CHU de Quebec-Universite Laval
2015 Phase 4 NCT02242474 Canada;
Anti-TNF therapy
Barts & The London NHS Trust
2010 - NCT02528292 United Kingdom;
Anti-TNF therapy (etanercept or adalimumab)
Imperial College London
2010 - NCT01060098 United Kingdom;
Anti-TNF-alpha
Hoffmann-La Roche
2016 Phase 2 NCT03001219 Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Anti-TNFa continued perioperatively
CHU de Quebec-Universite Laval
2015 Phase 4 NCT02242474 Canada;
Anti-Tumor Necrosing Factor (TNF) Therapy
Bristol-Myers Squibb
2005 Phase 3 NCT00124982 Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
Anti-Tumor Necrosis Factor Alpha Drug (Product)
R.Bos
2021 Phase 4 NCT04985435 Netherlands;
Anti-inflammatory drugs
Genentech, Inc.
2007 Phase 3 NCT00443651 United States;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Anticorpo monoclonale anti GM-CSF umano
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2015 Phase 2 EUCTR2014-003453-34-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R.
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-020065-24-ES Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
Antihistamine
Hoffmann-La Roche
2011 Phase 4 NCT01382940 United States;
Antihuman granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Apratastat
WYETH LEDERLE
2005 - EUCTR2004-000012-13-IT Czech Republic;Estonia;Italy;
Apremilast
Amgen
2010 Phase 2 NCT01285310 Czech Republic;Czechia;Poland;Spain;United States;
Baylor Research Institute
2010 Phase 2 NCT01250548 United States;
Celgene Corporation
2011 - EUCTR2010-019926-15-CZ Czech Republic;United States;
Arava
Karolinska Institutet
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
University Hospitals Leuven
2009 Phase 4 EUCTR2008-007225-39-BE Belgium;
University of Leeds
2006 Phase 4 EUCTR2005-004582-41-GB United Kingdom;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
Sandoz
2002 Phase 1 NCT00946686 -
Arava 20 mg filmdrasjerte tabletter
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
Arm B: Rituxan®/Mabthera®
Dr. Reddy's Laboratories Limited
2020 Phase 3 NCT04268771 United States;
Arthroscopic synovectomy of the wrist
Maasstad Hospital
2021 - NCT04755127 Netherlands;
Arthroscopic synovial tissue biopsy
Nathan Wei, MD, FACP, FACR:
2011 Phase 3 NCT01374971 United States;
Arthroscopy & saline irrigation alone
Newcastle University
2012 Phase 1 NCT01352858 United Kingdom;
Artilog
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Ascal(r) / carbasalate calcium
Leiden University Medical Center
2006 - EUCTR2006-001359-36-NL Netherlands;
Asendis
CombinatoRx, Inc
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
Aspirin 81mg tablet
Inova Health Care Services
2018 Phase 4 NCT03699293 United States;
Aspirin Tablets
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Atacicept
EMD Serono
2006 Phase 2 NCT00430495 Canada;United States;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck KGaA
2008 Phase 2 NCT00664521 Finland;France;Netherlands;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-DE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
2008 - EUCTR2006-004140-23-GB Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 2 EUCTR2006-004140-23-SK Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-PT Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-CZ Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-BE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-FI Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-SE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany
2006 - EUCTR2006-004140-23-NL Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono International
2008 Phase 2 EUCTR2007-003647-75-FR Finland;France;Netherlands;Sweden;United Kingdom;
2008 Phase 2 EUCTR2007-002536-29-FR Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 Phase 2 EUCTR2007-002536-29-ES Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-003647-75-SE Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-003647-75-NL Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-003647-75-FI Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-002536-29-PT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-GR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-DE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-CZ Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BG Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BE Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 Phase 2 EUCTR2007-002536-29-FI Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-SE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-AT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
- - EUCTR2007-002536-29-PL Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck Serono International S.A.
2007 - EUCTR2006-004140-23-GR Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono SA - Geneva
2008 Phase 2 EUCTR2007-003647-75-GB Finland;France;Netherlands;Sweden;United Kingdom;
Serono International S.A.
2007 Phase 2 EUCTR2006-004140-23-ES Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-BG Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Atacicept: with loading dose
EMD Serono
2007 Phase 2 NCT00595413 Germany;United States;
Atorvastatin
Gilead Sciences
2020 Phase 1 NCT04608344 United States;
Hospital Central Dr. Ignacio Morones Prieto
2018 Phase 2 NCT04056039 Mexico;
Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital
2017 - ChiCTR-INR-17011772 China;
Pfizer
2010 Phase 2 NCT01059864 Korea, Republic of;United States;
University of California, Los Angeles
2003 Phase 4 NCT00356473 -
Atorvastatin tablet
Chengdu PLA General Hospital
2014 - NCT02219191 China;
Auto-Injector Device (AID)
Sanofi
2014 Phase 3 NCT02057250 Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
Autoinjector
Momenta Pharmaceuticals, Inc.
2016 Phase 3 NCT02722044 United States;
Samsung Bioepis Co., Ltd.
2017 Phase 2 NCT03193957 Poland;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous adipose derived stem cells
Celltex Therapeutics Corporation
2021 Phase 1/Phase 2 NCT04170426 -
Autologous apoptotic cells injection
Centre Hospitalier Universitaire de Besancon
2021 Phase 1/Phase 2 NCT02903212 -
Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
UMC Utrecht
2021 Phase 1/Phase 2 NCT05251870 Netherlands;
Autologous mesenchymal stem cells
Mashhad University of Medical Sciences
2016 Phase 1 NCT03333681 -
Autologous stromal vascular fraction cells
Translational Biosciences
2013 Phase 1/Phase 2 NCT01885819 Panama;
Avelox- Moxifloxacin
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
Avelox®
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
Azathioprin
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Azathioprine
Hoffmann-La Roche
2013 Phase 3 NCT01941095 Greece;
Sanofi
2018 Phase 4 NCT03449758 France;
The Karolinska Institutet, ClinTRID
2014 Phase 4 EUCTR2014-002374-36-SE Sweden;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
B03BB01
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
BAT1806
Bio-Thera Solutions
2018 Phase 3 NCT03830203 China;
Bio-Thera Solutions, Ltd.
2019 Phase 3 EUCTR2018-002202-31-BG Bulgaria;China;Georgia;Poland;Ukraine;
BAT1806 injection
Bio-Thera Solutions
2018 Phase 1 NCT03606876 China;
BCD-055
Biocad
2016 Phase 3 NCT02762838 Belarus;India;Russian Federation;
BCD-089
Biocad
2019 Phase 3 NCT04227366 Russian Federation;
BCD-089, 162 mg, s/c, q2w
Biocad
2018 Phase 2 NCT03455842 Belarus;Russian Federation;
BCD-089, 162 mg, s/c, qw
Biocad
2018 Phase 2 NCT03455842 Belarus;Russian Federation;
BDMARD
CHU Saint-Etienne
2020 Phase 4 EUCTR2019-003700-12-FR France;
BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
Medical University of Graz
2012 Phase 4 NCT01602302 Austria;
BETAMETHASONE ACIBUTATE
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
BG00012
Biogen Idec
2008 Phase 2 NCT00810836 Australia;Canada;Czech Republic;India;Poland;Slovakia;
Biogen Idec Limited
2009 Phase 2 EUCTR2008-004754-33-SK Czech Republic;Poland;Slovakia;
2009 - EUCTR2008-004754-33-PL Czech Republic;Poland;
2009 - EUCTR2008-004754-33-CZ Czech Republic;Poland;
BG9924
Biogen Idec
2007 Phase 2 NCT00523328 Belgium;Canada;United Kingdom;United States;
2007 Phase 2 NCT00458861 United States;
2005 Phase 2 NCT00292422 Poland;United States;
Biogen Idec Ltd
2007 Phase 2 EUCTR2006-005467-26-GB Belgium;United Kingdom;
2007 Phase 2 EUCTR2006-005466-39-GB Hungary;United Kingdom;
2007 - EUCTR2007-000734-38-GB United Kingdom;
2007 - EUCTR2007-000734-38-BE Belgium;United Kingdom;
2007 - EUCTR2007-000733-19-HU Hungary;United Kingdom;
2007 - EUCTR2007-000733-19-GB Hungary;United Kingdom;
2007 - EUCTR2006-005467-26-BE Belgium;United Kingdom;
2007 - EUCTR2006-005466-39-HU Hungary;United Kingdom;
BGX-0214
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
BI 655064
Boehringer Ingelheim B.V
2013 - EUCTR2012-004090-16-NL Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
Boehringer Ingelheim España, S.A.
2013 - EUCTR2012-004090-16-ES Australia;Czech Republic;Germany;Netherlands;New Zealand;Spain;
Boehringer Ingelheim Pharma GmbH & Co. KG
2013 - EUCTR2012-004090-16-DE Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2013 Phase 1;Phase 2 EUCTR2012-004090-16-CZ Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
BI 655064 high dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 low dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 medium dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 695500
Boehringer Ingelheim
2013 Phase 3 NCT01955733 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Germany;Greece;Hungary;Ireland;Mexico;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2012 Phase 3 NCT01682512 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Boehringer Ingelheim International GmbH
2013 Phase 1;Phase 3 EUCTR2011-002894-48-NO Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 Phase 1;Phase 3 EUCTR2011-002894-48-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002894-48-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002894-48-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002894-48-PT Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-GR Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-GB Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-EE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002894-48-NL Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002894-48-HU Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
BI 695501
Boehringer Ingelheim
2016 Phase 3 NCT02640612 Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2015 Phase 3 NCT02137226 Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
Boehringer Ingelheim International GmbH
2016 Phase 3 EUCTR2015-002634-41-PL Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-HU Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-DE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-BG Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2015 Phase 3 EUCTR2015-002634-41-ES Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-HU Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Estonia;France;Germany;Hungary;Indonesia;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-EE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-DE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-BG Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
BI 695501 Autoinjector
Boehringer Ingelheim
2016 Phase 2 NCT02636907 Poland;Ukraine;United States;
BI 695501 Prefilled syringe
Boehringer Ingelheim
2016 Phase 2 NCT02636907 Poland;Ukraine;United States;
BIBR 796 BS
Boehringer Ingelheim
2001 Phase 2 NCT02209779 -
BIIB023
Biogen Idec
2008 Phase 1 NCT00771329 Russian Federation;Ukraine;United States;
BIIB057
Biogen Idec
2012 Phase 2 NCT01652937 Canada;
BIIL 284 BS high dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIIL 284 BS low dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIIL 284 BS medium dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIRB 796 BS, high dose
Boehringer Ingelheim
2003 Phase 2 NCT02214888 -
BIRB 796 BS, low dose
Boehringer Ingelheim
2003 Phase 2 NCT02214888 -
BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
Bristol-Myers Squibb
2016 Phase 1 NCT02762123 United States;
BMS-188667
Academisch Medisch Centrum Amsterdam
2010 - EUCTR2010-021435-14-NL Netherlands;
BRISTOL-M.SQUIBB
2005 - EUCTR2004-005102-68-IT Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-IT Belgium;Germany;Italy;Spain;United Kingdom;
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 3 EUCTR2020-000350-96-IT Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001275-50-IT Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-000784-26-IT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
- - EUCTR2005-000443-28-Outside-EU/EEA Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
Bristol-Myers Squibb Company
- Phase 2 EUCTR2015-005450-36-Outside-EU/EEA United States;
Bristol-Myers Squibb International Corporation
2022 Phase 3 EUCTR2020-000350-96-DE Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-PL Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-FR Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-ES Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-CZ Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001275-50-RO Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2016 Phase 3 EUCTR2015-001275-50-NL Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2016 Phase 3 EUCTR2015-001275-50-HU Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-SE Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-GB Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-FR Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-FI Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-ES Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-DE Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-CZ Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-AT Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-AT Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
BMS-582949
Bristol Myers Squibb International Corporation
2008 Phase 2 EUCTR2008-000170-20-FR Czech Republic;France;Spain;
2008 Phase 2 EUCTR2008-000170-20-ES Czech Republic;France;Spain;
2008 - EUCTR2008-000170-20-CZ Czech Republic;France;Spain;
Bristol-Myers Squibb
2008 Phase 2 NCT00605735 Argentina;Brazil;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;United States;
BMS-582949 and Methotrexate
Bristol-Myers Squibb
2005 Phase 1 NCT00162292 Mexico;United States;
BMS-817399
Bristol-Myers Squibb
2011 Phase 2 NCT01404585 Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002024-40-ES Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
BMS-945429
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb International Corporation
2014 - EUCTR2013-003780-65-IT Argentina;Australia;Canada;Czech Republic;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
2014 - EUCTR2013-003780-65-HU Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-HU Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-DE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-BE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
CSL Behring
2011 Phase 2 NCT01373151 Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS-986104
Bristol-Myers Squibb
2014 Phase 1 NCT02211469 United States;
BMS-986142
Bristol-Myers Squibb
2016 Phase 2 NCT02638948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 1 NCT02762123 United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2015-002887-17-FR Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb K.K.
2016 Phase 2 JPRN-JapicCTI-163317 Japan, Asia except Japan, North America, South America, Europe, Oceania;
BMS-986195
Bristol-Myers Squibb
2017 Phase 1 NCT03262740 United States;
2017 Phase 1 NCT03245515 Netherlands;
2017 Phase 1 NCT03131973 United States;
2016 Phase 1 NCT02705989 Australia;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986251
Bristol-Myers Squibb
2017 Phase 1/Phase 2 NCT03329885 Netherlands;
BMS188667
Bristol Myers Squibb International Corporation
2010 - EUCTR2010-018674-20-IT Denmark;Finland;France;Germany;Italy;Sweden;
BMS986142
Bristol-Myers Squibb International Corporation
2016 Phase 2 EUCTR2015-002887-17-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNP
Itabashi Chuo Medical Center
2012 - JPRN-UMIN000013885 Japan;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
BOW015
Epirus Biopharmaceuticals (Switzerland) GmbH
2016 Phase 3 NCT02683564 -
BR9001
Boryung Pharmaceutical Co., Ltd
2018 Phase 1 NCT03718611 Korea, Republic of;
BR900A
Boryung Pharmaceutical Co., Ltd
2018 Phase 1 NCT03718611 Korea, Republic of;
BRL-049653
GlaxoSmithKline Research & Development Ltd.
2005 - EUCTR2004-000482-35-LT Lithuania;United Kingdom;
2004 Phase 2 EUCTR2004-000482-35-GB Lithuania;United Kingdom;
BT061
Biotest
2010 Phase 2 NCT01481493 Czech Republic;Germany;Hungary;Italy;Latvia;Poland;Spain;
Biotest AG
2013 Phase 2 EUCTR2013-000114-38-CZ Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-SK Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-LT Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-HU Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-EE Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-DE Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-BG Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2012 - EUCTR2010-018485-24-LV Czech Republic;Germany;Hungary;Latvia;Spain;
2012 - EUCTR2010-018485-24-HU Czech Republic;Germany;Hungary;Latvia;Spain;
2011 - EUCTR2010-018485-24-ES Czech Republic;Germany;Hungary;Latvia;Spain;
2011 - EUCTR2010-018485-24-DE Czech Republic;Germany;Hungary;Latvia;Spain;
2010 - EUCTR2010-018485-24-CZ Czech Republic;Germany;Hungary;Latvia;Spain;
BT061 (CD4 monoclonal antibody)
Biotest AG
2008 - EUCTR2008-001241-26-HU Bulgaria;Hungary;
2008 - EUCTR2008-001241-26-BG Bulgaria;Hungary;
BT971
Biotest AG
2008 - EUCTR2008-001241-26-HU Bulgaria;Hungary;
2008 - EUCTR2008-001241-26-BG Bulgaria;Hungary;
BTK Inhibitor
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2015-002887-17-FR Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BTT-1023
Biotie Therapies Corp.
2009 Phase 1 NCT00851240 Bulgaria;
BUMEKIZUMAB
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Background Treatment
Galvani Bioelectronics
2021 - NCT05003310 United States;
Baminercept alfa
Biogen Idec
2007 Phase 2 NCT00664716 Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baminercept alfa (BG9924)
Biogen Idec
2007 Phase 2 NCT00664573 Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baricitinib
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo college of Medicine
2020 - JPRN-UMIN000040094 Japan;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-142405 -
- Phase 3 JPRN-JapicCTI-132156 -
- Phase 3 JPRN-JapicCTI-132138 -
- Phase 3 JPRN-JapicCTI-132134 -
- Phase 3 JPRN-JapicCTI-132125 -
Eli Lilly and Company
2020 Phase 4 NCT04086745 United States;
2019 Phase 4 NCT03915964 Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 NCT02265705 Argentina;Brazil;China;
2014 Phase 3 EUCTR2012-003686-17-SI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2012-003686-17-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 NCT01885078 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 NCT01721044 Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002339-27-GB Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 Phase 3 EUCTR2012-002324-32-GB Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002324-32-BE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-GB Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-DK Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-BE Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-SI Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-GB Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-DE Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002339-27-SK Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-PT Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-HU Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-DE Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-CZ Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-BE Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002324-32-SE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-PT Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-GR Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-DE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-AT Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002323-15-PL Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-NL Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-HR Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-GR Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-AT Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002322-73-SK Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-PT Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-NL Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-LV Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-LT Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-HU Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-GR Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-CZ Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-BE Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 NCT01721057 Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 NCT01711359 Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2012 Phase 3 NCT01710358 Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2011 Phase 2 NCT01469013 Japan;
Galvani Bioelectronics
2021 - NCT05003310 United States;
Lilly S.A.
2013 - EUCTR2012-003686-17-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002339-27-ES Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002323-15-ES Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002322-73-ES Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
Transparency in Healthcare
2019 Phase 4 EUCTR2019-000505-72-NL Netherlands;
University of Erlangen-Nürnberg Medical School
2018 Phase 3 NCT03701789 Germany;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Baricitinib Oral Tablet [Olumiant]
Assistance Publique - Hôpitaux de Paris
2022 Phase 4 NCT05238896 France;
Baricitinib treatment
University Hospital, Bordeaux
2021 Phase 3 NCT04870203 France;Monaco;
Baricitinib, olumiant®
Shinshu University
2018 Phase 2 NCT03755466 Japan;
Belatacept
Bristol-Myers Squibb
2000 Phase 1/Phase 2 NCT00279760 Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Belimumab
Human Genome Sciences Inc.
2005 Phase 2 NCT00583557 Poland;United States;
2003 Phase 2 NCT00071812 United States;
Human Genome Sciences Inc., a GSK Company
2009 Phase 4 NCT00931086 United States;
Benepali
Biogen
2017 - NCT03327454 Germany;
2017 - NCT03100734 Germany;
Department of Clinical Biochemestry, Aarhus University Hospital
2015 Phase 4 EUCTR2015-004173-32-DK Denmark;
University of Leeds
2019 Phase 4 NCT03813771 United Kingdom;
2018 Phase 4 EUCTR2016-002344-16-GB United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Bi 695500
Boehringer Ingelheim International GmbH
2014 Phase 3 EUCTR2013-002622-23-PT Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-002622-23-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-NL Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-HU Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-GR Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Bicain spinal
Helsinki University Central Hospital
2016 Phase 4 EUCTR2016-002035-15-FI Finland;
Bimekizumab
UCB Biopharma Sprl
2016 Phase 2 EUCTR2016-000393-37-BG Bulgaria;Georgia;Hungary;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;United Kingdom;
UCB Celltech
2015 Phase 2 NCT02430909 Czech Republic;Czechia;Hungary;Moldova, Republic of;Poland;Russian Federation;Slovakia;United Kingdom;
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 Phase 2 EUCTR2014-003307-30-GB Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Binyrebarkhormon
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Binyrebsrkhormon
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
Biodmards
Pfizer
2012 - NCT01438892 United States;
Biologic Agents
Simon Krabbe
2006 - NCT03496831 -
Biologic DMARD
Seoul National University Hospital
2013 - NCT01965132 Korea, Republic of;
Biologic TNFi
Pfizer
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Biologic/targeted therapy
Tuen Mun Hospital
2022 - NCT05182203 China;
Biological Drug
Sohag University
2022 - NCT05267431 Egypt;
Biological agents
Astellas Pharma Inc
2012 - NCT01870908 Japan;
Biological disease-modifying antirheumatic drugs (bDMARDs)
Universidade Nova de Lisboa
2020 - NCT04973787 Portugal;
Biologics
Shinshu University
2018 Phase 2 NCT03755466 Japan;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Biosimilar Infliximab
Hikma Pharmaceuticals LLC
2017 - NCT03348046 Jordan;
Janssen Scientific Affairs, LLC
2016 - NCT02728934 United States;
Biosimilar infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Biosimilar product to adalimumab
Amgen Inc
2014 Phase 3 EUCTR2013-000525-31-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-000525-31-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Blood
Centre Hospitalier Universitaire, Amiens
2013 - NCT02894047 France;
Blood Collection for PK Testing (15 Mins Before Injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (15 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (18-20 hours post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (180 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (60 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (after injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood sample
Centre Hospitalier Universitaire de Saint Etienne
2020 Phase 4 NCT04470453 France;
2018 Phase 4 NCT03445871 France;
University Hospital, Bordeaux
2018 - NCT03550833 France;
Blood samples
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT01954381 France;
Blood sampling
University Hospital, Toulouse
2021 - NCT05039216 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood tests
Assistance Publique - Hôpitaux de Paris
2020 - NCT04584541 France;
Boostrix®
Eli Lilly and Company
2011 - EUCTR2010-022205-17-PL Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
2011 - EUCTR2010-022205-17-BG Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
Bortezomib
Charite University, Berlin, Germany
2014 Phase 2 NCT02102594 Germany;
Bovine intesastinal alkaline phosphatase (bIAP)
Alloksys Life Sciences B.V.
2011 - EUCTR2008-007346-63-GB United Kingdom;
Branebrutinib
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
Bredinin tablet
Chong Kun Dang Pharmaceutical
2013 Phase 2 NCT02005757 Korea, Republic of;
Bucillamine
BASIC study group
2007 - JPRN-UMIN000000837 Japan;
Higashi-Hiroshima Memorial Hospital
2009 Phase 4 JPRN-UMIN000002169 Japan;
Japan Association of Rheumatologists in Private Practice
2010 - JPRN-UMIN000003807 Japan;
KONAMON Study Group
2013 - JPRN-UMIN000007404 Japan;
National hospital organization Chiba east national hospital Clinical Research Center
2013 - JPRN-UMIN000012690 Japan;
Saitama Medical University
2007 Phase 4 NCT00716248 Japan;
Sanofi
2015 Phase 3 NCT02373202 Japan;
St Luke'
Tokyo Medical and Dental University
2012 - JPRN-UMIN000006702 Japan;
s International Hospital
Bupivacaine hydrochloride (Marcaine, Pfizer)
Sohag University
2020 Phase 4 NCT04361513 Egypt;
Buprenorphine Transdermal Patch
Mundipharma Pharmaceuticals Sdn. Bhd.
2013 Phase 4 NCT02519387 Malaysia;
Buprenorphine transdermal patch
Mundipharma Pte Ltd.
2013 Phase 4 NCT01961271 Hong Kong;Korea, Republic of;Philippines;
C-Stem™ AMT Femoral Component (standard and high off-set variants)
DePuy International
2006 Phase 4 NCT00872573 United Kingdom;
C. albicans
Genentech, Inc.
2006 Phase 2 NCT00282308 United States;
C10AA05
Reade
2015 Phase 4 EUCTR2013-005524-42-NL Netherlands;
CAM-3001
MedImmune Limited
2013 Phase 2 EUCTR2011-005649-10-GB Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
MedImmune Ltd
2013 Phase 2 EUCTR2011-005648-93-SK Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2013 Phase 2 EUCTR2011-005648-93-GB Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2013 - EUCTR2011-005649-10-SK Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-PT Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-HU Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-DE Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-CZ Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005648-93-PT Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-GR Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-ES Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-DE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-BG Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005649-10-GR Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-005649-10-ES Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-005648-93-HU Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005648-93-EE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005648-93-CZ Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005634-19-PL Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-HU Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-ES Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-EE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-DE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-CZ Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-BG Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2010 - EUCTR2009-014735-20-PL Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-LT Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-HU Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
2010 - EUCTR2009-014735-20-CZ Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-BG Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
2009 - EUCTR2009-014735-20-LV Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2009 - EUCTR2009-014735-20-EE Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2008 Phase 1 NCT00771420 Germany;
CAPTURE
Dept. of orthopedic surgery, Osaka Medical College
2014 - JPRN-UMIN000012650 Japan;
GlaxoSmithKline
2017 - NCT03285191 United Kingdom;
CC-10004
Celgene Corporation
2011 - EUCTR2010-019926-15-CZ Czech Republic;United States;
CC-292
Celgene
2013 Phase 2 NCT01975610 United States;
CCI-779
Wyeth is now a wholly owned subsidiary of Pfizer
2003 Phase 2 NCT00076206 United States;
CCR1 Antagonist
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002024-40-ES Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
CCX 354-C
ChemoCentryx
2009 Phase 1/Phase 2 NCT01027728 Belgium;Romania;
CCX-354-C
ChemoCentryx
2010 Phase 2 NCT01242917 Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
CCX354-C
ChemoCentryx
2010 Phase 2 NCT01242917 Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
ChemoCentryx, Inc.
2010 Phase 2 EUCTR2010-019964-36-BE Belgium;Czech Republic;Germany;Hungary;
2010 - EUCTR2010-019964-36-HU Belgium;Czech Republic;Hungary;
2010 - EUCTR2010-019964-36-DE Belgium;Czech Republic;Germany;Hungary;
2010 - EUCTR2010-019964-36-CZ Belgium;Czech Republic;Germany;Hungary;
CDMARD
Eli Lilly and Company
2013 Phase 3 NCT01721044 Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
2012 Phase 3 NCT01721057 Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
CDP 6038 SC
UCB Pharma
2009 Phase 1/Phase 2 NCT01009242 Germany;United States;
CDP6038
R-Pharm
2016 Phase 3 EUCTR2014-004719-36-BG Belarus;Bulgaria;Russian Federation;Turkey;
UCB BIOSCIENCES, Inc.
2011 Phase 2 NCT01296711 Belgium;United Kingdom;United States;
UCB Biosciences Inc
2011 - EUCTR2010-022224-77-GB Belgium;United Kingdom;United States;
UCB Biosciences, Inc
2011 - EUCTR2010-020839-39-GB United Kingdom;United States;
UCB Biosciences, Inc.
2011 Phase 2 EUCTR2010-022224-77-BE Belgium;United Kingdom;United States;
UCB Biosciences, Inc. A Member of the UCB Group of Companies
2011 Phase 2 EUCTR2010-020839-39-BE Belgium;United Kingdom;United States;
UCB Celltech
2009 - EUCTR2009-010813-57-DE Germany;
UCB Pharma
2010 Phase 2 NCT01242488 Belgium;United Kingdom;United States;
2009 Phase 1/Phase 2 NCT01009242 Germany;United States;
CDP870
Astellas Pharma Inc
2011 Phase 3 NCT02586246 Japan;
Celltech R&D Ltd
2005 Phase 3 EUCTR2004-002993-49-FI Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2004-002993-49-LV Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-HU Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-GB Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-002993-49-DE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-BE Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
Korea Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT00993317 Korea, Republic of;
Otsuka Pharmaceutical Co., Ltd.
2008 Phase 3 NCT00791921 Japan;
2008 Phase 2/Phase 3 NCT00791999 Japan;
UCB Celltech
2007 - EUCTR2004-002993-49-EE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2006 Phase 3 EUCTR2005-002629-30-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2006 - EUCTR2005-002629-30-LV Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002326-63-EE Czech Republic;Estonia;Latvia;Lithuania;
2005 Phase 3 EUCTR2005-002326-63-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2004-002993-49-SK Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2005-002326-63-LV Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2005-002326-63-LT Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-LT Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-CZ Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Inc
2006 - EUCTR2005-002629-30-LT Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-EE Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Pharma
2003 Phase 3 NCT00548834 -
2002 Phase 3 NCT00544154 -
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
2009 - EUCTR2007-005288-86-FR France;
2009 - EUCTR2007-000828-40-PL Austria;France;Germany;Italy;Poland;
2008 Phase 3 EUCTR2007-000828-40-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-AT Austria;France;Germany;Italy;Poland;
2005 - EUCTR2005-002326-63-CZ Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-SE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Pharma SA
2015 - EUCTR2011-002067-20-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2011-002067-20-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-PT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-IE Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-GB Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-BG Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-SE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-IE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-GB Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-AT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-NL Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-HU Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-ES Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-DE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-CZ Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-AT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-005427-28-FR France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-NL France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-IT France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-ES France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-DE France;Germany;Italy;Netherlands;Spain;
UCB S.A. (Casa Madre)
2008 - EUCTR2007-000830-38-IT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-IT Austria;France;Germany;Italy;Poland;
CDP870 Fab'-PEG
UCB Celltech
2005 Phase 3 EUCTR2005-001350-24-SK Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
UCB Inc.
2005 - EUCTR2005-001350-24-LV Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-LT Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-HU Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-FI Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-EE Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-CZ Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
CE 224,535
Pfizer
2009 Phase 1 NCT00838058 United States;
CE-224,535
PFIZER S.A.
2008 Phase 2 EUCTR2008-000327-25-ES Czech Republic;Poland;Spain;
Pfizer
2009 Phase 1 NCT00838058 United States;
2008 Phase 2/Phase 3 NCT00628095 Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain;United States;
2007 Phase 1 NCT00446784 United States;
Pfizer Inc. 235 East 42nd Street NY10017
2008 Phase 2 EUCTR2008-000327-25-PL Czech Republic;Poland;Spain;
2008 - EUCTR2008-000327-25-CZ Czech Republic;Poland;Spain;
CELBESTA®
Dong-A ST Co., Ltd.
2015 Phase 4 NCT02780323 Korea, Republic of;
CELEBREX
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX 200MG 20CPS
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX®
Dong-A ST Co., Ltd.
2015 Phase 4 NCT02780323 Korea, Republic of;
CERTOLUZIMAB PEGOL
UCB PHARMA
2011 - EUCTR2011-000385-35-IT Italy;
CF101
Can-Fite BioPharma
2017 Phase 3 NCT02647762 Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
2010 Phase 2 NCT01034306 Bulgaria;Israel;
2008 Phase 2 NCT00556894 Bulgaria;Czech Republic;Czechia;Former Serbia and Montenegro;Israel;Poland;Serbia;Ukraine;
2006 Phase 2 NCT00280917 Bulgaria;Former Serbia and Montenegro;Israel;Poland;Romania;Serbia;Ukraine;United States;
Can-Fite BioPharma Ltd.
2008 - EUCTR2007-006527-13-BG Bulgaria;
Can-Fite BioPharma, Ltd.
2019 Phase 3 EUCTR2016-003682-26-PL Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
CFZ533
Novartis Pharmaceuticals
2013 Phase 1 NCT02089087 Taiwan;United States;
CH-1504
Chelsea Therapeutics
2008 Phase 2 NCT00658047 Canada;
CH-4051
Chelsea Therapeutics
2010 Phase 2 NCT01116141 -
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-CZ Bulgaria;Czech Republic;
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
CHS-0214
COHERUS BIOSCIENCES, INC.
2015 Phase 3 EUCTR2015-000665-30-IT Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus BioSciences, Inc
2014 Phase 3 EUCTR2014-000443-33-PL Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-GB Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus Biosciences, Inc
2014 Phase 3 EUCTR2014-000443-33-IT Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-HU Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-ES Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-DE Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus Biosciences, Inc.
2015 Phase 3 NCT02486939 Japan;
2014 Phase 3 NCT02115750 Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
CIMZIA (Certolizumab Pegol)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
CKD-374 5mg Tab.
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03858725 Korea, Republic of;
CKD-506
Chong Kun Dang Pharmaceutical
2018 Phase 2 NCT04204603 Czechia;Georgia;Poland;Russian Federation;Ukraine;
Chong Kun Dang Pharmaceutical Corporation (CKD)
2018 Phase 2 EUCTR2018-001377-24-CZ Czech Republic;Georgia;Poland;Russian Federation;Ukraine;
CLS Brevius stem with Kinectiv technology
Zimmer Biomet
2011 - NCT03410940 Italy;Poland;Spain;
CMAB008
Shanghai Biomabs Pharmaceutical Co., Ltd.
2018 Phase 3 NCT03478111 China;
CNTO 136
Centocor, Inc.
2008 Phase 2 NCT00718718 Argentina;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Taiwan;Ukraine;United States;
Janssen-Cilag International N.V.
2014 Phase 3 EUCTR2013-001417-32-LT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-HU Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-ES Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-DE Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
CNTO 136 IgG
Centocor B.V.
2009 - EUCTR2007-006603-20-HU Hungary;
CNTO 148
CENTOCOR
2010 - EUCTR2009-010582-23-IT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Janssen Pharmaceutical K.K.
2008 Phase 3 NCT00771251 Japan;
2008 Phase 3 NCT00727987 Japan;
CNTO 1959 + MTX (Group 4)
Janssen Research & Development, LLC
2012 Phase 2 NCT01645280 Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 + MTX (Group 5)
Janssen Research & Development, LLC
2012 Phase 2 NCT01645280 Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 IgG
Janssen-Cilag International NV
2013 - EUCTR2011-001122-18-BG Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 Phase 2 EUCTR2011-001122-18-CZ Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 - EUCTR2011-001122-18-HU Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO 6785
Janssen Research & Development, LLC
2013 Phase 2 NCT01909427 Argentina;Colombia;Czech Republic;Philippines;Poland;Russian Federation;Thailand;
CNTO1275
Janssen-Cilag International NV
2013 - EUCTR2011-001122-18-BG Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 Phase 2 EUCTR2011-001122-18-CZ Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 - EUCTR2011-001122-18-HU Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO136
Centocor B.V.
2009 - EUCTR2007-006603-20-HU Hungary;
JANSSEN-CILAG INTERNATIONAL N.V.
2012 - EUCTR2010-022243-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
Janssen-Cilag International N.V.
2015 Phase 3 EUCTR2012-001176-10-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-LT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-HU Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-ES Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-DE Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2012-001176-10-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2010-022242-24-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2013 - EUCTR2010-022243-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022243-38-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022242-24-LT Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2012 - EUCTR2010-022243-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
CNTO148
CENTOCOR
2006 Phase 3 EUCTR2004-003295-10-IT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor B.V.
2010 - EUCTR2008-006064-11-HU Hungary;Lithuania;
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2009 - EUCTR2008-006064-11-LT Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
CNTO6785
Janssen-Cilag International NV
2013 - EUCTR2012-003629-40-CZ Argentina;China;Colombia;Czech Republic;India;Philippines;Poland;Russian Federation;Thailand;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 vaccine
Paul R Fortin
2022 Phase 2/Phase 3 NCT05236491 -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
CP 690,550
PFIZER
2005 - EUCTR2004-002846-36-IT Germany;Italy;Spain;
PFIZER INC
2017 Phase 3 EUCTR2016-001825-15-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
Pfizer
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Pfizer Inc.
2017 Phase 3;Phase 4 EUCTR2016-001825-15-SK Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-CZ Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, New York
2017 Phase 3;Phase 4 EUCTR2016-001825-15-PL Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-HU Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-GB Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-ES Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-DE Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-BG Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-BE Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
CP 690550 MR
Pfizer Inc.
2020 Phase 2 EUCTR2019-002676-14-SE Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-HU Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-CZ Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-BG Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
CP-195,543
Pfizer
2006 Phase 2 NCT00424294 United States;
CP-690, 550 - 10
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2016 Phase 3;Phase 4 EUCTR2014-000358-13-DE Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2015 Phase 3;Phase 4 EUCTR2014-000358-13-HR Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2015 Phase 3;Phase 4 EUCTR2014-000358-13-ES Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-RO Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-LV Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-LT Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-GB Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-EE Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-CZ Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-BG Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
CP-690,55-10
Arthritis Alapítvány
2016 - EUCTR2015-002523-26-HU Hungary;
CP-690,550
PFIZER
2010 Phase 3 EUCTR2009-016987-34-ES Belgium;Bulgaria;Czech Republic;Germany;Hungary;Poland;Slovakia;Spain;Sweden;
2008 - EUCTR2007-002066-35-IT Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2007 Phase 2 EUCTR2006-005035-19-IT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-001984-31-IT Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Pfizer
2016 Phase 4 NCT02831855 Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2012 Phase 1 NCT01484561 Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
2011 Phase 2 NCT01359150 Poland;United States;
2010 Phase 3 NCT01039688 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 Phase 2 NCT01059864 Korea, Republic of;United States;
2009 Phase 3 NCT00960440 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2009 Phase 3 NCT00856544 Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;United States;Venezuela;
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
2009 Phase 3 NCT00847613 Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;United States;Venezuela;
2009 Phase 3 NCT00814307 Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
2009 Phase 2 NCT00687193 Japan;
2008 Phase 3 NCT00661661 Japan;
2008 Phase 2 NCT00603512 Japan;
2007 Phase 3 NCT00413699 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;United States Minor Outlying Islands;
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
2007 Phase 2 NCT00413660 Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey;United States;
2007 - NCT00414661 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;Ukraine;United States;
2005 Phase 2 NCT00147498 Austria;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2010 Phase 2;Phase 3 EUCTR2006-005035-19-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-007023-26-GR Bulgaria;Czech Republic;Greece;Poland;
2009 - EUCTR2008-008337-11-GB Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-007023-26-PL Bulgaria;Czech Republic;Poland;
2009 - EUCTR2008-007023-26-BG Bulgaria;Czech Republic;Poland;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
2009 - EUCTR2008-008337-11-DE Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
Pfizer Inc.
2011 - EUCTR2010-020890-18-CZ Czech Republic;Hungary;
2009 Phase 3 EUCTR2008-008337-11-SK Denmark;Finland;Germany;Greece;Poland;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008338-35-CZ Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-008337-11-SE Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-GR Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-FI Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-DK Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-007788-17-CZ Bulgaria;Czech Republic;Germany;
2009 - EUCTR2008-007023-26-CZ Bulgaria;Czech Republic;Poland;
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2011 - EUCTR2010-020890-18-HU Czech Republic;Hungary;
2010 - EUCTR2009-014296-40-IT Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 - EUCTR2008-008337-11-PL Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2009 Phase 2;Phase 3 EUCTR2006-006373-25-GB Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2006-006373-25-FI Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-006373-25-GR Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-006373-25-BG Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-006373-25-CZ Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 3 EUCTR2009-014296-40-FR Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-016987-34-SE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-PL Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
2010 - EUCTR2009-016987-34-HU Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
2010 - EUCTR2009-014296-40-IE Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-014296-40-GB Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-014296-40-BE Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Spain;Sweden;Taiwan;Tanzania, United Republic of;United Kingdom;United States;
2010 - EUCTR2009-014296-40-AT Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-008338-35-SK Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-008338-35-DK Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 - EUCTR2009-014296-40-DE Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-GB Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-FI Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-DE Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-BG Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007788-17-DE Bulgaria;Czech Republic;Germany;
2009 - EUCTR2008-007788-17-BG Bulgaria;Czech Republic;Germany;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
2010 Phase 3 EUCTR2009-016987-34-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 Phase 3 EUCTR2009-016987-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK
2007 Phase 2 EUCTR2006-006373-25-SK Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-SE Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-AT Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
Pfizer S.A.
2009 Phase 3 EUCTR2009-014296-40-ES Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
Pfizer, S.A
2009 Phase 3 EUCTR2008-008338-35-ES Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
Pfizer, S.A.
2009 - EUCTR2008-008337-11-ES Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-ES Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
CP-690,550 (tasocitinib)
Pfizer
2011 Phase 1 NCT01262118 Hungary;United States;
CP-690,550 (tofacitinib)
Pfizer
2005 Phase 1 NCT01745055 United States;
CP-690,550 + methotrexate
Pfizer
2009 Phase 2 NCT00976599 United States;
CP-690,550 – 10
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2014 - EUCTR2014-000706-34-GB Germany;Hungary;United Kingdom;United States;
CP-690,550-10
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2007-002066-35-SK Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2010 Phase 2;Phase 3 EUCTR2006-005035-19-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2 EUCTR2007-002066-35-GR Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-BG Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-HU Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-DE Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-CZ Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Pfizer Inc.
2017 Phase 2 EUCTR2016-002337-30-SK Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-CZ Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc., 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2017 Phase 2 EUCTR2016-002337-30-HU Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-HR Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-ES Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-DE Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-BG Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-PL Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
CP-690-550
Pfizer
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
CP690,550
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
CR 1
Pfizer
2008 Phase 1 NCT00782600 United States;
CR 2
Pfizer
2008 Phase 1 NCT00782600 United States;
CR 3
Pfizer
2008 Phase 1 NCT00782600 United States;
CR0686
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086
Rottapharm Biotech
2017 Phase 2 NCT03163966 Czechia;
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-PL Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-DK Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-CZ Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-BG Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086Z
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-PL Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-DK Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-CZ Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-BG Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CRx-102
CombinatoRx, Inc
2006 - EUCTR2004-001930-18-EE Estonia;
CombinatoRx, Incorporated
2008 - EUCTR2007-004399-38-LT Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-GB Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-EE Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-LT Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-HU Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-GB Estonia;Hungary;Lithuania;United Kingdom;
2007 - EUCTR2007-003069-42-EE Estonia;Hungary;Lithuania;United Kingdom;
Zalicus
2004 Phase 2 NCT00747214 -
CRx-102 (2.7/180)
Zalicus
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-102 (2.7/360)
Zalicus
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-139
CombinatoRx, Inc.
2006 Phase 2 EUCTR2004-004995-35-GB Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
2006 - EUCTR2004-004995-35-DK Czech Republic;Denmark;Germany;Italy;United Kingdom;
2005 - EUCTR2004-004995-35-CZ Czech Republic;Denmark;Germany;Italy;United Kingdom;
2005 - EUCTR2004-004995-35-AT Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
CRx-150
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
CT- P10
CELLTRION, Inc.
2014 Phase 3 EUCTR2013-004555-21-SK Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-PT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-LV Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-HU Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-GR Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-DE Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-AT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
CT-P10
Celltrion
2014 Phase 3 NCT02149121 Austria;Korea, Republic of;
CT-P13
CELLTRION, INC.
2012 - EUCTR2011-004468-31-IT Austria;Bosnia and Herzegovina;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Spain;Ukraine;United Kingdom;
CELLTRION, Inc
2012 Phase 3 EUCTR2011-004468-31-GB Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 Phase 3 EUCTR2011-004468-31-ES Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-PL Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-LV Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-LT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-AT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2011 - EUCTR2011-004468-31-SK Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2010 Phase 3 EUCTR2010-018646-31-SK Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018646-31-ES Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-PT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-LV Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-LT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Indonesia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
2010 - EUCTR2010-018646-31-IT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-GB Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-BG Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-AT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Celltrion
2018 Phase 3 NCT03707535 China;
2016 Phase 3 NCT03147248 Korea, Republic of;
Celltrion, Inc
2017 Phase 1;Phase 3 EUCTR2016-002125-11-ES Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-LV Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-HU Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-EE Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Hungary;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-BG Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
Pfizer
2015 - NCT02605642 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CT-P17
CELLTRION, Inc.
2019 Phase 3 EUCTR2019-000660-25-PL Poland;
Celltrion, Inc
2019 Phase 3 EUCTR2018-001690-25-LT Bulgaria;Hungary;Lithuania;Peru;Poland;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-PL Bosnia and Herzegovina;Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Russian Federation;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-HU Bosnia and Herzegovina;Bulgaria;Hungary;Lithuania;Peru;Poland;Russian Federation;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-BG Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Ukraine;
CT-P17 SC
Celltrion
2018 Phase 3 NCT03789292 Bulgaria;
CT-P17 SC AI (adalimumab)
Celltrion
2019 Phase 3 NCT04171414 Poland;
CTLA4Ig
BRISTOL-M.SQUIBB
2005 - EUCTR2004-002620-18-IT Belgium;Germany;Italy;Spain;United Kingdom;
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
CZP
Astellas Pharma Inc
2011 Phase 3 NCT01451203 Japan;
Caffeine
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Janssen Research & Development, LLC
2012 Phase 1 NCT01636557 Germany;Korea, Republic of;Moldova, Republic of;South Africa;
R-Pharm International, LLC
2021 Phase 1 NCT04246762 Bulgaria;Moldova, Republic of;
Calcitriol
Atlanta VA Medical Center
2007 - NCT00427804 United States;
Guangdong Provincial Hospital of Chinese Medicine
2016 - ChiCTR-IPR-16009029 China;
The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042329 China;
Calcium
Centre Hospitalier Universitaire de Nimes
2016 - NCT02636829 France;
University of Aarhus
2015 Phase 2 NCT02944799 Denmark;
Calcium and cholecalciferol
University of Missouri-Columbia
1995 Phase 3 NCT00570934 United States;
Calcium carbonate
Children's Hospital Medical Center, Cincinnati
1996 Phase 2 NCT00000429 United States;
Calcium citrate
Brigham and Women's Hospital
2011 Phase 4 NCT01400516 United States;
Canakinumab
NOVARTIS FARMA
2007 - EUCTR2007-001665-15-IT Germany;Italy;Netherlands;Spain;
Novartis
2006 Phase 2 NCT00424346 Austria;Belgium;Canada;Finland;Germany;Spain;United States;
Novartis Farmacéutica S.A.
2009 Phase 2 EUCTR2008-005320-81-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2009 - EUCTR2008-005320-81-DE Austria;Germany;Spain;
2009 - EUCTR2008-005320-81-BE Austria;Belgium;Germany;Spain;
2008 - EUCTR2008-005320-81-AT Austria;Germany;Spain;
Canakinumab (investigational)
Novartis
2007 Phase 2 NCT00487825 Belgium;Germany;Italy;Netherlands;Spain;United States;
Canakinumab (proposed)
Novartis Farmaceutica S.A.
2007 - EUCTR2007-001665-15-ES Belgium;Germany;Italy;Netherlands;Spain;
Novartis Farmacéutica S.A
2007 - EUCTR2006-004669-32-ES Spain;
Novartis Farmacéutica, S.A.
2007 - EUCTR2007-000491-16-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2007 - EUCTR2007-001665-15-NL Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-DE Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-BE Belgium;Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-DE Austria;Germany;Spain;
2007 - EUCTR2007-000491-16-BE Austria;Belgium;Germany;Spain;
2007 - EUCTR2007-000491-16-AT Austria;Germany;Spain;
2007 - EUCTR2006-004666-14-DE Germany;
2007 - EUCTR2006-004666-14-BE Belgium;Germany;
Canakinumab Injection
Jeffrey Curtis
2021 Phase 4 NCT05080218 United States;
Cannabidiol by capsules twice daily
University of California, Los Angeles
2021 Phase 1/Phase 2 NCT04911127 United States;
Cannabidiol tablet
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Cannabis
University Hospital, Clermont-Ferrand
2020 - NCT04402554 France;
Carbon Modular Radial Head
Ascension Orthopedics, Inc.
2009 - NCT00825409 United States;
Carbon Modular Radial Head replacement
Integra LifeSciences Corporation
2009 - NCT02405234 United States;
Celebra
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebra (celecoxib)
University of Dundee
2007 Phase 4 EUCTR2007-000012-90-DK Denmark;Netherlands;United Kingdom;
Celebrex
Daewon Pharmaceutical Co., Ltd.
2010 Phase 3 NCT01781702 -
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
2019 Phase 4 EUCTR2018-004539-54-DE Germany;
GlaxoSmithKline Research & Development Limited
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
University of Dundee
2011 - EUCTR2007-000012-90-NL Denmark;Netherlands;United Kingdom;
2008 Phase 4 EUCTR2007-000012-90-GB Denmark;Netherlands;United Kingdom;
Celebrex 200 mg Hartkapseln
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebrex 200 mg capsule, hard
GlaxoSmithKline Research & Development Limited
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Celecoxib
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Guangdong Provincial Hospital of Chinese Medicine
2016 - ChiCTR-IPR-16009029 China;
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
2014 Phase 4 JPRN-UMIN000014624 Japan;
National Institute of Mental Health (NIMH)
2019 Phase 1/Phase 2 NCT03912428 United States;
Pfizer
2006 Phase 2 NCT00424294 United States;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006 Phase 4 NCT00346216 Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
2005 Phase 4 NCT00141102 Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
University of Dundee
2007 Phase 4 NCT00447759 Denmark;Netherlands;United Kingdom;
Celecoxib 200mg capsule
Inova Health Care Services
2018 Phase 4 NCT03699293 United States;
Ceramic on Ceramic articulation
Zimmer Biomet
2013 - NCT02036931 France;Germany;Ireland;Netherlands;Spain;United States;
Ceramic on Polyethylene articulation
Zimmer Biomet
2013 - NCT02036931 France;Germany;Ireland;Netherlands;Spain;United States;
Certolizumab
Brigham and Women's Hospital
2016 - NCT02714881 United States;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Rochester
2010 - NCT01098201 United States;
Certolizumab Pegol (CZP)
Nathan Wei, MD, FACP, FACR:
2011 Phase 3 NCT01374971 United States;
UCB Pharma
2010 Phase 4 NCT01255761 United States;
2010 Phase 3 NCT01235598 Denmark;Netherlands;Poland;Sweden;
UCB Pharma SA
2011 Phase 4 NCT01500278 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Certolizumab Pegol + Methotrexate (MTX)
UCB Pharma
2012 Phase 3 NCT01521923 Argentina;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab Pegol 200 MG/ML [Cimzia]
RenJi Hospital
2020 - NCT04569890 China;
Certolizumab pegol
Astellas Pharma Inc
2009 Phase 3 NCT00851318 Japan;
2009 Phase 3 NCT00850343 Japan;
Celltech R&D Ltd
2005 - EUCTR2004-002993-49-LV Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-HU Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-GB Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-002993-49-DE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-BE Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
Oklahoma Medical Research Foundation
2010 Phase 3 NCT01213017 United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
UCB Biopharma SRL
2021 Phase 1 NCT04740814 United States;
UCB Celltech
2007 - EUCTR2004-002993-49-EE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2006 Phase 3 EUCTR2005-002629-30-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2006 - EUCTR2005-002629-30-LV Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002326-63-EE Czech Republic;Estonia;Latvia;Lithuania;
2005 Phase 3 EUCTR2005-002326-63-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2005-001350-24-SK Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2004-002993-49-SK Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2005-002326-63-LV Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2005-002326-63-LT Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-LT Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-CZ Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Inc
2006 - EUCTR2005-002629-30-LT Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-EE Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Inc.
2005 - EUCTR2005-001350-24-LV Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-LT Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-HU Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-FI Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-EE Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-CZ Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
UCB Italy s.p.a.
2011 Phase 4 NCT01443364 Italy;
UCB Pharma
2009 Phase 4 NCT00993668 United States;
2008 Phase 3 NCT00753454 Canada;United States;
2008 Phase 3 NCT00674362 Austria;France;Germany;Italy;Poland;
2007 Phase 4 NCT00580840 Austria;Canada;France;United States;
UCB Pharma S.A.
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
2009 - EUCTR2007-005288-86-FR France;
2009 - EUCTR2007-000828-40-PL Austria;France;Germany;Italy;Poland;
2008 Phase 3 EUCTR2007-000828-40-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-AT Austria;France;Germany;Italy;Poland;
2005 - EUCTR2005-002326-63-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Pharma SA
2009 Phase 3 EUCTR2008-005427-28-FR France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-NL France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-IT France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-ES France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-DE France;Germany;Italy;Netherlands;Spain;
UCB S.A. (Casa Madre)
2008 - EUCTR2007-000830-38-IT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-IT Austria;France;Germany;Italy;Poland;
Certolizumab pegol (CDP870)
UCB Pharma
2005 Phase 3 NCT00152386 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Israel;Latvia;Russian Federation;Ukraine;United States;
Certolizumab pegol (CDP870, tradename Cimzia)
University of Illinois at Chicago
2015 Phase 4 NCT02451748 United States;
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
University of Illinois at Chicago
2015 Phase 4 NCT02451748 United States;
Certolizumab pegol (CZP)
UCB Pharma
2008 Phase 3 NCT00717236 Canada;France;Germany;Italy;Netherlands;Spain;United States;
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
Cetrorelix
Betanien Hospital
2008 Phase 2 NCT00667758 Norway;
Cevidoplenib
Oscotec Inc.
2019 Phase 2 EUCTR2018-003330-32-PL Czech Republic;Korea, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Chicken type II collagen
National Eye Institute (NEI)
1997 Phase 1 NCT00001614 United States;
Chimeric Human-Murine IgG1
Centocor BV
2009 Phase 4 EUCTR2007-003288-36-GB Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-003288-36-ES Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 Phase 4 EUCTR2007-003288-36-FR Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-NL Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-FI Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-DE Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-AT Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
Chimeric human/mouse anti-CD-20 monoclonal antibody
Samsung Electronics Co. Ltd.
2012 - EUCTR2011-004171-36-PL Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-HU Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-GB Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-ES Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-CZ Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Chloroquine
Hoffmann-La Roche
2013 Phase 3 NCT01941095 Greece;
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
Sanofi
2018 Phase 4 NCT03449758 France;
University of Alberta
2020 - NCT04347798 Canada;
Cholecalciferol
University Hospital, Clermont-Ferrand
2011 Phase 3 NCT02243800 France;
Chong Kun Dang Tofacitinib Tablet
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03868072 Korea, Republic of;
Chromium
Akiyama Haruhiko
2011 Phase 4 JPRN-jRCTs032180273 Japan;
Kume Shinichiro
2012 Phase 4 JPRN-jRCTs032180245 Japan;
Zimmer Biomet
2009 - NCT03681639 Germany;
Ciclosporin
King's College London
2007 Phase 4 EUCTR2007-001190-28-GB United Kingdom;
PFIZER
2007 - EUCTR2007-001984-31-IT Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Cimzia
Karolinska Institutet
2015 Phase 4 NCT02466581 Sweden;
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 Phase 4 EUCTR2011-004720-35-DK Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
2012 Phase 4 NCT01491815 Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
Kings College London
2008 Phase 4 EUCTR2007-005464-26-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
2012 Phase 4 EUCTR2011-005204-15-AT Austria;
Michael Schiff, MD
2010 Phase 4 NCT01147341 United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
The Karolinska Institute, ClinTRID
2017 Phase 4 EUCTR2011-004720-35-NL Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
2012 - EUCTR2011-004720-35-SE Sweden;
The Karolinska Institutet, ClinTRID
2014 Phase 4 EUCTR2014-002374-36-SE Sweden;
The Karolinska Instutute, ClinTRID
2013 Phase 4 EUCTR2011-004720-35-IS Denmark;Finland;Iceland;Norway;Sweden;
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 Phase 2 EUCTR2014-003307-30-HU Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
2015 Phase 2 EUCTR2014-003307-30-GB Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
2015 Phase 2 EUCTR2014-003307-30-CZ Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
UCB PHARMA SA/NV.
2012 - EUCTR2011-002067-20-IT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-IT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
UCB Pharma SA
2015 - EUCTR2011-002067-20-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2011-002067-20-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-PT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-IE Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-GB Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-BG Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-SE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-IE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-GB Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-AT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-NL Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-HU Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-ES Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-DE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-CZ Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-AT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
University of California, San Francisco
2013 - NCT01773681 United States;
Universitätsklinikum Erlangen
2015 Phase 3 EUCTR2013-000337-13-PT Germany;Portugal;Serbia;United States;
2013 Phase 3 EUCTR2013-000337-13-DE Germany;Portugal;Serbia;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Cimzia 200 mg injeksjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
Cimzia 200 mg solution for injection
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
Cimzia®
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
Citalopram
Vrije Universiteit Brussel
2010 - NCT01154647 Belgium;
Classic DMARDs treatment group
Zhang, Xiao, M.D.
2013 - NCT01915537 China;
Clazakizumab
Bristol-Myers K.K.
2014 Phase 2 JPRN-JapicCTI-142497 -
2011 Phase 2 JPRN-JapicCTI-111628 -
CSL Behring
2012 Phase 2 NCT02015520 Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
Clindamycin
Hammersmith Hospitals NHS trust
2005 Phase 3 EUCTR2004-004893-96-GB United Kingdom;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Co-medication: Synthetic DMARDs
Diakonhjemmet Hospital
2013 Phase 4 NCT01881308 Norway;
Cobalt
Akiyama Haruhiko
2011 Phase 4 JPRN-jRCTs032180273 Japan;
Kume Shinichiro
2012 Phase 4 JPRN-jRCTs032180245 Japan;
Zimmer Biomet
2009 - NCT03681639 Germany;
Cobalt™ Bone Cement
Zimmer Biomet
2006 - NCT00589485 United States;
Cobiprostone
Sucampo Pharma Americas, LLC
2007 Phase 2 NCT00597818 United States;
Cod liver oil
National Institute of Nutrition and Seafood Research, Norway
2008 - NCT00805116 Norway;
Coenzyme Q10
the Second Hospital of Shanxi Medical University
2017 - ChiCTR-IPR-17010325 China;
Colchicine
Hospital Central Dr. Ignacio Morones Prieto
2018 Phase 2 NCT04056039 Mexico;
Colecalciferol
AZIENDA OSPEDALIERA ORDINE MAURIZIANO
2010 Phase 3 EUCTR2009-015835-34-IT Italy;
Collect of 10 ml of peripheric blood for DNA extraction
Centre Hospitalier Universitaire de Fort-de-France
2010 - NCT01111357 Martinique;
Combination Product: Exercise, and methotrexate
Cairo University
2020 - NCT04758689 Egypt;
Combination Product: Laser, exercise, and methotrexate
Cairo University
2020 - NCT04758689 Egypt;
Combination Product: Methotrexate
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2019 Phase 2 NCT04038970 China;
Combination Steroid
All India Institute of Medical Sciences, New Delhi
2009 Phase 3 NCT01870128 India;
Combination fish oil and borage seed oil
National Center for Complementary and Integrative Health (NCCIH)
2006 Phase 3 NCT00072982 United States;
Combination of Minocycline and MTX or MTX alone
University of Nebraska
2001 Phase 3 NCT00579644 -
Comirnaty
Sint Maartenskliniek
2021 Phase 4 EUCTR2021-000710-42-NL Netherlands;
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
Commercial Formulation Etanercept
Amgen
2016 Phase 3 NCT02986139 Puerto Rico;United States;
Comparator: Diclofenac sodium
Organon and Co
2003 Phase 3 NCT00250445 -
2003 Phase 3 NCT00092742 United States;
Comparator: diclofenac
Organon and Co
2006 Phase 2 NCT00264147 Canada;Colombia;Puerto Rico;Switzerland;United States;
Comparator: naproxen tablet
Merck Sharp & Dohme Corp.
2004 Phase 4 NCT00157872 China;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Control
Chengdu PLA General Hospital
2013 Phase 2 NCT02254655 China;
Laval University
2022 - NCT04688398 -
Control group
University of Erlangen-Nürnberg Medical School
2009 Phase 3 NCT02779114 Germany;
Control intervention (no dexamethasone)
University of Calgary
2016 - NCT02666443 Canada;
Conventional DMARD combination
Karolinska Institutet
2002 Phase 4 NCT00764725 -
Conventional DMARDs
Ain Shams University
2019 Phase 2 NCT03863405 Egypt;
Conventional Synthetic DMARD
SetPoint Medical Corporation
2021 Phase 3 NCT04539964 United States;
Conventional syringe - BD Ref 309604
University of New Mexico
2004 - NCT00651625 United States;
Corn oil capsules
Zhejiang University
2014 - NCT02173587 China;
Corticosteroid and non-biological agents.
University of Athens
2017 - NCT03288584 Greece;
Corticosteroid or NSAID
Hoffmann-La Roche
2007 Phase 4 NCT00462345 Korea, Republic of;
Corticosteroids
Genentech, Inc.
2003 Phase 2 NCT00074438 United States;
Corticotrophin 80 units
Gaylis, Norman B., M.D.
2013 Phase 4 NCT01948388 United States;
Creatine
Bangor University
2013 - NCT01767844 United Kingdom;
Creatinine
Affiliated Hospital of North Sichuan Medical College
2018 - ChiCTR1800018637 China;
CsDMARD(s)
GlaxoSmithKline
2020 Phase 3 NCT04333147 Argentina;Australia;Belgium;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Hungary;India;Japan;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
CsDMARDs
Gilead Sciences
2016 Phase 3 NCT02873936 Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
GlaxoSmithKline
2019 Phase 3 NCT04134728 Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 NCT03970837 Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
Hoffmann-La Roche
2014 Phase 3 NCT02001987 France;
Cura-100
Cura Biotech LLC
2007 Phase 1/Phase 2 NCT00455208 United States;
Curcumin (Longvida™)
University of California, Los Angeles
2010 Phase 0 NCT00752154 United States;
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States;
Hoffmann-La Roche
2001 Phase 2 NCT02693210 Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Cyclosporin A
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
Cyklokapron®
University Hospital of North Tees and Hartlepool
2009 - EUCTR2009-012141-34-GB United Kingdom;
D2E7
Reade
2019 Phase 4 EUCTR2019-001793-28-NL Netherlands;
2019 Phase 1;Phase 4 EUCTR2019-001554-25-NL Netherlands;
D569 Tab.
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03858725 Korea, Republic of;
DECORTIN (PREDNISONA) 5 MG COMPRIMIDOS
Pfizer S.A.
2009 Phase 2 EUCTR2009-013223-37-ES Czech Republic;Hungary;Spain;
DELTACORTENE FORTE*10CPR
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
DEPALGOS*20+325MG 28CPR RP
A.U.S.L. RIMINI
2006 - EUCTR2006-004062-13-IT Italy;
DEXA scan
University of Texas Southwestern Medical Center
2006 - NCT00286689 United States;
DIBASE*IM OS 2F 1ML 300000UI/M
AZIENDA OSPEDALIERA ORDINE MAURIZIANO
2010 Phase 3 EUCTR2009-015835-34-IT Italy;
DMARD
Amgen
2001 - NCT00116714 United States;
Hoffmann-La Roche
2013 Phase 3 NCT01995201 Ireland;Portugal;Spain;
2011 Phase 4 NCT01251120 Finland;
DMARD Therapy
Amgen
2011 Phase 4 NCT01313208 Canada;United States;
Zalicus
2004 Phase 2 NCT00747214 -
DMARD cessation
Newcastle-upon-Tyne Hospitals NHS Trust
2014 - NCT02219347 United Kingdom;
DMARD maintenance
Assistance Publique - Hôpitaux de Paris
2008 Phase 4 NCT00780793 France;
DMARDS
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00783536 Mexico;
DMARDs
Columbia University
2011 Phase 4 NCT01548768 United States;
Hoffmann-La Roche
2014 Phase 3 NCT02046603 United Kingdom;
2013 Phase 4 NCT01715831 Brazil;
2013 Phase 3 NCT01941940 Italy;
2009 Phase 3 NCT00996606 Italy;
JW Pharmaceutical
2010 Phase 3 NCT01256736 Korea, Republic of;
2009 Phase 3 NCT01211834 Korea, Republic of;
Mycenax Biotech Inc.
2013 Phase 3 NCT01787149 Taiwan;
Sun Yat-sen University
2018 Phase 4 NCT04066803 China;
DMARDs (disease-modifying antirheumatic drugs)
Hoffmann-La Roche
2009 Phase 4 NCT00996203 Russian Federation;
DMARDs (methotrexate
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
DMARDs or Biologics
Pfizer
2009 - NCT00929357 Denmark;
DRL_RI
Dr. Reddy's Laboratories Limited
2014 Phase 1/Phase 2 NCT02296775 India;Ukraine;
DW1809-1
Daewon Pharmaceutical Co., Ltd.
2020 Phase 1 NCT05214690 Korea, Republic of;
2020 Phase 1 NCT05214677 Korea, Republic of;
DW1809-T2
Daewon Pharmaceutical Co., Ltd.
2020 Phase 1 NCT05214690 Korea, Republic of;
DWP422
Daewoong Pharmaceutical Co. LTD.
2012 Phase 1 NCT01635686 Korea, Republic of;
Dacortin ®
Zalicus, Inc.
2012 - EUCTR2011-002392-41-HU Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2012 - EUCTR2011-002392-41-BG Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-PL Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-HU Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-BG Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Daily supplementation
Adeline BLOT
2018 - NCT04696718 France;
Dalacin C phosphate
Hammersmith Hospitals NHS trust
2005 Phase 3 EUCTR2004-004893-96-GB United Kingdom;
Decortin
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2011 - EUCTR2010-023782-22-CZ Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
2011 - EUCTR2010-023782-22-DE Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 - EUCTR2010-023782-22-SK Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
2011 - EUCTR2010-023782-22-HU Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
2011 - EUCTR2010-023782-22-BG Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer, S.L.U.
2011 - EUCTR2010-023782-22-ES Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Decortin 5mg tablets
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
2009 - EUCTR2007-006150-25-DE Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
2008 - EUCTR2007-006150-25-HU Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2008 Phase 2 EUCTR2007-006150-25-FR Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 Phase 2 EUCTR2007-006150-25-BE Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 - EUCTR2007-006150-25-NL Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 - EUCTR2007-006150-25-AT Austria;Belgium;France;Germany;Hungary;Netherlands;
Decortin®
Pfizer Inc.
2009 Phase 2 EUCTR2009-013223-37-CZ Czech Republic;Hungary;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2009 - EUCTR2009-013223-37-HU Hungary;Spain;
Pfizer S.A.
2009 Phase 2 EUCTR2009-013223-37-ES Czech Republic;Hungary;Spain;
Decrease Tocilizumab, Abatacept
Assistance Publique - Hôpitaux de Paris
2012 Phase 4 NCT01557374 France;
Defanyl 50 and
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
Dekavil
Philogen S.p.A.
2015 Phase 2 EUCTR2013-005418-37-DE Germany;Italy;Switzerland;
2014 - EUCTR2013-005418-37-IT Germany;Italy;
Deltacortril Enteric
GlaxoSmithKline Research & Development Limited
2005 Phase 2 EUCTR2005-001977-82-GB United Kingdom;
Denosumab
Amgen
2011 Phase 1 NCT01294397 United States;
2004 Phase 2 NCT00095498 United States;
Chinese University of Hong Kong
2017 Phase 2 NCT03239080 China;
2012 Phase 4 NCT01770106 Hong Kong;
DAIICHISANKYO Co.,Ltd.
2013 Phase 3 JPRN-JapicCTI-132277 -
2010 Phase 2 JPRN-JapicCTI-101263 -
Daiichi Sankyo Company, Limited
2018 - JPRN-UMIN000030575 Japan;
Daiichi Sankyo, Inc.
2013 - NCT01973569 Japan;
Hokkaido Medical Center for Rheumatic Diseases
2017 - JPRN-UMIN000028376 Japan;
Indiana University
2019 Phase 1/Phase 2 NCT02418273 United States;
Kawakami Atsushi
2018 Phase 4 JPRN-jRCTs071180018 Japan;
Osaka City University Graduate School of Medicine
2018 - JPRN-UMIN000030828 Japan;
Yokohama City University Medical Center
2014 - JPRN-UMIN000014737 Japan;
Depemedrone
University Hospital Birmingham
2007 Phase 4 NCT00523692 United Kingdom;
Depo Medrol
Sun Pharma Global FZE
2016 Phase 3 EUCTR2015-002924-17-BE Belgium;Netherlands;
2015 Phase 3 EUCTR2015-002924-17-NL Belgium;Netherlands;
Depo medrol
Attune Health Research, Inc.
2018 Phase 3 NCT03511625 United States;
Depo-Medrone
University Hospitals Birmingham NHS Foundation Trust
2006 Phase 4 EUCTR2006-001428-38-GB United Kingdom;
Dexamethason
UMC Utrecht
2010 - EUCTR2009-017051-10-NL Netherlands;
Dexmedetomidine
West China Hospital, Sichuan University
2021 Phase 0 ChiCTR2000036316 China;
2021 Phase 0 ChiCTR2000036164 china;
Dextromethorphan hydrobromide
Taichung Veterans General Hospital
2010 - NCT02368093 -
Diacerein
TRB Chemedica
2010 Phase 2 NCT01264211 Thailand;
Diazepam, melatonin
Kobe University
2006 - NCT00287794 Japan;
Diclofenac
Mallinckrodt
2012 - NCT01579890 -
Northumbria Healthcare NHS Foundation Trust
2010 Phase 4 NCT01067430 United Kingdom;
University of Dundee
2007 Phase 4 NCT00447759 Denmark;Netherlands;United Kingdom;
Diclofenac + Omeprazole
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005 Phase 4 NCT00141102 Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Diclofenac sodium
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Dietary Fiber Supplementation
University Hospital, Montpellier
2020 - NCT04421313 France;
Dietary supplement omega3 fatty acids aand vitamins
Physicians Committee for Responsible Medicine
2011 - NCT01544101 United States;
Digoxin
AstraZeneca
2011 Phase 1 NCT01355354 United Kingdom;
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Tanta University
2021 Phase 2 NCT04834557 -
Dihuang
Shanghai Traditional Chinese Medicine Hospital
2020 Phase 0 ChiCTR2000037675 China;
Dimeythl Fumarate
Biogen Idec Limited
2009 Phase 2 EUCTR2008-004754-33-SK Czech Republic;Poland;Slovakia;
2009 - EUCTR2008-004754-33-PL Czech Republic;Poland;
2009 - EUCTR2008-004754-33-CZ Czech Republic;Poland;
Dipotassium Salt
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-CZ Bulgaria;Czech Republic;
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Diprofos Depot
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
Dipyridamole
CombinatoRx, Incorporated
2008 - EUCTR2007-004399-38-LT Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-GB Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-EE Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-LT Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-HU Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-GB Estonia;Hungary;Lithuania;United Kingdom;
2007 - EUCTR2007-003069-42-EE Estonia;Hungary;Lithuania;United Kingdom;
Zalicus
2011 Phase 2 NCT01369745 United States;
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
Zalicus, Inc.
2012 - EUCTR2011-002392-41-HU Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2012 - EUCTR2011-002392-41-BG Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Dipyridamole and Amoxapine
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
Disease modified antirheumatic drugs or biological agents
Nanfang Hospital of Southern Medical University
2018 - NCT03508713 -
Disease-modifying anti-rheumatic drugs
Hoffmann-La Roche
2005 Phase 3 NCT00720798 Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Disease-modifying antirheumatic drug
Pfizer
2010 Phase 3 NCT01039688 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Disease-modifying antirheumatic drugs (DMARDs)
Astellas Pharma China, Inc.
2018 Phase 3 NCT03660059 China;Korea, Republic of;Taiwan;
Hoffmann-La Roche
2010 Phase 3 NCT01194414 Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
DnaJ peptide
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1999 Phase 2 NCT00000435 United States;
Dolquine
Fundació Clínic per a la Recerca Biomèdica
2019 Phase 4 EUCTR2017-004543-20-ES Spain;
Donepezil
RenJi Hospital
2018 Phase 3 NCT02927522 China;
Doppler ultrasound.
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT01954381 France;
Dose level 1
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 2
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 3
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 4
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Double-blind Abatacept
Bristol-Myers Squibb
2002 Phase 3 NCT00048932 United States;
Double-blind adalimumab
Abbott
2009 Phase 3 NCT00870467 Japan;
Doxycycline
Hong Kong Baptist University
2015 - ChiCTR-OPB-15007284 China;
New York University School of Medicine
2010 - NCT01198509 United States;
Doxycycline Tablets
Assiut University
2019 - NCT03194204 Egypt;
Dr. Reddy’s Rituximab (DRL_RI)
Dr. Reddy’s Laboratories S.A.
2020 Phase 3 EUCTR2019-002810-37-PL Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-LT Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-DE Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
Dronabinol capsule
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Groupe Hospitalier Pitie-Salpetriere
2018 - NCT03480529 France;
Drug protocol
Federal University of São Paulo
2014 - NCT04752748 -
Drug treatment
Xijing Hospital
2019 - NCT04037111 China;
Dummy Qing Re Huo Xue (QRHX)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT04170504 -
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
E1-Hip Bearing
Zimmer Biomet
2013 - NCT02087449 Korea, Republic of;
E6011
Eisai Co., Ltd.
2016 Phase 2 NCT02960490 Japan;
2016 Phase 2 NCT02960438 Japan;
2014 Phase 1/Phase 2 NCT02196558 Japan;
EC 3.1.3.1
Alloksys Life Sciences B.V.
2011 - EUCTR2008-007346-63-GB United Kingdom;
EMEA/H/C/004214
Erasmus Medical Center
2022 Phase 4 EUCTR2021-004131-84-NL Netherlands;
EMEA/H/C000262
University Hospitals Leuven
2013 - EUCTR2012-004631-22-BE Belgium;
ENBREL (Etanercept)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL
AMGEN INC.
2016 Phase 3 EUCTR2014-004868-38-IT Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
ENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
ENBREL 25MG PFS INJ.
Daewoong Pharmaceutical Co. LTD.
2012 Phase 1 NCT01635686 Korea, Republic of;
ENBREL*SC 4FL 25MG+4SIR 1ML
WYETH LEDERLE
2004 - EUCTR2004-000563-96-IT Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth Pharmaceuticals France, Wyeth Research Division
2008 - EUCTR2007-000896-41-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4FL 50MG+4SIR+4AGHI+
Wyeth Pharmaceuticals France, Wyeth Research Division
2008 - EUCTR2007-000896-41-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 25MG 0,5ML+8TAM
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 50MG 1ML+8TAMP
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL®
Amgen
2002 - NCT00116727 United States;
ENIA11
Mycenax Biotech Inc.
2012 Phase 3 NCT01709760 Taiwan;
EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)
Rabin Medical Center
2011 - NCT01274910 Israel;
ERB-041
WYETH LEDERLE
2005 - EUCTR2005-001319-23-IT Hungary;Italy;Spain;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
2005 Phase 2 EUCTR2005-001319-23-ES Hungary;Italy;Spain;
2005 - EUCTR2005-001319-23-HU Hungary;Italy;Spain;
ERMM-1
CIS bio international
2007 Phase 4 EUCTR2006-006380-22-DE Germany;
ESAOTE MyLab60
University Hospital, Rouen
2011 Phase 4 NCT01765374 France;
ETN
Research Center, the University of Tokyo
22nd Century Medical &
TAP Corporation
2009 - JPRN-UMIN000002687 Japan,Asia(except Japan);
ETN Alone
Japan Biological Agent Study Integrated Consortium
2005 Phase 4 NCT00688103 Japan;
ETN+MTX
Japan Biological Agent Study Integrated Consortium
2005 Phase 4 NCT00688103 Japan;
EU-Humira
Fresenius Kabi SwissBioSim GmbH
2017 Phase 3 NCT03052322 Bulgaria;Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
EU-approved RoActemra
Fresenius Kabi SwissBioSim GmbH
2020 Phase 3 NCT04512001 Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
EU/1/99/126/017
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
EU/1/99/126/020
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Ebetrexat
Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation
2008 - EUCTR2007-006288-56-AT Austria;
Edoxaban
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
2016 - JPRN-UMIN000026819 Japan;
Yokohama City University School of Medicine
2012 - JPRN-UMIN000018101 Japan;
Efalizumab
XOMA (US) LLC
2002 Phase 2 NCT00034203 United States;
Efexor XL 75 mg (venlafaxine)
Newcastle upon Tyne Hospitals NHS Trust
2005 - EUCTR2004-002482-20-GB United Kingdom;
Eldecalcitol
Department of Orthopaedic Surgery Shinshu University School of Medicine
2016 - JPRN-UMIN000022364 Japan;
Enalapril Maleate
University of Guadalajara
2017 Phase 2 NCT03667131 Mexico;
Enbrel
AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
2018 Phase 3 EUCTR2017-004079-30-IT Belgium;Italy;Portugal;Spain;
Amgen
2000 Phase 4 NCT00132418 United States;
Amgen Inc.
2017 Phase 3 EUCTR2014-004868-38-DE Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-PT Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-HU Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-GR Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-FR Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-ES Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-BG Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2015 Phase 3 EUCTR2014-004868-38-CZ Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
AstraZeneca AB
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
Biogen
2017 - NCT03100734 Germany;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
Coherus BioSciences, Inc
2014 Phase 3 EUCTR2014-000443-33-PL Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-GB Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus Biosciences, Inc
2014 Phase 3 EUCTR2014-000443-33-IT Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-HU Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-ES Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-DE Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
Department of Clinical Biochemestry, Aarhus University Hospital
2015 Phase 4 EUCTR2015-004173-32-DK Denmark;
Derby Hospitals NHS Foundation Trust
2008 Phase 4 EUCTR2006-006562-42-GB United Kingdom;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 4 EUCTR2018-003351-37-IT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 3;Phase 4 EUCTR2018-003351-37-FR Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-PL Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-NL Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-LT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-HU Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-GR Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-GB Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-DK Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-DE Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-AT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
2019 Phase 4 EUCTR2018-004539-54-DE Germany;
Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
2020 Phase 4 EUCTR2018-004558-30-PT Portugal;Spain;
2020 Phase 4 EUCTR2018-004558-30-DK Denmark;Portugal;Spain;
2019 Phase 4 EUCTR2018-004558-30-ES Spain;
Greater Glasgow Health Board
2006 Phase 4 EUCTR2006-000363-28-GB United Kingdom;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Joint Research & Development Office (QMUL)
2018 Phase 3 EUCTR2017-004079-30-PT Belgium;Italy;Portugal;Spain;
2018 Phase 3 EUCTR2017-004079-30-ES Belgium;Italy;Portugal;Spain;
2018 Phase 3 EUCTR2017-004079-30-BE Belgium;Italy;Portugal;Spain;
2014 Phase 3 EUCTR2014-003529-16-GB United Kingdom;
Joint Stock Company Farmak
2018 Phase 3 NCT04079374 Ukraine;
Kings College London
2008 Phase 4 EUCTR2007-005464-26-GB United Kingdom;
LG Life Sciences
2015 Phase 3 NCT02357069 Japan;Korea, Republic of;
Lilly S.A
2019 Phase 3;Phase 4 EUCTR2018-003351-37-ES Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
2012 Phase 4 EUCTR2011-005204-15-AT Austria;
NHS Greater Glasgow and Clyde
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Eye Institute (NEI)
1999 Phase 2 NCT00001862 United States;
Pfizer
2020 - NCT04428424 Iraq;
2011 - NCT01411215 China;
Pfizer Inc.
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2013 Phase 4 EUCTR2012-003644-71-BE Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;New Zealand;Poland;Russian Federation;Spain;
2013 - EUCTR2012-003644-71-ES Australia;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 EAst 42nd Street, New York, NY 10017, United States
2013 - EUCTR2012-003644-71-NL Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
Pfizer Inc., 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2015 Phase 1 NCT02481180 China;
Sorrento Therapeutics, Inc.
2021 Phase 1 NCT04559412 United States;
University Hospital Birmingham NHS Foundation Trust
2007 Phase 4 EUCTR2006-006275-21-GB United Kingdom;
University Hospitals Birmingham NHS Foundation Trust
2006 Phase 4 EUCTR2006-001428-38-GB United Kingdom;
University Hospitals Leuven
2013 - EUCTR2012-004631-22-BE Belgium;
University of Leeds
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Wyeth Pharmaceuticals France
2008 Phase 4 EUCTR2007-001625-10-ES Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-001625-10-PL Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-DE Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-AT Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000896-41-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2008 - EUCTR2007-000896-41-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2010 - EUCTR2007-000896-41-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2007-000896-41-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
2008 - EUCTR2007-000896-41-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2003 - NCT00245934 -
YL Biologics Ltd
2016 Phase 3 EUCTR2015-002809-12-BG Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-LV Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-HU Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-ES Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-CZ Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
Enbrel (Etanercept)
Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
- - EUCTR2012-001171-37-Outside-EU/EEA Canada;United States;
- - EUCTR2012-001145-40-Outside-EU/EEA Canada;United States;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2004 - NCT00484809 -
Enbrel (etanercept)
EMS
2013 Phase 3 NCT01394913 Brazil;
Pfizer
2007 - NCT00503139 Japan;
Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
2009 - EUCTR2008-005450-20-BE Belgium;
Samsung Bioepis Co., Ltd.
2013 Phase 3 NCT01895309 Poland;United Kingdom;
Wyeth Pharmaceuticals
2005 - EUCTR2004-000563-96-FI Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2005 - EUCTR2004-000563-96-AT Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-SE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-IE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-HU Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-ES Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-DK Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
- Phase 4 EUCTR2004-000563-96-NO Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth is now a wholly owned subsidiary of Pfizer
2005 - NCT00503503 -
Enbrel 25 mg powder and solvent for solution for injection
Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
2010 - EUCTR2007-006657-63-IS Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-SE Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-FI Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-DK Denmark;Finland;Hungary;Iceland;Norway;Sweden;
Wyeth Pharmaceuticals France
2010 Phase 4 EUCTR2007-006657-63-HU Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 25mg PFS
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50 mg powder and solvent for solution for injection
Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
2010 - EUCTR2007-006657-63-IS Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-SE Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-FI Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-DK Denmark;Finland;Hungary;Iceland;Norway;Sweden;
Wyeth Pharmaceuticals France
2010 Phase 4 EUCTR2007-006657-63-HU Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 50 mg solution for injection in pre-filled syringe
Hexal AG
2016 Phase 3 EUCTR2012-002009-23-HU Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2012-002009-23-DE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-SK Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-PL Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LV Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-GB Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-ES Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-EE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-CZ Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2015 Phase 3 EUCTR2013-004569-16-DE Bulgaria;Colombia;Croatia;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;
sanofi-aventis Recherche & Développement
2013 Phase 3 EUCTR2012-001984-66-NO Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001984-66-GB Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-LV Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-LT Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-IT Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-HU Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-GR Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-FI Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-ES Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-DE Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-CZ Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Enbrel 50mg PFS
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50mg pre-filled pen
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Enbrel 50mg pre-filled syringe
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Enbrel Auto Injector
Wyeth Pharmaceuticals France
2008 - EUCTR2006-006591-37-GR Austria;Greece;
2008 - EUCTR2006-006591-37-AT Austria;Greece;
2007 Phase 3 EUCTR2006-005137-38-GB Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005137-38-FR Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-006591-37-BE Austria;Belgium;Greece;
2007 - EUCTR2006-005137-38-SE Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-FI Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-DK Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel Pre-filled syringe
Wyeth Pharmaceuticals France
2007 Phase 3 EUCTR2006-005137-38-FR Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel liquid
Amgen
2005 Phase 3 NCT00249041 Canada;United States;
Enbrel pre-filled pen
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Enbrel pre-filled syringe
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Enbrel, Benepali, Erelzi
Reade
2019 Phase 4 EUCTR2019-001754-25-NL Netherlands;
Enbrel®
Amgen
2002 - NCT00121056 -
2000 - NCT00078793 Canada;United States;
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-020065-24-NL Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-LV Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-HU Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-GR Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-GB Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-ES Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-DE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-CZ Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-AT Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020065-24-LT Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020065-24-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
ROCHE
2011 Phase 4 EUCTR2010-020065-24-IT Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-LT Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Enbrel® 50 mg Solution for Injection in Pre-filled Syringe
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 - EUCTR2011-005448-87-HU Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
2012 - EUCTR2011-005448-87-CZ Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
Engineered humanized monoclonal anti-human CD19 antibody.
Xencor Inc.
2012 Phase 2 EUCTR2012-003057-29-HU Czech Republic;Hungary;Slovakia;
2012 - EUCTR2012-003057-29-SK Czech Republic;Hungary;Slovakia;
Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml)
Xencor Inc.
2013 - EUCTR2012-003057-29-CZ Czech Republic;Hungary;Slovakia;
Enoxaparin
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
2016 - JPRN-UMIN000026819 Japan;
Entanercept
Peking University First Hospital
2015 - NCT02320630 China;
Entecavir
Department of general internal medicine, Kyushu-University hospital
2012 - JPRN-UMIN000018017 Japan;
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Taipei Veterans General Hospital, Taiwan
2013 Phase 4 NCT01907230 Taiwan;
Epaxal
HY, HUS
2011 - EUCTR2009-016055-22-SE Finland;Sweden;
2009 - EUCTR2009-016055-22-FI Finland;Sweden;
Epinephrine
Nekoyama Miyao Hospital
2017 - JPRN-UMIN000029759 Japan;
2017 - JPRN-UMIN000029003 Japan;
Epoetin alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004 Phase 2 NCT00236678 -
Ortho Biotech Products, L.P.
2005 Phase 2 NCT00123149 -
Erbium citrate
CIS bio international
2007 Phase 4 EUCTR2006-006380-22-DE Germany;
Ergocalciferol
Johns Hopkins University
2009 - NCT01426347 United States;
Ergocalciferol 1.25 mg tablet
Tanta University
2019 Phase 4 NCT04472481 Egypt;
Esbriet
University Hospitals of Leicester NHS Trust
2017 Phase 2 EUCTR2017-000149-30-GB Australia;Canada;United Kingdom;United States;
Esomeprazole
AstraZeneca
2007 Phase 3 NCT00595517 Japan;
2007 Phase 3 NCT00542789 Japan;
- Phase 3 JPRN-JapicCTI-080565 -
- Phase 3 JPRN-JapicCTI-080531 -
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Eszopiclone
Sunovion
2004 Phase 3 NCT00367965 United States;
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
Reade
2019 Phase 4 EUCTR2019-001754-25-NL Netherlands;
Etanercept
Amgen
2013 Phase 4 NCT01927757 Canada;Puerto Rico;United States;
2011 Phase 4 NCT01313208 Canada;United States;
2011 Phase 1 NCT01294397 United States;
2008 Phase 4 NCT00654368 Canada;
2006 Phase 4 NCT00346294 United States;
2006 Phase 3 NCT00413452 Canada;United States;
2006 Phase 1 NCT00361634 United Kingdom;United States;
2005 Phase 4 NCT00115219 United States;
2005 Phase 3 NCT00249041 Canada;United States;
2004 Phase 4 NCT00099554 Canada;United States;
2004 Phase 4 NCT00094341 United States;
2001 Phase 3 NCT00078806 Canada;United States;
2000 Phase 3 NCT03781375 -
1998 Phase 3 NCT00356590 Canada;United States;
1997 Phase 3 NCT00357903 Canada;United States;
1997 Phase 2/Phase 3 NCT03780959 -
AryoGen Pharmed Co.
2014 - NCT04582084 Iran, Islamic Republic of;
Astellas Pharma Inc
2014 Phase 3 NCT02308163 Japan;Korea, Republic of;Taiwan;
AstraZeneca
2008 Phase 2 NCT00713544 Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
2007 Phase 2 NCT00520572 Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AstraZeneca AB
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
Biogen
2006 Phase 2 NCT00298272 United States;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus Biosciences, Inc.
2014 Phase 3 NCT02115750 Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
Department of Rheumatology and infectious disease, Kitasato university school of medicine
2012 - JPRN-UMIN000008572 Japan;
Department of Rheumatosurgery, Osaka City University Medical School
2009 Phase 4 JPRN-UMIN000002340 Japan;
Dept. of orthopedic surgery, Osaka Medical College
2012 - JPRN-UMIN000012613 Japan;
Derby Hospitals NHS Foundation Trust
2008 Phase 4 EUCTR2006-006562-42-GB United Kingdom;
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
2011 - JPRN-UMIN000013750 Japan;
Dr. Frank Behrens
2019 Phase 4 NCT04485325 Germany;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Faiq Gorial
2017 Phase 1/Phase 2 NCT03160001 Iraq;
Fen Li
2016 Phase 4 NCT02878161 -
Gema Biotech S.A.
2016 Phase 3 NCT03403140 Argentina;
2016 Phase 3 NCT03332719 Argentina;
Georgetown University
2013 Phase 4 NCT01793519 United States;
Greater Glasgow Health Board
2006 Phase 4 EUCTR2006-000363-28-GB United Kingdom;
Hanwha Chemical
2010 Phase 3 NCT01270997 Korea, Republic of;
Hoffmann-La Roche
2011 Phase 4 NCT01331837 Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - NCT01592292 Korea, Republic of;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Innovaderm Research Inc.
2014 Phase 4 NCT02109289 Canada;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Johoku Biological Summit
2006 Phase 4 JPRN-C000000452 Japan;
Joint Stock Company Farmak
2018 Phase 3 NCT04079374 Ukraine;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Kawakami Atsushi
2020 Phase 4 JPRN-jRCTs071200054 Japan;
2020 Phase 4 JPRN-jRCTs071190046 Japan;
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Lawson Health Research Institute
2020 Phase 4 NCT03976245 Canada;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
Merck Sharp & Dohme Corp.
2008 - NCT00724672 -
NHS Greater Glasgow and Clyde
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2009 Phase 4 NCT00837434 United States;
2008 Phase 4 NCT00796705 United States;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 Phase 2 NCT00034060 United States;
Osaka City University Medical School
2011 Phase 4 JPRN-UMIN000008164 Japan;
Pfizer
2018 - NCT04267614 Iraq;
2015 Phase 3 NCT02378506 Bulgaria;Croatia;Germany;Greece;Hungary;Poland;Russian Federation;Serbia;Slovakia;South Africa;
2015 - NCT02486302 Germany;
2014 Phase 4 NCT02092467 Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 - NCT02202837 Belgium;
2013 Phase 4 NCT01783015 Australia;Belgium;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
2013 - NCT01558089 Greece;
2012 Phase 4 NCT01578850 Brazil;China;Colombia;Czech Republic;Egypt;Hungary;Jordan;Lebanon;Malaysia;Mexico;Philippines;Qatar;Romania;Russian Federation;Saudi Arabia;South Africa;Taiwan;Thailand;Ukraine;United Arab Emirates;
2012 - NCT01646385 -
2012 - NCT01623752 -
2011 - NCT01557322 -
2009 Phase 4 NCT00913458 France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom;
2009 Phase 4 NCT00858780 Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2008 Phase 4 NCT00565409 Australia;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;
2006 Phase 3 NCT00445770 Japan;
2006 - NCT00488475 Germany;
2004 - NCT00195403 Korea, Republic of;
2004 - NCT00195338 Luxembourg;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Samsung Bioepis Co., Ltd.
2017 Phase 2 NCT03193957 Poland;
Sanofi
2013 Phase 3 NCT01764997 Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Takarazuka city hospital
2014 - JPRN-UMIN000013362 Japan;
Team RA, Rheumatosurgery, Osaka City University Medical School
2008 - JPRN-UMIN000001798 Japan;
University of Alabama at Birmingham
2004 Phase 4 NCT00259610 United States;
University of California, Davis
2017 - NCT03178955 United States;
University of Leeds
2011 Phase 4 NCT02433184 United Kingdom;
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Pittsburgh
2009 Phase 4 NCT01009879 United States;
Università Popolare Homo & Natura
2015 Phase 1 NCT02633332 Italy;
VA Office of Research and Development
2007 - NCT00405275 Canada;United States;
Wyeth Pharmaceuticals France
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2010 Phase 4 EUCTR2008-002623-85-SE France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 Phase 4 EUCTR2008-002623-85-FR France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2008-002623-85-ES France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00768053 France;Monaco;
2007 Phase 3 NCT00484237 Japan;
2007 Phase 3 NCT00418717 Japan;
2006 Phase 3 NCT00443950 China;
2004 Phase 4 NCT00252668 -
2004 Phase 4 NCT00195494 United States;
2003 Phase 4 NCT00546533 -
2003 - NCT00195377 Spain;
2003 - NCT00195364 Spain;
2000 Phase 3 NCT00393471 Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom;
Etanercept (ETN)
University of Leeds
2006 Phase 4 NCT01303874 United Kingdom;
Etanercept (Enbrel)
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Etanercept (EnbrelTM)
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00706797 Austria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;United States;
Etanercept + Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00783536 Mexico;
Etanercept , Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 4 NCT00422227 Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Etanercept / Autoinjector A
Amgen
2013 Phase 3 NCT01901185 United States;
Etanercept 50 MG/ML
P. Verschueren
2018 Phase 4 NCT03649061 Belgium;
Etanercept Auto-Injector
Wyeth Pharmaceuticals France
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Liquid
Amgen
2004 Phase 3 NCT00110903 -
Etanercept Optimal dosing
Duke University
2023 Phase 1 NCT04585711 United States;
Etanercept Pre-filled syringe
Wyeth Pharmaceuticals France
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Treatment
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT02164214 France;
Etanercept biosimilar
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
Etanercept or adalimumab
University of Glasgow
2010 Phase 4 NCT01021735 United Kingdom;
Etanercept pre-filled syringe sq injection
Amgen
2015 Phase 3 NCT02373813 Argentina;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Etanercept via Autoinjector A
Amgen
2013 Phase 4 NCT01875991 Canada;United States;
Etanercept via Autoinjector B
Amgen
2013 Phase 4 NCT01875991 Canada;United States;
Etanercept, methotrexate and depomedrone
University Hospital Birmingham
2007 Phase 4 NCT00523692 United Kingdom;
Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
Pfizer
2013 - NCT01932372 Japan;
Etoricoxib
Chung Shan Medical University
2007 Phase 4 NCT04144101 -
Northumbria Healthcare NHS Foundation Trust
2010 Phase 4 NCT01067430 United Kingdom;
Organon and Co
2010 Phase 3 NCT01208181 Argentina;Austria;Canada;Colombia;Czech Republic;Finland;Germany;Guatemala;India;Lithuania;Mexico;Panama;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2006 Phase 2 NCT00264147 Canada;Colombia;Puerto Rico;Switzerland;United States;
2006 - NCT01685424 United States;
Eupatilin
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Evobrutinib
Merck KGaA
2017 Phase 2 EUCTR2017-000384-32-CZ Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2017 Phase 2 EUCTR2017-000384-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Exhaled nitric oxide assessment
GlaxoSmithKline
2004 - NCT00242853 United Kingdom;
Experimental: Arm A: DRL_RI
Dr. Reddy's Laboratories Limited
2020 Phase 3 NCT04268771 United States;
Extracorporeal Photopheresis
Mallinckrodt
2003 Phase 2 NCT00221000 Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa;United States;
F8IL10
Philogen S.p.A.
2015 Phase 2 EUCTR2013-005418-37-DE Germany;Italy;Switzerland;
2014 Phase 2 NCT02270632 Germany;Italy;Switzerland;
2014 - EUCTR2013-005418-37-IT Germany;Italy;
2011 Phase 1 NCT02076659 Italy;
FANG(30)
Juan C. Bertoglio, MD
2006 Phase 2 NCT00749645 Chile;
FB704A
Fountain Biopharma Inc.
2019 Phase 1 NCT03890302 United States;
FBL-MTX
SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
2021 Phase 1 NCT05117593 Portugal;
FKB327
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 NCT02405780 Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-ES Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000109-11-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000109-11-BG Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 NCT02260791 Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2014-000109-11-ES Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2014-000109-11-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 AI
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 EUCTR2014-000110-61-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 PFS
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 EUCTR2014-000110-61-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FMT+MTX
Peking Union Medical College Hospital
2019 Phase 2 NCT03944096 China;
FPA008
Five Prime Therapeutics, Inc.
2013 Phase 1 NCT01962337 Hungary;Netherlands;Poland;
FR104
OSE Immunotherapeutics
2015 Phase 1 NCT02800811 Belgium;
FURESTEM-RA Inj
Kang Stem Biotech Co., Ltd.
2018 Phase 1/Phase 2 NCT03618784 Korea, Republic of;
FURESTEM-RA Inj.
Kang Stem Biotech Co., Ltd.
2016 - NCT03106259 Korea, Republic of;
2014 Phase 1 NCT02221258 Korea, Republic of;
FX125L
Funxional Therapeutics Ltd
2011 - EUCTR2011-005036-26-GB United Kingdom;
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Faecal sampling
Assistance Publique - Hôpitaux de Paris
2020 - NCT04292067 France;
Famotidine
Hoshigaoka Koseinenkin Hospital
2009 - JPRN-UMIN000004271 Japan;
Fang yi qing feng shi granule
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
2014 Phase 2 NCT02029599 China;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
Fentanyl
Yamaguchi University
2018 - JPRN-UMIN000031692 Japan;
Fentanyl transdermal patch
Janssen Pharmaceutica N.V., Belgium
2001 Phase 4 NCT00524160 -
Ferrograd Folic Tablets
University of Leeds
2006 Phase 4 EUCTR2005-005013-37-GB United Kingdom;
Fexofenadine
October 6 University
2022 Phase 1/Phase 2 NCT05264025 -
Filgotinib
DeparShinshu University School of Medicine
2021 - JPRN-UMIN000043547 Japan;
GILEAD SCIENCES INCORPORATED
2017 Phase 3 EUCTR2016-000568-41-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Galapagos NV
2021 - NCT04871919 Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2019 Phase 2 NCT03926195 Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
2017 Phase 3 NCT03025308 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02065700 Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences
2020 Phase 1 NCT04608344 United States;
2018 Phase 1 NCT03417778 Germany;New Zealand;United States;
2016 Phase 3 NCT02889796 Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02886728 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02873936 Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02885181 Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
Kawakami Atsushi
2021 - JPRN-jRCTs071200107 Japan;
R.Bos
2021 Phase 4 NCT04985435 Netherlands;
Filgotinib 200mg/day
Atsushi Kawakami
2021 Phase 3 NCT05090410 Japan;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Fish oil supplement
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2004 Phase 2 NCT00094562 United States;
Fish oil, gamma-linolenic acid
Charite University, Berlin, Germany
2008 Phase 2 NCT01179971 -
Fludarabine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1998 Phase 2 NCT00001677 United States;
Fluorescence Imaging
University Medical Center Groningen
2022 Phase 1 NCT03938701 Netherlands;
Flurbiprofen
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Focetria
Div KIR AMC
2010 - EUCTR2009-016789-10-NL Netherlands;
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
Folate
Biogen
2006 Phase 2 NCT00298272 United States;
Genentech, Inc.
2006 Phase 3 NCT00299104 United States;
2006 Phase 3 NCT00266227 United States;
2005 Phase 3 NCT00299130 United States;
2005 Phase 2 NCT00243412 United States;
Hoffmann-La Roche
2011 Phase 4 NCT01283971 Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
2007 Phase 4 NCT00462345 Korea, Republic of;
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Folic (or folinic) acid
GlaxoSmithKline
2019 Phase 3 NCT03980483 Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02799472 Germany;Poland;United States;
Folic acid
Biocad
2016 Phase 3 NCT02762838 Belarus;India;Russian Federation;
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
2015 Phase 2 NCT02504671 Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Hoffmann-La Roche
2009 Phase 1 NCT00965653 Canada;New Zealand;Spain;United Kingdom;
Kaneko Yuko
2018 Phase 4 JPRN-jRCT1031180088 Japan;South Korea;Taiwan;
Kojima Toshihisa
2020 - JPRN-jRCTs041200048 Japan;
Sanofi
2014 Phase 3 NCT02293902 Japan;
2013 Phase 1 NCT01850680 Japan;
Takahashi Nobunori
2020 - JPRN-jRCT1041190125 Japan;
The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042659 China;
2021 Phase 0 ChiCTR2100042329 China;
The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041819 China;
University of Alabama at Birmingham
1996 Phase 2 NCT00000395 United States;
University of Dundee
2005 Phase 4 EUCTR2005-000551-15-GB United Kingdom;
University of Leeds
2006 Phase 4 NCT01308255 United Kingdom;
Yunnan Hospital of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041894 China;
Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)
2021 Phase 0 ChiCTR2100042328 China;
Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042440 China;
Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041821 China;
Folic acid or folate
Hoffmann-La Roche
2007 Phase 3 NCT00578305 Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
Folic/folinic acid
Sanofi
2010 Phase 2 NCT01217814 Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
Takeda
2014 Phase 2 NCT02379091 Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
Folimet
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Folinic acid
University of Alabama at Birmingham
1996 Phase 2 NCT00000395 United States;
Fontolizumab
PDL BioPharma, Inc.
2005 Phase 2 NCT00281294 United States;
FosD
ASTRAZENECA
2011 - EUCTR2010-020892-22-IT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020745-27-IT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020744-35-IT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Astra Zeneca AB
2010 - EUCTR2010-020743-12-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 - EUCTR2010-020892-22-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020745-27-HU Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020745-27-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020744-35-DE Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-020745-27-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-GB Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-FR Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-BE Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 - EUCTR2010-020892-22-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-PT Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-ES Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020745-27-PT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-ES Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 - EUCTR2010-020744-35-PT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-LV Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-LT Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-GB Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-ES Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-CZ Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020743-12-HU Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
Fosfamatinib Disodium
RIGEL PHARMACEUTICALS INC
2009 - EUCTR2008-000744-13-IT Bulgaria;France;Germany;Italy;
Fostamatinib
AstraZeneca
2012 Phase 2 NCT01640054 Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
2012 Phase 2 NCT01569074 Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
2012 Phase 2 NCT01563978 Argentina;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 Phase 1 NCT01725230 United States;
2011 Phase 3 NCT01242514 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 2 NCT02092961 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
2011 Phase 2 NCT01264770 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 Phase 1 NCT01355354 United Kingdom;
2011 Phase 1 NCT01336218 United States;
2011 Phase 1 NCT01311622 United Kingdom;
2011 Phase 1 NCT01309854 United States;
2011 Phase 1 NCT01276262 United Kingdom;
2010 Phase 3 NCT01197755 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 NCT01197534 Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 NCT01197521 Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 1 NCT01245790 United States;
- Phase 2 JPRN-JapicCTI-121990 -
- Phase 2 JPRN-JapicCTI-121843 -
Fostamatinib 50 mg blue film-coated tablet
AstraZeneca AB
2012 - EUCTR2011-006070-73-DE Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-CZ Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-BG Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
Fostamatinib Disodium
AstraZeneca AB
2009 - EUCTR2008-000744-13-BG Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
2008 Phase 2 EUCTR2008-000744-13-BE Belgium;Bulgaria;France;Germany;Italy;
- - EUCTR2008-000744-13-DE Belgium;Bulgaria;France;Germany;Italy;
Rigel Pharmaceuticals, Inc
2009 - EUCTR2008-000744-13-FR Bulgaria;France;Germany;Italy;
Rigel Pharmaceuticals, Inc.
2008 - EUCTR2008-000743-34-FR France;Germany;Italy;
2008 - EUCTR2008-000743-34-DE France;Germany;Italy;
2008 - EUCTR2008-000743-34-BE Belgium;France;Germany;Italy;
2008 - EUCTR2008-000742-30-PL Bulgaria;Hungary;Poland;
2008 - EUCTR2008-000742-30-HU Bulgaria;Hungary;Poland;
2008 - EUCTR2008-000742-30-BG Bulgaria;Hungary;Poland;
Fostamatinib Disodium (R935788)
AstraZeneca
2008 Phase 2 NCT00805467 Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
Fostamatinib disodium
ASTRAZENECA
2011 - EUCTR2010-020892-22-IT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020745-27-IT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020744-35-IT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Astra Zeneca AB
2010 - EUCTR2010-020743-12-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 - EUCTR2010-020892-22-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-006070-73-DE Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-CZ Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-BG Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2011 Phase 2 EUCTR2010-023692-26-SK Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 Phase 2 EUCTR2010-023692-26-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020745-27-HU Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020745-27-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020744-35-DE Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-020745-27-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-GB Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-FR Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-BE Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 - EUCTR2010-020892-22-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-PT Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-ES Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020745-27-PT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-ES Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 - EUCTR2010-020744-35-PT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-LV Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-LT Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-GB Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-ES Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-CZ Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020743-12-HU Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
- - EUCTR2010-023692-26-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Fostamatinib disodium (R935788)
Rigel Pharmaceuticals
2008 Phase 2 NCT00665925 Bulgaria;Colombia;Israel;Mexico;Poland;Romania;United States;
2008 Phase 2 NCT00665626 Belgium;Brazil;Colombia;France;Germany;Italy;Peru;United States;
Fresenius-Kabi)
Humanis Klinikum Niederosterreich
2004 Phase 3 NCT00412256 Austria;
G1567970
Galapagos NV
2020 Phase 2 EUCTR2020-000658-83-BG Bulgaria;Georgia;Poland;Ukraine;
GB224
Genor Biopharma Co., Ltd.
2019 Phase 1 NCT04179513 China;
2017 Phase 1 NCT04178070 China;
GB242
Genor Biopharma Co., Ltd.
2017 Phase 3 NCT04178850 China;
GCK
Zhejiang Hisun Pharmaceutical Co. Ltd.
2017 Phase 1 NCT03755258 China;
GDC-0853
Genentech, Inc.
2016 Phase 2 NCT02983227 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2016 Phase 2 NCT02833350 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-000335-40-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GDC-0853 RO7010939
Genentech, Inc.
2016 Phase 2 EUCTR2016-000498-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GFI 38518168-AEK-B-007
Janssen-Cilag International NV
2009 - EUCTR2009-012118-27-NL Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-GB Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-ES Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-CZ Czech Republic;Netherlands;Spain;United Kingdom;
GLPG0259
Galápagos NV
2010 - EUCTR2009-015898-12-NL Belgium;Netherlands;
2010 - EUCTR2009-015898-12-BE Belgium;Netherlands;
GLPG0259 (Part B)
Galapagos NV
2010 Phase 2 NCT01211249 Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0259 oral capsule
Galapagos NV
2010 Phase 2 NCT01211249 Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0634
Galapagos NV
2019 Phase 2 EUCTR2018-003933-14-LV Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-ES Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-EE Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BG Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BE Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2017 Phase 2 EUCTR2012-003655-11-FR Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-LV Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003635-31-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 Phase 2 NCT01894516 Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2013 Phase 2 NCT01888874 Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-ES Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-LV Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-ES Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-BE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2012 Phase 2 NCT01668641 Hungary;Moldova, Republic of;Russian Federation;Ukraine;
2011 Phase 2 NCT01384422 Moldova, Republic of;
Galapagos SASU
2012 - EUCTR2011-005008-14-HU European Union;Hungary;Moldova, Republic of;Russian Federation;Ukraine;
Gilead Sciences Inc.
2014 Phase 2 EUCTR2012-003655-11-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
GLPG3970
Galapagos NV
2020 Phase 2 NCT04577781 Bulgaria;Georgia;Poland;Ukraine;
2020 Phase 2 EUCTR2020-000658-83-BG Bulgaria;Georgia;Poland;Ukraine;
GOL
University Medical Center Utrecht (UMCU)
2016 Phase 4 EUCTR2015-004858-17-NL Netherlands;
GP2013
Hexal AG
2015 Phase 1;Phase 2 EUCTR2010-021184-32-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 2 EUCTR2010-021184-32-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2011 Phase 2 EUCTR2010-021184-32-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2011 Phase 2 EUCTR2010-021184-32-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-FR Austria;Belgium;Bulgaria;Estonia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
Hexal AG (a Sandoz company)
2015 Phase 3 EUCTR2012-003876-38-PL Germany;Hungary;Poland;United States;
2015 Phase 3 EUCTR2012-003876-38-HU Germany;Hungary;Poland;United States;
2015 Phase 3 EUCTR2012-003876-38-DE Germany;Hungary;Poland;United States;
Sandoz
2011 Phase 1/Phase 2 NCT01274182 Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
GP2013 - A Proposed biosimilar rituximab
Sandoz
2015 Phase 3 NCT02514772 Germany;Hungary;Poland;United States;
GP2015
Hexal AG
2016 Phase 3 EUCTR2012-002009-23-HU Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2012-002009-23-DE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-SK Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-PL Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LV Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-GB Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-ES Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-EE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-CZ Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
Sandoz
2015 Phase 3 NCT02638259 Bulgaria;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
GP2017
HEXAL AG
2016 Phase 3 EUCTR2015-003433-10-IT Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
Hexal, AG
2016 Phase 3 EUCTR2015-003433-10-HU Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-GB Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-ES Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-DE Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-CZ Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
GRC 4039
Glenmark Pharmaceuticals SA
2011 - EUCTR2011-000107-40-GB India;Philippines;Poland;Sri Lanka;United Kingdom;
GS-5745
Gilead Sciences
2014 Phase 1 NCT02176876 Czech Republic;Hungary;
Gilead Sciences, Inc.
2017 Phase 2 EUCTR2016-000897-39-HU Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
2017 Phase 2 EUCTR2016-000897-39-DE Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
2017 Phase 2 EUCTR2016-000897-39-BE Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
GS-6034
GILEAD SCIENCES INCORPORATED
2017 Phase 3 EUCTR2016-000568-41-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Galapagos NV
2017 Phase 3 EUCTR2016-003630-25-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-DE Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-BE Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2012-003655-11-HU Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 Phase 2 EUCTR2012-003655-11-BG Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 Phase 2 EUCTR2012-003655-11-BE Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2013 Phase 2 EUCTR2012-003655-11-LV Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
- Phase 3 EUCTR2016-003630-25-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2012-003655-11-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences Inc.
2014 Phase 2 EUCTR2012-003655-11-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-003630-25-NL Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-PL Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-HU Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-GB Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-PL Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-NL Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-FR Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-ES Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-DE Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-BE Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000569-21-HU Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000569-21-GB Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001496-75-PL Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-001496-75-CZ Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GS-9876
Gilead Sciences
2016 Phase 2 NCT02885181 Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
Gilead Sciences, Inc.
2016 Phase 2 EUCTR2016-001496-75-PL Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-001496-75-CZ Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GSK 3196165
GlaxoSmithKline Research & Development Limited
2021 Phase 3 EUCTR2019-000878-30-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-000878-30-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
GSK1827771
GlaxoSmithKline
2007 Phase 1 NCT00539760 United States;
GSK1841157
GlaxoSmithKline Research & Development Ltd
2008 Phase 1;Phase 2 EUCTR2008-002046-27-FR Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-DE Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-BE Belgium;France;Germany;Spain;
GlaxoSmithKline S.A.
2008 - EUCTR2008-002046-27-ES Belgium;France;Germany;Spain;
GSK2982772
GlaxoSmithKline
2016 Phase 2 NCT02858492 Germany;Italy;Poland;Russian Federation;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000912-13-PL Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-GB Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-DE Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK2982772A, where A denotes the free base
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000912-13-PL Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-GB Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-DE Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK3117391
GlaxoSmithKline
2016 Phase 2 NCT02965599 Mexico;Poland;Romania;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2015-005800-27-PL Poland;Romania;Russian Federation;
GSK3152314A
GlaxoSmithKline
2008 Phase 2 NCT00674635 Australia;Former Serbia and Montenegro;New Zealand;Russian Federation;Serbia;Ukraine;United Kingdom;
GSK315234
GlaxoSmithKline Research & Development Ltd
2008 - EUCTR2006-000923-32-GB United Kingdom;
GSK315234 Injection 100mg/mL
GlaxoSmithKline Research & Development Limited
2010 Phase 2 EUCTR2009-012055-19-FR Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-IE Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-GB Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-BE Belgium;France;Ireland;United Kingdom;
GSK3196165
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2019 Phase 3 EUCTR2019-000868-18-IT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-IT Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003453-34-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
GlaxoSmithKline
2016 Phase 2 NCT02799472 Germany;Poland;United States;
2015 Phase 2 NCT02504671 Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GlaxoSmithKline Research & Development Limited
2020 Phase 3 EUCTR2019-000868-18-DE Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000867-26-DE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-LT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-HU Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-ES Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-CZ Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-PL Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-HU Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-GB Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-ES Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-EE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-BG Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LV Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LT Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-HU Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-GB Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-ES Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-CZ Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2015-004386-91-PL Germany;Poland;United States;
2016 Phase 2 EUCTR2015-004386-91-DE Germany;Poland;United States;
2015 Phase 2 EUCTR2014-003453-34-PL Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-HU Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-GB Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-ES Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-EE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-DE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-CZ Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GSK3196165 (Otilimab)
GlaxoSmithKline
2019 Phase 3 NCT04134728 Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 NCT03980483 Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03970837 Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
GSK3196165 Dose 1
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK3196165 Dose 2
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK3196165 Dose 3
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK706769
GlaxoSmithKline
2010 Phase 2 NCT00979771 Netherlands;
GlaxoSmithKline Research & Development Limited
2009 - EUCTR2009-012204-42-IE Belgium;Ireland;
2009 - EUCTR2009-012204-42-BE Belgium;Ireland;
GW274150
GlaxoSmithKline
2006 Phase 2 NCT00379990 Serbia;United Kingdom;
2005 Phase 2 NCT00370435 United Kingdom;
GW274150 Tablets
GlaxoSmithKline Research & Development Limited
2005 Phase 2 EUCTR2005-001977-82-GB United Kingdom;
GW406381
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline
2005 Phase 3 NCT00113308 Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2004 - EUCTR2004-000106-41-SE Sweden;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW406381X
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW856553
GlaxoSmithKline
2007 Phase 1 NCT00517543 United States;
2006 Phase 2 NCT00393146 Romania;Russian Federation;Spain;
2005 Phase 2 NCT00256919 Bulgaria;Germany;Spain;Sweden;Ukraine;
GlaxoSmithKline Research & Development Ltd
2005 - EUCTR2005-002969-37-SE Germany;Spain;Sweden;
- - EUCTR2005-002969-37-DE Germany;Spain;Sweden;
GlaxoSmithKline S.A.
2005 Phase 2 EUCTR2005-002969-37-ES Germany;Spain;Sweden;
Gadobutrol
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
Gadolinium
Tokyo Medical and Dental University
2013 - JPRN-UMIN000012399 Japan;
Gamma-Linolenic acid
FDA Office of Orphan Products Development
1994 - NCT00004420 -
Geleli
Peking University People's Hospital
2022 - NCT05240859 China;
General anesthesia with tourniquet
Riku Antero Palanne
2016 - NCT03364088 Finland;
General anesthesia without tourniquet
Riku Antero Palanne
2016 - NCT03364088 Finland;
Gerilimzumab
Bird Rock Bio, Inc.
2018 Phase 2 NCT02795299 -
Ginger
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Ginseng
Zhejiang Provincal Hospital of TCM
2019 Phase 2 ChiCTR1900026257 China;
Ginsenoside
Institute of Clinical Pharmacology, Central South University
2015 Phase 1 study ChiCTR-IPR-15006107 China;
2015 Phase 1 study ChiCTR-IPR-15005787 China;
2014 Phase 1 study ChiCTR-TRC-14004824 China;
GlucoCorticoid
University Hospital, Toulouse
2017 Phase 4 NCT02997605 France;
Glucocorticoid Agent
Hoffmann-La Roche
2017 - NCT03291457 Belgium;
Glucocorticoids (permitted,not necessary)
Fen Li
2016 Phase 4 NCT02878161 -
Glucophage (metformin)
Queen Mary University of London
2010 Phase 2 EUCTR2008-005708-18-GB United Kingdom;
Gold
Affiliated Hospital of North Sichuan Medical College
2018 - ChiCTR1800018637 China;
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2011 - ChiCTR-DDT-12002268 China;
Peking University People's Hospital
2012 - ChiCTR-DDT-12002658 China;
Golimumab
CENTOCOR
2010 - EUCTR2009-010582-23-IT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 Phase 3 EUCTR2004-003295-10-IT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor B.V.
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
Centocor BV
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor, Inc.
2010 Phase 3 NCT01248780 China;
2009 Phase 3 NCT00973479 Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
2007 Phase 1 NCT01362153 United States;
2006 Phase 3 NCT00361335 Argentina;Australia;Belgium;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Russian Federation;Ukraine;United States;
2006 Phase 3 NCT00299546 Australia;Austria;Canada;Finland;France;Germany;Netherlands;New Zealand;Spain;Switzerland;United Kingdom;United States;
2005 Phase 3 NCT00264550 Argentina;Australia;Brazil;Canada;Chile;Germany;Hungary;India;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Turkey;United States;
2003 Phase 2 NCT00207714 -
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
Janssen Inc.
2019 - NCT03729349 Canada;
Janssen-Cilag, S.A.
2015 - NCT02414984 Colombia;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
MedImmune LLC
2013 Phase 2 NCT01715896 Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;Turkey;United Kingdom;
MedImmune Ltd
2013 - EUCTR2011-005649-10-PT Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2010 - EUCTR2009-011137-26-PT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
Osaka City University Medical School
2012 Phase 4 JPRN-UMIN000009425 Japan;
Osaka Medical College
2015 - JPRN-UMIN000016950 Japan;
Peking Union Medical College Hospital
2019 - NCT04188249 China;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumatology, Internal MedicineJuntendo University School of Medicine, Juntendo Koshigaya Hospital
2013 - JPRN-UMIN000014485 Japan;
Sanofi
2010 Phase 2 NCT01217814 Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
Schering-Plough Research Institute, A Division of Schering Corporation
2010 Phase 3 EUCTR2009-011137-26-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-PL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-CZ Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-AT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-SK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-GB Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-ES Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-FI Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-DK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-DE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
Shering Plough Research Institute, A division of Schering Plough Corporation
2010 - EUCTR2009-011137-26-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
St.Marianna University School of Medicine
2013 - JPRN-UMIN000011891 Japan;
Takarazuka city hospital
2014 - JPRN-UMIN000016844 Japan;
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Golimumab 100 mg injections
Centocor, Inc.
2005 Phase 3 NCT00264537 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab 2 mg/kg IV
Janssen Biotech, Inc.
2013 Phase 3 NCT01962974 Argentina;Brazil;Canada;Colombia;Mexico;United States;
2009 Phase 3 NCT01004432 Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg SC
Janssen Biotech, Inc.
2009 Phase 3 NCT01004432 Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg injections
Centocor, Inc.
2005 Phase 3 NCT00264537 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab Final Vialed Product (FVP)
Centocor B.V.
2010 - EUCTR2008-006064-11-HU Hungary;Lithuania;
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2008-006064-11-LT Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
Golimumab Intravenous
Janssen Inc.
2015 - NCT02390700 Canada;
Golimumab Intravenous (IV)
Janssen Scientific Affairs, LLC
2016 - NCT02728934 United States;
Golimumab Liquid in Vial
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab Liquid in prefilled syringe
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Golimumab Pre-Filled Syringe
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab liquid in prefilled pen
Janssen Biologics B.V.
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or Prefilled Syringe
Janssen Biologics B.V.
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or prefilled syringe
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab pre-filled syringe
Centocor B.V.
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
Golimumab prefilled pen
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab prefilled pen or prefilled syringe
Janssen Biologics B.V.
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Grapefruit
Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
2014 - JPRN-UMIN000013546 Japan;
Green tea group
King Saud University
2015 - NCT03719469 -
Group 1 or Orencia treated group
University of California, Los Angeles
2012 Phase 4 NCT01717846 United States;
Guna-Anti Interleukin 1
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Antiinterleukin 1 alfa
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Antiinterleukin 1 beta
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Interleukin 10
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Interleukin 4
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
H.P. Acthar Gel
Ronald J. Rapoport, MD
2014 - NCT02434757 United States;
H.P. Acthar gel
Iraj Sabahi Research Inc.
2017 Phase 4 NCT03082573 United States;
H02AB04
Leiden University medical Centre
2015 Phase 2 EUCTR2014-004472-35-NL Netherlands;
H02AB07
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
HA20 (IMMU-106)
Nycomed GmbH
2011 - EUCTR2010-022378-15-GB Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
2011 - EUCTR2010-022378-15-CZ Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HA20 (Immu-106)
Nycomed GmbH
2011 - EUCTR2010-022378-15-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2010-022378-15-ES Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
2011 - EUCTR2010-022378-15-DE Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HB-adMSCs
Hope Biosciences
2018 Phase 1/Phase 2 NCT03691909 United States;
HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HBVAXPRO® 40 micrograms
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HCQ
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
Peking University First Hospital
2015 - NCT02320630 China;
Qilu Hospital of Shandong University
2017 Phase 4 NCT03855007 China;
HD-TIV
McGill University Health Centre/Research Institute of the McGill University Health Centre
2016 Phase 4 NCT02936180 Canada;
HE3286
Harbor Therapeutics
2008 Phase 1/Phase 2 NCT00712114 United States;
HEPATITIS B VACCINE (RDNA)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HL237
Hanlim Pharm. Co., Ltd.
2018 Phase 1 NCT03896594 Korea, Republic of;
2017 Phase 1 NCT03278470 Korea, Republic of;
HL237 tablet
Hanlim Pharm. Co., Ltd.
2020 Phase 2 NCT04638426 Korea, Republic of;
HLX01
Shanghai Henlius Biotech
2018 Phase 3 NCT03522415 China;
2016 Phase 1/Phase 2 NCT03355872 -
HM71224 Multiple ascending dose
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HM71224 food effect
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HM71224 single ascending dose
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HMPL-523
Hutchison Medipharma Limited
2014 Phase 1 NCT02105129 Australia;
HUC-MSC + DMARDs
Shenzhen Hornetcorn Bio-technology Company, LTD
2016 Phase 1 NCT02643823 China;
HUC-MSC infusion (BC-U001)
Beijing Baylx Biotech Co., Ltd.
2021 Phase 1/Phase 2 NCT04971980 China;
HUC-MSC suspension
Baylx Inc.
2020 Phase 1 NCT03828344 -
HUMIRA
CHRU de TOURS
2010 - EUCTR2010-021449-28-FR France;
FRANCISCO J. BLANCO GARCÍA
2013 - EUCTR2012-004482-40-ES Spain;
Helsingin reumakeskus
2010 - EUCTR2009-017325-19-FI Finland;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
HUMIRA (ADALIMUMAB)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
HUMIRA 40 mg solución inyectable en jeringa precargada
Abbott GmbH & Co. KG
2011 - EUCTR2010-019514-24-ES Austria;Czech Republic;Germany;Spain;
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-023587-40-ES Denmark;Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
2010 Phase 4 EUCTR2009-015845-21-ES Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
GENENTECH, Inc
2011 - EUCTR2010-021577-37-ES Bulgaria;Germany;Hungary;Spain;
Pfizer, S.A
2009 Phase 3 EUCTR2008-008338-35-ES Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
HYDROXYCHLOROQUINE SULFATE
Karolinska Institutet
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
HZT-501
Horizon Pharma Ireland, Ltd., Dublin Ireland
2009 Phase 3 NCT00984815 United States;
2007 Phase 3 NCT00613106 United States;
Havrix
HY, HUS
2011 - EUCTR2009-016055-22-SE Finland;Sweden;
Hematopoietic Stem Cell Transplantation
Northwestern University
2002 Phase 1 NCT00282412 United States;
Hemay007 1200 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hemay007 600 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hemay007 800 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hepatitis A vaccine ( HAVRIX or EPAXAL)
Lars Rombo
2009 Phase 2 NCT01360970 Finland;Sweden;
Hepatitis A vaccine and tetanus vaccine
University of Zurich
2013 - NCT01947465 Switzerland;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2014 Phase 2 NCT01967316 United States;
2013 Phase 2 NCT02538757 United States;
High dose ORTD-1
Oryn Therapeutics, LLC
2021 Phase 1 NCT04286789 United States;
High dose of BIIL 284 BS tablets
Boehringer Ingelheim
2000 Phase 1 NCT02247375 -
High dose vehicle control
Oryn Therapeutics, LLC
2021 Phase 1 NCT04286789 United States;
High frequency ultrasonography
GlaxoSmithKline
2004 - NCT00242853 United Kingdom;
High-resolution peripheral quantitative computed tomography (HR-pQCT)
University of California, San Francisco
2013 - NCT01773681 United States;
HrIL-2 active
Peking University People's Hospital
2015 Phase 2 NCT02467504 China;
HuMax-CD20
GENMAB A/S
2007 - EUCTR2007-002945-18-IT Czech Republic;Italy;
Genmab A/S
2008 Phase 3 EUCTR2007-002951-18-FR Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-SE Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-DK Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002950-42-BE Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002951-18-IT Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-002951-18-ES Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-002951-18-NL Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-002950-42-LT Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-HU Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-ES Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002945-18-CZ Czech Republic;
2006 - EUCTR2004-003771-37-HU Hungary;
GlaxoSmithKline Research & Development
2008 Phase 3 EUCTR2007-002951-18-GB Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-DE Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002950-42-GB Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2008 Phase 1;Phase 2 EUCTR2008-002046-27-FR Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-DE Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-BE Belgium;France;Germany;Spain;
2007 Phase 2 EUCTR2007-004878-31-GB Denmark;Hungary;United Kingdom;
2007 - EUCTR2007-004878-31-DK Denmark;Hungary;United Kingdom;
GlaxoSmithKline Research & Development Ltd.
2008 - EUCTR2007-004878-31-HU Denmark;Hungary;United Kingdom;
GlaxoSmithKline Research and Development
2008 - EUCTR2007-002950-42-PL Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-CZ Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
GlaxoSmithKline S.A.
2008 - EUCTR2008-002046-27-ES Belgium;France;Germany;Spain;
HuMax-CD4
Emergent Product Development Seattle LLC
2002 Phase 2/Phase 3 NCT00042406 Canada;United States;
Huang qi gui zhi wu wu granule
Cui xuejun
2018 Phase 2/Phase 3 NCT03593837 -
Human Anti-TNF IgG1 Monoclonal Antibody
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Human Anti-TNFalfa
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Human Recombinant IgG1, lambda
MorphoSys AG
2010 - EUCTR2007-006129-29-PL Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2010 - EUCTR2007-006129-29-NL Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2010 - EUCTR2007-006129-29-BG Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2009 - EUCTR2007-006129-29-DE Bulgaria;Germany;Netherlands;Poland;Ukraine;
Human anti TNF-alpha monoclonal
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti TNF-alpha monoclonal antibody
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti-IL6 monoclonal antibody
JANSSEN-CILAG INTERNATIONAL N.V.
2012 - EUCTR2010-022243-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
Janssen-Cilag International N.V.
2015 Phase 3 EUCTR2012-001176-10-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2010-022242-24-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2013 - EUCTR2010-022243-38-NL Argentina;Australia;Austria;Belgium;Brazil;C
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+) isomer of racemic mefloquine
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+) isomer or racemic mefloquine
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(+)erythromefloquine
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile,
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
(3R,4R)-4-methyl-3-(methyl-1H-pyrrolo [2,3-d]pyrimidin-4-ylamino)-ß-oxo-1-piperidinepropanenitrile,
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-beta-oxo-1-
Pfizer S.A.
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(3R,4R)-4-metil-3-(metil-1H-pirrolo [2,3-d]pirimidin-4-ilamino)-ß-oxo-1-
Pfizer S.A.
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
(CDP6038
R-Pharm
2017 Phase 3 EUCTR2015-005309-35-LV Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-HU Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-GB Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005307-83-LV Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005308-27-HU Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
2016 Phase 3 EUCTR2015-005308-27-DE Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;Russian Federation;Turkey;United States;
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-LT Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-HU Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-DE Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International LLC
2017 Phase 3 EUCTR2015-005309-35-PL Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-LT Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-DE Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2015-005309-35-CZ Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005308-27-CZ Argentina;Brazil;Colombia;Czech Republic;Germany;Hungary;Korea, Republic of;Mexico;Poland;United States;
2016 Phase 3 EUCTR2015-005307-83-CZ Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-BG Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International, LLC.
2017 Phase 3 EUCTR2015-005309-35-BG Argentina;Belarus;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;Turkey;United Kingdom;United States;
0109-0012A 100 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2014 Phase 2 EUCTR2013-001492-20-PT Ireland;Portugal;Spain;United Kingdom;
2014 Phase 2 EUCTR2013-001492-20-ES Ireland;Portugal;Spain;United Kingdom;
2013 Phase 2 EUCTR2013-001492-20-GB Belgium;Czech Republic;Germany;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 25 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0109-0012A 50 mg/ml
NOVO NORDISK
2013 - EUCTR2012-000610-11-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-IT Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
Novo Nordisk A/S
2013 - EUCTR2012-000610-11-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000610-11-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-000609-58-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-000609-58-BE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 Phase 2 EUCTR2012-000609-58-GB Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000610-11-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000610-11-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United States;
2012 - EUCTR2012-000609-58-HU Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2012-000609-58-DE Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
- - EUCTR2012-000609-58-ES Argentina;Belgium;Brazil;Canada;Czech Republic;European Union;Germany;Hungary;Italy;Mexico;Russian Federation;Spain;Ukraine;United Kingdom;United States;
0114-0006B
Novo Nordisk A/S
2012 Phase 2 EUCTR2011-005376-42-ES Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-LV Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-HU Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
2012 - EUCTR2011-005376-42-BG Bulgaria;Hungary;Latvia;Poland;Russian Federation;Serbia;Spain;
0881
Wyeth Pharmaceuticals
2005 - EUCTR2004-000563-96-FI Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2005 - EUCTR2004-000563-96-AT Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-SE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-IE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-HU Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-ES Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-DK Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
- Phase 4 EUCTR2004-000563-96-NO Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth Pharmaceuticals France
2008 Phase 4 EUCTR2007-000896-41-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-001625-10-PL Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-DE Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-AT Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000896-41-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2010 Phase 4 EUCTR2008-002623-85-SE France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2010 - EUCTR2007-000896-41-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2007-000896-41-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 Phase 4 EUCTR2008-002623-85-FR France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2008-002623-85-ES France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
2008 - EUCTR2007-000896-41-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
1 ml NaCl
Vrije Universiteit Brussel
2010 - NCT01154647 Belgium;
1,5-anhydro-2,3-dideoxy-3-[[(1R,3S)-3-[[7,8-dihydro-3- (trifluoromethyl)-1,6-naphthyridin-6(5H)-yl]c
Merck Sharp & Dohme (Sweden) AB
2004 - EUCTR2004-000074-31-SE Sweden;
Merck Sharp & Dohme BV
2005 Phase 2 EUCTR2004-000074-31-BE Belgium;Sweden;
118-42-3
Karolinska Institutet
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
13-valent pneumococcal conjugate vaccine
Region Skane
2016 Phase 4 NCT03762824 -
15-O labeled water
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2001 Phase 1 NCT00014794 United States;
18F-FDG
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
18F-GE-180
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
18F]PEG-Folate
VU Medical Center, department of Rheumatology
2020 Phase 4 EUCTR2018-004429-94-NL Netherlands;
2018 Phase 4 EUCTR2018-001114-15-NL Netherlands;
2 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
2-HOBA
Vanderbilt University Medical Center
2022 Phase 2 NCT05274243 United States;
2-{7-[1,1-dimethyl-3-(4-sulfobutyl)-benz[e]indolin-2-ylidene]-1,3,5-heptatrienyl}-1,1-dimethyl-3-(sulfobutyl)-1H-benz[e]-indolium hydroxide,inner salt
Knowledge Centre for Rheumatology and Back Diseases
2013 Phase 4 EUCTR2013-004006-26-DK Denmark;
23-Valent Pneumococcal Polysaccharide Vaccine
Genentech, Inc.
2010 Phase 4 NCT01163747 United States;
23-valent pneumococcal polysaccharide vaccine
Genentech, Inc.
2006 Phase 2 NCT00282308 United States;
Region Skane
2016 Phase 4 NCT03762824 -
2593
Aarhus University Hospital, Denmark
2007 Phase 4 EUCTR2007-000082-38-DK Denmark;
331731-18-1
AbbVie Deutschland GmbH & Co. KG
2015 Phase 4 EUCTR2014-001114-26-SE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 4 EUCTR2014-001114-26-NL Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 4 EUCTR2014-001114-26-IT Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-IE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-HU Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-GR Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-GB Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-FR Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-ES Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2014 Phase 4 EUCTR2014-001114-26-DE Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 4 EUCTR2014-001114-26-AT Australia;Austria;Canada;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Abbott Japan Co., Ltd.
- - EUCTR2014-004558-33-Outside-EU/EEA Japan;
35565011
DIPARTIMENTO DI MEDICINA CLINICA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI NAPOLI FEDERICO II
2016 Phase 3 EUCTR2015-000570-35-IT Italy;
4 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)- 1H-pyrazol-1-yl] benzenesulfonamide
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide
Astellas Pharma Global Development
2013 Phase 2 EUCTR2011-006021-23-CZ Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 Phase 2 EUCTR2011-006021-23-BG Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 - EUCTR2011-006021-23-HU Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2012 - EUCTR2011-006021-23-BE Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
Astellas Pharma Global Development Inc. (APGD)
2013 Phase 2 EUCTR2011-006021-23-PL Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
42942019
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLI
2016 Phase 4 EUCTR2016-002061-54-IT Italy;
5-Chlor-6'-methyl- 3-[4-(methylsulfonyl)phenyl]- 2,3'-bipyridin
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
2010 Phase 3 EUCTR2010-019871-31-GB Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2011 Phase 3 EUCTR2010-019871-31-SK Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
2011 Phase 3 EUCTR2010-019871-31-BE Austria;Belgium;Czech Republic;Finland;Germany;Lithuania;Slovakia;United Kingdom;
2011 - EUCTR2010-019871-31-CZ Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-LT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-FI Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-DE Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2010 - EUCTR2010-019871-31-AT Argentina;Austria;Belgium;Canada;Colombia;Czech Republic;Finland;Germany;India;Lithuania;Mexico;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
6 million hMSC
MetroHealth Medical Center
2017 Phase 1 NCT03186417 United States;
6-(nitrooxy)hexyl(2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
68Ga-BNOTA-PRGD2
Peking Union Medical College Hospital
2012 Early Phase 1 NCT01940926 China;
68Ga-FAPI
Peking Union Medical College Hospital
2020 Early Phase 1 NCT04514614 China;
68Ga-NEB
Peking Union Medical College Hospital
2019 Phase 1 NCT04273334 China;
7-valent Pneumococcal Conjugate vaccine
Dept of Rheumatology, Lund University Hospital, Lund, Sweden
2008 - EUCTR2007-006539-29-SE Sweden;
70930.00.00
medac Gesellschaft für klinische Spezialpräparate mbH
2012 - EUCTR2012-000222-21-DE Germany;
8594739041288
Merck & Co., Inc.
2005 Phase 2 EUCTR2004-004302-24-CZ Czech Republic;Finland;Germany;Italy;Spain;
89Zr-DFO-CZP
Robert Flavell, MD, PhD
2018 Phase 1 NCT03546335 United States;
9-Chloro-2,3-dimethyl-6-(N,N-dimethylaminoethylamino-2-oxoethyl)-6H-indolo[2,3-b] quinoxaline
OxyPharma AB
2008 - EUCTR2006-004834-33-PL Bulgaria;Latvia;Poland;United Kingdom;
2007 Phase 2 EUCTR2006-004834-33-GB Belgium;Bulgaria;Latvia;Lithuania;Poland;United Kingdom;
2007 - EUCTR2006-004834-33-BE Belgium;Bulgaria;Latvia;Poland;United Kingdom;
9512
Center for Research and Development Uppsala University/County Council of Gävleborg
2014 Phase 4 EUCTR2014-000993-20-SE Sweden;
99mTc-3PRGD2
First Affiliated Hospital of Fujian Medical University
2015 Phase 0 NCT02723760 China;
99mTc-S-HYNIC Certolizumab pegol
Ghent University Hospital
2017 Phase 4 EUCTR2016-004300-65-BE Belgium;
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
99mTc-rhAnnexin V-128
Advanced Accelerator Applications
2014 Phase 1/Phase 2 NCT02328027 Switzerland;
A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
University of Minnesota - Clinical and Translational Science Institute
2004 - NCT01600521 China;
AB1010
AB Science
2014 - EUCTR2010-020992-21-DE Argentina;Bosnia and Herzegovina;Czech Republic;Germany;Greece;India;Mexico;Monaco;Morocco;Philippines;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Tunisia;Ukraine;United States;
2012 Phase 3 EUCTR2010-020992-21-GR Czech Republic;Germany;Greece;India;Monaco;Poland;Romania;Slovakia;Spain;Thailand;Turkey;United States;
2011 Phase 3 EUCTR2010-020992-21-SK Czech Republic;France;Germany;Greece;India;Poland;Romania;Slovakia;Spain;Thailand;Tunisia;Turkey;United States;
2011 - EUCTR2010-020992-21-ES Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
2011 - EUCTR2010-020992-21-CZ Czech Republic;Germany;Greece;India;Slovakia;Spain;Thailand;Turkey;United States;
ABA, open-label (OL)
Bristol-Myers Squibb
2005 Phase 3 NCT00095147 Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
ABBV-105
AbbVie
2019 Phase 2 NCT03823378 Belgium;Canada;Czechia;Hungary;Poland;Spain;United Kingdom;
2018 Phase 2 NCT03682705 Belgium;Canada;Czechia;Germany;Hungary;Ireland;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-002306-31-HU Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-BE Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-BE Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
ABBV-105, A-1519938.0
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-000666-10-HU Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-000666-10-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2018 Phase 2 EUCTR2018-000666-10-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABBV-154
ABBVIE DEUTSCHLAND GMBH & CO. KG
2021 Phase 2 EUCTR2020-005303-39-IT Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2021 Phase 2 NCT04888585 Australia;Canada;Czechia;France;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie Deutschland GmbH & Co. KG
2021 Phase 2 EUCTR2020-005303-39-PL Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-NL Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-GR Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-ES Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2021 Phase 2 EUCTR2020-005303-39-DE Australia;Canada;Czechia;Germany;Greece;Hungary;Israel;Italy;Japan;Korea, Republic of;Netherlands;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
ABBV-257
AbbVie
2015 Phase 1 NCT02531178 Germany;
ABBV-3373
AbbVie
2019 Phase 2 NCT03823391 Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-003053-21-PL Israel;Poland;Puerto Rico;United States;
ABP 501
Amgen
2014 Phase 3 NCT02114931 Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 Phase 3 NCT01970475 Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Amgen Inc
2014 Phase 3 EUCTR2013-000525-31-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-000525-31-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Amgen Inc.
2014 Phase 3 EUCTR2013-004654-13-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2013-004654-13-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-004654-13-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
ABP 710
Amgen
2016 Phase 3 NCT02937701 Australia;Bulgaria;Canada;Czech Republic;Czechia;Germany;Hungary;Poland;Spain;United States;
ABP 710 - Biosimilar to infliximab
Amgen Inc.
2016 Phase 3 EUCTR2014-004704-29-PL Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-HU Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-ES Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-DE Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-CZ Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
2016 Phase 3 EUCTR2014-004704-29-BG Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;Poland;Romania;Spain;United States;
ABP 798
Amgen
2016 Phase 3 NCT02792699 Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 - Biosimilar to rituximab
Amgen Inc
2015 Phase 1;Phase 3 EUCTR2013-005543-90-BG Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-PL Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-HU Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
2014 Phase 1;Phase 3 EUCTR2013-005543-90-DE Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABP 798 Biosimilar to Rituximab
Amgen Inc
2017 Phase 1;Phase 3 EUCTR2013-005543-90-EE Bulgaria;Canada;Estonia;Germany;Hungary;Poland;United States;
ABT 494
AbbVie Deutschland GmbH & Co. KG
2014 Phase 2 EUCTR2013-003984-72-LV Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 Phase 2 EUCTR2013-003984-72-CZ Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 Phase 2 EUCTR2013-003530-33-NL Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-LV Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-ES Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Netherlands;Puerto Rico;Russian Federation;Serbia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-NL Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-CZ Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 Phase 2 EUCTR2013-002358-57-BE Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
2014 - EUCTR2013-003984-72-SK Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 - EUCTR2013-002358-57-HU Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie Deutschland GmbH & Co.KG
2014 - EUCTR2013-003984-72-HU Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
AbbVie Inc.
2014 - EUCTR2013-003984-72-ES Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United States;
2014 - EUCTR2013-002358-57-ES Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;Poland;Puerto Rico;Spain;United Kingdom;United States;
ABT-122
AbbVie
2015 Phase 2 NCT02433340 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 NCT02141997 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
2013 Phase 1 NCT01853033 United States;
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2014-001471-31-RO Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2014-001471-31-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2014-001471-31-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
ABT-494
ABBVIE DEUTSCHLAND GMBH & CO. KG
2017 Phase 3 EUCTR2016-000933-37-IT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;European Union;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-IT Argentina;Australia;Austria;Barbados;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Japan;Kazakhstan;Korea, Democratic People's Republic of;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
AbbVie
2014 Phase 2 NCT02049138 Australia;Belgium;Bulgaria;Chile;Czech Republic;Czechia;Hungary;Israel;Latvia;Mexico;New Zealand;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 Phase 2 NCT01960855 Australia;Belgium;Canada;Czech Republic;Hungary;Netherlands;New Zealand;Poland;Puerto Rico;Spain;United Kingdom;United States;
AbbVie (prior sponsor, Abbott)
2012 Phase 1 NCT01741493 United States;
AbbVie Deutschland GmbH & Co. KG
2019 Phase 2 EUCTR2018-002306-31-HU Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-002306-31-BE Belgium;Canada;Czech Republic;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-HU Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2019 Phase 2 EUCTR2018-000666-10-ES Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2019 Phase 2 EUCTR2018-000666-10-BE Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Spain;United Kingdom;
2018 Phase 3 EUCTR2016-000933-37-BG Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2018 Phase 2 EUCTR2018-000666-10-GB Belgium;Canada;Czech Republic;Germany;Hungary;Poland;Puerto Rico;Spain;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-SK Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-SE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-PT Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-NL Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-DE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-CZ Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000933-37-BE Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-LV Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-HU Argentina;Australia;Belarus;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Democratic People's Republic of;Latvia;Mexico;Netherlands;New Zealand;Norway;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000933-37-ES Argentina;Australia;Belarus;Brazil;Canada;Chile;Colombia;European Union;Hungary;Israel;Korea, Democratic People's Republic of;Latvia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Spain;Switzerland;Turkey;United States;
2016 Phase 3 EUCTR2015-003376-75-PT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-PL Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-GR Argentina;Australia;Austria;Belgium;Chile;Colombia;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-ES Argentina;Australia;Austria;Chile;Colombia;European Union;Israel;Japan;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-BE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003376-75-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;European Union;Greece;Hungary;Israel;Japan;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Spain;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003335-35-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-SI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-NO Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-LV Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-IE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-HU Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-GR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-FR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-DK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003335-35-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Denmark;European Union;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;New Zealand;Norway;Portugal;Puerto Rico;Russian Federation;Slovakia;Slovenia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-SI Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-RO Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-PT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-PL Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-LV Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-LT Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-IE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-HU Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003334-27-HR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-GR Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003334-27-GB Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-FI Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-ES Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Colombia;Croatia;Egypt;European Union;Greece;Hong Kong;Hungary;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-CZ Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-BG Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003334-27-BE Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003333-95-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-ES Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Croatia;Denmark;Egypt;European Union;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003333-95-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-DE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003333-95-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-PT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-PL Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-LV Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-LT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-IE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-HU Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-HR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-GR Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-GB Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-FI Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-ES Argentina;Australia;Austria;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Malaysia;Mexico;New Zealand;Norway;Poland;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United States;
2016 Phase 3 EUCTR2015-003332-13-DK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-CZ Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-BG Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-BE Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003332-13-AT Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2016 - EUCTR2015-003332-13-NO Argentina;Australia;Belarus;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Denmark;Egypt;European Union;Finland;Hong Kong;Israel;Kazakhstan;Korea, Republic of;Malaysia;Mexico;New Zealand;Norway;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Switzerland;Taiwan;Turkey;Ukraine;United States;
2015 Phase 3 EUCTR2015-003334-27-SK Argentina;Australia;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;Czech Republic;Egypt;European Union;Finland;Greece;Hong Kong;Hungary;Ireland;Israel;Japan;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Poland;Portugal;Puerto Rico;Russian Federation;Serbia;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2015 Phase 3 EUCTR2015-003333-95-SK Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Denmark;Egypt;European Union;Finland;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Portugal;Puerto Rico;Russian Federation;Serbia;Singapore;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2013-003530-33-LV Belgium;Bulgaria;Chile;Czech Republic;European Union;Hungary;Israel;Latvia;Mexico;Netherlands;New Zealand;Puerto Rico;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
ABT-Humira
Abbott GmbH & Co. KG
2008 - EUCTR2007-005905-23-GB Germany;United Kingdom;
2008 - EUCTR2007-005905-23-DE Germany;United Kingdom;
ABX464
Abivax
2019 Phase 2 EUCTR2019-001578-27-HU Hungary;
2019 Phase 2 EUCTR2018-004677-27-HU Belgium;Hungary;
2019 Phase 2 EUCTR2018-004677-27-BE Belgium;Hungary;
Abivax S.A.
2019 Phase 2 NCT04049448 Belgium;Czechia;France;Hungary;Poland;
2019 Phase 2 NCT03813199 Belgium;Czechia;France;Hungary;Poland;
AC430
Daiichi Sankyo Inc.
2010 Phase 1 NCT01287858 United States;
ACZ885
NOVARTIS FARMA
2007 - EUCTR2007-001665-15-IT Germany;Italy;Netherlands;Spain;
2007 - EUCTR2006-001553-10-IT Germany;Italy;Netherlands;
Novartis
2007 Phase 2 NCT00554606 Belgium;Germany;Italy;Netherlands;Russian Federation;Spain;Switzerland;Turkey;United States;
2007 Phase 1/Phase 2 NCT00505089 Belgium;Germany;Netherlands;Poland;
2003 Phase 1/Phase 2 NCT00619905 Germany;Netherlands;Switzerland;
Novartis Farmacéutica S.A.
2009 Phase 2 EUCTR2008-005320-81-ES Austria;Belgium;Germany;Spain;
Novartis Pharma AG
2007 - EUCTR2006-001550-27-FI Austria;Finland;Germany;Spain;
2007 - EUCTR2006-001550-27-DE Austria;Finland;Germany;Spain;
2006 - EUCTR2006-001550-27-BE Austria;Belgium;Finland;Germany;Spain;
2006 - EUCTR2006-001550-27-AT Austria;Finland;Germany;Spain;
Novartis Pharma Services AG
2009 - EUCTR2008-005320-81-DE Austria;Germany;Spain;
2009 - EUCTR2008-005320-81-BE Austria;Belgium;Germany;Spain;
2008 - EUCTR2008-005320-81-AT Austria;Germany;Spain;
2007 - EUCTR2007-001665-15-DE Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-DE Austria;Germany;Spain;
2007 - EUCTR2006-001553-10-DE Germany;Italy;Netherlands;
ACZ885 (investigational)
Novartis
2007 Phase 2 NCT00504595 Russian Federation;Spain;Switzerland;Turkey;
ACZ885 Drug Substance
Novartis Farmaceutica S.A.
2007 - EUCTR2007-001665-15-ES Belgium;Germany;Italy;Netherlands;Spain;
Novartis Farmacéutica S.A
2007 - EUCTR2006-004669-32-ES Spain;
Novartis Farmacéutica, S.A.
2007 - EUCTR2007-000491-16-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2007 Phase 2 EUCTR2006-001553-10-BE Belgium;Germany;Italy;Netherlands;
2007 - EUCTR2007-001665-15-NL Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-BE Belgium;Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-BE Austria;Belgium;Germany;Spain;
2007 - EUCTR2007-000491-16-AT Austria;Germany;Spain;
2007 - EUCTR2006-004666-14-DE Germany;
2007 - EUCTR2006-004666-14-BE Belgium;Germany;
2007 - EUCTR2006-001553-10-NL Germany;Italy;Netherlands;
AD 452
Arakis Ltd.
2005 - EUCTR2005-002421-31-DE Germany;United Kingdom;
Sosei
2005 Phase 2 NCT00141934 United States;
AD 452 18 mg tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
AD 452 4.5 mg Tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
AD 452 9 mg tablet
Arakis Ltd
2005 - EUCTR2005-002421-31-GB Germany;United Kingdom;
ADALIMUMAB HUMIRA
Pfizer Inc
2020 Phase 4 EUCTR2019-000284-24-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2019 Phase 3 EUCTR2019-000284-24-LT Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
ADALIMUMAB-EU
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
ADL5859
Cubist Pharmaceuticals LLC
2007 Phase 2 NCT00626275 United States;
AGM 719
Amgen
2002 Phase 2 NCT00038298 United States;
AI-1000 G2
Hoffmann-La Roche
2016 Phase 4 NCT02682823 United States;
AIN457
NOVARTIS FARMA
2012 - EUCTR2012-002760-27-IT Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000275-13-IT Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
Novartis Farma S.p.A.
2013 - EUCTR2013-000944-25-IT Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
Novartis Farmaceutica, S.A.
2012 - EUCTR2012-002760-27-ES Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Novartis Farmacéutica S.A.
2011 - EUCTR2011-000102-21-ES Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
Novartis Pharma AG
2012 - EUCTR2012-002760-27-SK Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2012-002760-27-HU Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2012-002760-27-CZ Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2011-006058-94-PT Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2012 - EUCTR2011-006058-94-GR Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 - EUCTR2011-000275-13-HU Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000275-13-GB Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000275-13-BE Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Peru;Thailand;Turkey;United Kingdom;United States;
2011 - EUCTR2011-000102-21-SK Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2010-024516-34-SK Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
2011 - EUCTR2010-024516-34-HU Bulgaria;Canada;Hungary;Italy;United States;
2011 - EUCTR2010-024516-34-BG Bulgaria;Canada;Hungary;Italy;Slovakia;United States;
Novartis Pharma K.K.
2013 Phase 3 JPRN-JapicCTI-132209 -
2012 Phase 3 JPRN-JapicCTI-132091 -
Novartis Pharma Services AG
2013 - EUCTR2012-002760-27-BG Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Novartis Pharma Services AG
2013 - EUCTR2013-000944-25-HU Argentina;Belgium;Canada;Colombia;Guatemala;Hungary;India;Italy;Japan;Mexico;Panama;Thailand;United States;
2013 - EUCTR2011-006058-94-DE Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2012 - EUCTR2012-002760-27-DE Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2012 - EUCTR2011-006058-94-CZ Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Japan;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 Phase 2 EUCTR2011-001220-38-GB Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 Phase 2 EUCTR2011-001220-38-BE Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 - EUCTR2011-001220-38-DE Belgium;Germany;Russian Federation;United Kingdom;United States;
2011 - EUCTR2011-000102-21-HU Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-DE Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-CZ Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2011-000102-21-BG Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2009 - EUCTR2009-011000-34-SK Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-HU Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-DE Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-CZ Czech Republic;Germany;Hungary;Slovakia;
2009 - EUCTR2009-011000-34-BE Belgium;Czech Republic;Germany;Hungary;Slovakia;
Novartis Pharmaceuticals
2011 Phase 3 NCT01350804 Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
2005 Phase 1/Phase 2 NCT00669942 Belgium;Germany;Netherlands;Singapore;Spain;United States;
AIN457F
NOVARTIS FARMA
2012 - EUCTR2011-006058-94-IT Argentina;Brazil;Colombia;Czech Republic;Dominican Republic;Ecuador;Germany;Greece;Guatemala;India;Italy;Korea, Republic of;Panama;Portugal;South Africa;United States;
2011 - EUCTR2011-000102-21-IT Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;Italy;Mexico;Russian Federation;Slovakia;Spain;United States;
2011 - EUCTR2010-024516-34-IT Bulgaria;Canada;Hungary;Italy;United States;
AK106-001616
Asahi Kasei Pharma Corporation
2011 Phase 2 NCT01285752 Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-SK Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-HU Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
2011 - EUCTR2010-021558-21-GB Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2011 - EUCTR2010-021558-21-DE Czech Republic;Germany;Hungary;Slovakia;United Kingdom;
2010 - EUCTR2010-021558-21-CZ Czech Republic;Germany;Hungary;Slovakia;Ukraine;United Kingdom;
2009 Phase 2 NCT00902369 Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
2009 - EUCTR2008-006075-75-HU Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-GB Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-DE Czech Republic;Germany;Hungary;United Kingdom;
2009 - EUCTR2008-006075-75-CZ Czech Republic;Germany;Hungary;United Kingdom;
ALD518 monoclonal antibody (anti IL-6 mAb)
Alder Biopharmaceuticals, Inc
2008 - EUCTR2008-004931-39-PL Poland;
ALX-0061
Ablynx
2015 Phase 2 NCT02518620 Belgium;Bulgaria;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;
2015 Phase 2 NCT02309359 Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 NCT02287922 Belgium;Bulgaria;Czech Republic;Czechia;Georgia;Germany;Hungary;Macedonia, The Former Yugoslav Republic of;Mexico;Moldova, Republic of;North Macedonia;Poland;Romania;Serbia;Spain;United States;
2014 Phase 1 NCT02101073 Netherlands;
2011 Phase 1/Phase 2 NCT01284569 Czech Republic;Czechia;Hungary;Netherlands;Poland;
Ablynx NV
2015 Phase 2 EUCTR2014-003034-42-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003034-42-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;
2015 Phase 2 EUCTR2014-003033-26-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-CZ Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003033-26-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-HU Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-ES Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-DE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-CZ Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-BG Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
2015 Phase 2 EUCTR2014-003012-36-BE Argentina;Belgium;Bulgaria;Czech Republic;Georgia;Germany;Hungary;Macedonia, the former Yugoslav Republic of;Mexico;Moldova, Republic of;Poland;Romania;Serbia;Spain;United States;
ALX-0061 Nanobody
Ablynx NV
2011 - EUCTR2010-022865-81-HU Czech Republic;Hungary;
2011 - EUCTR2010-022865-81-CZ Czech Republic;Hungary;
AMG 108
AMGEN S.P.A.
2007 - EUCTR2006-003698-29-IT Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-IT Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
Amgen
2006 Phase 2 NCT00369473 Australia;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;United Kingdom;United States;
2006 Phase 2 NCT00293826 Australia;Austria;Belgium;Canada;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Mexico;Netherlands;Poland;Puerto Rico;Slovakia;Spain;Sweden;United Kingdom;United States;
Amgen Inc.
2007 - EUCTR2006-003698-29-LV Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-IE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-HU Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-EE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2006-003698-29-AT Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-LV Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-IE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2005-003558-83-EE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2006-003698-29-SK Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
2006 Phase 2 EUCTR2006-003698-29-FR Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Slovakia;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-SK Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-GB Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 Phase 2 EUCTR2005-003558-83-ES Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-SE Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-NL Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-GB Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-CZ Austria;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2006-003698-29-BE Austria;Belgium;Czech Republic;Estonia;France;Hungary;Ireland;Italy;Latvia;Netherlands;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-SE Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-NL Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-CZ Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-BE Austria;Belgium;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2005-003558-83-AT Austria;Czech Republic;Estonia;Ireland;Italy;Latvia;Netherlands;Spain;Sweden;United Kingdom;
AMG 162
DAIICHISANKYO Co.,Ltd.
2013 Phase 3 JPRN-JapicCTI-132277 -
2010 Phase 2 JPRN-JapicCTI-101263 -
AMG 357
Amgen
2015 Phase 1 NCT02499315 United States;
AMG 570
Amgen
2017 Phase 1 NCT03156023 Germany;United States;
AMG 592
Amgen
2018 Phase 1/Phase 2 NCT03410056 Bulgaria;Germany;Poland;Spain;United States;
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-001944-36-ES Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2017-001944-36-PL Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMG 714
Amgen
2002 Phase 2 NCT00433875 -
AMG 719
Amgen
2002 Phase 2 NCT00038298 United States;
AMG 827
Amgen
2010 Phase 2 NCT01059448 Bulgaria;Canada;Czech Republic;Latvia;Mexico;Poland;United Kingdom;United States;
2009 Phase 2 NCT00950989 Bulgaria;Canada;Czech Republic;Hungary;Latvia;Mexico;Poland;United Kingdom;United States;
2008 Phase 1/Phase 2 NCT00771030 Canada;Mexico;United States;
Amgen Inc
2010 Phase 2 EUCTR2009-012566-32-HU Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-PL Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-LV Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-GB Australia;Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-CZ Bulgaria;Czech Republic;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-016119-38-BG Bulgaria;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-012566-32-CZ Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2010 - EUCTR2009-012566-32-BG Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-PL Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-LV Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
2009 - EUCTR2009-012566-32-GB Bulgaria;Czech Republic;Hungary;Latvia;Poland;United Kingdom;
AMG592
Amgen Inc
2018 Phase 1;Phase 2 EUCTR2017-001944-36-ES Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2018 Phase 1;Phase 2 EUCTR2017-001944-36-BG Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
2017 Phase 1;Phase 2 EUCTR2017-001944-36-PL Australia;Bulgaria;Czech Republic;Germany;Mexico;New Zealand;Poland;Romania;Spain;United Kingdom;United States;
AMP-110
MedImmune LLC
2014 Phase 1 NCT02277574 United States;
2013 Phase 1 NCT01878123 United States;
AMT-101
Applied Molecular Transport Inc.
2020 Phase 2 EUCTR2020-003955-14-DE Germany;
AP1189
SynAct Pharma ApS
2020 Phase 2 EUCTR2019-001185-15-NO Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2020 Phase 2 EUCTR2019-001185-15-BG Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2019 Phase 2 EUCTR2019-001185-15-SE Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
2019 Phase 2 EUCTR2019-001185-15-DK Bulgaria;Denmark;Moldova, Republic of;Norway;Sweden;
SynAct Pharma Aps
2019 Phase 2 NCT04004429 Denmark;Norway;
APLA12
VA Office of Research and Development
2009 Phase 1 NCT01123655 United States;
ARA290
LUMC
2011 - EUCTR2010-023469-22-NL Netherlands;
ARAVA
sanofi-aventis Groupe
2008 - EUCTR2007-000886-40-IT Italy;Portugal;
ARAVA®
sanofi-aventis groupe
2007 Phase 3 EUCTR2007-000886-40-CZ Czech Republic;Italy;Portugal;
2007 - EUCTR2007-000886-40-PT Italy;Portugal;
ARRY-371797, p38 inhibitor
Array Biopharma, now a wholly owned subsidiary of Pfizer
2008 Phase 1 NCT00729209 United States;
ARRY-438162
Array BioPharma Inc.
2008 - EUCTR2007-007859-14-PL Hungary;Poland;
2008 - EUCTR2007-007859-14-HU Hungary;Poland;
ARRY-438162, MEK inhibitor
Array Biopharma, now a wholly owned subsidiary of Pfizer
2008 Phase 2 NCT00650767 Argentina;Brazil;Hungary;Peru;Poland;Romania;United States;
ART621
Arana Therapeutics Ltd
2009 Phase 2 NCT00928317 Argentina;Australia;Czech Republic;India;Malaysia;New Zealand;Poland;United States;
2009 Phase 2 NCT00854685 Sri Lanka;
2009 - EUCTR2009-014824-40-CZ Czech Republic;
2009 - EUCTR2008-006930-92-CZ Czech Republic;
AS Domelock System
Zimmer Biomet
2017 - NCT03312465 Belgium;Germany;Switzerland;United Kingdom;
ASK8007
Astellas Pharma Inc
2007 Phase 1/Phase 2 NCT00411424 Belgium;France;Hungary;Ireland;Netherlands;Spain;United Kingdom;
ASP015K
Astellas Pharma Global Development
2013 Phase 2 EUCTR2011-006021-23-CZ Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 Phase 2 EUCTR2011-006021-23-BG Belgium;Bulgaria;Colombia;Czech Republic;Germany;Hungary;Mexico;Poland;
2013 - EUCTR2011-006021-23-HU Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
2012 - EUCTR2011-006021-23-BE Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
Astellas Pharma Global Development Inc. (APGD)
2013 Phase 2 EUCTR2011-006021-23-PL Belgium;Bulgaria;Czech Republic;Germany;Hungary;Mexico;Poland;
ASP015K hydrobromide, AS1940150-BR, JKT-201A, 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide
Astellas Pharma Global Development, Inc. (APGD)
2013 - EUCTR2011-006020-20-PL Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006020-20-BG Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-PL Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-HU Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2013 - EUCTR2011-006018-15-BG Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 Phase 2 EUCTR2011-006018-15-BE Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006020-20-HU Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006020-20-CZ Bulgaria;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
2012 - EUCTR2011-006018-15-CZ Belgium;Bulgaria;Colombia;Czech Republic;Hungary;Mexico;Poland;Ukraine;United States;
ASP1707
Astellas Pharma Global Development, Inc.
2016 Phase 1 NCT02867306 Moldova, Republic of;
Astellas Pharma Inc
2016 Phase 2 NCT02884635 Japan;
ASP2408
Astellas Pharma Global Development, Inc.
2012 Phase 1 NCT02052375 United States;
ASP2409
Astellas Pharma Global Development, Inc.
2012 Phase 1 NCT02171143 United States;
ASP5094
Astellas Pharma Global Development, Inc.
2016 Phase 1 NCT02698657 Poland;United States;
Astellas Pharma Inc
2017 Phase 2 NCT03257852 Japan;
ATI-450
Aclaris Therapeutics, Inc.
2020 Phase 2 NCT04247815 United States;
ATN-103
Ablynx
2010 Phase 2 NCT01063803 Canada;Hungary;Japan;Russian Federation;Serbia;South Africa;Switzerland;United States;
2009 Phase 1/Phase 2 NCT00959036 Belgium;Canada;Germany;Hungary;Russian Federation;Serbia;South Africa;Switzerland;United States;
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
2010 - EUCTR2009-015636-15-HU Belgium;Canada;Germany;Hungary;Japan;Russian Federation;South Africa;Switzerland;United States;
2010 - EUCTR2008-007185-33-DE Belgium;Germany;Hungary;Netherlands;United Kingdom;
2010 - EUCTR2008-007185-33-BE Belgium;Germany;Hungary;Netherlands;United Kingdom;
Wyeth Pharmaceuticals Inc., Acting through its division Wyeth Research, a Pfizer Company
2009 - EUCTR2008-007185-33-GB Belgium;Germany;Hungary;Netherlands;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2010 - EUCTR2008-007185-33-NL Belgium;Germany;Hungary;Netherlands;United Kingdom;
2009 - EUCTR2008-007185-33-HU Belgium;Germany;Hungary;Netherlands;United Kingdom;
ATN-103 10 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 10 mg q8wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 30 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 80 mg q4wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
ATN-103 80 mg q8wks
Ablynx
2009 Phase 1/Phase 2 NCT01007175 Japan;
AVE9897
Millennium Pharmaceuticals Inc
2006 Phase 2 EUCTR2005-006165-14-GB Czech Republic;Netherlands;United Kingdom;
2006 - EUCTR2005-006165-14-NL Czech Republic;Netherlands;United Kingdom;
2006 - EUCTR2005-006165-14-CZ Czech Republic;Netherlands;United Kingdom;
AZD5672
ASTRAZENECA
2008 - EUCTR2007-007539-14-IT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AstraZeneca
2009 Phase 1 NCT00887770 United Kingdom;
2009 Phase 1 NCT00871767 United Kingdom;
2008 Phase 2 NCT00713544 Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
2008 Phase 1 NCT00711074 United Kingdom;
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
AZD9056
AstraZeneca
2009 Phase 1 NCT00920608 -
2008 Phase 1 NCT00700986 United Kingdom;
2007 Phase 2 NCT00520572 Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AZD9056 hydrochloride
AstraZeneca AB
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
AZD9567
AstraZeneca
2018 Phase 2 NCT03368235 Denmark;Netherlands;Sweden;
2016 Phase 1 NCT02760316 Germany;United Kingdom;
AZD9567 Monohydrat
AstraZeneca
2015 Phase 1 NCT02512575 Germany;
AZD9567 monohydrate
AstraZeneca AB
2017 Phase 2 EUCTR2017-000838-64-SE Denmark;Netherlands;Sweden;
2017 Phase 2 EUCTR2017-000838-64-NL Denmark;Netherlands;Sweden;
2017 Phase 2 EUCTR2017-000838-64-DK Denmark;Netherlands;Sweden;
Abatacept
AbbVie
2017 Phase 3 NCT03086343 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;Germany;Greece;Hungary;Ireland;Israel;Italy;Korea, Republic of;Latvia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Academisch Medisch Centrum Amsterdam
2010 - EUCTR2010-021435-14-NL Netherlands;
Arthritis & Rheumatic Disease Specialties Research
2011 Phase 3 NCT01351480 United States;
Astellas Pharma Inc
2011 - NCT01339481 United States;
Astellas Pharma Korea, Inc.
2019 Phase 4 NCT03737708 Korea, Republic of;
BRISTOL-M.SQUIBB
2005 - EUCTR2004-005102-68-IT Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 3 EUCTR2020-000350-96-IT Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
Brigham and Women's Hospital
2020 - NCT04529902 United States;
2020 - NCT04529876 United States;
2020 - NCT04529863 United States;
Bristol Myers Squibb International Corporation
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-IT Denmark;Finland;France;Germany;Italy;Sweden;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2006 - EUCTR2005-000784-26-IT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
- - EUCTR2005-000443-28-Outside-EU/EEA Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
Bristol-Myers Squibb
2021 Phase 3 NCT04909801 Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2018 Phase 1 NCT03714022 United States;
2017 - NCT03457792 Germany;
2017 - NCT03188081 Italy;
2016 - NCT02037737 -
2015 Phase 4 NCT02557100 Algeria;Canada;Mexico;United States;
2015 Phase 3 NCT02504268 Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Monaco;Netherlands;Peru;Poland;Puerto Rico;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;United States;
2015 - NCT02598466 -
2014 - NCT02169544 -
2013 Phase 4 NCT01758198 Japan;
2013 Phase 3 NCT01844895 -
2013 Phase 1 NCT01890473 Argentina;Mexico;Peru;South Africa;United States;
2012 - NCT02090556 Australia;Austria;France;Germany;Greece;Italy;Monaco;Netherlands;Spain;Switzerland;United Kingdom;
2010 Phase 3 NCT01142726 Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Norway;Poland;Russian Federation;South Africa;Sweden;United States;
2010 Phase 1 NCT01221636 United States;
2009 Phase 3 NCT00929864 Argentina;Canada;Chile;Peru;United States;
2008 Phase 3 NCT00767325 Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 - NCT02109666 Austria;Belgium;Canada;Czech Republic;Denmark;France;Germany;Greece;Ireland;Italy;Netherlands;Spain;Switzerland;
2007 Phase 3 NCT00989235 -
2007 Phase 3 NCT00547521 Australia;Brazil;Canada;Mexico;Peru;South Africa;United States;
2007 Phase 3 NCT00533897 Argentina;Brazil;Canada;Mexico;South Africa;United States;
2007 Phase 3 NCT00420199 Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 NCT00409838 Korea, Republic of;
2006 Phase 3 NCT00484289 Japan;
2006 Phase 2 NCT00345748 Japan;
2006 Phase 1/Phase 2 NCT00254293 United States;
2005 Phase 3 NCT00124982 Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
2005 Phase 3 NCT00122382 Australia;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Ireland;Italy;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Russian Federation;South Africa;Spain;United Kingdom;United States;
2005 Phase 2 NCT00124449 Australia;Belgium;France;Germany;Italy;Mexico;Puerto Rico;Spain;United Kingdom;United States;
2003 Phase 3 NCT00095173 Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
2003 Phase 1 NCT00162201 United Kingdom;
2002 Phase 3 NCT00048581 United States;
2002 Phase 3 NCT00048568 United States;
2000 Phase 2 NCT00162279 United States;
2000 Phase 1/Phase 2 NCT00279760 Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2008 - EUCTR2007-004241-15-IT Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-AT Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
Bristol-Myers Squibb K.K.
2013 Phase 4 JPRN-JapicCTI-132121 -
Cambridge University Hospitals NHS Foundation Trust
2018 Phase 2 NCT03084419 United Kingdom;
Columbia University
2019 Phase 4 NCT03619876 United States;
Dr. Larry W. Moreland
2015 Phase 4 NCT02353780 United States;
Hokkaido University Hospital
2013 - JPRN-UMIN000010286 Japan;
Jeffrey Curtis
2021 Phase 4 NCT05080218 United States;
Jiangsu Simcere Pharmaceutical Co., Ltd.
2016 Phase 1 NCT02805010 -
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Leiden University Medical Center
2018 Phase 4 NCT03492658 Netherlands;
Maldonado A Michael
2021 Phase 3 JPRN-jRCT2071210068 Australia;France;Germany;Japan;Taiwan;USA;
NHS Greater Glasgow and Clyde
2016 Phase 4 NCT02652273 United Kingdom;
2015 Phase 4 EUCTR2014-004419-35-GB United Kingdom;
NYU Langone Health
2019 Phase 4 NCT03652961 United States;
National Health Organization Nagoya Medical Center
2010 - JPRN-UMIN000011789 Japan;
Novartis Pharmaceuticals
2011 Phase 3 NCT01350804 Brazil;Bulgaria;Canada;Colombia;Czech Republic;France;Germany;Hungary;Italy;Mexico;Romania;Russian Federation;Slovakia;Spain;United States;
Osaka Medical College
2014 - JPRN-UMIN000013440 Japan;
Shinshu University
2018 Phase 2 NCT03784261 Japan;
St George's, University of London
2020 Phase 4 EUCTR2019-004468-23-GB United Kingdom;
St.Marianna University School of Medicine
2014 - JPRN-UMIN000015175 Japan;
The Cleveland Clinic
2013 Phase 2 NCT02027298 United States;
The First Hospital, Jilin University
2016 Phase 1 study ChiCTR-IIR-16008693 China;
University Hospital, Montpellier
2016 - NCT02547493 France;Monaco;
University of California, Los Angeles
2014 - NCT02053727 United States;
2011 Phase 3 NCT01299961 United States;
University of Leeds
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Occupational and Environmental Health, Japan
2010 - JPRN-UMIN000008756 Japan;
University of Washington
2019 Phase 4 NCT03882008 United States;
Vastra Gotaland Region
2017 - NCT03440892 Sweden;
Yokohama City University Graduate School of Medicine
2014 - JPRN-UMIN000015217 Japan;
Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)
Bristol-Myers Squibb
2005 Phase 3 NCT00095147 Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Korea, Republic of;Mexico;Peru;Poland;Puerto Rico;Russian Federation;South Africa;Spain;Sweden;Switzerland;United States;
Abatacept (BMS-188667)
Bristol-Myers Squibb
2011 Phase 1 NCT01439204 United States;
2000 Phase 2 NCT00162266 Argentina;Australia;Belgium;Canada;France;Germany;Ireland;Netherlands;South Africa;United Kingdom;United States;
Abatacept (IV)
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept (SC)
Bristol Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
Abatacept + Methotrexate
Bristol-Myers Squibb K.K.
2015 Phase 3 JPRN-JapicCTI-153081 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept + csDMARD
New York University School of Medicine
2019 Phase 4 NCT03700021 United States;
Abatacept Injection
Fundacion Clinic per a la Recerca Biomédica
2019 Phase 4 NCT03669367 -
St George's, University of London
2020 Phase 4 NCT04255134 United Kingdom;
University of Erlangen-Nürnberg Medical School
2019 Phase 2 NCT04120831 Germany;
Abatacept Placebo
Bristol-Myers Squibb K.K.
2015 Phase 3 JPRN-JapicCTI-153081 Japan, Asia except Japan, North America, South America, Europe, Oceania, Africa;
Abatacept Prefilled Syringe
Lille Catholic University
2018 Phase 4 NCT03227419 France;
Abatacept combination product (ACP)
Bristol-Myers Squibb
2009 Phase 3 NCT01173120 -
Abatacept, rituximab or tocilizumab
University Hospital, Strasbourg, France
2009 Phase 4 NCT01000441 France;Monaco;
Acalabrutinib
Acerta Pharma BV
2015 Phase 2 NCT02387762 United States;
Aceclofenac
Chung Shan Medical University
2007 Phase 4 NCT04144101 -
Acellbia
Biocad
2015 Phase 3 NCT02744196 -
Acetaminophen
Hoffmann-La Roche
2011 Phase 4 NCT01382940 United States;
Kojima Toshihisa
2016 - JPRN-jRCTs041180071 Japan;
Merck Sharp & Dohme Corp.
2011 Phase 1 NCT01390441 Belarus;Bulgaria;Colombia;Georgia;Hungary;Italy;Philippines;Poland;Russian Federation;Singapore;Spain;Ukraine;United Kingdom;United States;
Nekoyama Miyao Hospital
2016 - JPRN-UMIN000018931 Japan;
Osaka City University Medical School, Department of Orthopedic Surgery
2014 - JPRN-UMIN000012364 Japan;
Yamaguchi University
2018 - JPRN-UMIN000031692 Japan;
Acetaminophen tablets
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
2014 Phase 2 NCT02029599 China;
Acide folique
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
Actemra
F. Hoffmann- La Roche Ltd
2009 - EUCTR2008-000587-17-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
F. Hoffmann-La Roche Limited
2007 - EUCTR2007-001114-17-GB United Kingdom;
F. Hoffmann-La Roche Ltd
2010 Phase 3 EUCTR2008-006924-68-AT Austria;Czech Republic;France;Hungary;Italy;Netherlands;Portugal;Spain;United Kingdom;
2009 - EUCTR2008-000587-17-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-000587-17-DE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-SE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-PT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-GB Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-FI Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-DK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-CZ Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2008 - EUCTR2008-000587-17-AT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
ROCHE
2009 - EUCTR2008-000587-17-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Actemra(EU-licensed)
Bio-Thera Solutions
2018 Phase 3 NCT03830203 China;
Acthar
Veena Ranganath, MD, MS
2017 Phase 4 NCT02541955 United States;
Acthar Gel
Mallinckrodt
2016 Phase 4 NCT02919761 Argentina;Colombia;Mexico;Peru;Puerto Rico;United States;
Acthar Injectable Product
Attune Health Research, Inc.
2018 Phase 3 NCT03511625 United States;
Active Stimulation
Galvani Bioelectronics
2021 - NCT05003310 United States;
Active comparator
Asahi Kasei Pharma Corporation
2011 Phase 2 NCT01285752 Czech Republic;Germany;Hungary;Poland;Slovakia;Ukraine;United Kingdom;
2009 Phase 2 NCT00902369 Czech Republic;Germany;Hungary;Lithuania;Romania;United Kingdom;
Acupuncture
Chinese Academy of Sciences
2012 - NCT01619176 China;
Acycloguanosine
Università Popolare Homo & Natura
2015 Phase 1 NCT02633332 Italy;
Ad26.COV2.S
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
Adalimuab, Etanercept, Tocilizumab, or Abatacept
Hanyang University
2020 - NCT04449224 Korea, Republic of;
Adalimumab
Department of Rheumatology and Clinical Immunology
AbbVie
2019 Phase 2 NCT03823391 Germany;Hungary;Israel;Netherlands;Poland;Puerto Rico;United States;
2016 - NCT02750800 Hungary;
2016 - NCT02668640 China;
2015 Phase 4 NCT02198651 Australia;Austria;Canada;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
2015 Phase 3 NCT02629159 Argentina;Australia;Austria;Belarus;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;Czech Republic;Czechia;Denmark;Estonia;Finland;France;Germany;Greece;Hong Kong;Hungary;Ireland;Israel;Italy;Kazakhstan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02141997 Australia;Bulgaria;Canada;Czech Republic;Germany;Hungary;New Zealand;Poland;Romania;Turkey;United States;
2013 - NCT01768858 Austria;
2007 Phase 1 NCT00650156 China;
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01561313 Belgium;Czech Republic;
2012 Phase 2 NCT01502423 Australia;Canada;Germany;
2012 - NCT01736189 Japan;
2010 Phase 4 NCT01185288 Puerto Rico;United States;
2010 Phase 4 NCT01162421 Canada;
2010 Phase 3 NCT01185301 Argentina;Austria;Belgium;Canada;Czech Republic;Germany;Poland;Puerto Rico;Spain;United States;
2009 Phase 4 NCT00808509 Sweden;
2000 Phase 3 NCT00195663 Australia;Austria;Belgium;Canada;Czech Republic;Denmark;Finland;France;Germany;Ireland;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;Switzerland;United Kingdom;United States;
Abbott
2008 Phase 3 NCT00690573 Japan;
2007 Phase 3 NCT01231321 Russian Federation;
2007 Phase 3 NCT00647270 Australia;Canada;Germany;Puerto Rico;United Kingdom;United States;
2007 Phase 2/Phase 3 NCT00538902 China;
2006 Phase 4 NCT00420927 Argentina;Australia;Austria;Belgium;Canada;Czech Republic;France;Germany;Greece;Hungary;Mexico;Netherlands;New Zealand;Norway;Poland;Puerto Rico;Slovakia;South Africa;Spain;Sweden;United Kingdom;United States;
2006 Phase 3 NCT00603993 Japan;
2004 Phase 4 NCT00234897 United States;
2004 Phase 3 NCT00235872 Japan;
2004 Phase 2/Phase 3 NCT00647491 Japan;
2004 - NCT00650390 -
2003 Phase 4 NCT00649922 -
2003 Phase 3 NCT00647920 Taiwan;
2003 Phase 3 NCT00235859 -
2003 Phase 3 NCT00234936 -
2003 Phase 3 NCT00234845 United States;
2003 Phase 2 NCT00235833 Japan;
2003 - NCT00649545 -
2003 - NCT00234884 Australia;Austria;Belgium;France;Germany;Greece;Italy;Netherlands;Portugal;Spain;United Kingdom;
2002 Phase 3 NCT00448383 -
2002 Phase 3 NCT00049751 United States;
2002 - NCT00650026 -
2000 Phase 3 NCT00195702 Canada;United States;
2000 Phase 3 NCT00195650 Canada;United States;
Abbott GmbH & Co. KG
2008 - EUCTR2007-005905-23-GB Germany;United Kingdom;
2008 - EUCTR2007-005905-23-DE Germany;United Kingdom;
2008 - EUCTR2006-004139-31-NO Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-004139-31-GR Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-SK Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-HU Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 Phase 4 EUCTR2006-004139-31-FR Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-SE Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-NL Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-GB Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-ES Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-DE Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-CZ Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-BE Austria;Belgium;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Norway;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004139-31-AT Austria;Czech Republic;France;Germany;Greece;Hungary;Netherlands;Spain;Sweden;United Kingdom;
Abbott Japan Co., Ltd.
2009 Phase 3 JPRN-JapicCTI-090751 -
2008 Phase 3 JPRN-JapicCTI-080587 -
Abbott Scandinavia AB
2008 - EUCTR2008-004398-16-SE Sweden;
Amgen
2013 Phase 3 NCT01970475 Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Astellas Pharma Korea, Inc.
2019 Phase 4 NCT03737708 Korea, Republic of;
AstraZeneca
2011 Phase 2 NCT02092961 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
2011 Phase 2 NCT01264770 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Biogen
2006 Phase 2 NCT00298272 United States;
Biologic Mate Study Group
2014 - JPRN-UMIN000015616 Japan;
Bristol-Myers Squibb
2021 Phase 3 NCT04909801 Argentina;Australia;Czechia;France;Germany;Italy;Japan;Mexico;Poland;Spain;Switzerland;Taiwan;United Kingdom;United States;
2015 Phase 4 NCT02557100 Algeria;Canada;Mexico;United States;
2009 Phase 3 NCT00929864 Argentina;Canada;Chile;Peru;United States;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
CSL Behring
2011 Phase 2 NCT01373151 Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
Charité-Universitätsmedizin Berlin
Cinnagen
2015 Phase 3 NCT03172325 Iran, Islamic Republic of;
Columbia University
2019 Phase 4 NCT03619876 United States;
Department of Rheumatosurgery, Osaka City University Medical School
2009 Phase 4 JPRN-UMIN000002340 Japan;
Dept. of Rhematology UMAS
2005 - EUCTR2005-000129-47-SE Sweden;
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
2011 - JPRN-UMIN000013750 Japan;
EMD Serono
2007 Phase 2 NCT00595413 Germany;United States;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-132125 -
Eli Lilly and Company
2012 Phase 3 NCT01710358 Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F. Hoffmann-La Roche Ltd.
2011 - EUCTR2010-023587-40-IT Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Fen Li
2016 Phase 4 NCT02878161 -
Genentech, Inc.
2016 Phase 2 NCT02833350 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2010 Phase 2 NCT01225393 Bulgaria;Chile;Germany;Hungary;Mexico;Peru;Poland;Romania;Spain;United States;
Georgetown University
2013 Phase 4 NCT01793519 United States;
Gilead Sciences
2016 Phase 3 NCT02889796 Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Glostrup University Hospital, Copenhagen
2009 - NCT01029613 Denmark;
Goupe d'Etudes et de Recherche Clinique En Rhumatologie
2004 Phase 4 NCT00291915 France;
Hamed Rezaei
2012 Phase 4 NCT01609205 Sweden;
Heinrich-Heine University, Duesseldorf
2014 Phase 3 NCT02150473 Germany;
Hoffmann-La Roche
2011 Phase 4 NCT01283971 Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
2011 - NCT01592292 Korea, Republic of;
2010 Phase 4 NCT01119859 Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Norway;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Hvidovre University Hospital
2005 Phase 4 NCT00216177 Denmark;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Janssen Research & Development, LLC
2014 Phase 3 NCT02019472 Argentina;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
Jonathan Graf
2013 Phase 4 NCT01893996 United States;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Karolinska Institutet
2010 - NCT01197144 Sweden;
Keio University
2018 Phase 4 NCT03505008 Japan;Korea, Republic of;Taiwan;
2011 Phase 4 NCT01270035 Japan;
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Leeds University
2014 - JPRN-UMIN000016928 Japan,Europe;
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Maldonado A Michael
2021 Phase 3 JPRN-jRCT2071210068 Australia;France;Germany;Japan;Taiwan;USA;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
Merck Serono International
2008 Phase 2 EUCTR2007-002536-29-FR Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 Phase 2 EUCTR2007-002536-29-ES Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-PT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-GR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-DE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-CZ Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BG Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BE Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 Phase 2 EUCTR2007-002536-29-FI Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-SE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-AT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
- - EUCTR2007-002536-29-PL Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck Sharp & Dohme Corp.
2008 - NCT00724672 -
Mianyang Hospital of Traditional Chinese Medicine
2021 Phase 4 ChiCTR2100044045 China;
NHS Greater Glasgow and Clyde
2022 - NCT05090124 -
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2009 Phase 4 NCT00837434 United States;
2008 Phase 4 NCT00796705 United States;
Novo Nordisk A/S
2014 Phase 2 NCT02097264 Ireland;Portugal;Spain;United Kingdom;
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
Osaka City University Medical School
2012 - JPRN-UMIN000010315 Japan;
2010 - JPRN-UMIN000003880 Japan;
Osaka Medical College
2015 - JPRN-UMIN000016950 Japan;
Ottawa Hospital Research Institute
2022 Phase 4 NCT05153200 -
PFIZER
2008 - EUCTR2007-002066-35-IT Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Pfizer
2020 Phase 3 NCT04230213 Bosnia and Herzegovina;Bulgaria;Czechia;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2015 Phase 3 NCT02480153 Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Czechia;Estonia;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 4 NCT02092467 Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2007-002066-35-SK Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-GR Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-BG Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-HU Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-DE Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-CZ Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2009 - EUCTR2008-008338-35-DE Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Reade Rheumatology Research Institute
2020 Phase 4 NCT04251741 Netherlands;
2020 Phase 4 NCT04222920 Netherlands;
2020 Phase 4 NCT04194827 Netherlands;
Rennes University Hospital
2017 - NCT03110094 France;
Sanofi
2015 Phase 3 NCT02332590 Chile;Czech Republic;Czechia;France;Germany;Hungary;Israel;Korea, Republic of;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2013 Phase 3 NCT01764997 Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Skåne University Hospital
2005 Phase 4 NCT01270087 Sweden;
Takeda
2015 Phase 2 NCT02393378 Czech Republic;Czechia;Estonia;Russian Federation;Spain;United Kingdom;
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
The Rheumatological Center of Helsinki
2011 Phase 4 NCT01405326 Finland;
University Hospital, Bordeaux
2021 Phase 3 NCT04870203 France;Monaco;
University Hospital, Rouen
2006 Phase 4 NCT00234234 France;
University Hospital, Tours
2011 Phase 4 NCT01382160 France;
2006 - NCT00497614 France;
University of Aarhus
2007 Phase 3 NCT00660647 Denmark;
University of Leeds
2013 Phase 4 NCT02056184 United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Université de Sherbrooke
2013 Phase 4 NCT02035800 Canada;
2008 - NCT00814866 Canada;
Yazawa Rie
2017 Phase 1 JPRN-jRCT2071200057 Japan;
Yonemura Takuma
2015 Phase 1 JPRN-jRCT2071200058 Japan;
Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042440 China;
Adalimumab (ADA)
UCB Pharma SA
2011 Phase 4 NCT01500278 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Adalimumab (HUMIRA®)
Abbott
2006 - NCT01078571 Spain;
Adalimumab (Humira)
Hvidovre University Hospital
2004 Phase 4 NCT00696059 Denmark;
R-Pharm
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (Humira®)
R-Pharm
2017 Phase 3 EUCTR2015-005307-83-LV Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-PL Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-LT Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-HU Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-DE Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
R-Pharm International LLC
2016 Phase 3 EUCTR2015-005307-83-CZ Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Georgia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
2016 Phase 3 EUCTR2015-005307-83-BG Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab (up to 9 months exposure)
Abbott
2005 Phase 4 NCT00233558 United States;
Adalimumab - GP2017
Sandoz
2016 Phase 3 NCT02744755 Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab - US licensed Humira
Sandoz
2016 Phase 3 NCT02744755 Czech Republic;Czechia;Germany;Hungary;Italy;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;United Kingdom;United States;
Adalimumab 40 mg subcutaneous (SC) every other week (EOW)
Abbott
2000 Phase 3 NCT00233571 -
Adalimumab 40mg q2w
R-Pharm
2016 Phase 3 NCT02760407 Argentina;Brazil;Bulgaria;China;Colombia;Czech Republic;Czechia;Estonia;Germany;Hungary;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Romania;Russian Federation;Taiwan;United Kingdom;United States;
Adalimumab Injection
St George's, University of London
2020 Phase 4 NCT04255134 United Kingdom;
Adalimumab PFS and Pen
Samsung Bioepis Co., Ltd.
2015 Phase 2 NCT02565810 Poland;
Adalimumab delivered in Physiolis autoinjector
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in Physiolis syringe
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in current autoinjector
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab delivered in current syringe
AbbVie (prior sponsor, Abbott)
2010 Phase 2 NCT01163617 United States;
Adalimumab with methotrexate
Pfizer
2014 Phase 4 NCT02187055 Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Estonia;France;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
Adalimumab, Solution for Injection 40 mg/ (0.8 ml) Pre-filled Syringe
AbbVie Deutschland GmbH & Co. KG
2015 Phase 2 EUCTR2013-004019-37-DK Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 Phase 2 EUCTR2013-004019-37-BG Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2015 - EUCTR2013-004019-37-DE Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-RO Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 Phase 2 EUCTR2013-004019-37-CZ Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
2014 - EUCTR2013-004019-37-HU Australia;Bulgaria;Canada;Czech Republic;Denmark;Germany;Hungary;New Zealand;Poland;Romania;Turkey;
Adalimumab, current formulation
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01712178 Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, new formulation
AbbVie (prior sponsor, Abbott)
2012 Phase 2 NCT01712178 Belgium;Czech Republic;Germany;Puerto Rico;Romania;Slovakia;United States;
Adalimumab, plus prednisone
IRCCS Policlinico S. Matteo
2007 Phase 4 NCT00480272 Italy;
Adalimumab-Pfizer
Pfizer Inc
2020 Phase 4 EUCTR2019-000284-24-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2019 Phase 3 EUCTR2019-000284-24-LT Argentina;Bosnia and Herzegovina;Bulgaria;Czech Republic;Lithuania;Mexico;Peru;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Adalimummab
Hvidovre Hospital
2009 Phase 4 EUCTR2009-014394-41-DK Denmark;
Adefovir
Department of general internal medicine, Kyushu-University hospital
2012 - JPRN-UMIN000018017 Japan;
Administration of Cimzia®
University Hospital, Ghent
2012 Phase 3 NCT01590966 Belgium;
Agrippal S1 (Influenza vaccination)
Tel-Aviv Sourasky Medical Center
2009 Phase 4 NCT01002716 Israel;
Alemtuzumab (already received by alemtuzumab cohort between 1991 and 1994)
The Newcastle upon Tyne Hospitals NHS Foundation Trust
2012 Phase 4 EUCTR2010-021146-22-GB United Kingdom;
Alendronat Teva
Aarhus University Hospital
2015 Phase 2 EUCTR2015-003638-28-DK Denmark;
Alendronate
Chinese University of Hong Kong
2012 Phase 4 NCT01770106 Hong Kong;
People's Hospital, Peking University
2009 - ChiCTR-TRC-09000473 China;
University of Aarhus
2015 Phase 2 NCT02944799 Denmark;
Alendronate versus alfacalcidol (1-alpha OH vitamin D)
UMC Utrecht
2000 Phase 3 NCT00138983 Netherlands;
AlloRx
The Foundation for Orthopaedics and Regenerative Medicine
2022 Phase 1 NCT05003934 Antigua and Barbuda;
Allogeneic Mesenchymal Precursor Cells
Mesoblast, Ltd.
2013 Phase 2 NCT01851070 Australia;United States;
Allopurinol
University of Dundee
2005 Phase 4 EUCTR2005-000551-15-GB United Kingdom;
Amoxapine & dipyridamole
CombinatoRx, Inc
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
Amoxicilina
Dra Beatriz Lozano-Hospital Universitario de Canarias
2018 Phase 4 EUCTR2017-003259-40-ES Spain;
Anakinra
Amgen
2001 Phase 2 NCT00037700 United States;
2000 Phase 2 NCT00037648 United States;
Prof. Roberto Giacomelli
2013 Phase 4 NCT02236481 Italy;
Swedish Orphan Biovitrum
2012 - NCT02915094 Germany;
University of Athens
2011 - NCT01566201 Greece;
Xi-jing Hospital, the 4th Military Medical University, Shanghai Changzheng Hospital
2008 Phase 3 study ChiCTR-TRC-09000383 China;
Anakinra (Kineret®)
Amgen
2004 Phase 3 NCT00117091 -
Anakinra (r-metHuIL-1ra)
Amgen
2005 Phase 4 NCT00111410 -
Anakinra and PEG sTNF-R1
Amgen
2001 Phase 2 NCT00537667 -
Andecaliximab
Gilead Sciences
2016 Phase 2 NCT02862574 Australia;Hungary;Taiwan;United States;
Angiotensin receptor blockers
Sherief Abd-Elsalam
2018 Phase 3 NCT03770702 Egypt;
Anifrolumab
Josef Smolen, Univ. Prof. Dr.
2018 Phase 2 NCT03435601 Austria;
Anifrolumab (MEDI-546)
Medical University of Vienna
2017 Phase 2 EUCTR2017-001717-92-AT Austria;Italy;Switzerland;
Anit human granulocyt-macrophage colony-stimulating factor (GM-CSF)monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti IL 6 mAb
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti IL-1beta antibody, subclass IgG4
Eli Lilly and Company Limited
2007 - EUCTR2005-002660-29-HU Hungary;Spain;
Anti IL-1ß antibody, subclass IgG4
Eli Lilly and Company Limited
2007 - EUCTR2005-002660-29-HU Hungary;Spain;
Anti LP40 antibody, subclass IgG4 LA294
Eli Lilly and Company
2009 Phase 2 EUCTR2008-004875-23-FR Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-PL Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-HU Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-DE Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-BE Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-004875-23-AT Austria;Belgium;France;Germany;Hungary;Poland;
2009 - EUCTR2008-001105-42-PL Austria;Belgium;France;Germany;Poland;
2008 Phase 2 EUCTR2008-001105-42-FR Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-DE Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-BE Austria;Belgium;France;Germany;Poland;
2008 - EUCTR2008-001105-42-AT Austria;Belgium;France;Germany;Poland;
Eli Lilly and Company limited
2009 Phase 2 EUCTR2008-004894-16-HU Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-PL Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-DE Czech Republic;Germany;Hungary;Poland;
2009 - EUCTR2008-004894-16-CZ Czech Republic;Germany;Hungary;Poland;
Anti TNF + Meth
Hamad Medical Corporation
2012 Phase 3 NCT01724268 Qatar;
Anti human granulocyte-macrophage colo
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2019 Phase 3 EUCTR2019-000868-18-IT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2021 Phase 3 EUCTR2019-000878-30-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000868-18-DE Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000867-26-DE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-LT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-HU Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-ES Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-CZ Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-PL Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-HU Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-GB Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-ES Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-EE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-BG Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LV Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-HU Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-GB Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-ES Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-CZ Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-000878-30-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody
GlaxoSmithKline Research & Development Limited
2018 Phase 2 EUCTR2015-004386-91-PL Germany;Poland;United States;
2016 Phase 2 EUCTR2015-004386-91-DE Germany;Poland;United States;
2015 Phase 2 EUCTR2014-003453-34-PL Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-HU Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-GB Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-ES Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-EE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-DE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-CZ Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF)monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
Anti-C5aR
Novo Nordisk A/S
2012 - EUCTR2009-011791-30-HU Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 Phase 2 EUCTR2009-011791-30-GB Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 - EUCTR2009-011791-30-DK Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
2010 - EUCTR2009-011791-30-CZ Czech Republic;Denmark;Germany;Hungary;Poland;Romania;Russian Federation;Ukraine;United Kingdom;
Anti-CD20 small modular immunopharmaceutical, WYE-400087
Wyeth Pharmaceuticals Inc. Acting through its division Wyeth Research, a Pfizer Company
2010 - EUCTR2009-010516-15-PL Greece;Hungary;Poland;Spain;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2010 Phase 2 EUCTR2009-010516-15-GR Greece;Hungary;Poland;Spain;
2010 Phase 2 EUCTR2009-010516-15-ES Greece;Hungary;Poland;Spain;
2009 - EUCTR2009-010516-15-HU Greece;Hungary;Poland;Spain;
Anti-GM-CSF receptor alpha
MedImmune Ltd
2010 - EUCTR2009-014735-20-PL Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-LT Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-HU Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
2010 - EUCTR2009-014735-20-CZ Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-BG Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
2009 - EUCTR2009-014735-20-LV Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2009 - EUCTR2009-014735-20-EE Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
Anti-IL-20
Novo Nordisk A/S
2010 Phase 1 NCT01038674 Belgium;Poland;
2008 Phase 1 NCT00818064 Netherlands;
Anti-IL-20 (109-0012)
NOVO NORDISK
2011 - EUCTR2010-021283-14-IT Hungary;Italy;Portugal;Spain;United Kingdom;
Novo Nordisk A/S
2011 Phase 2 EUCTR2010-021283-14-PT Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-HU Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-GB Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-021283-14-ES Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-021283-14-CZ Czech Republic;Hungary;Italy;Portugal;Spain;United Kingdom;
Anti-IL-6 mAb
Bristol-Myers Squibb International Corporation
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-HU Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-DE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-BE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Anti-Interleukin-6 Monoclonal Antibody
Bristol-Myers Squibb International Corporation
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
Anti-TNF
Hospital Universitari Vall d'Hebron Research Institute
2016 - NCT02804204 Spain;
Anti-TNF Biologics Therapy
Queen Mary University of London
2015 - NCT02620189 United Kingdom;
Anti-TNF humanized antibody Fab fragment - PEG conjugate
UCB Pharma S.A.
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
Anti-TNF humanized antibody Fab' fragment - PEG conjugate
UCB Pharma S.A.
2009 - EUCTR2007-005288-86-FR France;
Anti-TNF suspended perioperatively
CHU de Quebec-Universite Laval
2015 Phase 4 NCT02242474 Canada;
Anti-TNF therapy
Barts & The London NHS Trust
2010 - NCT02528292 United Kingdom;
Anti-TNF therapy (etanercept or adalimumab)
Imperial College London
2010 - NCT01060098 United Kingdom;
Anti-TNF-alpha
Hoffmann-La Roche
2016 Phase 2 NCT03001219 Argentina;Austria;Colombia;Czech Republic;Czechia;Germany;Guatemala;Italy;Mexico;Peru;Poland;Spain;United Kingdom;United States;
Anti-TNFa continued perioperatively
CHU de Quebec-Universite Laval
2015 Phase 4 NCT02242474 Canada;
Anti-Tumor Necrosing Factor (TNF) Therapy
Bristol-Myers Squibb
2005 Phase 3 NCT00124982 Belgium;Canada;Czech Republic;France;Germany;Ireland;Italy;Mexico;Spain;United Kingdom;United States;
Anti-Tumor Necrosis Factor Alpha Drug (Product)
R.Bos
2021 Phase 4 NCT04985435 Netherlands;
Anti-inflammatory drugs
Genentech, Inc.
2007 Phase 3 NCT00443651 United States;
Anti-pandemic H1N1 influenza vaccine
University of Sao Paulo
2010 Phase 4 NCT01151644 Brazil;
Anti-thymocyte globulin
Fairview University Medical Center
2000 - NCT00006055 United States;
Anticorpo monoclonale anti GM-CSF umano
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2015 Phase 2 EUCTR2014-003453-34-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
Anticuerpo monoclonal anti-humano recombinante humanizado, receptor de IL-6R.
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-020065-24-ES Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
Antihistamine
Hoffmann-La Roche
2011 Phase 4 NCT01382940 United States;
Antihuman granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal
GlaxoSmithKline Research & Development Limited
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
Apratastat
WYETH LEDERLE
2005 - EUCTR2004-000012-13-IT Czech Republic;Estonia;Italy;
Apremilast
Amgen
2010 Phase 2 NCT01285310 Czech Republic;Czechia;Poland;Spain;United States;
Baylor Research Institute
2010 Phase 2 NCT01250548 United States;
Celgene Corporation
2011 - EUCTR2010-019926-15-CZ Czech Republic;United States;
Arava
Karolinska Institutet
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
University Hospitals Leuven
2009 Phase 4 EUCTR2008-007225-39-BE Belgium;
University of Leeds
2006 Phase 4 EUCTR2005-004582-41-GB United Kingdom;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)
Sandoz
2002 Phase 1 NCT00946686 -
Arava 20 mg filmdrasjerte tabletter
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
Arm B: Rituxan®/Mabthera®
Dr. Reddy's Laboratories Limited
2020 Phase 3 NCT04268771 United States;
Arthroscopic synovectomy of the wrist
Maasstad Hospital
2021 - NCT04755127 Netherlands;
Arthroscopic synovial tissue biopsy
Nathan Wei, MD, FACP, FACR:
2011 Phase 3 NCT01374971 United States;
Arthroscopy & saline irrigation alone
Newcastle University
2012 Phase 1 NCT01352858 United Kingdom;
Artilog
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Ascal(r) / carbasalate calcium
Leiden University Medical Center
2006 - EUCTR2006-001359-36-NL Netherlands;
Asendis
CombinatoRx, Inc
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
Aspirin 81mg tablet
Inova Health Care Services
2018 Phase 4 NCT03699293 United States;
Aspirin Tablets
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Atacicept
EMD Serono
2006 Phase 2 NCT00430495 Canada;United States;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck KGaA
2008 Phase 2 NCT00664521 Finland;France;Netherlands;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Seron SA an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-DE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Serono SA an affiliate of Merck KGaA, Darmstadt, Germany
2008 - EUCTR2006-004140-23-GB Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 Phase 2 EUCTR2006-004140-23-SK Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-PT Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-CZ Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-BE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch of Laboratoires Serono SA, an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-FI Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int, a branch ofLaboratories Serono S.A. an affiliate of Merck KGaA, Darmstadt, Germany
2007 - EUCTR2006-004140-23-SE Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono Int.a branch of Laboratoires Serono SA an affiliate of Merck KgaA, Darmstadt, Germany
2006 - EUCTR2006-004140-23-NL Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono International
2008 Phase 2 EUCTR2007-003647-75-FR Finland;France;Netherlands;Sweden;United Kingdom;
2008 Phase 2 EUCTR2007-002536-29-FR Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 Phase 2 EUCTR2007-002536-29-ES Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-003647-75-SE Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-003647-75-NL Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-003647-75-FI Finland;France;Netherlands;Sweden;United Kingdom;
2008 - EUCTR2007-002536-29-PT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-GR Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-DE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-CZ Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BG Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2008 - EUCTR2007-002536-29-BE Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 Phase 2 EUCTR2007-002536-29-FI Austria;Belgium;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-SE Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
2007 - EUCTR2007-002536-29-AT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
- - EUCTR2007-002536-29-PL Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Merck Serono International S.A.
2007 - EUCTR2006-004140-23-GR Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Merck Serono SA - Geneva
2008 Phase 2 EUCTR2007-003647-75-GB Finland;France;Netherlands;Sweden;United Kingdom;
Serono International S.A.
2007 Phase 2 EUCTR2006-004140-23-ES Belgium;Bulgaria;Czech Republic;Finland;Germany;Greece;Italy;Netherlands;Portugal;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-004140-23-BG Belgium;Bulgaria;Finland;Germany;Greece;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;
Atacicept: with loading dose
EMD Serono
2007 Phase 2 NCT00595413 Germany;United States;
Atorvastatin
Gilead Sciences
2020 Phase 1 NCT04608344 United States;
Hospital Central Dr. Ignacio Morones Prieto
2018 Phase 2 NCT04056039 Mexico;
Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital
2017 - ChiCTR-INR-17011772 China;
Pfizer
2010 Phase 2 NCT01059864 Korea, Republic of;United States;
University of California, Los Angeles
2003 Phase 4 NCT00356473 -
Atorvastatin tablet
Chengdu PLA General Hospital
2014 - NCT02219191 China;
Auto-Injector Device (AID)
Sanofi
2014 Phase 3 NCT02057250 Chile;France;Mexico;Poland;Russian Federation;South Africa;United States;
Autoinjector
Momenta Pharmaceuticals, Inc.
2016 Phase 3 NCT02722044 United States;
Samsung Bioepis Co., Ltd.
2017 Phase 2 NCT03193957 Poland;
Autologous Peripheral Blood Stem Cell Transplantation
Fairview University Medical Center
2000 - NCT00006055 United States;
Autologous adipose derived stem cells
Celltex Therapeutics Corporation
2021 Phase 1/Phase 2 NCT04170426 -
Autologous apoptotic cells injection
Centre Hospitalier Universitaire de Besancon
2021 Phase 1/Phase 2 NCT02903212 -
Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70
UMC Utrecht
2021 Phase 1/Phase 2 NCT05251870 Netherlands;
Autologous mesenchymal stem cells
Mashhad University of Medical Sciences
2016 Phase 1 NCT03333681 -
Autologous stromal vascular fraction cells
Translational Biosciences
2013 Phase 1/Phase 2 NCT01885819 Panama;
Avelox- Moxifloxacin
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
Avelox®
AstraZeneca AB
2009 - EUCTR2009-011044-20-GB United Kingdom;
Azathioprin
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Azathioprine
Hoffmann-La Roche
2013 Phase 3 NCT01941095 Greece;
Sanofi
2018 Phase 4 NCT03449758 France;
The Karolinska Institutet, ClinTRID
2014 Phase 4 EUCTR2014-002374-36-SE Sweden;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
B03BB01
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
BAT1806
Bio-Thera Solutions
2018 Phase 3 NCT03830203 China;
Bio-Thera Solutions, Ltd.
2019 Phase 3 EUCTR2018-002202-31-BG Bulgaria;China;Georgia;Poland;Ukraine;
BAT1806 injection
Bio-Thera Solutions
2018 Phase 1 NCT03606876 China;
BCD-055
Biocad
2016 Phase 3 NCT02762838 Belarus;India;Russian Federation;
BCD-089
Biocad
2019 Phase 3 NCT04227366 Russian Federation;
BCD-089, 162 mg, s/c, q2w
Biocad
2018 Phase 2 NCT03455842 Belarus;Russian Federation;
BCD-089, 162 mg, s/c, qw
Biocad
2018 Phase 2 NCT03455842 Belarus;Russian Federation;
BDMARD
CHU Saint-Etienne
2020 Phase 4 EUCTR2019-003700-12-FR France;
BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)
Medical University of Graz
2012 Phase 4 NCT01602302 Austria;
BETAMETHASONE ACIBUTATE
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
BG00012
Biogen Idec
2008 Phase 2 NCT00810836 Australia;Canada;Czech Republic;India;Poland;Slovakia;
Biogen Idec Limited
2009 Phase 2 EUCTR2008-004754-33-SK Czech Republic;Poland;Slovakia;
2009 - EUCTR2008-004754-33-PL Czech Republic;Poland;
2009 - EUCTR2008-004754-33-CZ Czech Republic;Poland;
BG9924
Biogen Idec
2007 Phase 2 NCT00523328 Belgium;Canada;United Kingdom;United States;
2007 Phase 2 NCT00458861 United States;
2005 Phase 2 NCT00292422 Poland;United States;
Biogen Idec Ltd
2007 Phase 2 EUCTR2006-005467-26-GB Belgium;United Kingdom;
2007 Phase 2 EUCTR2006-005466-39-GB Hungary;United Kingdom;
2007 - EUCTR2007-000734-38-GB United Kingdom;
2007 - EUCTR2007-000734-38-BE Belgium;United Kingdom;
2007 - EUCTR2007-000733-19-HU Hungary;United Kingdom;
2007 - EUCTR2007-000733-19-GB Hungary;United Kingdom;
2007 - EUCTR2006-005467-26-BE Belgium;United Kingdom;
2007 - EUCTR2006-005466-39-HU Hungary;United Kingdom;
BGX-0214
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
BI 655064
Boehringer Ingelheim B.V
2013 - EUCTR2012-004090-16-NL Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
Boehringer Ingelheim España, S.A.
2013 - EUCTR2012-004090-16-ES Australia;Czech Republic;Germany;Netherlands;New Zealand;Spain;
Boehringer Ingelheim Pharma GmbH & Co. KG
2013 - EUCTR2012-004090-16-DE Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
Boehringer Ingelheim RCV GmbH & Co KG
2013 Phase 1;Phase 2 EUCTR2012-004090-16-CZ Czech Republic;Germany;Netherlands;New Zealand;Poland;Spain;
BI 655064 high dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 low dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 655064 medium dose
Boehringer Ingelheim
2012 Phase 1 NCT01751776 Czech Republic;Germany;Netherlands;New Zealand;Poland;Romania;Spain;
BI 695500
Boehringer Ingelheim
2013 Phase 3 NCT01955733 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Germany;Greece;Hungary;Ireland;Mexico;Netherlands;Poland;Portugal;Spain;United Kingdom;United States;
2012 Phase 3 NCT01682512 Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Boehringer Ingelheim International GmbH
2013 Phase 1;Phase 3 EUCTR2011-002894-48-NO Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 Phase 1;Phase 3 EUCTR2011-002894-48-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002894-48-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2013 - EUCTR2011-002894-48-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 3 EUCTR2011-002894-48-PT Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-GR Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-GB Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-EE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 Phase 1;Phase 3 EUCTR2011-002894-48-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002894-48-NL Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-002894-48-HU Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
BI 695501
Boehringer Ingelheim
2016 Phase 3 NCT02640612 Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2015 Phase 3 NCT02137226 Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
Boehringer Ingelheim International GmbH
2016 Phase 3 EUCTR2015-002634-41-PL Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-HU Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-DE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2016 Phase 3 EUCTR2015-002634-41-BG Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2015 Phase 3 EUCTR2015-002634-41-ES Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-HU Argentina;Bulgaria;Chile;Colombia;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-ES Argentina;Belgium;Bulgaria;Chile;Colombia;Estonia;France;Germany;Hungary;Indonesia;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-EE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-DE Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
2014 Phase 3 EUCTR2012-002945-40-BG Bulgaria;Chile;Estonia;Germany;Hungary;Korea, Republic of;Malaysia;New Zealand;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United States;
BI 695501 Autoinjector
Boehringer Ingelheim
2016 Phase 2 NCT02636907 Poland;Ukraine;United States;
BI 695501 Prefilled syringe
Boehringer Ingelheim
2016 Phase 2 NCT02636907 Poland;Ukraine;United States;
BIBR 796 BS
Boehringer Ingelheim
2001 Phase 2 NCT02209779 -
BIIB023
Biogen Idec
2008 Phase 1 NCT00771329 Russian Federation;Ukraine;United States;
BIIB057
Biogen Idec
2012 Phase 2 NCT01652937 Canada;
BIIL 284 BS high dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIIL 284 BS low dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIIL 284 BS medium dose
Boehringer Ingelheim
2001 Phase 2 NCT02251210 -
BIRB 796 BS, high dose
Boehringer Ingelheim
2003 Phase 2 NCT02214888 -
BIRB 796 BS, low dose
Boehringer Ingelheim
2003 Phase 2 NCT02214888 -
BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)
Bristol-Myers Squibb
2016 Phase 1 NCT02762123 United States;
BMS-188667
Academisch Medisch Centrum Amsterdam
2010 - EUCTR2010-021435-14-NL Netherlands;
BRISTOL-M.SQUIBB
2005 - EUCTR2004-005102-68-IT Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-IT Belgium;Germany;Italy;Spain;United Kingdom;
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
2021 Phase 3 EUCTR2020-000350-96-IT Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2015 Phase 3 EUCTR2015-001275-50-IT Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Czechia;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-000784-26-IT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
- - EUCTR2005-000443-28-Outside-EU/EEA Austria;Brazil;France;Germany;Italy;Mexico;Peru;Portugal;Spain;Switzerland;United States;
Bristol-Myers Squibb Company
- Phase 2 EUCTR2015-005450-36-Outside-EU/EEA United States;
Bristol-Myers Squibb International Corporation
2022 Phase 3 EUCTR2020-000350-96-DE Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-PL Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-FR Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-ES Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-000350-96-CZ Argentina;Australia;Czech Republic;Czechia;France;Germany;Italy;Japan;Mexico;Netherlands;Poland;Spain;Sweden;Switzerland;Taiwan;United Kingdom;United States;
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2015-001275-50-RO Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2016 Phase 3 EUCTR2015-001275-50-NL Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2016 Phase 3 EUCTR2015-001275-50-HU Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-SE Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-GB Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-FR Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-FI Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-ES Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-DE Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-CZ Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2015 Phase 3 EUCTR2015-001275-50-AT Argentina;Australia;Austria;Brazil;Canada;Chile;Colombia;Czech Republic;Finland;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Qatar;Romania;Russian Federation;Saudi Arabia;Singapore;South Africa;Spain;Sweden;Taiwan;United Arab Emirates;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-AT Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
BMS-582949
Bristol Myers Squibb International Corporation
2008 Phase 2 EUCTR2008-000170-20-FR Czech Republic;France;Spain;
2008 Phase 2 EUCTR2008-000170-20-ES Czech Republic;France;Spain;
2008 - EUCTR2008-000170-20-CZ Czech Republic;France;Spain;
Bristol-Myers Squibb
2008 Phase 2 NCT00605735 Argentina;Brazil;Czech Republic;France;Korea, Republic of;Mexico;Spain;Taiwan;United States;
BMS-582949 and Methotrexate
Bristol-Myers Squibb
2005 Phase 1 NCT00162292 Mexico;United States;
BMS-817399
Bristol-Myers Squibb
2011 Phase 2 NCT01404585 Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002024-40-ES Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
BMS-945429
BRISTOL-M.SQUIBB
2011 - EUCTR2010-023956-99-IT Argentina;Belgium;Brazil;Canada;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Peru;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb International Corporation
2014 - EUCTR2013-003780-65-IT Argentina;Australia;Canada;Czech Republic;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
2014 - EUCTR2013-003780-65-HU Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
2011 - EUCTR2010-023956-99-NL Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-HU Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-ES Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-DE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-CZ Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
2011 - EUCTR2010-023956-99-BE Argentina;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Russian Federation;South Africa;Spain;Taiwan;United States;
CSL Behring
2011 Phase 2 NCT01373151 Argentina;Belgium;Brazil;Canada;Czech Republic;Czechia;France;Germany;Hungary;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Peru;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS-986104
Bristol-Myers Squibb
2014 Phase 1 NCT02211469 United States;
BMS-986142
Bristol-Myers Squibb
2016 Phase 2 NCT02638948 Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 1 NCT02762123 United States;
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2015-002887-17-FR Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
Bristol-Myers Squibb K.K.
2016 Phase 2 JPRN-JapicCTI-163317 Japan, Asia except Japan, North America, South America, Europe, Oceania;
BMS-986195
Bristol-Myers Squibb
2017 Phase 1 NCT03262740 United States;
2017 Phase 1 NCT03245515 Netherlands;
2017 Phase 1 NCT03131973 United States;
2016 Phase 1 NCT02705989 Australia;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BMS-986251
Bristol-Myers Squibb
2017 Phase 1/Phase 2 NCT03329885 Netherlands;
BMS188667
Bristol Myers Squibb International Corporation
2010 - EUCTR2010-018674-20-IT Denmark;Finland;France;Germany;Italy;Sweden;
BMS986142
Bristol-Myers Squibb International Corporation
2016 Phase 2 EUCTR2015-002887-17-AT Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BMS986195
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
BNP
Itabashi Chuo Medical Center
2012 - JPRN-UMIN000013885 Japan;
BNT162b2
National Institute of Allergy and Infectious Diseases (NIAID)
2021 Phase 2 NCT05000216 United States;
BOW015
Epirus Biopharmaceuticals (Switzerland) GmbH
2016 Phase 3 NCT02683564 -
BR9001
Boryung Pharmaceutical Co., Ltd
2018 Phase 1 NCT03718611 Korea, Republic of;
BR900A
Boryung Pharmaceutical Co., Ltd
2018 Phase 1 NCT03718611 Korea, Republic of;
BRL-049653
GlaxoSmithKline Research & Development Ltd.
2005 - EUCTR2004-000482-35-LT Lithuania;United Kingdom;
2004 Phase 2 EUCTR2004-000482-35-GB Lithuania;United Kingdom;
BT061
Biotest
2010 Phase 2 NCT01481493 Czech Republic;Germany;Hungary;Italy;Latvia;Poland;Spain;
Biotest AG
2013 Phase 2 EUCTR2013-000114-38-CZ Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-SK Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-LT Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-HU Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-EE Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-DE Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2013 - EUCTR2013-000114-38-BG Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Sweden;Ukraine;United States;
2012 - EUCTR2010-018485-24-LV Czech Republic;Germany;Hungary;Latvia;Spain;
2012 - EUCTR2010-018485-24-HU Czech Republic;Germany;Hungary;Latvia;Spain;
2011 - EUCTR2010-018485-24-ES Czech Republic;Germany;Hungary;Latvia;Spain;
2011 - EUCTR2010-018485-24-DE Czech Republic;Germany;Hungary;Latvia;Spain;
2010 - EUCTR2010-018485-24-CZ Czech Republic;Germany;Hungary;Latvia;Spain;
BT061 (CD4 monoclonal antibody)
Biotest AG
2008 - EUCTR2008-001241-26-HU Bulgaria;Hungary;
2008 - EUCTR2008-001241-26-BG Bulgaria;Hungary;
BT971
Biotest AG
2008 - EUCTR2008-001241-26-HU Bulgaria;Hungary;
2008 - EUCTR2008-001241-26-BG Bulgaria;Hungary;
BTK Inhibitor
Bristol-Myers Squibb International Corporation
2017 Phase 2 EUCTR2015-002887-17-FR Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-NL Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-ES Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
2016 Phase 2 EUCTR2015-002887-17-BE Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;South Africa;Spain;Taiwan;United States;
BTT-1023
Biotie Therapies Corp.
2009 Phase 1 NCT00851240 Bulgaria;
BUMEKIZUMAB
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Background Treatment
Galvani Bioelectronics
2021 - NCT05003310 United States;
Baminercept alfa
Biogen Idec
2007 Phase 2 NCT00664716 Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baminercept alfa (BG9924)
Biogen Idec
2007 Phase 2 NCT00664573 Argentina;Brazil;Hungary;Mexico;Poland;Romania;Russian Federation;United Kingdom;
Baricitinib
Division of Diabetes, Endocrinology and Clinical Immunology, Department of Internal Medicine, Hyogo college of Medicine
2020 - JPRN-UMIN000040094 Japan;
Eli Lilly Japan K.K.
- Phase 3 JPRN-JapicCTI-142405 -
- Phase 3 JPRN-JapicCTI-132156 -
- Phase 3 JPRN-JapicCTI-132138 -
- Phase 3 JPRN-JapicCTI-132134 -
- Phase 3 JPRN-JapicCTI-132125 -
Eli Lilly and Company
2020 Phase 4 NCT04086745 United States;
2019 Phase 4 NCT03915964 Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2014 Phase 3 NCT02265705 Argentina;Brazil;China;
2014 Phase 3 EUCTR2012-003686-17-SI Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2014 Phase 3 EUCTR2012-003686-17-GR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 NCT01885078 Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 NCT01721044 Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-SK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-SE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-PL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-LV Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-HU Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-HR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-FR Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-DK Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-CZ Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-003686-17-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002339-27-GB Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 Phase 3 EUCTR2012-002324-32-GB Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002324-32-BE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-GB Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-DK Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002323-15-BE Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-SI Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-GB Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 Phase 3 EUCTR2012-002322-73-DE Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002339-27-SK Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-PT Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-HU Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-DE Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-CZ Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002339-27-BE Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002324-32-SE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-PT Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-GR Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-DE Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002324-32-AT Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2013 - EUCTR2012-002323-15-PL Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-NL Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-HR Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-GR Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002323-15-AT Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002322-73-SK Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-PT Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-NL Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-LV Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-LT Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-HU Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-GR Argentina;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-CZ Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2013 - EUCTR2012-002322-73-BE Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2012 Phase 3 NCT01721057 Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 NCT01711359 Argentina;Austria;Belgium;Brazil;Canada;Germany;Greece;India;Italy;Japan;Korea, Republic of;Mexico;Portugal;Puerto Rico;Russian Federation;South Africa;Sweden;United Kingdom;United States;
2012 Phase 3 NCT01710358 Argentina;Belgium;Canada;China;Croatia;Czech Republic;Czechia;France;Germany;Greece;Hungary;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
2011 Phase 2 NCT01469013 Japan;
Galvani Bioelectronics
2021 - NCT05003310 United States;
Lilly S.A.
2013 - EUCTR2012-003686-17-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;India;Israel;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002339-27-ES Argentina;Belgium;Canada;Croatia;Czech Republic;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;
2013 - EUCTR2012-002323-15-ES Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2012-002322-73-ES Argentina;Australia;Belgium;Canada;China;Croatia;Czech Republic;France;Germany;Greece;Hungary;Israel;Japan;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Switzerland;Taiwan;United Kingdom;United States;
Transparency in Healthcare
2019 Phase 4 EUCTR2019-000505-72-NL Netherlands;
University of Erlangen-Nürnberg Medical School
2018 Phase 3 NCT03701789 Germany;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Baricitinib Oral Tablet [Olumiant]
Assistance Publique - Hôpitaux de Paris
2022 Phase 4 NCT05238896 France;
Baricitinib treatment
University Hospital, Bordeaux
2021 Phase 3 NCT04870203 France;Monaco;
Baricitinib, olumiant®
Shinshu University
2018 Phase 2 NCT03755466 Japan;
Belatacept
Bristol-Myers Squibb
2000 Phase 1/Phase 2 NCT00279760 Belgium;Canada;France;Germany;Ireland;Netherlands;Switzerland;United Kingdom;United States;
Belimumab
Human Genome Sciences Inc.
2005 Phase 2 NCT00583557 Poland;United States;
2003 Phase 2 NCT00071812 United States;
Human Genome Sciences Inc., a GSK Company
2009 Phase 4 NCT00931086 United States;
Benepali
Biogen
2017 - NCT03327454 Germany;
2017 - NCT03100734 Germany;
Department of Clinical Biochemestry, Aarhus University Hospital
2015 Phase 4 EUCTR2015-004173-32-DK Denmark;
University of Leeds
2019 Phase 4 NCT03813771 United Kingdom;
2018 Phase 4 EUCTR2016-002344-16-GB United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Bi 695500
Boehringer Ingelheim International GmbH
2014 Phase 3 EUCTR2013-002622-23-PT Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-002622-23-BE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-NL Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-HU Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-GR Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-ES Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-DE Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 - EUCTR2013-002622-23-BG Argentina;Belgium;Brazil;Bulgaria;Canada;Chile;Estonia;France;Germany;Greece;Guatemala;Hungary;Ireland;Italy;Mexico;Netherlands;New Zealand;Norway;Peru;Poland;Portugal;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
Bicain spinal
Helsinki University Central Hospital
2016 Phase 4 EUCTR2016-002035-15-FI Finland;
Bimekizumab
UCB Biopharma Sprl
2016 Phase 2 EUCTR2016-000393-37-BG Bulgaria;Georgia;Hungary;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Poland;Romania;Russian Federation;Serbia;United Kingdom;
UCB Celltech
2015 Phase 2 NCT02430909 Czech Republic;Czechia;Hungary;Moldova, Republic of;Poland;Russian Federation;Slovakia;United Kingdom;
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 Phase 2 EUCTR2014-003307-30-GB Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
Binyrebarkhormon
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Binyrebsrkhormon
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
Biodmards
Pfizer
2012 - NCT01438892 United States;
Biologic Agents
Simon Krabbe
2006 - NCT03496831 -
Biologic DMARD
Seoul National University Hospital
2013 - NCT01965132 Korea, Republic of;
Biologic TNFi
Pfizer
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Biologic/targeted therapy
Tuen Mun Hospital
2022 - NCT05182203 China;
Biological Drug
Sohag University
2022 - NCT05267431 Egypt;
Biological agents
Astellas Pharma Inc
2012 - NCT01870908 Japan;
Biological disease-modifying antirheumatic drugs (bDMARDs)
Universidade Nova de Lisboa
2020 - NCT04973787 Portugal;
Biologics
Shinshu University
2018 Phase 2 NCT03755466 Japan;
Biosimilar
McGill University Health Centre/Research Institute of the McGill University Health Centre
2018 - NCT03729674 Canada;
Opal Rheumatology Ltd.
2018 - NCT03470688 Australia;
Biosimilar Infliximab
Hikma Pharmaceuticals LLC
2017 - NCT03348046 Jordan;
Janssen Scientific Affairs, LLC
2016 - NCT02728934 United States;
Biosimilar infliximab
Diakonhjemmet Hospital
2014 Phase 4 NCT02148640 Norway;
Biosimilar product to adalimumab
Amgen Inc
2014 Phase 3 EUCTR2013-000525-31-DE Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2014 - EUCTR2013-000525-31-RO Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-PL Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-HU Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-GB Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-ES Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-CZ Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
2013 - EUCTR2013-000525-31-BG Argentina;Bulgaria;Canada;Czech Republic;Germany;Hungary;Mexico;Poland;Romania;Russian Federation;Spain;United Kingdom;United States;
Blood
Centre Hospitalier Universitaire, Amiens
2013 - NCT02894047 France;
Blood Collection for PK Testing (15 Mins Before Injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (15 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (18-20 hours post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (180 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (60 minutes post injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood Collection for PK Testing (after injection)
Navidea Biopharmaceuticals
2017 Phase 1/Phase 2 NCT02865434 United States;
Blood sample
Centre Hospitalier Universitaire de Saint Etienne
2020 Phase 4 NCT04470453 France;
2018 Phase 4 NCT03445871 France;
University Hospital, Bordeaux
2018 - NCT03550833 France;
Blood samples
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT01954381 France;
Blood sampling
University Hospital, Toulouse
2021 - NCT05039216 France;
Blood sampling from infant
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from mother
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood sampling from umbilical cord
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02019602 France;Netherlands;Switzerland;United States;
Blood tests
Assistance Publique - Hôpitaux de Paris
2020 - NCT04584541 France;
Boostrix®
Eli Lilly and Company
2011 - EUCTR2010-022205-17-PL Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
2011 - EUCTR2010-022205-17-BG Argentina;Australia;Brazil;Bulgaria;Colombia;Croatia;Hungary;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Sri Lanka;Taiwan;Ukraine;United States;
Bortezomib
Charite University, Berlin, Germany
2014 Phase 2 NCT02102594 Germany;
Bovine intesastinal alkaline phosphatase (bIAP)
Alloksys Life Sciences B.V.
2011 - EUCTR2008-007346-63-GB United Kingdom;
Branebrutinib
Bristol-Myers Squibb
2020 Phase 2 NCT04186871 Argentina;Australia;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Bristol-Myers Squibb International Corporation
2021 Phase 2 EUCTR2019-002205-22-NL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-PL Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-GB Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-FR Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-ES Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
2020 Phase 2 EUCTR2019-002205-22-DE Argentina;Belgium;France;Germany;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
Breast milk sampling
UCB BIOSCIENCES, Inc.
2014 Phase 1 NCT02154425 France;Netherlands;Switzerland;United States;
Bredinin tablet
Chong Kun Dang Pharmaceutical
2013 Phase 2 NCT02005757 Korea, Republic of;
Bucillamine
BASIC study group
2007 - JPRN-UMIN000000837 Japan;
Higashi-Hiroshima Memorial Hospital
2009 Phase 4 JPRN-UMIN000002169 Japan;
Japan Association of Rheumatologists in Private Practice
2010 - JPRN-UMIN000003807 Japan;
KONAMON Study Group
2013 - JPRN-UMIN000007404 Japan;
National hospital organization Chiba east national hospital Clinical Research Center
2013 - JPRN-UMIN000012690 Japan;
Saitama Medical University
2007 Phase 4 NCT00716248 Japan;
Sanofi
2015 Phase 3 NCT02373202 Japan;
St Luke'
Tokyo Medical and Dental University
2012 - JPRN-UMIN000006702 Japan;
s International Hospital
Bupivacaine hydrochloride (Marcaine, Pfizer)
Sohag University
2020 Phase 4 NCT04361513 Egypt;
Buprenorphine Transdermal Patch
Mundipharma Pharmaceuticals Sdn. Bhd.
2013 Phase 4 NCT02519387 Malaysia;
Buprenorphine transdermal patch
Mundipharma Pte Ltd.
2013 Phase 4 NCT01961271 Hong Kong;Korea, Republic of;Philippines;
C-Stem™ AMT Femoral Component (standard and high off-set variants)
DePuy International
2006 Phase 4 NCT00872573 United Kingdom;
C. albicans
Genentech, Inc.
2006 Phase 2 NCT00282308 United States;
C10AA05
Reade
2015 Phase 4 EUCTR2013-005524-42-NL Netherlands;
CAM-3001
MedImmune Limited
2013 Phase 2 EUCTR2011-005649-10-GB Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
MedImmune Ltd
2013 Phase 2 EUCTR2011-005648-93-SK Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2013 Phase 2 EUCTR2011-005648-93-GB Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2013 - EUCTR2011-005649-10-SK Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-PT Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-HU Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-DE Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005649-10-CZ Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2013 - EUCTR2011-005648-93-PT Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-GR Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-ES Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-DE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 Phase 2 EUCTR2011-005648-93-BG Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005649-10-GR Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-005649-10-ES Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
2012 - EUCTR2011-005648-93-HU Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005648-93-EE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005648-93-CZ Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Greece;Hungary;Mexico;Portugal;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-005634-19-PL Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-HU Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-ES Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-EE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-DE Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-CZ Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2012 - EUCTR2011-005634-19-BG Argentina;Bulgaria;Chile;Czech Republic;Estonia;France;Germany;Hungary;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;
2010 - EUCTR2009-014735-20-PL Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-LT Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-HU Bulgaria;Czech Republic;Estonia;Hungary;Lithuania;Poland;
2010 - EUCTR2009-014735-20-CZ Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2010 - EUCTR2009-014735-20-BG Bulgaria;Czech Republic;Estonia;Hungary;Latvia;Lithuania;Poland;
2009 - EUCTR2009-014735-20-LV Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2009 - EUCTR2009-014735-20-EE Bulgaria;Czech Republic;Estonia;Hungary;Japan;Latvia;Lithuania;Poland;Romania;Russian Federation;Ukraine;
2008 Phase 1 NCT00771420 Germany;
CAPTURE
Dept. of orthopedic surgery, Osaka Medical College
2014 - JPRN-UMIN000012650 Japan;
GlaxoSmithKline
2017 - NCT03285191 United Kingdom;
CC-10004
Celgene Corporation
2011 - EUCTR2010-019926-15-CZ Czech Republic;United States;
CC-292
Celgene
2013 Phase 2 NCT01975610 United States;
CCI-779
Wyeth is now a wholly owned subsidiary of Pfizer
2003 Phase 2 NCT00076206 United States;
CCR1 Antagonist
Bristol-Myers Squibb International Corporation
2012 - EUCTR2011-002024-40-ES Argentina;Korea, Republic of;Mexico;Russian Federation;South Africa;Spain;United States;
CCX 354-C
ChemoCentryx
2009 Phase 1/Phase 2 NCT01027728 Belgium;Romania;
CCX-354-C
ChemoCentryx
2010 Phase 2 NCT01242917 Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
CCX354-C
ChemoCentryx
2010 Phase 2 NCT01242917 Belgium;Czech Republic;Germany;Hungary;Netherlands;Poland;Romania;Ukraine;
ChemoCentryx, Inc.
2010 Phase 2 EUCTR2010-019964-36-BE Belgium;Czech Republic;Germany;Hungary;
2010 - EUCTR2010-019964-36-HU Belgium;Czech Republic;Hungary;
2010 - EUCTR2010-019964-36-DE Belgium;Czech Republic;Germany;Hungary;
2010 - EUCTR2010-019964-36-CZ Belgium;Czech Republic;Germany;Hungary;
CDMARD
Eli Lilly and Company
2013 Phase 3 NCT01721044 Argentina;Australia;Austria;Belgium;Canada;Croatia;Denmark;France;Germany;Greece;India;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Puerto Rico;Spain;Switzerland;Turkey;United Kingdom;United States;
2012 Phase 3 NCT01721057 Argentina;Australia;Belgium;Canada;Croatia;Czech Republic;Czechia;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Portugal;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Taiwan;United Kingdom;United States;
CDP 6038 SC
UCB Pharma
2009 Phase 1/Phase 2 NCT01009242 Germany;United States;
CDP6038
R-Pharm
2016 Phase 3 EUCTR2014-004719-36-BG Belarus;Bulgaria;Russian Federation;Turkey;
UCB BIOSCIENCES, Inc.
2011 Phase 2 NCT01296711 Belgium;United Kingdom;United States;
UCB Biosciences Inc
2011 - EUCTR2010-022224-77-GB Belgium;United Kingdom;United States;
UCB Biosciences, Inc
2011 - EUCTR2010-020839-39-GB United Kingdom;United States;
UCB Biosciences, Inc.
2011 Phase 2 EUCTR2010-022224-77-BE Belgium;United Kingdom;United States;
UCB Biosciences, Inc. A Member of the UCB Group of Companies
2011 Phase 2 EUCTR2010-020839-39-BE Belgium;United Kingdom;United States;
UCB Celltech
2009 - EUCTR2009-010813-57-DE Germany;
UCB Pharma
2010 Phase 2 NCT01242488 Belgium;United Kingdom;United States;
2009 Phase 1/Phase 2 NCT01009242 Germany;United States;
CDP870
Astellas Pharma Inc
2011 Phase 3 NCT02586246 Japan;
Celltech R&D Ltd
2005 Phase 3 EUCTR2004-002993-49-FI Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2004-002993-49-LV Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-HU Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-GB Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-002993-49-DE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-BE Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
Korea Otsuka Pharmaceutical Co., Ltd.
2009 Phase 3 NCT00993317 Korea, Republic of;
Otsuka Pharmaceutical Co., Ltd.
2008 Phase 3 NCT00791921 Japan;
2008 Phase 2/Phase 3 NCT00791999 Japan;
UCB Celltech
2007 - EUCTR2004-002993-49-EE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2006 Phase 3 EUCTR2005-002629-30-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2006 - EUCTR2005-002629-30-LV Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002326-63-EE Czech Republic;Estonia;Latvia;Lithuania;
2005 Phase 3 EUCTR2005-002326-63-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2004-002993-49-SK Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2005-002326-63-LV Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2005-002326-63-LT Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-LT Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-CZ Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Inc
2006 - EUCTR2005-002629-30-LT Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-EE Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Pharma
2003 Phase 3 NCT00548834 -
2002 Phase 3 NCT00544154 -
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
2009 - EUCTR2007-005288-86-FR France;
2009 - EUCTR2007-000828-40-PL Austria;France;Germany;Italy;Poland;
2008 Phase 3 EUCTR2007-000828-40-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-AT Austria;France;Germany;Italy;Poland;
2005 - EUCTR2005-002326-63-CZ Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-SE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Pharma SA
2015 - EUCTR2011-002067-20-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2011-002067-20-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-PT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-IE Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-GB Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-BG Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-SE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-IE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-GB Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-AT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-NL Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-HU Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-ES Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-DE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-CZ Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-AT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 3 EUCTR2008-005427-28-FR France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-NL France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-IT France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-ES France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-DE France;Germany;Italy;Netherlands;Spain;
UCB S.A. (Casa Madre)
2008 - EUCTR2007-000830-38-IT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-IT Austria;France;Germany;Italy;Poland;
CDP870 Fab'-PEG
UCB Celltech
2005 Phase 3 EUCTR2005-001350-24-SK Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
UCB Inc.
2005 - EUCTR2005-001350-24-LV Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-LT Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-HU Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-FI Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-EE Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-CZ Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
CE 224,535
Pfizer
2009 Phase 1 NCT00838058 United States;
CE-224,535
PFIZER S.A.
2008 Phase 2 EUCTR2008-000327-25-ES Czech Republic;Poland;Spain;
Pfizer
2009 Phase 1 NCT00838058 United States;
2008 Phase 2/Phase 3 NCT00628095 Chile;Czech Republic;Korea, Republic of;Mexico;Poland;Spain;United States;
2007 Phase 1 NCT00446784 United States;
Pfizer Inc. 235 East 42nd Street NY10017
2008 Phase 2 EUCTR2008-000327-25-PL Czech Republic;Poland;Spain;
2008 - EUCTR2008-000327-25-CZ Czech Republic;Poland;Spain;
CELBESTA®
Dong-A ST Co., Ltd.
2015 Phase 4 NCT02780323 Korea, Republic of;
CELEBREX
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX 200MG 20CPS
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
CELEBREX®
Dong-A ST Co., Ltd.
2015 Phase 4 NCT02780323 Korea, Republic of;
CERTOLUZIMAB PEGOL
UCB PHARMA
2011 - EUCTR2011-000385-35-IT Italy;
CF101
Can-Fite BioPharma
2017 Phase 3 NCT02647762 Bosnia and Herzegovina;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
2010 Phase 2 NCT01034306 Bulgaria;Israel;
2008 Phase 2 NCT00556894 Bulgaria;Czech Republic;Czechia;Former Serbia and Montenegro;Israel;Poland;Serbia;Ukraine;
2006 Phase 2 NCT00280917 Bulgaria;Former Serbia and Montenegro;Israel;Poland;Romania;Serbia;Ukraine;United States;
Can-Fite BioPharma Ltd.
2008 - EUCTR2007-006527-13-BG Bulgaria;
Can-Fite BioPharma, Ltd.
2019 Phase 3 EUCTR2016-003682-26-PL Bosnia and Herzegovina;Bulgaria;Canada;Israel;Moldova, Republic of;Poland;Romania;Serbia;
CFZ533
Novartis Pharmaceuticals
2013 Phase 1 NCT02089087 Taiwan;United States;
CH-1504
Chelsea Therapeutics
2008 Phase 2 NCT00658047 Canada;
CH-4051
Chelsea Therapeutics
2010 Phase 2 NCT01116141 -
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-CZ Bulgaria;Czech Republic;
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
CHS-0214
COHERUS BIOSCIENCES, INC.
2015 Phase 3 EUCTR2015-000665-30-IT Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus BioSciences, Inc
2014 Phase 3 EUCTR2014-000443-33-PL Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-GB Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus Biosciences, Inc
2014 Phase 3 EUCTR2014-000443-33-IT Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-HU Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-ES Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-DE Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus Biosciences, Inc.
2015 Phase 3 NCT02486939 Japan;
2014 Phase 3 NCT02115750 Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
CIMZIA (Certolizumab Pegol)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
CIMZIA - 200MG-SOLUZIONE INIETTABILE-USO SOTTOCUTANEO-SIRINGA PRERIEMPITA(VETRO) 1ML 6(3X2) SIRINGHE PRERIEMPITE+6(3X2) SALVIETTINE IMBEVUTE DI ALCOOL
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
CKD-374 5mg Tab.
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03858725 Korea, Republic of;
CKD-506
Chong Kun Dang Pharmaceutical
2018 Phase 2 NCT04204603 Czechia;Georgia;Poland;Russian Federation;Ukraine;
Chong Kun Dang Pharmaceutical Corporation (CKD)
2018 Phase 2 EUCTR2018-001377-24-CZ Czech Republic;Georgia;Poland;Russian Federation;Ukraine;
CLS Brevius stem with Kinectiv technology
Zimmer Biomet
2011 - NCT03410940 Italy;Poland;Spain;
CMAB008
Shanghai Biomabs Pharmaceutical Co., Ltd.
2018 Phase 3 NCT03478111 China;
CNTO 136
Centocor, Inc.
2008 Phase 2 NCT00718718 Argentina;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Taiwan;Ukraine;United States;
Janssen-Cilag International N.V.
2014 Phase 3 EUCTR2013-001417-32-LT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-HU Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-ES Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-DE Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
CNTO 136 IgG
Centocor B.V.
2009 - EUCTR2007-006603-20-HU Hungary;
CNTO 148
CENTOCOR
2010 - EUCTR2009-010582-23-IT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Janssen Pharmaceutical K.K.
2008 Phase 3 NCT00771251 Japan;
2008 Phase 3 NCT00727987 Japan;
CNTO 1959 + MTX (Group 4)
Janssen Research & Development, LLC
2012 Phase 2 NCT01645280 Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 + MTX (Group 5)
Janssen Research & Development, LLC
2012 Phase 2 NCT01645280 Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Republic of;Mexico;Peru;Poland;Russian Federation;Singapore;Turkey;Ukraine;United States;
CNTO 1959 IgG
Janssen-Cilag International NV
2013 - EUCTR2011-001122-18-BG Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 Phase 2 EUCTR2011-001122-18-CZ Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 - EUCTR2011-001122-18-HU Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO 6785
Janssen Research & Development, LLC
2013 Phase 2 NCT01909427 Argentina;Colombia;Czech Republic;Philippines;Poland;Russian Federation;Thailand;
CNTO1275
Janssen-Cilag International NV
2013 - EUCTR2011-001122-18-BG Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 Phase 2 EUCTR2011-001122-18-CZ Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
2012 - EUCTR2011-001122-18-HU Argentina;Bulgaria;Chile;Colombia;Czech Republic;Hungary;Korea, Democratic People's Republic of;Mexico;Peru;Russian Federation;Singapore;Turkey;United States;
CNTO136
Centocor B.V.
2009 - EUCTR2007-006603-20-HU Hungary;
JANSSEN-CILAG INTERNATIONAL N.V.
2012 - EUCTR2010-022243-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
Janssen-Cilag International N.V.
2015 Phase 3 EUCTR2012-001176-10-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-LT Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-HU Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2013-001417-32-ES Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-DE Argentina;Austria;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2013-001417-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Germany;Hungary;Lithuania;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2012-001176-10-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2010-022242-24-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2013 - EUCTR2010-022243-38-NL Argentina;Australia;Austria;Belgium;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022243-38-GB Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 Phase 3 EUCTR2010-022242-24-LT Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2012 - EUCTR2010-022243-38-PT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-LT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-ES Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;Portugal;Serbia;Spain;Sweden;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-DE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-BE Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
2012 - EUCTR2010-022243-38-AT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Mexico;Netherlands;New Zealand;Poland;Portugal;Russian Federation;Serbia;Spain;Taiwan;United Kingdom;United States;
CNTO148
CENTOCOR
2006 Phase 3 EUCTR2004-003295-10-IT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor B.V.
2010 - EUCTR2008-006064-11-HU Hungary;Lithuania;
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2009 - EUCTR2008-006064-11-LT Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
CNTO6785
Janssen-Cilag International NV
2013 - EUCTR2012-003629-40-CZ Argentina;China;Colombia;Czech Republic;India;Philippines;Poland;Russian Federation;Thailand;
COVID-19 Vaccine (ChAdOx1-S [recombinant])
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA Vaccine (nucleoside modified)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA vaccine (nucleoside-modified)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 mRNA vaccine Moderna (CX-024414)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
COVID-19 vaccine
Paul R Fortin
2022 Phase 2/Phase 3 NCT05236491 -
COVID-19 vaccine AstraZeneca (ChAdOx1 nCoV-19)
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
CP 690,550
PFIZER
2005 - EUCTR2004-002846-36-IT Germany;Italy;Spain;
PFIZER INC
2017 Phase 3 EUCTR2016-001825-15-IT Bulgaria;Czech Republic;Germany;Hungary;Italy;Poland;Slovakia;Spain;
Pfizer
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
Pfizer Inc.
2017 Phase 3;Phase 4 EUCTR2016-001825-15-SK Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-CZ Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, New York
2017 Phase 3;Phase 4 EUCTR2016-001825-15-PL Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-HU Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-GB Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-ES Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-DE Australia;Belgium;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-BG Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2017 Phase 3;Phase 4 EUCTR2016-001825-15-BE Australia;Belgium;Bulgaria;Czech Republic;Germany;Hungary;Italy;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
CP 690550 MR
Pfizer Inc.
2020 Phase 2 EUCTR2019-002676-14-SE Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-HU Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-CZ Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
2020 Phase 2 EUCTR2019-002676-14-BG Bosnia and Herzegovina;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;Georgia;Hungary;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Sweden;Ukraine;
CP-195,543
Pfizer
2006 Phase 2 NCT00424294 United States;
CP-690, 550 - 10
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2016 Phase 3;Phase 4 EUCTR2014-000358-13-DE Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2015 Phase 3;Phase 4 EUCTR2014-000358-13-HR Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2015 Phase 3;Phase 4 EUCTR2014-000358-13-ES Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-RO Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-LV Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-LT Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Hungary;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-GB Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-EE Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-CZ Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-BG Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
CP-690,55-10
Arthritis Alapítvány
2016 - EUCTR2015-002523-26-HU Hungary;
CP-690,550
PFIZER
2010 Phase 3 EUCTR2009-016987-34-ES Belgium;Bulgaria;Czech Republic;Germany;Hungary;Poland;Slovakia;Spain;Sweden;
2008 - EUCTR2007-002066-35-IT Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2007 Phase 2 EUCTR2006-005035-19-IT Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-001984-31-IT Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Pfizer
2016 Phase 4 NCT02831855 Australia;Belgium;Bulgaria;Czechia;Germany;Hungary;Korea, Republic of;Mexico;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;United Kingdom;United States;
2012 Phase 1 NCT01484561 Czech Republic;Germany;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United States;
2011 Phase 2 NCT01359150 Poland;United States;
2010 Phase 3 NCT01039688 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 Phase 2 NCT01059864 Korea, Republic of;United States;
2009 Phase 3 NCT00960440 Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Puerto Rico;Spain;Taiwan;United Kingdom;United States;
2009 Phase 3 NCT00856544 Australia;Chile;China;Colombia;Croatia;Denmark;Finland;Germany;Greece;Malaysia;Mexico;Poland;Russian Federation;Slovakia;Spain;Sweden;Thailand;United Kingdom;United States;Venezuela;
2009 Phase 3 NCT00853385 Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;Germany;Korea, Republic of;Mexico;Philippines;Poland;Slovakia;Spain;Thailand;United Kingdom;United States;
2009 Phase 3 NCT00847613 Australia;Brazil;Bulgaria;Canada;Colombia;Czech Republic;Greece;India;Japan;Korea, Republic of;Mexico;Poland;Taiwan;Ukraine;United States;Venezuela;
2009 Phase 3 NCT00814307 Brazil;Bulgaria;Chile;Colombia;Czech Republic;Dominican Republic;Germany;India;Malaysia;Mexico;Philippines;Poland;Puerto Rico;Russian Federation;Ukraine;United States;
2009 Phase 2 NCT00687193 Japan;
2008 Phase 3 NCT00661661 Japan;
2008 Phase 2 NCT00603512 Japan;
2007 Phase 3 NCT00413699 Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;United States Minor Outlying Islands;
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
2007 Phase 2 NCT00413660 Argentina;Brazil;Bulgaria;Chile;Czech Republic;Hungary;Mexico;Poland;Slovakia;Spain;Sweden;Turkey;United States;
2007 - NCT00414661 Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Dominican Republic;Finland;Greece;Hungary;India;Italy;Japan;Korea, Republic of;Mexico;Poland;Puerto Rico;Romania;Slovakia;Spain;Sweden;Ukraine;United States;
2005 Phase 2 NCT00147498 Austria;Belgium;Brazil;Canada;Germany;Italy;Mexico;Slovakia;Spain;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2010 Phase 2;Phase 3 EUCTR2006-005035-19-HU Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2009 Phase 3 EUCTR2008-007023-26-GR Bulgaria;Czech Republic;Greece;Poland;
2009 - EUCTR2008-008337-11-GB Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-007023-26-PL Bulgaria;Czech Republic;Poland;
2009 - EUCTR2008-007023-26-BG Bulgaria;Czech Republic;Poland;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017, USA
2009 - EUCTR2008-008337-11-DE Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
Pfizer Inc.
2011 - EUCTR2010-020890-18-CZ Czech Republic;Hungary;
2009 Phase 3 EUCTR2008-008337-11-SK Denmark;Finland;Germany;Greece;Poland;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008338-35-CZ Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 - EUCTR2008-008337-11-SE Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-GR Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-FI Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-008337-11-DK Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-007788-17-CZ Bulgaria;Czech Republic;Germany;
2009 - EUCTR2008-007023-26-CZ Bulgaria;Czech Republic;Poland;
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2011 - EUCTR2010-020890-18-HU Czech Republic;Hungary;
2010 - EUCTR2009-014296-40-IT Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 - EUCTR2008-008337-11-PL Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
Pfizer Inc. 235 East 42nd Street, New York, NY10017
2009 Phase 2;Phase 3 EUCTR2006-006373-25-GB Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
2009 - EUCTR2006-006373-25-FI Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-GR Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-006373-25-GR Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-006373-25-BG Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2008 - EUCTR2006-005036-24-BG Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-006373-25-CZ Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005036-24-HU Bulgaria;Czech Republic;Hungary;Sweden;
2007 - EUCTR2006-005036-24-CZ Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2010 Phase 3 EUCTR2009-014296-40-FR Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-016987-34-SE Argentina;Australia;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-PL Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
2010 - EUCTR2009-016987-34-HU Bulgaria;Czech Republic;Germany;Hungary;Poland;Spain;Sweden;
2010 - EUCTR2009-014296-40-IE Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-014296-40-GB Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2010 - EUCTR2009-014296-40-BE Australia;Austria;Belgium;Brazil;Canada;France;Germany;Ireland;Italy;Korea, Republic of;Spain;Sweden;Taiwan;Tanzania, United Republic of;United Kingdom;United States;
2010 - EUCTR2009-014296-40-AT Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-008338-35-SK Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-008338-35-DK Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
2009 - EUCTR2009-014296-40-DE Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-GB Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-FI Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-DE Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-008338-35-BG Bulgaria;Czech Republic;Denmark;Finland;Germany;Spain;United Kingdom;
2009 - EUCTR2008-007788-17-DE Bulgaria;Czech Republic;Germany;
2009 - EUCTR2008-007788-17-BG Bulgaria;Czech Republic;Germany;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
2010 Phase 3 EUCTR2009-016987-34-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 Phase 3 EUCTR2009-016987-34-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
2010 - EUCTR2009-016987-34-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Denmark;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Pfizer Ltd - Ramsgate Road, Sandwich CT139NJ, UK.
2007 Phase 2 EUCTR2006-005036-24-SK Bulgaria;Czech Republic;Hungary;Slovakia;Sweden;
2007 - EUCTR2006-005036-24-SE Bulgaria;Czech Republic;Hungary;Sweden;
Pfizer Ltd, Ramsgate Road, Sandwich CT139NJ, UK
2007 Phase 2 EUCTR2006-006373-25-SK Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Slovakia;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-SE Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-AT Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
Pfizer S.A.
2009 Phase 3 EUCTR2009-014296-40-ES Austria;Belgium;France;Germany;Ireland;Italy;Spain;United Kingdom;
2007 Phase 2 EUCTR2006-005035-19-ES Austria;Belgium;Bulgaria;Czech Republic;Denmark;Finland;Germany;Greece;Hungary;Ireland;Italy;Slovakia;Spain;Sweden;United Kingdom;
Pfizer, S.A
2009 Phase 3 EUCTR2008-008338-35-ES Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
Pfizer, S.A.
2009 - EUCTR2008-008337-11-ES Denmark;Finland;Germany;Greece;Poland;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-006373-25-ES Austria;Bulgaria;Czech Republic;Finland;Germany;Greece;Spain;Sweden;United Kingdom;
CP-690,550 (tasocitinib)
Pfizer
2011 Phase 1 NCT01262118 Hungary;United States;
CP-690,550 (tofacitinib)
Pfizer
2005 Phase 1 NCT01745055 United States;
CP-690,550 + methotrexate
Pfizer
2009 Phase 2 NCT00976599 United States;
CP-690,550 – 10
Pfizer Inc. 235 East 42nd Street, New York, NY 10017
2014 - EUCTR2014-000706-34-GB Germany;Hungary;United Kingdom;United States;
CP-690,550-10
Pfizer Inc, 235 East 42nd Street, New York 10017
2013 - EUCTR2011-005689-39-HU Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 Phase 2 EUCTR2007-002066-35-SK Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2010 Phase 2;Phase 3 EUCTR2006-005035-19-IE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-GB Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-FI Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2009 Phase 2;Phase 3 EUCTR2006-005035-19-DK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-DE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2;Phase 3 EUCTR2006-005035-19-BG Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2008 Phase 2 EUCTR2007-002066-35-GR Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;Slovakia;
2008 Phase 2 EUCTR2007-002066-35-BG Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-HU Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-DE Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2008 - EUCTR2007-002066-35-CZ Bulgaria;Czech Republic;Germany;Greece;Hungary;Italy;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-SK Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-SE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-BE Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-AT Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
Pfizer Inc.
2017 Phase 2 EUCTR2016-002337-30-SK Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-CZ Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2011-005689-39-SK Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-NL Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
2014 - EUCTR2011-005689-39-DE Belgium;Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 Phase 2 EUCTR2011-005689-39-ES Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Slovakia;Spain;Taiwan;United States;
2013 - EUCTR2011-005689-39-CZ Canada;Czech Republic;Germany;Hungary;Korea, Republic of;Netherlands;Poland;Russian Federation;Spain;Taiwan;United States;
Pfizer Inc., 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2017 Phase 2 EUCTR2016-002337-30-HU Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-HR Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-ES Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-DE Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2017 Phase 2 EUCTR2016-002337-30-BG Australia;Bosnia and Herzegovina;Bulgaria;Colombia;Croatia;Czech Republic;Georgia;Germany;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;Spain;Taiwan;Ukraine;United States;
2014 Phase 3;Phase 4 EUCTR2014-000358-13-PL Argentina;Australia;Bosnia and Herzegovina;Bulgaria;Canada;Chile;Croatia;Czech Republic;Estonia;Germany;Israel;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Thailand;Turkey;United Kingdom;United States;
2007 Phase 2;Phase 3 EUCTR2006-005035-19-CZ Argentina;Australia;Austria;Belgium;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Chile;China;Colombia;Costa Rica;Croatia;Czech Republic;Denmark;Dominican Republic;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;Venezuela, Bolivarian Republic of;
CP-690-550
Pfizer
2007 Phase 2 NCT00550446 Brazil;Bulgaria;Chile;Croatia;Czech Republic;Germany;Greece;Hungary;Italy;Korea, Republic of;Mexico;Romania;Slovakia;Ukraine;United States;
CP690,550
Pfizer Corporation Austria Ges.m.b.H.
2005 - EUCTR2004-002846-36-AT Austria;Germany;Italy;Spain;
Pfizer Global & Developement, Pfizer Limited
2005 Phase 2 EUCTR2004-002846-36-SK Austria;Germany;Italy;Slovakia;Spain;
Pfizer Pharma GmbH
2005 - EUCTR2004-002846-36-DE Germany;Italy;Spain;
Pfizer, S.A.
2005 Phase 2 EUCTR2004-002846-36-ES Austria;Germany;Italy;Slovakia;Spain;
CR 1
Pfizer
2008 Phase 1 NCT00782600 United States;
CR 2
Pfizer
2008 Phase 1 NCT00782600 United States;
CR 3
Pfizer
2008 Phase 1 NCT00782600 United States;
CR0686
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086
Rottapharm Biotech
2017 Phase 2 NCT03163966 Czechia;
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-PL Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-DK Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-CZ Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-BG Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CR6086Z
Rottapharm Biotech S.r.l.
2017 Phase 2 EUCTR2016-004834-11-PL Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-GB Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-DK Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-CZ Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
2017 Phase 2 EUCTR2016-004834-11-BG Argentina;Bulgaria;Czech Republic;Denmark;Moldova, Republic of;Poland;Romania;United Kingdom;
CRx-102
CombinatoRx, Inc
2006 - EUCTR2004-001930-18-EE Estonia;
CombinatoRx, Incorporated
2008 - EUCTR2007-004399-38-LT Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-GB Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-EE Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-LT Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-HU Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-GB Estonia;Hungary;Lithuania;United Kingdom;
2007 - EUCTR2007-003069-42-EE Estonia;Hungary;Lithuania;United Kingdom;
Zalicus
2004 Phase 2 NCT00747214 -
CRx-102 (2.7/180)
Zalicus
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-102 (2.7/360)
Zalicus
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
CRx-139
CombinatoRx, Inc.
2006 Phase 2 EUCTR2004-004995-35-GB Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
2006 - EUCTR2004-004995-35-DK Czech Republic;Denmark;Germany;Italy;United Kingdom;
2005 - EUCTR2004-004995-35-CZ Czech Republic;Denmark;Germany;Italy;United Kingdom;
2005 - EUCTR2004-004995-35-AT Austria;Czech Republic;Denmark;Germany;Italy;United Kingdom;
CRx-150
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
2004 - EUCTR2004-001490-26-GB Estonia;United Kingdom;
CT- P10
CELLTRION, Inc.
2014 Phase 3 EUCTR2013-004555-21-SK Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-PT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-LV Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-HU Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-GR Austria;Bosnia and Herzegovina;Brazil;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-DE Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
2014 Phase 3 EUCTR2013-004555-21-AT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Germany;Greece;Hungary;Israel;Korea, Republic of;Latvia;Mexico;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;
CT-P10
Celltrion
2014 Phase 3 NCT02149121 Austria;Korea, Republic of;
CT-P13
CELLTRION, INC.
2012 - EUCTR2011-004468-31-IT Austria;Bosnia and Herzegovina;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Spain;Ukraine;United Kingdom;
CELLTRION, Inc
2012 Phase 3 EUCTR2011-004468-31-GB Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 Phase 3 EUCTR2011-004468-31-ES Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-PL Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-LV Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-LT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2012 - EUCTR2011-004468-31-AT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2011 - EUCTR2011-004468-31-SK Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Slovakia;Spain;Ukraine;United Kingdom;
2010 Phase 3 EUCTR2010-018646-31-SK Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018646-31-ES Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-PT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-LV Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-LT Austria;Bosnia and Herzegovina;Bulgaria;Chile;Colombia;Indonesia;Italy;Jordan;Latvia;Lithuania;Mexico;Peru;Philippines;Poland;Portugal;Romania;Russian Federation;Slovakia;Spain;Ukraine;United Kingdom;
2010 - EUCTR2010-018646-31-IT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-GB Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-BG Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-018646-31-AT Austria;Bulgaria;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Celltrion
2018 Phase 3 NCT03707535 China;
2016 Phase 3 NCT03147248 Korea, Republic of;
Celltrion, Inc
2017 Phase 1;Phase 3 EUCTR2016-002125-11-ES Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-LV Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-HU Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-EE Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-CZ Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Hungary;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;
2016 Phase 1;Phase 3 EUCTR2016-002125-11-BG Belgium;Bosnia and Herzegovina;Bulgaria;Chile;Czech Republic;Estonia;Hungary;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Peru;Poland;Russian Federation;Slovakia;South Africa;Spain;Ukraine;
Pfizer
2015 - NCT02605642 Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Italy;Spain;United Kingdom;
CT-P17
CELLTRION, Inc.
2019 Phase 3 EUCTR2019-000660-25-PL Poland;
Celltrion, Inc
2019 Phase 3 EUCTR2018-001690-25-LT Bulgaria;Hungary;Lithuania;Peru;Poland;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-PL Bosnia and Herzegovina;Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Russian Federation;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-HU Bosnia and Herzegovina;Bulgaria;Hungary;Lithuania;Peru;Poland;Russian Federation;Ukraine;
2018 Phase 3 EUCTR2018-001690-25-BG Bulgaria;Hungary;Korea, Republic of;Lithuania;Peru;Poland;Ukraine;
CT-P17 SC
Celltrion
2018 Phase 3 NCT03789292 Bulgaria;
CT-P17 SC AI (adalimumab)
Celltrion
2019 Phase 3 NCT04171414 Poland;
CTLA4Ig
BRISTOL-M.SQUIBB
2005 - EUCTR2004-002620-18-IT Belgium;Germany;Italy;Spain;United Kingdom;
Bristol Myers Squibb International Corporation
2011 Phase 3 EUCTR2008-001523-57-NO Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-018674-20-FR Belgium;Denmark;Finland;France;Germany;Italy;Sweden;
2010 Phase 3 EUCTR2010-018674-20-BE Australia;Belgium;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Poland;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-SE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;Sweden;United States;
2010 - EUCTR2010-018674-20-FI Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DK Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2010-018674-20-DE Australia;Canada;Denmark;Finland;France;Germany;Italy;Korea, Republic of;Mexico;Russian Federation;South Africa;Sweden;United States;
2010 - EUCTR2008-001523-57-HU Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2010 - EUCTR2008-001523-57-DE Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-GB Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 Phase 3 EUCTR2008-001523-57-ES Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2009 - EUCTR2008-001523-57-DK Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2008-001523-57-FR Denmark;France;Germany;Hungary;Italy;Norway;Spain;United Kingdom;
2008 Phase 3 EUCTR2007-005434-37-FR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-NL Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-IE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-HU Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-GR Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-DE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-BE Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2008 - EUCTR2007-005434-37-AT Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2006 - EUCTR2005-000784-26-AT Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-GB Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-ES Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2005-000784-26-DE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-IE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-BE Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-000922-59-DK Czech Republic;Denmark;Spain;Sweden;
2005 - EUCTR2004-000922-59-CZ Czech Republic;Denmark;Spain;Sweden;
2004 Phase 3 EUCTR2004-000922-59-ES Czech Republic;Denmark;Spain;Sweden;
2004 - EUCTR2004-000922-59-SE Czech Republic;Denmark;Spain;Sweden;
Bristol-Myers Squibb International Corporation
2008 Phase 3 EUCTR2007-005434-37-GB Austria;Belgium;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-GB Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-003768-67-ES Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-SE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-NL Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-DE Austria;Germany;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-003768-67-BE Austria;Belgium;Germany;Netherlands;Spain;Sweden;United Kingdom;
2006 - EUCTR2004-005102-68-CZ Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-GB Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 3 EUCTR2004-005102-68-ES Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-GB Belgium;Germany;Italy;Spain;United Kingdom;
2005 Phase 2 EUCTR2004-002620-18-ES Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2005-000784-26-CZ Austria;Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-IE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-DE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-005102-68-BE Belgium;Czech Republic;Germany;Ireland;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-DE Belgium;Germany;Italy;Spain;United Kingdom;
2005 - EUCTR2004-002620-18-BE Belgium;Germany;Italy;Spain;United Kingdom;
CZP
Astellas Pharma Inc
2011 Phase 3 NCT01451203 Japan;
Caffeine
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Janssen Research & Development, LLC
2012 Phase 1 NCT01636557 Germany;Korea, Republic of;Moldova, Republic of;South Africa;
R-Pharm International, LLC
2021 Phase 1 NCT04246762 Bulgaria;Moldova, Republic of;
Calcitriol
Atlanta VA Medical Center
2007 - NCT00427804 United States;
Guangdong Provincial Hospital of Chinese Medicine
2016 - ChiCTR-IPR-16009029 China;
The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042329 China;
Calcium
Centre Hospitalier Universitaire de Nimes
2016 - NCT02636829 France;
University of Aarhus
2015 Phase 2 NCT02944799 Denmark;
Calcium and cholecalciferol
University of Missouri-Columbia
1995 Phase 3 NCT00570934 United States;
Calcium carbonate
Children's Hospital Medical Center, Cincinnati
1996 Phase 2 NCT00000429 United States;
Calcium citrate
Brigham and Women's Hospital
2011 Phase 4 NCT01400516 United States;
Canakinumab
NOVARTIS FARMA
2007 - EUCTR2007-001665-15-IT Germany;Italy;Netherlands;Spain;
Novartis
2006 Phase 2 NCT00424346 Austria;Belgium;Canada;Finland;Germany;Spain;United States;
Novartis Farmacéutica S.A.
2009 Phase 2 EUCTR2008-005320-81-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2009 - EUCTR2008-005320-81-DE Austria;Germany;Spain;
2009 - EUCTR2008-005320-81-BE Austria;Belgium;Germany;Spain;
2008 - EUCTR2008-005320-81-AT Austria;Germany;Spain;
Canakinumab (investigational)
Novartis
2007 Phase 2 NCT00487825 Belgium;Germany;Italy;Netherlands;Spain;United States;
Canakinumab (proposed)
Novartis Farmaceutica S.A.
2007 - EUCTR2007-001665-15-ES Belgium;Germany;Italy;Netherlands;Spain;
Novartis Farmacéutica S.A
2007 - EUCTR2006-004669-32-ES Spain;
Novartis Farmacéutica, S.A.
2007 - EUCTR2007-000491-16-ES Austria;Belgium;Germany;Spain;
Novartis Pharma Services AG
2007 - EUCTR2007-001665-15-NL Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-DE Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-001665-15-BE Belgium;Germany;Italy;Netherlands;Spain;
2007 - EUCTR2007-000491-16-DE Austria;Germany;Spain;
2007 - EUCTR2007-000491-16-BE Austria;Belgium;Germany;Spain;
2007 - EUCTR2007-000491-16-AT Austria;Germany;Spain;
2007 - EUCTR2006-004666-14-DE Germany;
2007 - EUCTR2006-004666-14-BE Belgium;Germany;
Canakinumab Injection
Jeffrey Curtis
2021 Phase 4 NCT05080218 United States;
Cannabidiol by capsules twice daily
University of California, Los Angeles
2021 Phase 1/Phase 2 NCT04911127 United States;
Cannabidiol tablet
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Cannabis
University Hospital, Clermont-Ferrand
2020 - NCT04402554 France;
Carbon Modular Radial Head
Ascension Orthopedics, Inc.
2009 - NCT00825409 United States;
Carbon Modular Radial Head replacement
Integra LifeSciences Corporation
2009 - NCT02405234 United States;
Celebra
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebra (celecoxib)
University of Dundee
2007 Phase 4 EUCTR2007-000012-90-DK Denmark;Netherlands;United Kingdom;
Celebrex
Daewon Pharmaceutical Co., Ltd.
2010 Phase 3 NCT01781702 -
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
2019 Phase 4 EUCTR2018-004539-54-DE Germany;
GlaxoSmithKline Research & Development Limited
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
University of Dundee
2011 - EUCTR2007-000012-90-NL Denmark;Netherlands;United Kingdom;
2008 Phase 4 EUCTR2007-000012-90-GB Denmark;Netherlands;United Kingdom;
Celebrex 200 mg Hartkapseln
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Celebrex 200 mg capsule, hard
GlaxoSmithKline Research & Development Limited
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Celecoxib
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
Guangdong Provincial Hospital of Chinese Medicine
2016 - ChiCTR-IPR-16009029 China;
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Merck Sharp & Dohme (Sweden) AB
2004 Phase 2 EUCTR2004-000612-54-SE Sweden;
Mito medical center, Mito Kyodo General Hospital, University of Tsukuba
2014 Phase 4 JPRN-UMIN000014624 Japan;
National Institute of Mental Health (NIMH)
2019 Phase 1/Phase 2 NCT03912428 United States;
Pfizer
2006 Phase 2 NCT00424294 United States;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2006 Phase 4 NCT00346216 Australia;Brazil;Canada;Colombia;Costa Rica;Hong Kong;Mexico;Panama;Peru;Philippines;Taiwan;Ukraine;United States;
2005 Phase 4 NCT00141102 Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
University of Dundee
2007 Phase 4 NCT00447759 Denmark;Netherlands;United Kingdom;
Celecoxib 200mg capsule
Inova Health Care Services
2018 Phase 4 NCT03699293 United States;
Ceramic on Ceramic articulation
Zimmer Biomet
2013 - NCT02036931 France;Germany;Ireland;Netherlands;Spain;United States;
Ceramic on Polyethylene articulation
Zimmer Biomet
2013 - NCT02036931 France;Germany;Ireland;Netherlands;Spain;United States;
Certolizumab
Brigham and Women's Hospital
2016 - NCT02714881 United States;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Rochester
2010 - NCT01098201 United States;
Certolizumab Pegol (CZP)
Nathan Wei, MD, FACP, FACR:
2011 Phase 3 NCT01374971 United States;
UCB Pharma
2010 Phase 4 NCT01255761 United States;
2010 Phase 3 NCT01235598 Denmark;Netherlands;Poland;Sweden;
UCB Pharma SA
2011 Phase 4 NCT01500278 Australia;Austria;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Monaco;Poland;Portugal;Romania;Spain;Switzerland;United Kingdom;United States;
Certolizumab Pegol + Methotrexate (MTX)
UCB Pharma
2012 Phase 3 NCT01521923 Argentina;Australia;Austria;Belgium;Canada;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Ireland;Italy;Mexico;Monaco;Netherlands;Poland;Romania;Spain;Sweden;Switzerland;United Kingdom;United States;
Certolizumab Pegol 200 MG/ML [Cimzia]
RenJi Hospital
2020 - NCT04569890 China;
Certolizumab pegol
Astellas Pharma Inc
2009 Phase 3 NCT00851318 Japan;
2009 Phase 3 NCT00850343 Japan;
Celltech R&D Ltd
2005 - EUCTR2004-002993-49-LV Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-HU Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-GB Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;United Kingdom;
2005 - EUCTR2004-002993-49-DE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-BE Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Sweden;
Oklahoma Medical Research Foundation
2010 Phase 3 NCT01213017 United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
UCB Biopharma SRL
2021 Phase 1 NCT04740814 United States;
UCB Celltech
2007 - EUCTR2004-002993-49-EE Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2006 Phase 3 EUCTR2005-002629-30-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2006 - EUCTR2005-002629-30-LV Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002326-63-EE Czech Republic;Estonia;Latvia;Lithuania;
2005 Phase 3 EUCTR2005-002326-63-SK Czech Republic;Estonia;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2005-001350-24-SK Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;
2005 Phase 3 EUCTR2004-002993-49-SK Belgium;Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;Slovakia;Sweden;
2005 - EUCTR2005-002326-63-LV Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2005-002326-63-LT Czech Republic;Estonia;Latvia;Lithuania;
2005 - EUCTR2004-002993-49-LT Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
2005 - EUCTR2004-002993-49-CZ Czech Republic;Estonia;Finland;Germany;Hungary;Latvia;Lithuania;Sweden;
UCB Inc
2006 - EUCTR2005-002629-30-LT Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-EE Czech Republic;Estonia;Latvia;Lithuania;
2006 - EUCTR2005-002629-30-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Inc.
2005 - EUCTR2005-001350-24-LV Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-LT Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-HU Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-FI Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-EE Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
2005 - EUCTR2005-001350-24-CZ Czech Republic;Estonia;Finland;Hungary;Latvia;Lithuania;
UCB Italy s.p.a.
2011 Phase 4 NCT01443364 Italy;
UCB Pharma
2009 Phase 4 NCT00993668 United States;
2008 Phase 3 NCT00753454 Canada;United States;
2008 Phase 3 NCT00674362 Austria;France;Germany;Italy;Poland;
2007 Phase 4 NCT00580840 Austria;Canada;France;United States;
UCB Pharma S.A.
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
2009 - EUCTR2007-005288-86-FR France;
2009 - EUCTR2007-000828-40-PL Austria;France;Germany;Italy;Poland;
2008 Phase 3 EUCTR2007-000828-40-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-FR Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000830-38-AT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-DE Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-AT Austria;France;Germany;Italy;Poland;
2005 - EUCTR2005-002326-63-CZ Czech Republic;Estonia;Latvia;Lithuania;
UCB Pharma SA
2009 Phase 3 EUCTR2008-005427-28-FR France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-NL France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-IT France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-ES France;Germany;Italy;Netherlands;Spain;
2009 - EUCTR2008-005427-28-DE France;Germany;Italy;Netherlands;Spain;
UCB S.A. (Casa Madre)
2008 - EUCTR2007-000830-38-IT Austria;France;Germany;Italy;Poland;
2008 - EUCTR2007-000828-40-IT Austria;France;Germany;Italy;Poland;
Certolizumab pegol (CDP870)
UCB Pharma
2005 Phase 3 NCT00152386 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Croatia;Czech Republic;Czechia;Israel;Latvia;Russian Federation;Ukraine;United States;
Certolizumab pegol (CDP870, tradename Cimzia)
University of Illinois at Chicago
2015 Phase 4 NCT02451748 United States;
Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
University of Illinois at Chicago
2015 Phase 4 NCT02451748 United States;
Certolizumab pegol (CZP)
UCB Pharma
2008 Phase 3 NCT00717236 Canada;France;Germany;Italy;Netherlands;Spain;United States;
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
Cetrorelix
Betanien Hospital
2008 Phase 2 NCT00667758 Norway;
Cevidoplenib
Oscotec Inc.
2019 Phase 2 EUCTR2018-003330-32-PL Czech Republic;Korea, Republic of;Poland;Russian Federation;Serbia;Ukraine;United States;
Chicken type II collagen
National Eye Institute (NEI)
1997 Phase 1 NCT00001614 United States;
Chimeric Human-Murine IgG1
Centocor BV
2009 Phase 4 EUCTR2007-003288-36-GB Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2009 - EUCTR2007-003288-36-ES Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 Phase 4 EUCTR2007-003288-36-FR Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-NL Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-FI Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-DE Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
2008 - EUCTR2007-003288-36-AT Austria;Finland;France;Germany;Netherlands;Spain;United Kingdom;
Chimeric human/mouse anti-CD-20 monoclonal antibody
Samsung Electronics Co. Ltd.
2012 - EUCTR2011-004171-36-PL Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-HU Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-GB Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-ES Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
2012 - EUCTR2011-004171-36-CZ Argentina;Brazil;Canada;Czech Republic;Hungary;Korea, Republic of;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Switzerland;Taiwan;Turkey;United Kingdom;
Chloroquine
Hoffmann-La Roche
2013 Phase 3 NCT01941095 Greece;
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
Sanofi
2018 Phase 4 NCT03449758 France;
University of Alberta
2020 - NCT04347798 Canada;
Cholecalciferol
University Hospital, Clermont-Ferrand
2011 Phase 3 NCT02243800 France;
Chong Kun Dang Tofacitinib Tablet
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03868072 Korea, Republic of;
Chromium
Akiyama Haruhiko
2011 Phase 4 JPRN-jRCTs032180273 Japan;
Kume Shinichiro
2012 Phase 4 JPRN-jRCTs032180245 Japan;
Zimmer Biomet
2009 - NCT03681639 Germany;
Ciclosporin
King's College London
2007 Phase 4 EUCTR2007-001190-28-GB United Kingdom;
PFIZER
2007 - EUCTR2007-001984-31-IT Belgium;Czech Republic;France;Germany;Italy;Netherlands;Portugal;Spain;
Cimzia
Karolinska Institutet
2015 Phase 4 NCT02466581 Sweden;
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 Phase 4 EUCTR2011-004720-35-DK Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
2012 Phase 4 NCT01491815 Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
Kings College London
2008 Phase 4 EUCTR2007-005464-26-GB United Kingdom;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
2012 Phase 4 EUCTR2011-005204-15-AT Austria;
Michael Schiff, MD
2010 Phase 4 NCT01147341 United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
The Karolinska Institute, ClinTRID
2017 Phase 4 EUCTR2011-004720-35-NL Denmark;Finland;Iceland;Netherlands;Norway;Sweden;
2012 - EUCTR2011-004720-35-SE Sweden;
The Karolinska Institutet, ClinTRID
2014 Phase 4 EUCTR2014-002374-36-SE Sweden;
The Karolinska Instutute, ClinTRID
2013 Phase 4 EUCTR2011-004720-35-IS Denmark;Finland;Iceland;Norway;Sweden;
UCB Celltech, UK Registered Branch of UCB Pharma SA
2015 Phase 2 EUCTR2014-003307-30-HU Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
2015 Phase 2 EUCTR2014-003307-30-GB Czech Republic;Hungary;Russian Federation;Slovakia;United Kingdom;
2015 Phase 2 EUCTR2014-003307-30-CZ Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
2015 - EUCTR2014-003307-30-SK Czech Republic;Georgia;Hungary;Moldova, Republic of;Russian Federation;Slovakia;United Kingdom;
UCB PHARMA SA/NV.
2012 - EUCTR2011-002067-20-IT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-IT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
UCB Pharma SA
2015 - EUCTR2011-002067-20-FR Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;Turkey;United Kingdom;United States;
2013 - EUCTR2011-002067-20-GR Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-PT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-IE Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-GB Australia;Austria;Bulgaria;Canada;Czech Republic;European Union;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-DE Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-CZ Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 4 EUCTR2011-002067-20-BG Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-SE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-IE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 Phase 3 EUCTR2011-001729-25-GB Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;European Union;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-HU Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-ES Australia;Austria;Bulgaria;Canada;Czech Republic;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-002067-20-AT Australia;Austria;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Ireland;Italy;Mexico;Portugal;Spain;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-NL Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-HU Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-ES Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
2012 - EUCTR2011-001729-25-DE Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-CZ Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2012 - EUCTR2011-001729-25-AT Argentina;Australia;Austria;Brazil;Canada;Colombia;Czech Republic;Germany;Hungary;Ireland;Italy;Mexico;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
University of California, San Francisco
2013 - NCT01773681 United States;
Universitätsklinikum Erlangen
2015 Phase 3 EUCTR2013-000337-13-PT Germany;Portugal;Serbia;United States;
2013 Phase 3 EUCTR2013-000337-13-DE Germany;Portugal;Serbia;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Cimzia 200 mg injeksjonsvæske, oppløsning
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
Cimzia 200 mg solution for injection
Ghent University Hospital
2012 Phase 3 EUCTR2009-017998-37-BE Belgium;
Cimzia®
UCB Pharma S.A.
2011 - EUCTR2009-013758-33-NL Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-SE Denmark;Netherlands;Sweden;
2010 - EUCTR2009-013758-33-DK Denmark;Netherlands;Sweden;
2010 - EUCTR2007-000830-38-PL Austria;France;Germany;Italy;Poland;
Citalopram
Vrije Universiteit Brussel
2010 - NCT01154647 Belgium;
Classic DMARDs treatment group
Zhang, Xiao, M.D.
2013 - NCT01915537 China;
Clazakizumab
Bristol-Myers K.K.
2014 Phase 2 JPRN-JapicCTI-142497 -
2011 Phase 2 JPRN-JapicCTI-111628 -
CSL Behring
2012 Phase 2 NCT02015520 Argentina;Australia;Canada;France;Hungary;Italy;Japan;Mexico;South Africa;United States;
Clindamycin
Hammersmith Hospitals NHS trust
2005 Phase 3 EUCTR2004-004893-96-GB United Kingdom;
Clofarabine
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Co-medication: Synthetic DMARDs
Diakonhjemmet Hospital
2013 Phase 4 NCT01881308 Norway;
Cobalt
Akiyama Haruhiko
2011 Phase 4 JPRN-jRCTs032180273 Japan;
Kume Shinichiro
2012 Phase 4 JPRN-jRCTs032180245 Japan;
Zimmer Biomet
2009 - NCT03681639 Germany;
Cobalt™ Bone Cement
Zimmer Biomet
2006 - NCT00589485 United States;
Cobiprostone
Sucampo Pharma Americas, LLC
2007 Phase 2 NCT00597818 United States;
Cod liver oil
National Institute of Nutrition and Seafood Research, Norway
2008 - NCT00805116 Norway;
Coenzyme Q10
the Second Hospital of Shanxi Medical University
2017 - ChiCTR-IPR-17010325 China;
Colchicine
Hospital Central Dr. Ignacio Morones Prieto
2018 Phase 2 NCT04056039 Mexico;
Colecalciferol
AZIENDA OSPEDALIERA ORDINE MAURIZIANO
2010 Phase 3 EUCTR2009-015835-34-IT Italy;
Collect of 10 ml of peripheric blood for DNA extraction
Centre Hospitalier Universitaire de Fort-de-France
2010 - NCT01111357 Martinique;
Combination Product: Exercise, and methotrexate
Cairo University
2020 - NCT04758689 Egypt;
Combination Product: Laser, exercise, and methotrexate
Cairo University
2020 - NCT04758689 Egypt;
Combination Product: Methotrexate
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
2019 Phase 2 NCT04038970 China;
Combination Steroid
All India Institute of Medical Sciences, New Delhi
2009 Phase 3 NCT01870128 India;
Combination fish oil and borage seed oil
National Center for Complementary and Integrative Health (NCCIH)
2006 Phase 3 NCT00072982 United States;
Combination of Minocycline and MTX or MTX alone
University of Nebraska
2001 Phase 3 NCT00579644 -
Comirnaty
Sint Maartenskliniek
2021 Phase 4 EUCTR2021-000710-42-NL Netherlands;
Skåne University Hospital, department of rheumatology in Lud and Malmö
2021 Phase 4 EUCTR2021-000880-63-SE Sweden;
Commercial Formulation Etanercept
Amgen
2016 Phase 3 NCT02986139 Puerto Rico;United States;
Comparator: Diclofenac sodium
Organon and Co
2003 Phase 3 NCT00250445 -
2003 Phase 3 NCT00092742 United States;
Comparator: diclofenac
Organon and Co
2006 Phase 2 NCT00264147 Canada;Colombia;Puerto Rico;Switzerland;United States;
Comparator: naproxen tablet
Merck Sharp & Dohme Corp.
2004 Phase 4 NCT00157872 China;
Computed Tomography
Jonsson Comprehensive Cancer Center
2016 Early Phase 1 NCT02925351 United States;
Control
Chengdu PLA General Hospital
2013 Phase 2 NCT02254655 China;
Laval University
2022 - NCT04688398 -
Control group
University of Erlangen-Nürnberg Medical School
2009 Phase 3 NCT02779114 Germany;
Control intervention (no dexamethasone)
University of Calgary
2016 - NCT02666443 Canada;
Conventional DMARD combination
Karolinska Institutet
2002 Phase 4 NCT00764725 -
Conventional DMARDs
Ain Shams University
2019 Phase 2 NCT03863405 Egypt;
Conventional Synthetic DMARD
SetPoint Medical Corporation
2021 Phase 3 NCT04539964 United States;
Conventional syringe - BD Ref 309604
University of New Mexico
2004 - NCT00651625 United States;
Corn oil capsules
Zhejiang University
2014 - NCT02173587 China;
Corticosteroid and non-biological agents.
University of Athens
2017 - NCT03288584 Greece;
Corticosteroid or NSAID
Hoffmann-La Roche
2007 Phase 4 NCT00462345 Korea, Republic of;
Corticosteroids
Genentech, Inc.
2003 Phase 2 NCT00074438 United States;
Corticotrophin 80 units
Gaylis, Norman B., M.D.
2013 Phase 4 NCT01948388 United States;
Creatine
Bangor University
2013 - NCT01767844 United Kingdom;
Creatinine
Affiliated Hospital of North Sichuan Medical College
2018 - ChiCTR1800018637 China;
CsDMARD(s)
GlaxoSmithKline
2020 Phase 3 NCT04333147 Argentina;Australia;Belgium;Bulgaria;Canada;Colombia;Czechia;Estonia;Germany;Hungary;India;Japan;Korea, Republic of;Latvia;Lithuania;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
CsDMARDs
Gilead Sciences
2016 Phase 3 NCT02873936 Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
GlaxoSmithKline
2019 Phase 3 NCT04134728 Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 NCT03970837 Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
Hoffmann-La Roche
2014 Phase 3 NCT02001987 France;
Cura-100
Cura Biotech LLC
2007 Phase 1/Phase 2 NCT00455208 United States;
Curcumin (Longvida™)
University of California, Los Angeles
2010 Phase 0 NCT00752154 United States;
Cyclophosphamide
Fairview University Medical Center
2000 - NCT00006055 United States;
Hoffmann-La Roche
2001 Phase 2 NCT02693210 Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Netherlands;Poland;Spain;United Kingdom;
Cyclosporin A
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
Cyclosporine
Fairview University Medical Center
2000 - NCT00006055 United States;
Cyklokapron®
University Hospital of North Tees and Hartlepool
2009 - EUCTR2009-012141-34-GB United Kingdom;
D2E7
Reade
2019 Phase 4 EUCTR2019-001793-28-NL Netherlands;
2019 Phase 1;Phase 4 EUCTR2019-001554-25-NL Netherlands;
D569 Tab.
Chong Kun Dang Pharmaceutical
2019 Phase 1 NCT03858725 Korea, Republic of;
DECORTIN (PREDNISONA) 5 MG COMPRIMIDOS
Pfizer S.A.
2009 Phase 2 EUCTR2009-013223-37-ES Czech Republic;Hungary;Spain;
DELTACORTENE FORTE*10CPR
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
DEPALGOS*20+325MG 28CPR RP
A.U.S.L. RIMINI
2006 - EUCTR2006-004062-13-IT Italy;
DEXA scan
University of Texas Southwestern Medical Center
2006 - NCT00286689 United States;
DIBASE*IM OS 2F 1ML 300000UI/M
AZIENDA OSPEDALIERA ORDINE MAURIZIANO
2010 Phase 3 EUCTR2009-015835-34-IT Italy;
DMARD
Amgen
2001 - NCT00116714 United States;
Hoffmann-La Roche
2013 Phase 3 NCT01995201 Ireland;Portugal;Spain;
2011 Phase 4 NCT01251120 Finland;
DMARD Therapy
Amgen
2011 Phase 4 NCT01313208 Canada;United States;
Zalicus
2004 Phase 2 NCT00747214 -
DMARD cessation
Newcastle-upon-Tyne Hospitals NHS Trust
2014 - NCT02219347 United Kingdom;
DMARD maintenance
Assistance Publique - Hôpitaux de Paris
2008 Phase 4 NCT00780793 France;
DMARDS
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00783536 Mexico;
DMARDs
Columbia University
2011 Phase 4 NCT01548768 United States;
Hoffmann-La Roche
2014 Phase 3 NCT02046603 United Kingdom;
2013 Phase 4 NCT01715831 Brazil;
2013 Phase 3 NCT01941940 Italy;
2009 Phase 3 NCT00996606 Italy;
JW Pharmaceutical
2010 Phase 3 NCT01256736 Korea, Republic of;
2009 Phase 3 NCT01211834 Korea, Republic of;
Mycenax Biotech Inc.
2013 Phase 3 NCT01787149 Taiwan;
Sun Yat-sen University
2018 Phase 4 NCT04066803 China;
DMARDs (disease-modifying antirheumatic drugs)
Hoffmann-La Roche
2009 Phase 4 NCT00996203 Russian Federation;
DMARDs (methotrexate
Merck Sharp & Dohme Corp.
2007 Phase 3 NCT00521924 Austria;
DMARDs or Biologics
Pfizer
2009 - NCT00929357 Denmark;
DRL_RI
Dr. Reddy's Laboratories Limited
2014 Phase 1/Phase 2 NCT02296775 India;Ukraine;
DW1809-1
Daewon Pharmaceutical Co., Ltd.
2020 Phase 1 NCT05214690 Korea, Republic of;
2020 Phase 1 NCT05214677 Korea, Republic of;
DW1809-T2
Daewon Pharmaceutical Co., Ltd.
2020 Phase 1 NCT05214690 Korea, Republic of;
DWP422
Daewoong Pharmaceutical Co. LTD.
2012 Phase 1 NCT01635686 Korea, Republic of;
Dacortin ®
Zalicus, Inc.
2012 - EUCTR2011-002392-41-HU Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2012 - EUCTR2011-002392-41-BG Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-PL Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-HU Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2011 - EUCTR2011-000436-28-BG Argentina;Brazil;Bulgaria;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Daily supplementation
Adeline BLOT
2018 - NCT04696718 France;
Dalacin C phosphate
Hammersmith Hospitals NHS trust
2005 Phase 3 EUCTR2004-004893-96-GB United Kingdom;
Decortin
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2011 - EUCTR2010-023782-22-CZ Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA
2011 - EUCTR2010-023782-22-DE Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer Inc.235 East 42nd Street, New York, NY 10017
2012 - EUCTR2010-023782-22-SK Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
2011 - EUCTR2010-023782-22-HU Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
2011 - EUCTR2010-023782-22-BG Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Pfizer, S.L.U.
2011 - EUCTR2010-023782-22-ES Bulgaria;Canada;Colombia;Czech Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United States;
Decortin 5mg tablets
Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc.
2009 - EUCTR2007-006150-25-DE Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
2008 - EUCTR2007-006150-25-HU Austria;Belgium;France;Germany;Hungary;Mexico;Netherlands;Romania;Serbia;
Wyeth Research Division of Wyeth Pharmaceuticals Inc.
2008 Phase 2 EUCTR2007-006150-25-FR Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 Phase 2 EUCTR2007-006150-25-BE Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 - EUCTR2007-006150-25-NL Austria;Belgium;France;Germany;Hungary;Netherlands;
2008 - EUCTR2007-006150-25-AT Austria;Belgium;France;Germany;Hungary;Netherlands;
Decortin®
Pfizer Inc.
2009 Phase 2 EUCTR2009-013223-37-CZ Czech Republic;Hungary;Spain;
Pfizer Inc., 235 East 42nd Street, New York, NY 10017
2009 - EUCTR2009-013223-37-HU Hungary;Spain;
Pfizer S.A.
2009 Phase 2 EUCTR2009-013223-37-ES Czech Republic;Hungary;Spain;
Decrease Tocilizumab, Abatacept
Assistance Publique - Hôpitaux de Paris
2012 Phase 4 NCT01557374 France;
Defanyl 50 and
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
Dekavil
Philogen S.p.A.
2015 Phase 2 EUCTR2013-005418-37-DE Germany;Italy;Switzerland;
2014 - EUCTR2013-005418-37-IT Germany;Italy;
Deltacortril Enteric
GlaxoSmithKline Research & Development Limited
2005 Phase 2 EUCTR2005-001977-82-GB United Kingdom;
Denosumab
Amgen
2011 Phase 1 NCT01294397 United States;
2004 Phase 2 NCT00095498 United States;
Chinese University of Hong Kong
2017 Phase 2 NCT03239080 China;
2012 Phase 4 NCT01770106 Hong Kong;
DAIICHISANKYO Co.,Ltd.
2013 Phase 3 JPRN-JapicCTI-132277 -
2010 Phase 2 JPRN-JapicCTI-101263 -
Daiichi Sankyo Company, Limited
2018 - JPRN-UMIN000030575 Japan;
Daiichi Sankyo, Inc.
2013 - NCT01973569 Japan;
Hokkaido Medical Center for Rheumatic Diseases
2017 - JPRN-UMIN000028376 Japan;
Indiana University
2019 Phase 1/Phase 2 NCT02418273 United States;
Kawakami Atsushi
2018 Phase 4 JPRN-jRCTs071180018 Japan;
Osaka City University Graduate School of Medicine
2018 - JPRN-UMIN000030828 Japan;
Yokohama City University Medical Center
2014 - JPRN-UMIN000014737 Japan;
Depemedrone
University Hospital Birmingham
2007 Phase 4 NCT00523692 United Kingdom;
Depo Medrol
Sun Pharma Global FZE
2016 Phase 3 EUCTR2015-002924-17-BE Belgium;Netherlands;
2015 Phase 3 EUCTR2015-002924-17-NL Belgium;Netherlands;
Depo medrol
Attune Health Research, Inc.
2018 Phase 3 NCT03511625 United States;
Depo-Medrone
University Hospitals Birmingham NHS Foundation Trust
2006 Phase 4 EUCTR2006-001428-38-GB United Kingdom;
Dexamethason
UMC Utrecht
2010 - EUCTR2009-017051-10-NL Netherlands;
Dexmedetomidine
West China Hospital, Sichuan University
2021 Phase 0 ChiCTR2000036316 China;
2021 Phase 0 ChiCTR2000036164 china;
Dextromethorphan hydrobromide
Taichung Veterans General Hospital
2010 - NCT02368093 -
Diacerein
TRB Chemedica
2010 Phase 2 NCT01264211 Thailand;
Diazepam, melatonin
Kobe University
2006 - NCT00287794 Japan;
Diclofenac
Mallinckrodt
2012 - NCT01579890 -
Northumbria Healthcare NHS Foundation Trust
2010 Phase 4 NCT01067430 United Kingdom;
University of Dundee
2007 Phase 4 NCT00447759 Denmark;Netherlands;United Kingdom;
Diclofenac + Omeprazole
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2005 Phase 4 NCT00141102 Belgium;Brazil;Canada;China;Colombia;Costa Rica;Croatia;Czech Republic;Czechia;Ecuador;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Guatemala;Hong Kong;India;Ireland;Korea, Republic of;Latvia;Lithuania;Netherlands;Panama;Peru;Portugal;Russian Federation;Serbia;Singapore;South Africa;Spain;Sweden;Taiwan;Ukraine;United Kingdom;
Diclofenac sodium
Laboratórios Pfizer, Lda
2006 - EUCTR2004-001234-17-PT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer AB
2006 - EUCTR2004-001234-17-SE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Healthcare Ireland
2006 - EUCTR2004-001234-17-IE Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Inc.
2005 - EUCTR2004-001234-17-LT Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Limited
2006 Phase 4 EUCTR2004-001234-17-GB Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
2005 - EUCTR2004-001234-17-CZ Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer Pharma GmbH
2006 - EUCTR2004-001234-17-DE Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer SA/NV
2006 - EUCTR2004-001234-17-BE Belgium;Czech Republic;Estonia;Germany;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Pfizer, S.A.
2005 - EUCTR2004-001234-17-ES Czech Republic;Estonia;Greece;Ireland;Latvia;Lithuania;Portugal;Spain;Sweden;United Kingdom;
Dietary Fiber Supplementation
University Hospital, Montpellier
2020 - NCT04421313 France;
Dietary supplement omega3 fatty acids aand vitamins
Physicians Committee for Responsible Medicine
2011 - NCT01544101 United States;
Digoxin
AstraZeneca
2011 Phase 1 NCT01355354 United Kingdom;
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Tanta University
2021 Phase 2 NCT04834557 -
Dihuang
Shanghai Traditional Chinese Medicine Hospital
2020 Phase 0 ChiCTR2000037675 China;
Dimeythl Fumarate
Biogen Idec Limited
2009 Phase 2 EUCTR2008-004754-33-SK Czech Republic;Poland;Slovakia;
2009 - EUCTR2008-004754-33-PL Czech Republic;Poland;
2009 - EUCTR2008-004754-33-CZ Czech Republic;Poland;
Dipotassium Salt
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-CZ Bulgaria;Czech Republic;
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Diprofos Depot
Knowledge Centre for Rheumatology and Back Diseases
2013 - EUCTR2013-003486-34-DK Denmark;
Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet
2017 Phase 4 EUCTR2017-003425-15-DK Denmark;
Dipyridamole
CombinatoRx, Incorporated
2008 - EUCTR2007-004399-38-LT Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-GB Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-004399-38-EE Estonia;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-LT Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-HU Estonia;Hungary;Lithuania;United Kingdom;
2008 - EUCTR2007-003069-42-GB Estonia;Hungary;Lithuania;United Kingdom;
2007 - EUCTR2007-003069-42-EE Estonia;Hungary;Lithuania;United Kingdom;
Zalicus
2011 Phase 2 NCT01369745 United States;
2007 Phase 2 NCT00551707 Argentina;Canada;Estonia;Hungary;Lithuania;Mexico;Poland;Romania;Russian Federation;Serbia;South Africa;United States;
Zalicus, Inc.
2012 - EUCTR2011-002392-41-HU Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
2012 - EUCTR2011-002392-41-BG Argentina;Brazil;Bulgaria;Canada;Chile;Hungary;Mexico;Peru;Poland;Russian Federation;Serbia;Ukraine;United States;
Dipyridamole and Amoxapine
CombinatoRx, Inc
2006 - EUCTR2004-001490-26-EE Estonia;United Kingdom;
Disease modified antirheumatic drugs or biological agents
Nanfang Hospital of Southern Medical University
2018 - NCT03508713 -
Disease-modifying anti-rheumatic drugs
Hoffmann-La Roche
2005 Phase 3 NCT00720798 Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Czech Republic;Denmark;Finland;France;Germany;Hong Kong;Iceland;Israel;Italy;Lithuania;Mexico;Netherlands;Norway;Panama;Peru;Portugal;Puerto Rico;Russian Federation;Serbia;Slovenia;South Africa;Spain;Sweden;Switzerland;Thailand;United Kingdom;United States;
Disease-modifying antirheumatic drug
Pfizer
2010 Phase 3 NCT01039688 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Costa Rica;Czech Republic;Czechia;Dominican Republic;Germany;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Russian Federation;Slovakia;Spain;Sweden;Taiwan;Thailand;Ukraine;United States;
Disease-modifying antirheumatic drugs (DMARDs)
Astellas Pharma China, Inc.
2018 Phase 3 NCT03660059 China;Korea, Republic of;Taiwan;
Hoffmann-La Roche
2010 Phase 3 NCT01194414 Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;France;Germany;Guatemala;Hong Kong;Italy;Lithuania;Mexico;New Zealand;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Singapore;South Africa;Spain;Thailand;United Kingdom;United States;
DnaJ peptide
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1999 Phase 2 NCT00000435 United States;
Dolquine
Fundació Clínic per a la Recerca Biomèdica
2019 Phase 4 EUCTR2017-004543-20-ES Spain;
Donepezil
RenJi Hospital
2018 Phase 3 NCT02927522 China;
Doppler ultrasound.
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT01954381 France;
Dose level 1
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 2
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 3
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Dose level 4
Pfizer
2009 Phase 1 NCT00838565 Korea, Republic of;Spain;United States;
Double-blind Abatacept
Bristol-Myers Squibb
2002 Phase 3 NCT00048932 United States;
Double-blind adalimumab
Abbott
2009 Phase 3 NCT00870467 Japan;
Doxycycline
Hong Kong Baptist University
2015 - ChiCTR-OPB-15007284 China;
New York University School of Medicine
2010 - NCT01198509 United States;
Doxycycline Tablets
Assiut University
2019 - NCT03194204 Egypt;
Dr. Reddy’s Rituximab (DRL_RI)
Dr. Reddy’s Laboratories S.A.
2020 Phase 3 EUCTR2019-002810-37-PL Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-LT Bulgaria;Czechia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-DE Bulgaria;Czech Republic;Germany;Hungary;Lithuania;Poland;United States;
2020 Phase 3 EUCTR2019-002810-37-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Lithuania;Poland;United States;
Dronabinol capsule
King Christian 10th Hospital for Rheumatology
2018 Phase 2 EUCTR2017-004226-15-DK Denmark;
Drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
Groupe Hospitalier Pitie-Salpetriere
2018 - NCT03480529 France;
Drug protocol
Federal University of São Paulo
2014 - NCT04752748 -
Drug treatment
Xijing Hospital
2019 - NCT04037111 China;
Dummy Qing Re Huo Xue (QRHX)
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
2019 Phase 2/Phase 3 NCT04170504 -
E-Device
UCB Biopharma S.P.R.L.
2017 Phase 3 NCT03357471 United States;
E1-Hip Bearing
Zimmer Biomet
2013 - NCT02087449 Korea, Republic of;
E6011
Eisai Co., Ltd.
2016 Phase 2 NCT02960490 Japan;
2016 Phase 2 NCT02960438 Japan;
2014 Phase 1/Phase 2 NCT02196558 Japan;
EC 3.1.3.1
Alloksys Life Sciences B.V.
2011 - EUCTR2008-007346-63-GB United Kingdom;
EMEA/H/C/004214
Erasmus Medical Center
2022 Phase 4 EUCTR2021-004131-84-NL Netherlands;
EMEA/H/C000262
University Hospitals Leuven
2013 - EUCTR2012-004631-22-BE Belgium;
ENBREL (Etanercept)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
ENBREL - 50 MG POLV SOLUZ INIET SOTTOC. POLV. FLAC VETRO SOLV. SIRI. VET. SOLV 1 ML (50 MG/ML) 12 FLAC+12 SIRI. PRE+12 AGHI+12 ADAT PER FLAC+24 TAMP. PRE INIEZ
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
ENBREL - 50 MG SOLUZIONE INIETTABILE IN SIRINGA (VETRO DA 1 ML) PRERIEMPITA - USO SOTTOCUTANEO 12 SIRINGHE PRERIEMPITE + 24 TAMPONI IMBEVUTI DI ALCOL
AMGEN INC.
2016 Phase 3 EUCTR2014-004868-38-IT Bulgaria;Czech Republic;France;Germany;Greece;Hungary;Italy;Portugal;Spain;United Kingdom;
ENBREL 25 mg injeksjonsvæske, oppløsning i ferdigfylt sprøyte.
Diakonhjemmet Hospital AS
2013 Phase 4 EUCTR2012-005275-14-NO Norway;
ENBREL 25MG PFS INJ.
Daewoong Pharmaceutical Co. LTD.
2012 Phase 1 NCT01635686 Korea, Republic of;
ENBREL*SC 4FL 25MG+4SIR 1ML
WYETH LEDERLE
2004 - EUCTR2004-000563-96-IT Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth Pharmaceuticals France, Wyeth Research Division
2008 - EUCTR2007-000896-41-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4FL 50MG+4SIR+4AGHI+
Wyeth Pharmaceuticals France, Wyeth Research Division
2008 - EUCTR2007-000896-41-IT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 25MG 0,5ML+8TAM
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL*SC 4SIR 50MG 1ML+8TAMP
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
ENBREL®
Amgen
2002 - NCT00116727 United States;
ENIA11
Mycenax Biotech Inc.
2012 Phase 3 NCT01709760 Taiwan;
EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)
Rabin Medical Center
2011 - NCT01274910 Israel;
ERB-041
WYETH LEDERLE
2005 - EUCTR2005-001319-23-IT Hungary;Italy;Spain;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical resaearch and Development
2005 Phase 2 EUCTR2005-001319-23-ES Hungary;Italy;Spain;
2005 - EUCTR2005-001319-23-HU Hungary;Italy;Spain;
ERMM-1
CIS bio international
2007 Phase 4 EUCTR2006-006380-22-DE Germany;
ESAOTE MyLab60
University Hospital, Rouen
2011 Phase 4 NCT01765374 France;
ETN
Research Center, the University of Tokyo
22nd Century Medical &
TAP Corporation
2009 - JPRN-UMIN000002687 Japan,Asia(except Japan);
ETN Alone
Japan Biological Agent Study Integrated Consortium
2005 Phase 4 NCT00688103 Japan;
ETN+MTX
Japan Biological Agent Study Integrated Consortium
2005 Phase 4 NCT00688103 Japan;
EU-Humira
Fresenius Kabi SwissBioSim GmbH
2017 Phase 3 NCT03052322 Bulgaria;Czech Republic;Czechia;Germany;Hungary;Poland;United Kingdom;
EU-approved RoActemra
Fresenius Kabi SwissBioSim GmbH
2020 Phase 3 NCT04512001 Bulgaria;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Russian Federation;Serbia;Slovakia;
EU/1/99/126/017
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
EU/1/99/126/020
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Ebetrexat
Ludwig Boltzmann Cluster für Rheumatologie, Balneologie und Rehabilitation
2008 - EUCTR2007-006288-56-AT Austria;
Edoxaban
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
2016 - JPRN-UMIN000026819 Japan;
Yokohama City University School of Medicine
2012 - JPRN-UMIN000018101 Japan;
Efalizumab
XOMA (US) LLC
2002 Phase 2 NCT00034203 United States;
Efexor XL 75 mg (venlafaxine)
Newcastle upon Tyne Hospitals NHS Trust
2005 - EUCTR2004-002482-20-GB United Kingdom;
Eldecalcitol
Department of Orthopaedic Surgery Shinshu University School of Medicine
2016 - JPRN-UMIN000022364 Japan;
Enalapril Maleate
University of Guadalajara
2017 Phase 2 NCT03667131 Mexico;
Enbrel
AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA
2018 Phase 3 EUCTR2017-004079-30-IT Belgium;Italy;Portugal;Spain;
Amgen
2000 Phase 4 NCT00132418 United States;
Amgen Inc.
2017 Phase 3 EUCTR2014-004868-38-DE Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-PT Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-HU Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-GR Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-FR Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-ES Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2016 Phase 3 EUCTR2014-004868-38-BG Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
2015 Phase 3 EUCTR2014-004868-38-CZ Argentina;Bulgaria;Canada;Czech Republic;France;Germany;Greece;Hungary;Portugal;Spain;United States;
AstraZeneca AB
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
Biogen
2017 - NCT03100734 Germany;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
Coherus BioSciences, Inc
2014 Phase 3 EUCTR2014-000443-33-PL Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-GB Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
Coherus Biosciences, Inc
2014 Phase 3 EUCTR2014-000443-33-IT Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-HU Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-ES Argentina;Belarus;Brazil;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000443-33-DE Argentina;Belarus;France;Germany;Hungary;Israel;Italy;Japan;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
Department of Clinical Biochemestry, Aarhus University Hospital
2015 Phase 4 EUCTR2015-004173-32-DK Denmark;
Derby Hospitals NHS Foundation Trust
2008 Phase 4 EUCTR2006-006562-42-GB United Kingdom;
ELI LILLY & COMPANY, LILLY CORPORATE CENTER
2019 Phase 4 EUCTR2018-003351-37-IT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
Eli Lilly and Company
2020 Phase 3;Phase 4 EUCTR2018-003351-37-FR Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-PL Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-NL Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-LT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-HU Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-GR Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-GB Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-DK Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-DE Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
2019 Phase 3;Phase 4 EUCTR2018-003351-37-AT Australia;Austria;Belgium;Czechia;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Fraunhofer-Institute for Translational Medicine and Pharmacology ITMP
2019 Phase 4 EUCTR2018-004539-54-DE Germany;
Fundación Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
2020 Phase 4 EUCTR2018-004558-30-PT Portugal;Spain;
2020 Phase 4 EUCTR2018-004558-30-DK Denmark;Portugal;Spain;
2019 Phase 4 EUCTR2018-004558-30-ES Spain;
Greater Glasgow Health Board
2006 Phase 4 EUCTR2006-000363-28-GB United Kingdom;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Joint Research & Development Office (QMUL)
2018 Phase 3 EUCTR2017-004079-30-PT Belgium;Italy;Portugal;Spain;
2018 Phase 3 EUCTR2017-004079-30-ES Belgium;Italy;Portugal;Spain;
2018 Phase 3 EUCTR2017-004079-30-BE Belgium;Italy;Portugal;Spain;
2014 Phase 3 EUCTR2014-003529-16-GB United Kingdom;
Joint Stock Company Farmak
2018 Phase 3 NCT04079374 Ukraine;
Kings College London
2008 Phase 4 EUCTR2007-005464-26-GB United Kingdom;
LG Life Sciences
2015 Phase 3 NCT02357069 Japan;Korea, Republic of;
Lilly S.A
2019 Phase 3;Phase 4 EUCTR2018-003351-37-ES Australia;Austria;Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Lithuania;Netherlands;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;United Kingdom;United States;
MD, PhD Salome Kristensen
2017 Phase 4 EUCTR2017-001970-41-DK Denmark;
Med Uni Graz, Univ. Klinik Innere Medizin,Abt. Rheumatologie und Immunologie
2012 Phase 4 EUCTR2011-005204-15-AT Austria;
NHS Greater Glasgow and Clyde
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Eye Institute (NEI)
1999 Phase 2 NCT00001862 United States;
Pfizer
2020 - NCT04428424 Iraq;
2011 - NCT01411215 China;
Pfizer Inc.
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SK Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-CZ Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2013 Phase 4 EUCTR2012-003644-71-BE Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;New Zealand;Poland;Russian Federation;Spain;
2013 - EUCTR2012-003644-71-ES Australia;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
Pfizer Inc. 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-SE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
2014 Phase 3;Phase 4 EUCTR2013-003177-99-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Pfizer Inc., 235 EAst 42nd Street, New York, NY 10017, United States
2013 - EUCTR2012-003644-71-NL Australia;Belgium;Chile;Colombia;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
Pfizer Inc., 235 East 42nd Street, New York, 10017
2015 Phase 3;Phase 4 EUCTR2013-003177-99-FI Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Slovakia;Slovenia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
2015 Phase 1 NCT02481180 China;
Sorrento Therapeutics, Inc.
2021 Phase 1 NCT04559412 United States;
University Hospital Birmingham NHS Foundation Trust
2007 Phase 4 EUCTR2006-006275-21-GB United Kingdom;
University Hospitals Birmingham NHS Foundation Trust
2006 Phase 4 EUCTR2006-001428-38-GB United Kingdom;
University Hospitals Leuven
2013 - EUCTR2012-004631-22-BE Belgium;
University of Leeds
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
Wyeth Pharmaceuticals France
2008 Phase 4 EUCTR2007-001625-10-ES Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-FR Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-001625-10-PL Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-DE Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-001625-10-AT Austria;Czech Republic;Denmark;France;Germany;Greece;Hungary;Ireland;Italy;Poland;Spain;United Kingdom;
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-ES Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-000896-41-NL Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2008 - EUCTR2007-000896-41-SE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2010 - EUCTR2007-000896-41-AT Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2007-000896-41-GB Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 Phase 4 EUCTR2007-000896-41-BE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-000896-41-CZ Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmceuticals Inc. A Pfizer Company, Philadelphia, PA-19101, USA
2008 - EUCTR2007-000896-41-DE Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2003 - NCT00245934 -
YL Biologics Ltd
2016 Phase 3 EUCTR2015-002809-12-BG Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-LV Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-HU Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Romania;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-ES Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
2015 Phase 3 EUCTR2015-002809-12-CZ Bulgaria;Czech Republic;Hungary;India;Japan;Latvia;Poland;Romania;Russian Federation;Spain;Ukraine;
Enbrel (Etanercept)
Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
- - EUCTR2012-001171-37-Outside-EU/EEA Canada;United States;
- - EUCTR2012-001145-40-Outside-EU/EEA Canada;United States;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2004 - NCT00484809 -
Enbrel (etanercept)
EMS
2013 Phase 3 NCT01394913 Brazil;
Pfizer
2007 - NCT00503139 Japan;
Radboud University Nijmegen Medical Centre, department of Rheumatic Diseases
2009 - EUCTR2008-005450-20-BE Belgium;
Samsung Bioepis Co., Ltd.
2013 Phase 3 NCT01895309 Poland;United Kingdom;
Wyeth Pharmaceuticals
2005 - EUCTR2004-000563-96-FI Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2005 - EUCTR2004-000563-96-AT Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-SE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-IE Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-HU Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-ES Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
2004 - EUCTR2004-000563-96-DK Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
- Phase 4 EUCTR2004-000563-96-NO Austria;Denmark;Finland;Hungary;Ireland;Italy;Norway;Spain;Sweden;
Wyeth is now a wholly owned subsidiary of Pfizer
2005 - NCT00503503 -
Enbrel 25 mg powder and solvent for solution for injection
Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
2010 - EUCTR2007-006657-63-IS Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-SE Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-FI Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-DK Denmark;Finland;Hungary;Iceland;Norway;Sweden;
Wyeth Pharmaceuticals France
2010 Phase 4 EUCTR2007-006657-63-HU Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 25mg PFS
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50 mg powder and solvent for solution for injection
Pfizer Ltd., Ramsgate Road,Sandwich,Kent,CT13 9NJ,United Kingdom
2010 - EUCTR2007-006657-63-IS Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-SE Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-FI Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2009 - EUCTR2007-006657-63-DK Denmark;Finland;Hungary;Iceland;Norway;Sweden;
Wyeth Pharmaceuticals France
2010 Phase 4 EUCTR2007-006657-63-HU Denmark;Finland;Hungary;Iceland;Sweden;
Enbrel 50 mg solution for injection in pre-filled syringe
Hexal AG
2016 Phase 3 EUCTR2012-002009-23-HU Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2012-002009-23-DE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-SK Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-PL Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LV Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-GB Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-ES Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-EE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-CZ Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2015 Phase 3 EUCTR2013-004569-16-DE Bulgaria;Colombia;Croatia;Germany;Greece;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;South Africa;
sanofi-aventis Recherche & Développement
2013 Phase 3 EUCTR2012-001984-66-NO Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001984-66-GB Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-LV Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-LT Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-IT Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-HU Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-GR Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-FI Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-ES Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-DE Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 - EUCTR2012-001984-66-CZ Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Ecuador;Finland;France;Germany;Greece;Guatemala;Hungary;India;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Norway;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
Enbrel 50mg PFS
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 - EUCTR2008-002623-85-NL France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Enbrel 50mg pre-filled pen
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Enbrel 50mg pre-filled syringe
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Enbrel Auto Injector
Wyeth Pharmaceuticals France
2008 - EUCTR2006-006591-37-GR Austria;Greece;
2008 - EUCTR2006-006591-37-AT Austria;Greece;
2007 Phase 3 EUCTR2006-005137-38-GB Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 Phase 3 EUCTR2006-005137-38-FR Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-006591-37-BE Austria;Belgium;Greece;
2007 - EUCTR2006-005137-38-SE Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-FI Denmark;Finland;France;Germany;Sweden;United Kingdom;
2007 - EUCTR2006-005137-38-DK Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel Pre-filled syringe
Wyeth Pharmaceuticals France
2007 Phase 3 EUCTR2006-005137-38-FR Denmark;Finland;France;Germany;Sweden;United Kingdom;
Enbrel liquid
Amgen
2005 Phase 3 NCT00249041 Canada;United States;
Enbrel pre-filled pen
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Enbrel pre-filled syringe
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Enbrel, Benepali, Erelzi
Reade
2019 Phase 4 EUCTR2019-001754-25-NL Netherlands;
Enbrel®
Amgen
2002 - NCT00121056 -
2000 - NCT00078793 Canada;United States;
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-020065-24-NL Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-LV Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-HU Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-GR Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-GB Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-ES Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-DE Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Denmark;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-CZ Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 Phase 4 EUCTR2010-020065-24-AT Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020065-24-LT Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - EUCTR2010-020065-24-BE Argentina;Austria;Belgium;Bosnia and Herzegovina;Canada;Chile;Croatia;Czech Republic;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
ROCHE
2011 Phase 4 EUCTR2010-020065-24-IT Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Czech Republic;Ecuador;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
Samsung Bioepis Co., Ltd.
2013 Phase 3 EUCTR2012-005026-30-HU Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-PL Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-LT Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-CZ Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
2013 - EUCTR2012-005026-30-BG Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Enbrel® 50 mg Solution for Injection in Pre-filled Syringe
Pfizer Inc, 235 East 42nd Street, New York, NY 10017
2012 - EUCTR2011-005448-87-HU Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
2012 - EUCTR2011-005448-87-CZ Argentina;Brazil;China;Colombia;Czech Republic;Egypt;Hungary;India;Malaysia;Mexico;Philippines;Poland;Romania;Russian Federation;Saudi Arabia;Slovakia;South Africa;Taiwan;Thailand;Turkey;Ukraine;United Arab Emirates;
Engineered humanized monoclonal anti-human CD19 antibody.
Xencor Inc.
2012 Phase 2 EUCTR2012-003057-29-HU Czech Republic;Hungary;Slovakia;
2012 - EUCTR2012-003057-29-SK Czech Republic;Hungary;Slovakia;
Engineered humanized monoclonal anti-human CD19 antibody. Lot Numbers: 1-FIN-1588 (9.6mg/ml)
Xencor Inc.
2013 - EUCTR2012-003057-29-CZ Czech Republic;Hungary;Slovakia;
Enoxaparin
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
2016 - JPRN-UMIN000026819 Japan;
Entanercept
Peking University First Hospital
2015 - NCT02320630 China;
Entecavir
Department of general internal medicine, Kyushu-University hospital
2012 - JPRN-UMIN000018017 Japan;
Seoul National University Hospital
2012 Phase 3 NCT01694264 Korea, Republic of;
Taipei Veterans General Hospital, Taiwan
2013 Phase 4 NCT01907230 Taiwan;
Epaxal
HY, HUS
2011 - EUCTR2009-016055-22-SE Finland;Sweden;
2009 - EUCTR2009-016055-22-FI Finland;Sweden;
Epinephrine
Nekoyama Miyao Hospital
2017 - JPRN-UMIN000029759 Japan;
2017 - JPRN-UMIN000029003 Japan;
Epoetin alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
2004 Phase 2 NCT00236678 -
Ortho Biotech Products, L.P.
2005 Phase 2 NCT00123149 -
Erbium citrate
CIS bio international
2007 Phase 4 EUCTR2006-006380-22-DE Germany;
Ergocalciferol
Johns Hopkins University
2009 - NCT01426347 United States;
Ergocalciferol 1.25 mg tablet
Tanta University
2019 Phase 4 NCT04472481 Egypt;
Esbriet
University Hospitals of Leicester NHS Trust
2017 Phase 2 EUCTR2017-000149-30-GB Australia;Canada;United Kingdom;United States;
Esomeprazole
AstraZeneca
2007 Phase 3 NCT00595517 Japan;
2007 Phase 3 NCT00542789 Japan;
- Phase 3 JPRN-JapicCTI-080565 -
- Phase 3 JPRN-JapicCTI-080531 -
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Eszopiclone
Sunovion
2004 Phase 3 NCT00367965 United States;
Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
Reade
2019 Phase 4 EUCTR2019-001754-25-NL Netherlands;
Etanercept
Amgen
2013 Phase 4 NCT01927757 Canada;Puerto Rico;United States;
2011 Phase 4 NCT01313208 Canada;United States;
2011 Phase 1 NCT01294397 United States;
2008 Phase 4 NCT00654368 Canada;
2006 Phase 4 NCT00346294 United States;
2006 Phase 3 NCT00413452 Canada;United States;
2006 Phase 1 NCT00361634 United Kingdom;United States;
2005 Phase 4 NCT00115219 United States;
2005 Phase 3 NCT00249041 Canada;United States;
2004 Phase 4 NCT00099554 Canada;United States;
2004 Phase 4 NCT00094341 United States;
2001 Phase 3 NCT00078806 Canada;United States;
2000 Phase 3 NCT03781375 -
1998 Phase 3 NCT00356590 Canada;United States;
1997 Phase 3 NCT00357903 Canada;United States;
1997 Phase 2/Phase 3 NCT03780959 -
AryoGen Pharmed Co.
2014 - NCT04582084 Iran, Islamic Republic of;
Astellas Pharma Inc
2014 Phase 3 NCT02308163 Japan;Korea, Republic of;Taiwan;
AstraZeneca
2008 Phase 2 NCT00713544 Argentina;Bulgaria;Colombia;Czech Republic;Hungary;Italy;Latvia;Malta;Netherlands;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Ukraine;
2007 Phase 2 NCT00520572 Argentina;Australia;Belgium;Canada;Czech Republic;France;Hungary;Mexico;Poland;Romania;Russian Federation;Slovakia;Sweden;United States;
AstraZeneca AB
2008 Phase 2 EUCTR2007-007539-14-SK Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;Slovakia;
2008 - EUCTR2007-007539-14-PL Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-MT Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-LV Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-HU Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-CZ Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-007539-14-BG Bulgaria;Czech Republic;Hungary;Italy;Latvia;Malta;Poland;
2008 - EUCTR2007-001420-12-CZ Czech Republic;France;Poland;Sweden;
2007 Phase 2 EUCTR2007-001420-12-SK Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 Phase 2 EUCTR2007-001420-12-FR Belgium;Czech Republic;France;Poland;Slovakia;Sweden;
2007 - EUCTR2007-001420-12-SE Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-PL Czech Republic;France;Poland;Sweden;
2007 - EUCTR2007-001420-12-BE Belgium;Czech Republic;France;Poland;Sweden;
Biogen
2006 Phase 2 NCT00298272 United States;
CHU Saint-Etienne
2008 - EUCTR2008-006256-22-FR France;
Coherus BioSciences, Inc.
2015 Phase 3 EUCTR2015-000665-30-GB Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-ES Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
2015 Phase 3 EUCTR2015-000665-30-DE Australia;Canada;France;Germany;Israel;Italy;Japan;South Africa;Spain;United Kingdom;
Coherus Biosciences, Inc.
2014 Phase 3 NCT02115750 Belarus;France;Germany;Hungary;Israel;Japan;Poland;Russian Federation;South Africa;Spain;United Kingdom;United States;
DAIICHISANKYO Co.,Ltd.
2014 Phase 3 JPRN-JapicCTI-142621 -
Department of Rheumatology and infectious disease, Kitasato university school of medicine
2012 - JPRN-UMIN000008572 Japan;
Department of Rheumatosurgery, Osaka City University Medical School
2009 Phase 4 JPRN-UMIN000002340 Japan;
Dept. of orthopedic surgery, Osaka Medical College
2012 - JPRN-UMIN000012613 Japan;
Derby Hospitals NHS Foundation Trust
2008 Phase 4 EUCTR2006-006562-42-GB United Kingdom;
Division of Periodontology, Niigata University Graduate School of Medical and Dental Sciences
2011 - JPRN-UMIN000013750 Japan;
Dr. Frank Behrens
2019 Phase 4 NCT04485325 Germany;
F. Hoffmann-La Roche Ltd
2008 Phase 4 EUCTR2007-000593-24-GB Sweden;United Kingdom;
F.Hoffmann-La Roche Ltd
2008 - EUCTR2007-000593-24-SE Sweden;United Kingdom;
Faiq Gorial
2017 Phase 1/Phase 2 NCT03160001 Iraq;
Fen Li
2016 Phase 4 NCT02878161 -
Gema Biotech S.A.
2016 Phase 3 NCT03403140 Argentina;
2016 Phase 3 NCT03332719 Argentina;
Georgetown University
2013 Phase 4 NCT01793519 United States;
Greater Glasgow Health Board
2006 Phase 4 EUCTR2006-000363-28-GB United Kingdom;
Hanwha Chemical
2010 Phase 3 NCT01270997 Korea, Republic of;
Hoffmann-La Roche
2011 Phase 4 NCT01331837 Argentina;Austria;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;China;Croatia;Czech Republic;Czechia;Ecuador;France;Germany;Greece;Hungary;India;Israel;Italy;Latvia;Lithuania;Malaysia;Mexico;Netherlands;Philippines;Poland;Romania;Russian Federation;Serbia;South Africa;Spain;Turkey;United Kingdom;United States;
2011 - NCT01592292 Korea, Republic of;
Imperial College London South Kensington London
2009 Phase 4 EUCTR2009-012424-87-GB United Kingdom;
Innovaderm Research Inc.
2014 Phase 4 NCT02109289 Canada;
Jagiellonian University
2013 Phase 4 NCT02132234 Poland;
Johoku Biological Summit
2006 Phase 4 JPRN-C000000452 Japan;
Joint Stock Company Farmak
2018 Phase 3 NCT04079374 Ukraine;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Kawakami Atsushi
2020 Phase 4 JPRN-jRCTs071200054 Japan;
2020 Phase 4 JPRN-jRCTs071190046 Japan;
King's College London
2010 Phase 4 EUCTR2010-020738-24-GB United Kingdom;
Lawson Health Research Institute
2020 Phase 4 NCT03976245 Canada;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
Merck Sharp & Dohme Corp.
2008 - NCT00724672 -
NHS Greater Glasgow and Clyde
2009 - EUCTR2009-011268-13-GB United Kingdom;
National Institute of Allergy and Infectious Diseases (NIAID)
2009 Phase 4 NCT00837434 United States;
2008 Phase 4 NCT00796705 United States;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2002 Phase 2 NCT00034060 United States;
Osaka City University Medical School
2011 Phase 4 JPRN-UMIN000008164 Japan;
Pfizer
2018 - NCT04267614 Iraq;
2015 Phase 3 NCT02378506 Bulgaria;Croatia;Germany;Greece;Hungary;Poland;Russian Federation;Serbia;Slovakia;South Africa;
2015 - NCT02486302 Germany;
2014 Phase 4 NCT02092467 Argentina;Australia;Austria;Brazil;Bulgaria;Canada;Chile;China;Colombia;Czech Republic;Czechia;Finland;Hong Kong;Israel;Jordan;Lebanon;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Thailand;Turkey;United Kingdom;United States;
2014 - NCT02202837 Belgium;
2013 Phase 4 NCT01783015 Australia;Belgium;France;Hong Kong;Israel;Netherlands;Russian Federation;Spain;
2013 - NCT01558089 Greece;
2012 Phase 4 NCT01578850 Brazil;China;Colombia;Czech Republic;Egypt;Hungary;Jordan;Lebanon;Malaysia;Mexico;Philippines;Qatar;Romania;Russian Federation;Saudi Arabia;South Africa;Taiwan;Thailand;Ukraine;United Arab Emirates;
2012 - NCT01646385 -
2012 - NCT01623752 -
2011 - NCT01557322 -
2009 Phase 4 NCT00913458 France;Germany;Ireland;Italy;Monaco;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Switzerland;United Kingdom;
2009 Phase 4 NCT00858780 Denmark;Finland;Hungary;Iceland;Norway;Sweden;
2008 Phase 4 NCT00565409 Australia;Austria;Belgium;Brazil;Chile;Colombia;Czech Republic;Former Serbia and Montenegro;France;Germany;Hungary;Italy;Korea, Democratic People's Republic of;Korea, Republic of;Mexico;Netherlands;Poland;Russian Federation;Serbia;Spain;Sweden;Taiwan;United Kingdom;
2006 Phase 3 NCT00445770 Japan;
2006 - NCT00488475 Germany;
2004 - NCT00195403 Korea, Republic of;
2004 - NCT00195338 Luxembourg;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Samsung Bioepis Co., Ltd.
2017 Phase 2 NCT03193957 Poland;
Sanofi
2013 Phase 3 NCT01764997 Argentina;Australia;Brazil;Chile;Colombia;Czech Republic;Czechia;Ecuador;Finland;France;Germany;Greece;Hungary;Israel;Italy;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Takarazuka city hospital
2014 - JPRN-UMIN000013362 Japan;
Team RA, Rheumatosurgery, Osaka City University Medical School
2008 - JPRN-UMIN000001798 Japan;
University of Alabama at Birmingham
2004 Phase 4 NCT00259610 United States;
University of California, Davis
2017 - NCT03178955 United States;
University of Leeds
2011 Phase 4 NCT02433184 United Kingdom;
2011 Phase 4 EUCTR2010-023880-17-GB United Kingdom;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
University of Pittsburgh
2009 Phase 4 NCT01009879 United States;
Università Popolare Homo & Natura
2015 Phase 1 NCT02633332 Italy;
VA Office of Research and Development
2007 - NCT00405275 Canada;United States;
Wyeth Pharmaceuticals France
2008 - EUCTR2007-000896-41-HU Austria;Belgium;Czech Republic;France;Germany;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Pharmaceuticals Inc. Philadelphia (A Pfizer Company)
2009 Phase 4 EUCTR2008-002623-85-GB France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company, Philadelphia,PA-19101,USA
2010 Phase 4 EUCTR2008-002623-85-SE France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
2009 - EUCTR2008-002623-85-IE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
2009 - EUCTR2008-002623-85-DE France;Germany;Ireland;Italy;Netherlands;Poland;Qatar;Romania;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Wyeth Research Division of Wyeth Pharmaceuticals Inc. Clinical Research and Development
2009 Phase 4 EUCTR2008-002623-85-FR France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 4 EUCTR2008-002623-85-ES France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-002623-85-IT France;Germany;Ireland;Italy;Netherlands;Spain;Sweden;United Kingdom;
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00768053 France;Monaco;
2007 Phase 3 NCT00484237 Japan;
2007 Phase 3 NCT00418717 Japan;
2006 Phase 3 NCT00443950 China;
2004 Phase 4 NCT00252668 -
2004 Phase 4 NCT00195494 United States;
2003 Phase 4 NCT00546533 -
2003 - NCT00195377 Spain;
2003 - NCT00195364 Spain;
2000 Phase 3 NCT00393471 Australia;Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Israel;Italy;Netherlands;Norway;Poland;Portugal;Romania;Spain;Sweden;United Kingdom;
Etanercept (ETN)
University of Leeds
2006 Phase 4 NCT01303874 United Kingdom;
Etanercept (Enbrel)
University of Leeds
2011 Phase 4 EUCTR2010-023910-30-GB United Kingdom;
Etanercept (EnbrelTM)
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00706797 Austria;Croatia;Czech Republic;France;Germany;Hungary;Italy;Poland;Spain;Turkey;United Kingdom;United States;
Etanercept + Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer
2008 Phase 4 NCT00783536 Mexico;
Etanercept , Methotrexate
Wyeth is now a wholly owned subsidiary of Pfizer
2007 Phase 4 NCT00422227 Hong Kong;India;Korea, Republic of;Malaysia;Philippines;Singapore;Taiwan;Thailand;
Etanercept / Autoinjector A
Amgen
2013 Phase 3 NCT01901185 United States;
Etanercept 50 MG/ML
P. Verschueren
2018 Phase 4 NCT03649061 Belgium;
Etanercept Auto-Injector
Wyeth Pharmaceuticals France
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Liquid
Amgen
2004 Phase 3 NCT00110903 -
Etanercept Optimal dosing
Duke University
2023 Phase 1 NCT04585711 United States;
Etanercept Pre-filled syringe
Wyeth Pharmaceuticals France
2007 - EUCTR2006-005137-38-DE Denmark;Finland;France;Germany;Sweden;United Kingdom;
Etanercept Treatment
Assistance Publique Hopitaux De Marseille
2011 Phase 3 NCT02164214 France;
Etanercept biosimilar
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
Etanercept or adalimumab
University of Glasgow
2010 Phase 4 NCT01021735 United Kingdom;
Etanercept pre-filled syringe sq injection
Amgen
2015 Phase 3 NCT02373813 Argentina;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Greece;Hungary;Italy;Mexico;Poland;Portugal;South Africa;Spain;United States;
Etanercept via Autoinjector A
Amgen
2013 Phase 4 NCT01875991 Canada;United States;
Etanercept via Autoinjector B
Amgen
2013 Phase 4 NCT01875991 Canada;United States;
Etanercept, methotrexate and depomedrone
University Hospital Birmingham
2007 Phase 4 NCT00523692 United Kingdom;
Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
Pfizer
2013 - NCT01932372 Japan;
Etoricoxib
Chung Shan Medical University
2007 Phase 4 NCT04144101 -
Northumbria Healthcare NHS Foundation Trust
2010 Phase 4 NCT01067430 United Kingdom;
Organon and Co
2010 Phase 3 NCT01208181 Argentina;Austria;Canada;Colombia;Czech Republic;Finland;Germany;Guatemala;India;Lithuania;Mexico;Panama;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Taiwan;United Kingdom;United States;
2006 Phase 2 NCT00264147 Canada;Colombia;Puerto Rico;Switzerland;United States;
2006 - NCT01685424 United States;
Eupatilin
Seoul National University Boramae Hospital
2021 Phase 4 NCT04885751 -
Evobrutinib
Merck KGaA
2017 Phase 2 EUCTR2017-000384-32-CZ Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
2017 Phase 2 EUCTR2017-000384-32-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Czech Republic;Germany;Japan;Mexico;Poland;Russian Federation;Serbia;South Africa;Ukraine;United States;
Exhaled nitric oxide assessment
GlaxoSmithKline
2004 - NCT00242853 United Kingdom;
Experimental: Arm A: DRL_RI
Dr. Reddy's Laboratories Limited
2020 Phase 3 NCT04268771 United States;
Extracorporeal Photopheresis
Mallinckrodt
2003 Phase 2 NCT00221000 Australia;Austria;Belgium;Canada;France;Germany;Italy;Mexico;Slovakia;South Africa;United States;
F8IL10
Philogen S.p.A.
2015 Phase 2 EUCTR2013-005418-37-DE Germany;Italy;Switzerland;
2014 Phase 2 NCT02270632 Germany;Italy;Switzerland;
2014 - EUCTR2013-005418-37-IT Germany;Italy;
2011 Phase 1 NCT02076659 Italy;
FANG(30)
Juan C. Bertoglio, MD
2006 Phase 2 NCT00749645 Chile;
FB704A
Fountain Biopharma Inc.
2019 Phase 1 NCT03890302 United States;
FBL-MTX
SOLFARCOS - Pharmaceutical and Cosmetic Solutions Ltd
2021 Phase 1 NCT05117593 Portugal;
FKB327
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 NCT02405780 Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-ES Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000109-11-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000109-11-BG Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 NCT02260791 Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2014-000109-11-ES Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 Phase 3 EUCTR2014-000109-11-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 AI
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 EUCTR2014-000110-61-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FKB327 PFS
Fujifilm Kyowa Kirin Biologics Co., Ltd.
2015 Phase 3 EUCTR2014-000110-61-DE Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2015 Phase 3 EUCTR2014-000110-61-CZ Bulgaria;Canada;Chile;Czech Republic;Germany;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
FMT+MTX
Peking Union Medical College Hospital
2019 Phase 2 NCT03944096 China;
FPA008
Five Prime Therapeutics, Inc.
2013 Phase 1 NCT01962337 Hungary;Netherlands;Poland;
FR104
OSE Immunotherapeutics
2015 Phase 1 NCT02800811 Belgium;
FURESTEM-RA Inj
Kang Stem Biotech Co., Ltd.
2018 Phase 1/Phase 2 NCT03618784 Korea, Republic of;
FURESTEM-RA Inj.
Kang Stem Biotech Co., Ltd.
2016 - NCT03106259 Korea, Republic of;
2014 Phase 1 NCT02221258 Korea, Republic of;
FX125L
Funxional Therapeutics Ltd
2011 - EUCTR2011-005036-26-GB United Kingdom;
Faecal microbiota transplantation
Torkell Ellingsen
2022 Phase 2 NCT04924270 -
Faecal sampling
Assistance Publique - Hôpitaux de Paris
2020 - NCT04292067 France;
Famotidine
Hoshigaoka Koseinenkin Hospital
2009 - JPRN-UMIN000004271 Japan;
Fang yi qing feng shi granule
Maoxiang Group Jilin Pharmaceutical Co., Ltd.
2014 Phase 2 NCT02029599 China;
Fendrix suspension for injection Hepatitis B (rDNA) vaccine (adjuvanted, adsorbed).
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
Fentanyl
Yamaguchi University
2018 - JPRN-UMIN000031692 Japan;
Fentanyl transdermal patch
Janssen Pharmaceutica N.V., Belgium
2001 Phase 4 NCT00524160 -
Ferrograd Folic Tablets
University of Leeds
2006 Phase 4 EUCTR2005-005013-37-GB United Kingdom;
Fexofenadine
October 6 University
2022 Phase 1/Phase 2 NCT05264025 -
Filgotinib
DeparShinshu University School of Medicine
2021 - JPRN-UMIN000043547 Japan;
GILEAD SCIENCES INCORPORATED
2017 Phase 3 EUCTR2016-000568-41-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Galapagos NV
2021 - NCT04871919 Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2019 Phase 2 NCT03926195 Belgium;Bosnia and Herzegovina;Bulgaria;Czechia;Estonia;Georgia;Latvia;Poland;Spain;Ukraine;
2017 Phase 3 NCT03025308 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2014 Phase 2 NCT02065700 Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences
2020 Phase 1 NCT04608344 United States;
2018 Phase 1 NCT03417778 Germany;New Zealand;United States;
2016 Phase 3 NCT02889796 Argentina;Australia;Belgium;Bulgaria;Canada;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02886728 Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 NCT02873936 Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 2 NCT02885181 Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
Kawakami Atsushi
2021 - JPRN-jRCTs071200107 Japan;
R.Bos
2021 Phase 4 NCT04985435 Netherlands;
Filgotinib 200mg/day
Atsushi Kawakami
2021 Phase 3 NCT05090410 Japan;
Filgrastim
Fairview University Medical Center
2000 - NCT00006055 United States;
Fish oil supplement
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2004 Phase 2 NCT00094562 United States;
Fish oil, gamma-linolenic acid
Charite University, Berlin, Germany
2008 Phase 2 NCT01179971 -
Fludarabine
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
1998 Phase 2 NCT00001677 United States;
Fluorescence Imaging
University Medical Center Groningen
2022 Phase 1 NCT03938701 Netherlands;
Flurbiprofen
Bristol-Myers Squibb
2017 Phase 1 NCT03131973 United States;
Focetria
Div KIR AMC
2010 - EUCTR2009-016789-10-NL Netherlands;
Focetria (Monovalent MF59-Adjuvanted vaccine)
Tel-Aviv Sourasky Medical Center
2009 Phase 2 NCT01006681 -
Folate
Biogen
2006 Phase 2 NCT00298272 United States;
Genentech, Inc.
2006 Phase 3 NCT00299104 United States;
2006 Phase 3 NCT00266227 United States;
2005 Phase 3 NCT00299130 United States;
2005 Phase 2 NCT00243412 United States;
Hoffmann-La Roche
2011 Phase 4 NCT01283971 Denmark;Finland;France;Germany;Greece;Italy;Netherlands;Puerto Rico;Russian Federation;Spain;Sweden;United Kingdom;United States;
2007 Phase 4 NCT00462345 Korea, Republic of;
FolateScan (Technetium Tc 99mEC20)
Mayo Clinic
2006 Phase 2 NCT00588393 United States;
Folic (or folinic) acid
GlaxoSmithKline
2019 Phase 3 NCT03980483 Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2016 Phase 2 NCT02799472 Germany;Poland;United States;
Folic acid
Biocad
2016 Phase 3 NCT02762838 Belarus;India;Russian Federation;
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
2015 Phase 2 NCT02504671 Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
Hoffmann-La Roche
2009 Phase 1 NCT00965653 Canada;New Zealand;Spain;United Kingdom;
Kaneko Yuko
2018 Phase 4 JPRN-jRCT1031180088 Japan;South Korea;Taiwan;
Kojima Toshihisa
2020 - JPRN-jRCTs041200048 Japan;
Sanofi
2014 Phase 3 NCT02293902 Japan;
2013 Phase 1 NCT01850680 Japan;
Takahashi Nobunori
2020 - JPRN-jRCT1041190125 Japan;
The Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042659 China;
2021 Phase 0 ChiCTR2100042329 China;
The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041819 China;
University of Alabama at Birmingham
1996 Phase 2 NCT00000395 United States;
University of Dundee
2005 Phase 4 EUCTR2005-000551-15-GB United Kingdom;
University of Leeds
2006 Phase 4 NCT01308255 United Kingdom;
Yunnan Hospital of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041894 China;
Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine)
2021 Phase 0 ChiCTR2100042328 China;
Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine
2021 Phase 0 ChiCTR2100042440 China;
Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
2021 Phase 0 ChiCTR2100041821 China;
Folic acid or folate
Hoffmann-La Roche
2007 Phase 3 NCT00578305 Argentina;Brazil;Canada;Czech Republic;Denmark;Estonia;Former Serbia and Montenegro;France;Germany;Greece;Latvia;Lithuania;Netherlands;Norway;Romania;Russian Federation;Serbia;Spain;Switzerland;Turkey;United Kingdom;
Folic/folinic acid
Sanofi
2010 Phase 2 NCT01217814 Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
Takeda
2014 Phase 2 NCT02379091 Argentina;Brazil;Bulgaria;Colombia;Czech Republic;Czechia;Germany;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;United Kingdom;
Folimet
Chelsea Therapeutics, Inc
2010 - EUCTR2010-019134-27-BG Argentina;Bulgaria;Czech Republic;Mexico;Poland;United States;
Folinic acid
University of Alabama at Birmingham
1996 Phase 2 NCT00000395 United States;
Fontolizumab
PDL BioPharma, Inc.
2005 Phase 2 NCT00281294 United States;
FosD
ASTRAZENECA
2011 - EUCTR2010-020892-22-IT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020745-27-IT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020744-35-IT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Astra Zeneca AB
2010 - EUCTR2010-020743-12-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 - EUCTR2010-020892-22-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020745-27-HU Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020745-27-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020744-35-DE Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-020745-27-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-GB Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-FR Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-BE Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 - EUCTR2010-020892-22-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-PT Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-ES Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020745-27-PT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-ES Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 - EUCTR2010-020744-35-PT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-LV Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-LT Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-GB Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-ES Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-CZ Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020743-12-HU Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
Fosfamatinib Disodium
RIGEL PHARMACEUTICALS INC
2009 - EUCTR2008-000744-13-IT Bulgaria;France;Germany;Italy;
Fostamatinib
AstraZeneca
2012 Phase 2 NCT01640054 Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
2012 Phase 2 NCT01569074 Hong Kong;Japan;Korea, Republic of;Taiwan;Thailand;Vietnam;
2012 Phase 2 NCT01563978 Argentina;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 Phase 1 NCT01725230 United States;
2011 Phase 3 NCT01242514 Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 Phase 2 NCT02092961 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;South Africa;United Kingdom;United States;
2011 Phase 2 NCT01264770 Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 Phase 1 NCT01355354 United Kingdom;
2011 Phase 1 NCT01336218 United States;
2011 Phase 1 NCT01311622 United Kingdom;
2011 Phase 1 NCT01309854 United States;
2011 Phase 1 NCT01276262 United Kingdom;
2010 Phase 3 NCT01197755 Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 NCT01197534 Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 NCT01197521 Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 1 NCT01245790 United States;
- Phase 2 JPRN-JapicCTI-121990 -
- Phase 2 JPRN-JapicCTI-121843 -
Fostamatinib 50 mg blue film-coated tablet
AstraZeneca AB
2012 - EUCTR2011-006070-73-DE Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-CZ Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-BG Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
Fostamatinib Disodium
AstraZeneca AB
2009 - EUCTR2008-000744-13-BG Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
2008 Phase 2 EUCTR2008-000744-13-BE Belgium;Bulgaria;France;Germany;Italy;
- - EUCTR2008-000744-13-DE Belgium;Bulgaria;France;Germany;Italy;
Rigel Pharmaceuticals, Inc
2009 - EUCTR2008-000744-13-FR Bulgaria;France;Germany;Italy;
Rigel Pharmaceuticals, Inc.
2008 - EUCTR2008-000743-34-FR France;Germany;Italy;
2008 - EUCTR2008-000743-34-DE France;Germany;Italy;
2008 - EUCTR2008-000743-34-BE Belgium;France;Germany;Italy;
2008 - EUCTR2008-000742-30-PL Bulgaria;Hungary;Poland;
2008 - EUCTR2008-000742-30-HU Bulgaria;Hungary;Poland;
2008 - EUCTR2008-000742-30-BG Bulgaria;Hungary;Poland;
Fostamatinib Disodium (R935788)
AstraZeneca
2008 Phase 2 NCT00805467 Belgium;Bulgaria;Colombia;France;Germany;Italy;Mexico;Peru;Poland;Romania;United States;
Fostamatinib disodium
ASTRAZENECA
2011 - EUCTR2010-020892-22-IT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020745-27-IT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2011 - EUCTR2010-020744-35-IT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
Astra Zeneca AB
2010 - EUCTR2010-020743-12-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
AstraZeneca AB
2013 - EUCTR2010-020892-22-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2012 - EUCTR2011-006070-73-DE Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-CZ Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2012 - EUCTR2011-006070-73-BG Argentina;Brazil;Bulgaria;Czech Republic;Germany;Mexico;Peru;Poland;South Africa;Ukraine;United States;
2011 Phase 2 EUCTR2010-023692-26-SK Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 Phase 2 EUCTR2010-023692-26-GB Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-HU Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-CZ Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-023692-26-BG Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020892-22-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020745-27-HU Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020745-27-DE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2011 - EUCTR2010-020744-35-DE Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2011 - EUCTR2010-020743-12-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020892-22-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-GB Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020745-27-FR Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 Phase 3 EUCTR2010-020745-27-BE Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-GB Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-FR Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 Phase 3 EUCTR2010-020743-12-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Chile;Estonia;France;Germany;Hungary;India;Mexico;Peru;Poland;Russian Federation;Slovakia;Ukraine;United Kingdom;United States;
2010 Phase 3 EUCTR2010-020743-12-BE Belgium;Bulgaria;Estonia;France;Germany;Hungary;Poland;Slovakia;United Kingdom;
2010 - EUCTR2010-020892-22-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-PT Belgium;Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-HU Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-ES Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Netherlands;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020892-22-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020892-22-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Israel;Italy;Latvia;Lithuania;Mexico;Netherlands;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020745-27-PT Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-ES Belgium;Czech Republic;France;Germany;Hungary;Italy;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020745-27-CZ Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;France;Germany;Hungary;Israel;Italy;Mexico;Portugal;South Africa;Spain;United Kingdom;United States;
2010 - EUCTR2010-020744-35-PT Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-LV Canada;Czech Republic;Germany;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-LT Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-GB Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020744-35-ES Czech Republic;Germany;Italy;Latvia;Lithuania;Portugal;Spain;United Kingdom;
2010 - EUCTR2010-020744-35-CZ Canada;Czech Republic;Germany;India;Israel;Italy;Latvia;Lithuania;Portugal;Romania;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2010 - EUCTR2010-020743-12-HU Bulgaria;Estonia;France;Germany;Hungary;Poland;United Kingdom;
- - EUCTR2010-023692-26-DE Bulgaria;Canada;Czech Republic;Germany;Hungary;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Ukraine;United Kingdom;United States;
Fostamatinib disodium (R935788)
Rigel Pharmaceuticals
2008 Phase 2 NCT00665925 Bulgaria;Colombia;Israel;Mexico;Poland;Romania;United States;
2008 Phase 2 NCT00665626 Belgium;Brazil;Colombia;France;Germany;Italy;Peru;United States;
Fresenius-Kabi)
Humanis Klinikum Niederosterreich
2004 Phase 3 NCT00412256 Austria;
G1567970
Galapagos NV
2020 Phase 2 EUCTR2020-000658-83-BG Bulgaria;Georgia;Poland;Ukraine;
GB224
Genor Biopharma Co., Ltd.
2019 Phase 1 NCT04179513 China;
2017 Phase 1 NCT04178070 China;
GB242
Genor Biopharma Co., Ltd.
2017 Phase 3 NCT04178850 China;
GCK
Zhejiang Hisun Pharmaceutical Co. Ltd.
2017 Phase 1 NCT03755258 China;
GDC-0853
Genentech, Inc.
2016 Phase 2 NCT02983227 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2016 Phase 2 NCT02833350 Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-000335-40-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GDC-0853 RO7010939
Genentech, Inc.
2016 Phase 2 EUCTR2016-000498-19-BG Argentina;Brazil;Bulgaria;Chile;Colombia;Korea, Republic of;Mexico;Poland;Russian Federation;Serbia;Ukraine;United States;
GFI 38518168-AEK-B-007
Janssen-Cilag International NV
2009 - EUCTR2009-012118-27-NL Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-GB Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-ES Czech Republic;Netherlands;Spain;United Kingdom;
2009 - EUCTR2009-012118-27-CZ Czech Republic;Netherlands;Spain;United Kingdom;
GLPG0259
Galápagos NV
2010 - EUCTR2009-015898-12-NL Belgium;Netherlands;
2010 - EUCTR2009-015898-12-BE Belgium;Netherlands;
GLPG0259 (Part B)
Galapagos NV
2010 Phase 2 NCT01211249 Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0259 oral capsule
Galapagos NV
2010 Phase 2 NCT01211249 Belgium;Netherlands;Poland;Russian Federation;Ukraine;
GLPG0634
Galapagos NV
2019 Phase 2 EUCTR2018-003933-14-LV Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-ES Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-EE Bulgaria;Czech Republic;Estonia;Latvia;Poland;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-CZ Belgium;Bulgaria;Czech Republic;Estonia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BG Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Czechia;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2019 Phase 2 EUCTR2018-003933-14-BE Belgium;Bosnia and Herzegovina;Bulgaria;Czech Republic;Estonia;Georgia;Germany;India;Latvia;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;
2017 Phase 2 EUCTR2012-003655-11-FR Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-LV Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003654-86-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2014 - EUCTR2012-003635-31-AT Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 Phase 2 NCT01894516 Argentina;Australia;Austria;Bulgaria;Chile;Colombia;Germany;Guatemala;Hungary;Latvia;Mexico;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2013 Phase 2 NCT01888874 Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Puerto Rico;Russian Federation;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-ES Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003654-86-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-LV Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-HU Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-ES Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-BG Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2013 - EUCTR2012-003635-31-BE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Lithuania;Mexico;Moldova, Republic of;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Spain;Ukraine;United States;
2012 Phase 2 NCT01668641 Hungary;Moldova, Republic of;Russian Federation;Ukraine;
2011 Phase 2 NCT01384422 Moldova, Republic of;
Galapagos SASU
2012 - EUCTR2011-005008-14-HU European Union;Hungary;Moldova, Republic of;Russian Federation;Ukraine;
Gilead Sciences Inc.
2014 Phase 2 EUCTR2012-003655-11-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
GLPG3970
Galapagos NV
2020 Phase 2 NCT04577781 Bulgaria;Georgia;Poland;Ukraine;
2020 Phase 2 EUCTR2020-000658-83-BG Bulgaria;Georgia;Poland;Ukraine;
GOL
University Medical Center Utrecht (UMCU)
2016 Phase 4 EUCTR2015-004858-17-NL Netherlands;
GP2013
Hexal AG
2015 Phase 1;Phase 2 EUCTR2010-021184-32-PL Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-HU Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-GB Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2015 Phase 1;Phase 2 EUCTR2010-021184-32-BG Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Russian Federation;Spain;Turkey;United Kingdom;United States;
2012 Phase 2 EUCTR2010-021184-32-EE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2011 Phase 2 EUCTR2010-021184-32-IT Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2011 Phase 2 EUCTR2010-021184-32-BE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-FR Austria;Belgium;Bulgaria;Estonia;France;Germany;Hungary;Italy;Poland;Spain;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-DE Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
2010 Phase 2 EUCTR2010-021184-32-AT Argentina;Austria;Belgium;Brazil;Bulgaria;Estonia;France;Germany;Hungary;India;Italy;Poland;Romania;Spain;Turkey;United Kingdom;
Hexal AG (a Sandoz company)
2015 Phase 3 EUCTR2012-003876-38-PL Germany;Hungary;Poland;United States;
2015 Phase 3 EUCTR2012-003876-38-HU Germany;Hungary;Poland;United States;
2015 Phase 3 EUCTR2012-003876-38-DE Germany;Hungary;Poland;United States;
Sandoz
2011 Phase 1/Phase 2 NCT01274182 Argentina;Austria;Belgium;Brazil;Estonia;France;Germany;Hungary;India;Italy;Romania;Spain;Turkey;United States;
GP2013 - A Proposed biosimilar rituximab
Sandoz
2015 Phase 3 NCT02514772 Germany;Hungary;Poland;United States;
GP2015
Hexal AG
2016 Phase 3 EUCTR2012-002009-23-HU Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2016 Phase 3 EUCTR2012-002009-23-DE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-SK Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-PL Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LV Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-LT Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-GB Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-ES Bulgaria;Czech Republic;Estonia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-EE Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-CZ Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
2015 Phase 3 EUCTR2012-002009-23-BG Bulgaria;Czech Republic;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
Sandoz
2015 Phase 3 NCT02638259 Bulgaria;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Poland;Russian Federation;Serbia;Slovakia;Spain;United Kingdom;United States;
GP2017
HEXAL AG
2016 Phase 3 EUCTR2015-003433-10-IT Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
Hexal, AG
2016 Phase 3 EUCTR2015-003433-10-HU Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-GB Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-ES Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-DE Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
2016 Phase 3 EUCTR2015-003433-10-CZ Czech Republic;France;Germany;Hungary;Italy;Korea, Republic of;Malaysia;Mexico;Poland;Romania;Russian Federation;Serbia;Spain;Turkey;United Kingdom;United States;
GRC 4039
Glenmark Pharmaceuticals SA
2011 - EUCTR2011-000107-40-GB India;Philippines;Poland;Sri Lanka;United Kingdom;
GS-5745
Gilead Sciences
2014 Phase 1 NCT02176876 Czech Republic;Hungary;
Gilead Sciences, Inc.
2017 Phase 2 EUCTR2016-000897-39-HU Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
2017 Phase 2 EUCTR2016-000897-39-DE Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
2017 Phase 2 EUCTR2016-000897-39-BE Australia;Belgium;Germany;Hungary;Mexico;Taiwan;United States;
GS-6034
GILEAD SCIENCES INCORPORATED
2017 Phase 3 EUCTR2016-000568-41-IT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;Czechia;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
Galapagos NV
2017 Phase 3 EUCTR2016-003630-25-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-DE Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-BE Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2014 Phase 2 EUCTR2012-003655-11-HU Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 Phase 2 EUCTR2012-003655-11-BG Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2014 Phase 2 EUCTR2012-003655-11-BE Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
2013 Phase 2 EUCTR2012-003655-11-LV Argentina;Australia;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
- Phase 3 EUCTR2016-003630-25-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
- Phase 2 EUCTR2012-003655-11-DE Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;Czechia;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences Inc.
2014 Phase 2 EUCTR2012-003655-11-CZ Argentina;Australia;Austria;Belgium;Bulgaria;Chile;Colombia;Czech Republic;France;Germany;Guatemala;Hungary;Israel;Latvia;Mexico;Moldova, Republic of;Peru;Poland;Romania;Russian Federation;Spain;Ukraine;United States;
Gilead Sciences, Inc.
2018 Phase 3 EUCTR2016-003630-25-NL Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-PL Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-HU Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-GB Argentina;Australia;Belgium;Bulgaria;Canada;Chile;Colombia;Czechia;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-003630-25-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Georgia;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Moldova, Republic of;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000570-37-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-PL Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-NL Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-FR Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-ES Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-DE Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000569-21-BE Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-PL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-NL Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-ES Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2017 Phase 3 EUCTR2016-000568-41-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000570-37-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000569-21-HU Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000569-21-GB Argentina;Australia;Belgium;France;Germany;Hungary;Israel;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Poland;Spain;Switzerland;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-SK Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 3 EUCTR2016-000568-41-GB Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;Chile;Colombia;Czech Republic;France;Germany;Hong Kong;Hungary;India;Ireland;Israel;Italy;Japan;Korea, Republic of;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Romania;Russian Federation;Serbia;Slovakia;South Africa;Spain;Switzerland;Taiwan;Thailand;Ukraine;United Kingdom;United States;
2016 Phase 2 EUCTR2016-001496-75-PL Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-001496-75-CZ Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GS-9876
Gilead Sciences
2016 Phase 2 NCT02885181 Bulgaria;Czech Republic;Czechia;Georgia;Hungary;Moldova, Republic of;Poland;Ukraine;United States;
Gilead Sciences, Inc.
2016 Phase 2 EUCTR2016-001496-75-PL Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
2016 Phase 2 EUCTR2016-001496-75-CZ Bulgaria;Czech Republic;Hungary;Poland;Serbia;Ukraine;United States;
GSK 3196165
GlaxoSmithKline Research & Development Limited
2021 Phase 3 EUCTR2019-000878-30-DE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LV Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-LT Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-HU Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-CZ Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BG Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000878-30-BE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Czechia;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
- Phase 3 EUCTR2019-000878-30-EE Argentina;Australia;Belgium;Brazil;Bulgaria;Canada;China;Colombia;Czech Republic;Estonia;France;Germany;Hungary;India;Italy;Japan;Korea, Republic of;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Thailand;Ukraine;United Kingdom;United States;
GSK1827771
GlaxoSmithKline
2007 Phase 1 NCT00539760 United States;
GSK1841157
GlaxoSmithKline Research & Development Ltd
2008 Phase 1;Phase 2 EUCTR2008-002046-27-FR Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-DE Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-BE Belgium;France;Germany;Spain;
GlaxoSmithKline S.A.
2008 - EUCTR2008-002046-27-ES Belgium;France;Germany;Spain;
GSK2982772
GlaxoSmithKline
2016 Phase 2 NCT02858492 Germany;Italy;Poland;Russian Federation;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000912-13-PL Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-GB Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-DE Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK2982772A, where A denotes the free base
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2016-000912-13-PL Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-GB Germany;Italy;Poland;Romania;Spain;United Kingdom;
2016 Phase 2 EUCTR2016-000912-13-DE Germany;Italy;Poland;Romania;Spain;United Kingdom;
GSK3117391
GlaxoSmithKline
2016 Phase 2 NCT02965599 Mexico;Poland;Romania;
GlaxoSmithKline Research & Development Ltd
2016 Phase 2 EUCTR2015-005800-27-PL Poland;Romania;Russian Federation;
GSK3152314A
GlaxoSmithKline
2008 Phase 2 NCT00674635 Australia;Former Serbia and Montenegro;New Zealand;Russian Federation;Serbia;Ukraine;United Kingdom;
GSK315234
GlaxoSmithKline Research & Development Ltd
2008 - EUCTR2006-000923-32-GB United Kingdom;
GSK315234 Injection 100mg/mL
GlaxoSmithKline Research & Development Limited
2010 Phase 2 EUCTR2009-012055-19-FR Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-IE Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-GB Belgium;France;Ireland;United Kingdom;
2010 - EUCTR2009-012055-19-BE Belgium;France;Ireland;United Kingdom;
GSK3196165
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT
2019 Phase 3 EUCTR2019-000868-18-IT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Sweden;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-IT Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Sweden;Ukraine;United Kingdom;United States;
2015 Phase 2 EUCTR2014-003453-34-IT Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
GlaxoSmithKline
2016 Phase 2 NCT02799472 Germany;Poland;United States;
2015 Phase 2 NCT02504671 Bulgaria;Canada;Czech Republic;Czechia;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GlaxoSmithKline Research & Development Limited
2020 Phase 3 EUCTR2019-000868-18-DE Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2020 Phase 3 EUCTR2019-000867-26-DE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-PL Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-LT Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-HU Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-GB Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-ES Argentina;Belgium;Canada;China;Czech Republic;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Poland;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000868-18-CZ Argentina;Belgium;Canada;China;Czech Republic;Czechia;Germany;Hungary;Italy;Japan;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-PL Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-HU Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-GB Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-ES Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-EE Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000867-26-BG Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-PL Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LV Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-LT Argentina;Brazil;Canada;China;Czech Republic;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-HU Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-GB Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-ES Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 EUCTR2019-000797-39-CZ Argentina;Brazil;Canada;China;Czech Republic;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Philippines;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2018 Phase 2 EUCTR2015-004386-91-PL Germany;Poland;United States;
2016 Phase 2 EUCTR2015-004386-91-DE Germany;Poland;United States;
2015 Phase 2 EUCTR2014-003453-34-PL Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-HU Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-GB Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Romania;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-ES Argentina;Belgium;Bulgaria;Canada;Chile;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Netherlands;Poland;Romania;Russian Federation;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-EE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-DE Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
2015 Phase 2 EUCTR2014-003453-34-CZ Argentina;Bulgaria;Canada;Czech Republic;Estonia;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;South Africa;Spain;Ukraine;United Kingdom;
GSK3196165 (Otilimab)
GlaxoSmithKline
2019 Phase 3 NCT04134728 Argentina;Belgium;Canada;Czechia;Germany;Hungary;Italy;Japan;Korea, Republic of;Lithuania;Poland;South Africa;Spain;United Kingdom;United States;
2019 Phase 3 NCT03980483 Argentina;Canada;China;Czechia;Hungary;India;Italy;Latvia;Lithuania;Malaysia;Mexico;Poland;Russian Federation;Serbia;South Africa;Spain;Ukraine;United Kingdom;United States;
2019 Phase 3 NCT03970837 Argentina;Australia;Brazil;Bulgaria;China;Colombia;Estonia;France;Germany;Hungary;Japan;Korea, Republic of;Mexico;Poland;Russian Federation;Spain;Thailand;United Kingdom;United States;
GSK3196165 Dose 1
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK3196165 Dose 2
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK3196165 Dose 3
GlaxoSmithKline
2017 Phase 1/Phase 2 NCT03028467 Japan;
GSK706769
GlaxoSmithKline
2010 Phase 2 NCT00979771 Netherlands;
GlaxoSmithKline Research & Development Limited
2009 - EUCTR2009-012204-42-IE Belgium;Ireland;
2009 - EUCTR2009-012204-42-BE Belgium;Ireland;
GW274150
GlaxoSmithKline
2006 Phase 2 NCT00379990 Serbia;United Kingdom;
2005 Phase 2 NCT00370435 United Kingdom;
GW274150 Tablets
GlaxoSmithKline Research & Development Limited
2005 Phase 2 EUCTR2005-001977-82-GB United Kingdom;
GW406381
GLAXO SMITHKLINE
2005 - EUCTR2005-000158-61-IT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline
2005 Phase 3 NCT00113308 Argentina;Austria;Belgium;Bulgaria;Canada;Chile;Costa Rica;Czech Republic;Denmark;Estonia;Finland;France;Germany;Greece;Hungary;India;Ireland;Italy;Korea, Republic of;Latvia;Lithuania;Mexico;Netherlands;New Zealand;Norway;Pakistan;Peru;Philippines;Poland;Puerto Rico;Romania;Russian Federation;Slovakia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2004 - EUCTR2004-000106-41-SE Sweden;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW406381X
GlaxoSmithKline Research & Development Limited
2006 - EUCTR2005-000158-61-LT Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-EE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-DE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2006 - EUCTR2005-000158-61-CZ Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-LV Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-IE Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-HU Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-GB Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-DK Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
2005 - EUCTR2005-000158-61-AT Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GlaxoSmithKline s.a.
2005 Phase 3 EUCTR2005-000158-61-ES Austria;Czech Republic;Denmark;Estonia;Germany;Hungary;Ireland;Italy;Latvia;Lithuania;Spain;United Kingdom;
GW856553
GlaxoSmithKline
2007 Phase 1 NCT00517543 United States;
2006 Phase 2 NCT00393146 Romania;Russian Federation;Spain;
2005 Phase 2 NCT00256919 Bulgaria;Germany;Spain;Sweden;Ukraine;
GlaxoSmithKline Research & Development Ltd
2005 - EUCTR2005-002969-37-SE Germany;Spain;Sweden;
- - EUCTR2005-002969-37-DE Germany;Spain;Sweden;
GlaxoSmithKline S.A.
2005 Phase 2 EUCTR2005-002969-37-ES Germany;Spain;Sweden;
Gadobutrol
GlaxoSmithKline
2015 Phase 1 NCT02350426 United Kingdom;
Gadolinium
Tokyo Medical and Dental University
2013 - JPRN-UMIN000012399 Japan;
Gamma-Linolenic acid
FDA Office of Orphan Products Development
1994 - NCT00004420 -
Geleli
Peking University People's Hospital
2022 - NCT05240859 China;
General anesthesia with tourniquet
Riku Antero Palanne
2016 - NCT03364088 Finland;
General anesthesia without tourniquet
Riku Antero Palanne
2016 - NCT03364088 Finland;
Gerilimzumab
Bird Rock Bio, Inc.
2018 Phase 2 NCT02795299 -
Ginger
Hospital of Chengdu Military Area Command PLA
2008 - ChiCTR-TCC-12002824 China;
Ginseng
Zhejiang Provincal Hospital of TCM
2019 Phase 2 ChiCTR1900026257 China;
Ginsenoside
Institute of Clinical Pharmacology, Central South University
2015 Phase 1 study ChiCTR-IPR-15006107 China;
2015 Phase 1 study ChiCTR-IPR-15005787 China;
2014 Phase 1 study ChiCTR-TRC-14004824 China;
GlucoCorticoid
University Hospital, Toulouse
2017 Phase 4 NCT02997605 France;
Glucocorticoid Agent
Hoffmann-La Roche
2017 - NCT03291457 Belgium;
Glucocorticoids (permitted,not necessary)
Fen Li
2016 Phase 4 NCT02878161 -
Glucophage (metformin)
Queen Mary University of London
2010 Phase 2 EUCTR2008-005708-18-GB United Kingdom;
Gold
Affiliated Hospital of North Sichuan Medical College
2018 - ChiCTR1800018637 China;
Department of Clinical Immunology, Xijing Hospital, Fourth Military Medical University
2011 - ChiCTR-DDT-12002268 China;
Peking University People's Hospital
2012 - ChiCTR-DDT-12002658 China;
Golimumab
CENTOCOR
2010 - EUCTR2009-010582-23-IT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2006 Phase 3 EUCTR2004-003295-10-IT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor B.V.
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
Centocor BV
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Centocor, Inc.
2010 Phase 3 NCT01248780 China;
2009 Phase 3 NCT00973479 Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
2007 Phase 1 NCT01362153 United States;
2006 Phase 3 NCT00361335 Argentina;Australia;Belgium;Colombia;Germany;Hungary;Latvia;Lithuania;Malaysia;Malta;Mexico;New Zealand;Peru;Poland;Russian Federation;Ukraine;United States;
2006 Phase 3 NCT00299546 Australia;Austria;Canada;Finland;France;Germany;Netherlands;New Zealand;Spain;Switzerland;United Kingdom;United States;
2005 Phase 3 NCT00264550 Argentina;Australia;Brazil;Canada;Chile;Germany;Hungary;India;Korea, Republic of;Mexico;New Zealand;Poland;Taiwan;Turkey;United States;
2003 Phase 2 NCT00207714 -
Janssen Biotech, Inc.
2009 - NCT01081717 United States;
Janssen Inc.
2019 - NCT03729349 Canada;
Janssen-Cilag, S.A.
2015 - NCT02414984 Colombia;
Julia Brown
2011 Phase 4 NCT01295151 United Kingdom;
Mario Negri Institute for Pharmacological Research
2018 Phase 4 NCT03100253 Italy;
MedImmune LLC
2013 Phase 2 NCT01715896 Argentina;Colombia;Czech Republic;France;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Serbia;Slovakia;Spain;Turkey;United Kingdom;
MedImmune Ltd
2013 - EUCTR2011-005649-10-PT Argentina;Brazil;Czech Republic;France;Germany;Greece;Hungary;Israel;Mexico;Portugal;Russian Federation;Slovakia;Spain;United Kingdom;
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
2010 - EUCTR2009-011137-26-PT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
Osaka City University Medical School
2012 Phase 4 JPRN-UMIN000009425 Japan;
Osaka Medical College
2015 - JPRN-UMIN000016950 Japan;
Peking Union Medical College Hospital
2019 - NCT04188249 China;
READE
2015 - EUCTR2015-002284-42-FI Finland;
Rheumatology, Internal MedicineJuntendo University School of Medicine, Juntendo Koshigaya Hospital
2013 - JPRN-UMIN000014485 Japan;
Sanofi
2010 Phase 2 NCT01217814 Brazil;Canada;Colombia;Czech Republic;Czechia;Germany;Hungary;Italy;Mexico;Norway;Spain;United States;
Schering-Plough Research Institute, A Division of Schering Corporation
2010 Phase 3 EUCTR2009-011137-26-BE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-PL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-GR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-CZ Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2010 - EUCTR2009-011137-26-AT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-SK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-GB Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-FR Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 Phase 3 EUCTR2009-011137-26-ES Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Slovakia;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-NL Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-IE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-HU Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-FI Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-DK Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
2009 - EUCTR2009-011137-26-DE Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
Shering Plough Research Institute, A division of Schering Plough Corporation
2010 - EUCTR2009-011137-26-IT Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Greece;Hungary;Ireland;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom;
St.Marianna University School of Medicine
2013 - JPRN-UMIN000011891 Japan;
Takarazuka city hospital
2014 - JPRN-UMIN000016844 Japan;
TcLand Expression S.A.
2016 - NCT03016260 Czech Republic;Czechia;France;Israel;Netherlands;Turkey;
University of Nebraska
2007 Phase 3 NCT03414502 United States;
Golimumab 100 mg injections
Centocor, Inc.
2005 Phase 3 NCT00264537 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab 2 mg/kg IV
Janssen Biotech, Inc.
2013 Phase 3 NCT01962974 Argentina;Brazil;Canada;Colombia;Mexico;United States;
2009 Phase 3 NCT01004432 Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg SC
Janssen Biotech, Inc.
2009 Phase 3 NCT01004432 Austria;Belgium;Canada;France;Germany;Greece;Spain;Sweden;United Kingdom;United States;
Golimumab 50 mg injections
Centocor, Inc.
2005 Phase 3 NCT00264537 Argentina;Australia;Austria;Belgium;Brazil;Canada;Chile;Hungary;India;Korea, Republic of;Malaysia;Mexico;New Zealand;Philippines;Poland;Russian Federation;Singapore;Spain;Taiwan;Thailand;Turkey;Ukraine;United Kingdom;United States;
Golimumab Final Vialed Product (FVP)
Centocor B.V.
2010 - EUCTR2008-006064-11-HU Hungary;Lithuania;
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2008-006064-11-LT Argentina;Australia;Colombia;Hungary;Korea, Republic of;Lithuania;Malaysia;Mexico;New Zealand;Poland;Russian Federation;Ukraine;United States;
Golimumab Intravenous
Janssen Inc.
2015 - NCT02390700 Canada;
Golimumab Intravenous (IV)
Janssen Scientific Affairs, LLC
2016 - NCT02728934 United States;
Golimumab Liquid in Vial
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab Liquid in prefilled syringe
Janssen Biologics B.V.
2011 Phase 3 EUCTR2009-015019-42-BE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2011 - EUCTR2009-015019-42-DE Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
2010 - EUCTR2009-015019-42-LT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-FI Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
2010 - EUCTR2009-015019-42-AT Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
- - EUCTR2009-015019-42-Outside-EU/EEA Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Golimumab Pre-Filled Syringe
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Golimumab liquid in prefilled pen
Janssen Biologics B.V.
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or Prefilled Syringe
Janssen Biologics B.V.
2009 - EUCTR2009-010582-23-AT Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab liquid in prefilled pen or prefilled syringe
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab pre-filled syringe
Centocor B.V.
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
Golimumab prefilled pen
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Golimumab prefilled pen or prefilled syringe
Janssen Biologics B.V.
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Grapefruit
Department of Rheumatology and Clinical Immunology, Kyoto University Hospital
2014 - JPRN-UMIN000013546 Japan;
Green tea group
King Saud University
2015 - NCT03719469 -
Group 1 or Orencia treated group
University of California, Los Angeles
2012 Phase 4 NCT01717846 United States;
Guna-Anti Interleukin 1
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Antiinterleukin 1 alfa
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Antiinterleukin 1 beta
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Interleukin 10
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
Guna-Interleukin 4
GUNA SPA
2011 - EUCTR2011-003016-23-IT Italy;
H.P. Acthar Gel
Ronald J. Rapoport, MD
2014 - NCT02434757 United States;
H.P. Acthar gel
Iraj Sabahi Research Inc.
2017 Phase 4 NCT03082573 United States;
H02AB04
Leiden University medical Centre
2015 Phase 2 EUCTR2014-004472-35-NL Netherlands;
H02AB07
CHU de Bordeaux
2019 Phase 2 EUCTR2018-004287-56-FR France;
HA20 (IMMU-106)
Nycomed GmbH
2011 - EUCTR2010-022378-15-GB Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
2011 - EUCTR2010-022378-15-CZ Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HA20 (Immu-106)
Nycomed GmbH
2011 - EUCTR2010-022378-15-HU Czech Republic;Germany;Hungary;Spain;United Kingdom;
2011 - EUCTR2010-022378-15-ES Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
2011 - EUCTR2010-022378-15-DE Argentina;Canada;Czech Republic;Germany;Hungary;Mexico;Spain;United Kingdom;United States;
HB-adMSCs
Hope Biosciences
2018 Phase 1/Phase 2 NCT03691909 United States;
HBVAXPRO 5 micrograms/0.5 ml Suspension for injection Hepatitis B vaccine (rDNA)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HBVAXPRO® 40 micrograms
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HCQ
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
Peking University First Hospital
2015 - NCT02320630 China;
Qilu Hospital of Shandong University
2017 Phase 4 NCT03855007 China;
HD-TIV
McGill University Health Centre/Research Institute of the McGill University Health Centre
2016 Phase 4 NCT02936180 Canada;
HE3286
Harbor Therapeutics
2008 Phase 1/Phase 2 NCT00712114 United States;
HEPATITIS B VACCINE (RDNA)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HEPATITIS B VIRUS SURFACE ANTIGEN RECOMBINANT (S PROTEIN)
FUNDACIÓ HOSPITAL UNIVERSITARI VALL D’HEBRON – INSTITUT DE RECERCA (VHIR)
2018 Phase 4 EUCTR2018-002368-18-ES Spain;
HL237
Hanlim Pharm. Co., Ltd.
2018 Phase 1 NCT03896594 Korea, Republic of;
2017 Phase 1 NCT03278470 Korea, Republic of;
HL237 tablet
Hanlim Pharm. Co., Ltd.
2020 Phase 2 NCT04638426 Korea, Republic of;
HLX01
Shanghai Henlius Biotech
2018 Phase 3 NCT03522415 China;
2016 Phase 1/Phase 2 NCT03355872 -
HM71224 Multiple ascending dose
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HM71224 food effect
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HM71224 single ascending dose
Hanmi Pharmaceutical Company Limited
2013 Phase 1 NCT01765478 Netherlands;
HMPL-523
Hutchison Medipharma Limited
2014 Phase 1 NCT02105129 Australia;
HUC-MSC + DMARDs
Shenzhen Hornetcorn Bio-technology Company, LTD
2016 Phase 1 NCT02643823 China;
HUC-MSC infusion (BC-U001)
Beijing Baylx Biotech Co., Ltd.
2021 Phase 1/Phase 2 NCT04971980 China;
HUC-MSC suspension
Baylx Inc.
2020 Phase 1 NCT03828344 -
HUMIRA
CHRU de TOURS
2010 - EUCTR2010-021449-28-FR France;
FRANCISCO J. BLANCO GARCÍA
2013 - EUCTR2012-004482-40-ES Spain;
Helsingin reumakeskus
2010 - EUCTR2009-017325-19-FI Finland;
MERCK SERONO INTERNATIONAL SA
2008 - EUCTR2007-002536-29-IT Austria;Bulgaria;Czech Republic;Finland;France;Germany;Greece;Italy;Poland;Portugal;Spain;Sweden;
Pfizer Inc.
2015 Phase 3 EUCTR2014-000352-29-HR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-FR Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-EE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2015 Phase 3 EUCTR2014-000352-29-BG Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-LT Argentina;Australia;Bosnia and Herzegovina;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2014-000352-29-HU Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-GB Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-ES Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-DE Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
2014 Phase 3 EUCTR2014-000352-29-CZ Argentina;Australia;Brazil;Bulgaria;Canada;Colombia;Croatia;Czech Republic;Estonia;France;Georgia;Germany;Hungary;Japan;Korea, Republic of;Lithuania;Mexico;New Zealand;Peru;Poland;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;
HUMIRA (ADALIMUMAB)
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 2 SIRINGHE PRERIEMPITE 0.8 ML + 2 TAMPONI IMBEVUTI DI ALCOL IN 1 BLISTER
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 4 EUCTR2016-003129-40-IT Italy;
HUMIRA - 40MG/0.8ML SOLUZ. INIETTABILE- USO SOTTOCUTANEO-FLACONCINO(VETRO) 0.8ML 2 ASTUCCI:1 FLACONCINO+1SIRINGA+1AGO+1ADATT.STERILE-2TAMPONI IMBEVUTI ALCOOL
SOCIETA' ITALIANA DI REUMATOLOGIA - SIR
2017 Phase 4 EUCTR2016-001987-12-IT Italy;
HUMIRA 40 mg solución inyectable en jeringa precargada
Abbott GmbH & Co. KG
2011 - EUCTR2010-019514-24-ES Austria;Czech Republic;Germany;Spain;
F. Hoffmann-La Roche Ltd.
2011 Phase 4 EUCTR2010-023587-40-ES Denmark;Finland;Germany;Greece;Italy;Netherlands;Spain;Sweden;
2010 Phase 4 EUCTR2009-015845-21-ES Australia;Belgium;Brazil;Czech Republic;Finland;Germany;Greece;Mexico;Portugal;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
GENENTECH, Inc
2011 - EUCTR2010-021577-37-ES Bulgaria;Germany;Hungary;Spain;
Pfizer, S.A
2009 Phase 3 EUCTR2008-008338-35-ES Bulgaria;Czech Republic;Denmark;Finland;Germany;Slovakia;Spain;United Kingdom;
HUMIRA*SC 2SIR+F 40MG 0,8ML+2T
OSPEDALE POLICLINICO S. MATTEO
2006 - EUCTR2006-003843-22-IT Italy;
HYDROXYCHLOROQUINE SULFATE
Karolinska Institutet
2015 - EUCTR2011-004720-35-NO Denmark;Finland;Norway;Sweden;
2014 - EUCTR2011-004720-35-FI Denmark;Finland;Sweden;
Leiden University Medical Center, department of rheumatology
2007 - EUCTR2006-006186-16-NL Netherlands;
Universitätsklinkum Erlangen
2010 Phase 3 EUCTR2009-015740-42-DE Germany;
HZT-501
Horizon Pharma Ireland, Ltd., Dublin Ireland
2009 Phase 3 NCT00984815 United States;
2007 Phase 3 NCT00613106 United States;
Havrix
HY, HUS
2011 - EUCTR2009-016055-22-SE Finland;Sweden;
Hematopoietic Stem Cell Transplantation
Northwestern University
2002 Phase 1 NCT00282412 United States;
Hemay007 1200 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hemay007 600 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hemay007 800 mg QD group
Tianjin Hemay Pharmaceutical Co.,Ltd
2021 Phase 2 NCT05247216 China;
Hepatitis A vaccine ( HAVRIX or EPAXAL)
Lars Rombo
2009 Phase 2 NCT01360970 Finland;Sweden;
Hepatitis A vaccine and tetanus vaccine
University of Zurich
2013 - NCT01947465 Switzerland;
Herpes Zoster Vaccine
University of Alabama at Birmingham
2016 Phase 2 NCT02538341 United States;
2014 Phase 2 NCT01967316 United States;
2013 Phase 2 NCT02538757 United States;
High dose ORTD-1
Oryn Therapeutics, LLC
2021 Phase 1 NCT04286789 United States;
High dose of BIIL 284 BS tablets
Boehringer Ingelheim
2000 Phase 1 NCT02247375 -
High dose vehicle control
Oryn Therapeutics, LLC
2021 Phase 1 NCT04286789 United States;
High frequency ultrasonography
GlaxoSmithKline
2004 - NCT00242853 United Kingdom;
High-resolution peripheral quantitative computed tomography (HR-pQCT)
University of California, San Francisco
2013 - NCT01773681 United States;
HrIL-2 active
Peking University People's Hospital
2015 Phase 2 NCT02467504 China;
HuMax-CD20
GENMAB A/S
2007 - EUCTR2007-002945-18-IT Czech Republic;Italy;
Genmab A/S
2008 Phase 3 EUCTR2007-002951-18-FR Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-SE Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-DK Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002950-42-BE Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 Phase 3 EUCTR2007-002951-18-IT Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 Phase 3 EUCTR2007-002951-18-ES Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-002951-18-NL Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2007 - EUCTR2007-002950-42-LT Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-HU Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-ES Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002945-18-CZ Czech Republic;
2006 - EUCTR2004-003771-37-HU Hungary;
GlaxoSmithKline Research & Development
2008 Phase 3 EUCTR2007-002951-18-GB Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002951-18-DE Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2008 - EUCTR2007-002950-42-GB Belgium;Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
GlaxoSmithKline Research & Development Ltd
2008 Phase 1;Phase 2 EUCTR2008-002046-27-FR Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-DE Belgium;France;Germany;Spain;
2008 - EUCTR2008-002046-27-BE Belgium;France;Germany;Spain;
2007 Phase 2 EUCTR2007-004878-31-GB Denmark;Hungary;United Kingdom;
2007 - EUCTR2007-004878-31-DK Denmark;Hungary;United Kingdom;
GlaxoSmithKline Research & Development Ltd.
2008 - EUCTR2007-004878-31-HU Denmark;Hungary;United Kingdom;
GlaxoSmithKline Research and Development
2008 - EUCTR2007-002950-42-PL Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
2007 - EUCTR2007-002950-42-CZ Czech Republic;Hungary;Lithuania;Poland;Spain;United Kingdom;
GlaxoSmithKline S.A.
2008 - EUCTR2008-002046-27-ES Belgium;France;Germany;Spain;
HuMax-CD4
Emergent Product Development Seattle LLC
2002 Phase 2/Phase 3 NCT00042406 Canada;United States;
Huang qi gui zhi wu wu granule
Cui xuejun
2018 Phase 2/Phase 3 NCT03593837 -
Human Anti-TNF IgG1 Monoclonal Antibody
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Human Anti-TNFalfa
Centocor B.V.
2006 Phase 3 EUCTR2005-001742-16-GB Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-003232-21-MT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LV Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-LT Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-HU Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-003232-21-DE Germany;Hungary;Latvia;Lithuania;Malta;
2006 - EUCTR2005-001742-16-NL Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-ES Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2004-003296-36-HU Germany;Hungary;
2006 - EUCTR2004-003296-36-DE Germany;Hungary;
Centocor BV
2006 Phase 3 EUCTR2004-003295-10-GB Austria;Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-HU Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-ES Hungary;Italy;Spain;United Kingdom;
2006 - EUCTR2004-003295-10-AT Austria;Hungary;Italy;Spain;United Kingdom;
Janssen Biologics B.V.
2006 - EUCTR2005-001742-16-FI Austria;Finland;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-DE Austria;Germany;Netherlands;Spain;United Kingdom;
2006 - EUCTR2005-001742-16-AT Austria;Germany;Netherlands;Spain;United Kingdom;
Human Recombinant IgG1, lambda
MorphoSys AG
2010 - EUCTR2007-006129-29-PL Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2010 - EUCTR2007-006129-29-NL Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2010 - EUCTR2007-006129-29-BG Belarus;Bulgaria;Germany;Netherlands;Poland;Ukraine;
2009 - EUCTR2007-006129-29-DE Bulgaria;Germany;Netherlands;Poland;Ukraine;
Human anti TNF-alpha monoclonal
Centocor BV
2010 - EUCTR2009-010582-23-GR Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti TNF-alpha monoclonal antibody
Janssen Biologics B.V.
2010 Phase 3 EUCTR2009-010582-23-BE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2010 - EUCTR2009-010582-23-DE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 Phase 3 EUCTR2009-010582-23-GB Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
2009 - EUCTR2009-010582-23-SE Austria;Belgium;Germany;Greece;Italy;Sweden;United Kingdom;
Human anti-IL6 monoclonal antibody
JANSSEN-CILAG INTERNATIONAL N.V.
2012 - EUCTR2010-022243-38-IT Argentina;Australia;Austria;Belgium;Brazil;Canada;China;Croatia;Germany;Italy;Japan;Korea, Republic of;Lithuania;Netherlands;Portugal;Spain;Taiwan;United Kingdom;United States;
Janssen-Cilag International N.V.
2015 Phase 3 EUCTR2012-001176-10-BG Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-PL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-NL Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-IT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-HR Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-GB Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-DE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-BE Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2014 Phase 3 EUCTR2012-001176-10-AT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-LT Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2012-001176-10-ES Argentina;Australia;Austria;Belgium;Brazil;Bulgaria;Canada;Chile;China;Colombia;Croatia;France;Germany;Italy;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Netherlands;New Zealand;Peru;Poland;Portugal;Romania;Russian Federation;Serbia;South Africa;Spain;Taiwan;Ukraine;United Kingdom;United States;
2013 Phase 3 EUCTR2010-022242-24-BG Argentina;Brazil;Bulgaria;Canada;Chile;Colombia;Croatia;India;Japan;Korea, Republic of;Lithuania;Malaysia;Mexico;Peru;Poland;Romania;Russian Federation;Serbia;South Africa;Taiwan;Ukraine;United States;
2013 - EUCTR2010-022243-38-NL Argentina;Australia;Austria;Belgium;Brazil;C